1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35
,t,OMIM no.,Disease Name,Disease Name comments,Gene Affected,Enzyme/protein Defected,EC number/ Protein Entry,Drug name,Drug name comments,Drug ID,Study Type (Evidence code),Mutations improved by treatment,Mutations improved by treatment comments,Mutation that didn't get benefits out the treatment,Mutation that didn't get benefits out the treatment comments,Treatment mechanism of action,Abbreviation for treatment mechanism,new ontology category,possible alternative new ontology category,Comments(This column will be retired),phenotypes  improved,phenotypes  improved comments,Phenotypes  IDS,Reference,Reference,Reference,Reference,Reference,Reference,Reference,Reference,Reference,Reference,Reference
1,1,202110,17-alpha-hydroxylase deficiency,,CYP17A1 gene,Steroid 17-alpha-hydroxylase,1.14.14.19,Hydrocortisone,,DB00741,ECO:0000352,,,,,Functional interaction(Mechanistic B),B,metabolite replacement,,,Abnormal plasma aldosterone,,HP:0040085,https://www.ncbi.nlm.nih.gov/pubmed/26161337,,https://www.ncbi.nlm.nih.gov/pubmed/18458702,,,,,,,,
2,,202110,17-alpha-hydroxylase deficiency,,CYP17A1 gene,Steroid 17-alpha-hydroxylase,1.14.14.19,,,,,,,,,,,,,,Abnormality of potassium homeostasis,,HP:0011042,,,,,,,,,,,
3,,202110,17-alpha-hydroxylase deficiency,,CYP17A1 gene,Steroid 17-alpha-hydroxylase,1.14.14.19,,,,,,,,,,,,,,Abnormal circulating renin,,HP:0040084,,,,,,,,,,,
4,,202110,17-alpha-hydroxylase deficiency,,CYP17A1 gene,Steroid 17-alpha-hydroxylase,1.14.14.19,,,,,,,,,,,,,,Hypertension,,HP:0000822,,,,,,,,,,,
5,,202110,17-alpha-hydroxylase deficiency,,CYP17A1 gene,Steroid 17-alpha-hydroxylase,1.14.14.19,Dexamethasone,,DB01234,ECO:0000352,,,,,Functional interaction(Mechanistic B),B,metabolite replacement,,,Abnormal plasma aldosterone,,HP:0040085,https://www.ncbi.nlm.nih.gov/pubmed/18458702#,,,,,,,,,,
6,,202110,17-alpha-hydroxylase deficiency,,CYP17A1 gene,Steroid 17-alpha-hydroxylase,1.14.14.19,,,,,,,,,,,,,,Hypokalemia,,HP:0002900,https://www.ncbi.nlm.nih.gov/pubmed/27853336,https://www.ncbi.nlm.nih.gov/pubmed/18458702#,,,,,,,,,
7,,202110,17-alpha-hydroxylase deficiency,,CYP17A1 gene,Steroid 17-alpha-hydroxylase,1.14.14.19,,,,,,,,,,,,,,Abnormal circulating renin,,HP:0040084,,,,,,,,,,,
8,,202110,17-alpha-hydroxylase deficiency,,CYP17A1 gene,Steroid 17-alpha-hydroxylase,1.14.14.19,,,,,,,,,,,,,,Hypertension,,HP:0000822,https://www.ncbi.nlm.nih.gov/pubmed/27853336,https://www.ncbi.nlm.nih.gov/pubmed/18458702#,,,,,,,,,
9,,202110,17-alpha-hydroxylase deficiency,,CYP17A1 gene,Steroid 17-alpha-hydroxylase,1.14.14.19,,,,,,,,,,,,,,Bone mass loss,,NA,,,,,,,,,,,
10,,202110,17-alpha-hydroxylase deficiency,,CYP17A1 gene,Steroid 17-alpha-hydroxylase,1.14.14.19,Testosterone,,DB00624,ECO:0000352,,,,,Functional interaction(Mechanistic B),B,metabolite replacement,,,Puberty and gonadal disorders,,HP:0008373,https://www.ncbi.nlm.nih.gov/pubmed/26161337#,,,,,,,,,,
11,,202110,17-alpha-hydroxylase deficiency,,CYP17A1 gene,Steroid 17-alpha-hydroxylase,1.14.14.19,"Estrogen replacement (                                                             
Estradiol)",,DB00783,ECO:0000352,,,,,Functional interaction(Mechanistic B),B,metabolite replacement,,,Puberty and gonadal disorders,,HP:0008373,https://www.ncbi.nlm.nih.gov/pubmed/27853336,https://www.ncbi.nlm.nih.gov/pubmed/26161337#,https://www.ncbi.nlm.nih.gov/pubmed/18458702#,,,,,,,,
12,,202110,17-alpha-hydroxylase deficiency,,CYP17A1 gene,Steroid 17-alpha-hydroxylase,1.14.14.19,Cyclic medroxyprogesterone,,DB00603,ECO:0000352,,,,,Functional interaction(Mechanistic B),B,metabolite replacement,,,Puberty and gonadal disorders,,HP:0008373,https://www.ncbi.nlm.nih.gov/pubmed/26161337#,,,,,,,,,,
13,,202110,17-alpha-hydroxylase deficiency,,CYP17A1 gene,Steroid 17-alpha-hydroxylase,1.14.14.19,,,,,,,,,,,,,,Amenorrhea,,HP:0000141,,,,,,,,,,,
14,,202110,17-alpha-hydroxylase deficiency,,CYP17A1 gene,Steroid 17-alpha-hydroxylase,1.14.14.19,Pioglitazone,,DB01132,ECO:0007121 /ECO:0000352,,,,,Supportive (C),C,symptomatic treatment procedure,,,Insulin resistance,,HP:0000855,https://www.orpha.net/consor/cgi-bin/ResearchTrials_ClinicalTrials.php?lng=EN&data_id=38680&ClinicalTrialName=Effecten-van-Pioglitazone-bij-Congenitale-Bijnierhyperplasie&title=Effecten-van-Pioglitazone-bij-Congenitale-Bijnierhyperplasie&search=ResearchTrials_ClinicalTrials_Simple,https://www.ncbi.nlm.nih.gov/pubmed/19755409,https://clinicaltrials.gov/ct2/show/NCT00151710,,,,,,,,
15,,202110,17-alpha-hydroxylase deficiency,,CYP17A1 gene,Steroid 17-alpha-hydroxylase,1.14.14.19,,,,,,,,,,,,,,Hypertension,,HP:0000822,,,,,,,,,,,
16,2,# 236792,L-2-HYDROXYGLUTARIC ACIDEMIA,,L2HGDH,L-2-hydroxyglutarate dehydrogenase.,1.1.99.2,Riboflavin,,DB00140,ECO:0000352,,,,,Functional interaction(Mechanistic B),B,activity modification of a genetically defective protein,,,Cognitive impairment,,HP:0100543,https://www.ncbi.nlm.nih.gov/pubmed/22391998,,,,,,,,,,
17,,# 236792,L-2-HYDROXYGLUTARIC ACIDEMIA,,L2HGDH,L-2-hydroxyglutarate dehydrogenase.,1.1.99.2,,,,,,,,,,,,,,L-2-hydroxyglutaric aciduria,,HP:0040144,https://www.ncbi.nlm.nih.gov/pubmed/24321868,,,,,,,,,,
18,,# 236792,L-2-HYDROXYGLUTARIC ACIDEMIA,,L2HGDH,L-2-hydroxyglutarate dehydrogenase.,1.1.99.2,,,,,,,,,,,,,,Poor motor coordination,,HP:0002275,https://www.ncbi.nlm.nih.gov/pubmed/24321868,,,,,,,,,,
19,,# 236792,L-2-HYDROXYGLUTARIC ACIDEMIA,,L2HGDH,L-2-hydroxyglutarate dehydrogenase.,1.1.99.2,Flavin adenine dinucleotide + levocarnitine chloride.,,DB03147 +DB00583,ECO:0000352,,,,,Functional interaction(Mechanistic B)+Supportive (C),B+C,activity modification of a genetically defective protein,symptomatic treatment procedures,,defected  L-2-HGDH enzyme activity,,NA,https://www.ncbi.nlm.nih.gov/pubmed/18362286,https://www.ncbi.nlm.nih.gov/pubmed/22391998,,,,,,,,,
20,,# 236792,L-2-HYDROXYGLUTARIC ACIDEMIA,,L2HGDH,L-2-hydroxyglutarate dehydrogenase.,1.1.99.2,,,,,,,,,,,,,,L-2-hydroxyglutaric aciduria,,HP:0040144,https://www.ncbi.nlm.nih.gov/pubmed/18362286,https://www.ncbi.nlm.nih.gov/pubmed/22391998,,,,,,,,,
21,,# 236792,L-2-HYDROXYGLUTARIC ACIDEMIA,,L2HGDH,L-2-hydroxyglutarate dehydrogenase.,1.1.99.2,,,,,,,,,,,,,,Leukodystrophy,,HP:0002415,,,,,,,,,,,
22,,# 236792,L-2-HYDROXYGLUTARIC ACIDEMIA,,L2HGDH,L-2-hydroxyglutarate dehydrogenase.,1.1.99.2,,,,,,,,,,,,,,dystonia,,HP:0001332,,,,,,,,,,,
23,,# 236792,L-2-HYDROXYGLUTARIC ACIDEMIA,,L2HGDH,L-2-hydroxyglutarate dehydrogenase.,1.1.99.2,,,,,,,,,,,,,,Neurological impairment,,HP:0000707,https://n.neurology.org/content/70/13/1051,,,,,,,,,,
24,,# 236792,L-2-HYDROXYGLUTARIC ACIDEMIA,,L2HGDH,L-2-hydroxyglutarate dehydrogenase.,1.1.99.2,FAD+Riboflavin,,DB03147+DB00140,ECO:0000352,,,,,Direct interaction >>> activity modification,B,activity modification of a genetically defective protein,,,Neurological impairment,,HP:0000707,https://www.ncbi.nlm.nih.gov/pubmed/26208971,https://www.sciencedirect.com/science/article/pii/S109037980800010X,https://www.ncbi.nlm.nih.gov/pubmed/22840416/,https://www.sciencedirect.com/science/article/pii/S0303846712003952?via%3Dihub#bib0025,,,,,,,
25,,# 236792,L-2-HYDROXYGLUTARIC ACIDEMIA,,L2HGDH,L-2-hydroxyglutarate dehydrogenase.,1.1.99.2,,,,,,,,,,,,,,,,,,,,,,,,,,,
26,,# 203700,ALPERS SYNDROME,,POLG,DNA polymerase subunit gamma-1,2.7.7.7,Magnesium,,DB14513,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,,Status epilepticus,,,https://www.ncbi.nlm.nih.gov/pubmed/20803213?dopt=Abstract,,,,,,,,,,
27,,# 203700,ALPERS SYNDROME,,POLG,DNA polymerase subunit gamma-1,2.7.7.7,,,,,,,,,,,,,,,,,,,,,,,,,,,
28,,# 203700,ALPERS SYNDROME,,POLG,DNA polymerase subunit gamma-1,2.7.7.7,,,,,,,,,,,,,,,,,,,,,,,,,,,
29,,# 203700,ALPERS SYNDROME,,POLG,DNA polymerase subunit gamma-1,2.7.7.7,,,,,,,,,,,,,,,,,,,,,,,,,,,
30,,# 203700,ALPERS SYNDROME,,POLG,DNA polymerase subunit gamma-1,2.7.7.7,,,,,,,,,,,,,,,,,,,,,,,,,,,
31,,#615182,"Combined D,L-2-hydroxyglutaric aciduria",,SLC25A1,"Tricarboxylate transport protein, mitochondrial",P53007,Citrate treatment,,DB09125,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,metabolite replacement,,,seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/24687295,,,,,,,,,,
32,,#615182,"Combined D,L-2-hydroxyglutaric aciduria",,SLC25A1,"Tricarboxylate transport protein, mitochondrial",P53007,,,,,,,,,,,,,,D-2-hydroxyglutaric aciduria,,HP:0012321,,,,,,,,,,,
33,,#615182,"Combined D,L-2-hydroxyglutaric aciduria",,SLC25A1,"Tricarboxylate transport protein, mitochondrial",P53007,,,,,,,,,,,,,,L-2-hydroxyglutaric aciduria,,HP:0040144,,,,,,,,,,,
34,,#615182,"Combined D,L-2-hydroxyglutaric aciduria",,SLC25A1,"Tricarboxylate transport protein, mitochondrial",P53007,,,,,,,,,,,,,,low urinary excretion of TCA cycle intermediates malate and succinate,,,,,,,,,,,,,
35,,#615182,"Combined D,L-2-hydroxyglutaric aciduria",,SLC25A1,"Tricarboxylate transport protein, mitochondrial",P53007,,,,,,,,,,,,,,Hypocitraturia,,HP:0012405,,,,,,,,,,,
36,3,# 300438,2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY,Treatment attempts with isoleucine and protein restriction did not clearly alter or improve the course of the disease despite reduction in the excretion of 2-methyl-3-hydroxybutyrate and tiglylglycine. https://www.ncbi.nlm.nih.gov/pubmed/22132097. https://www.ncbi.nlm.nih.gov/pubmed/11102558,HSD17B10,3-hydroxyacyl-CoA dehydrogenase type II,1.1.1.35/1.1.1.51/1.1.1.178,Benzhexol,,DB00376,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,tremor,,HP:0001337,https://www.ncbi.nlm.nih.gov/pubmed/?term=2-Methyl-3-hydroxybutyryl-CoA+dehydrogenase+deficiency+in+a+23-year-old+man,,,,,,,,,,
37,,# 300438,2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY,,HSD17B10,3-hydroxyacyl-CoA dehydrogenase type II,1.1.1.35/1.1.1.51/1.1.1.178,,,,,,,,,,,,,,dystonia,,HP:0001332,https://www.ncbi.nlm.nih.gov/pubmed/?term=2-Methyl-3-hydroxybutyryl-CoA+dehydrogenase+deficiency+in+a+23-year-old+man,,,,,,,,,,
38,,# 300438,2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY,,HSD17B10,3-hydroxyacyl-CoA dehydrogenase type II,1.1.1.35/1.1.1.51/1.1.1.178,Vigabatrin,,DB01080,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,seizures,,HP:0001250,http://www.medlink.com/scripts/mpdf/print_friendly.php?title=2-methyl-3-hydroxybutyryl-coa_dehydrogenase_deficiency&action=download&channel=public_content&entryid=19985,https://www.ncbi.nlm.nih.gov/pubmed/11102558,,,,,,,,,
39,,# 300438,2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY,,HSD17B10,3-hydroxyacyl-CoA dehydrogenase type II,1.1.1.35/1.1.1.51/1.1.1.178,levodopa,,DB01235,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,dystonia,,HP:0001332,https://www.ncbi.nlm.nih.gov/pubmed/30013934,,,,,,,,,,
40,,# 300438,2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY,,HSD17B10,3-hydroxyacyl-CoA dehydrogenase type II,1.1.1.35/1.1.1.51/1.1.1.178,carbidopa,,DB00190,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,tremor,,HP:0001337,https://www.ncbi.nlm.nih.gov/pubmed/30013934,,,,,,,,,,
41,,# 300438,2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY,,HSD17B10,3-hydroxyacyl-CoA dehydrogenase type II,1.1.1.35/1.1.1.51/1.1.1.178,cefoperazone sodium,,DB01329,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,Abnormal inflammatory response,,HP:0012647,https://www.semanticscholar.org/paper/Clinical-Diagnosis-and-Treatment-of-Dehydrogenase-A-Cui-Wang/f6e88d647f2e2c7df2897e939ec33f9d86899b37,,,,,,,,,,
42,,# 300438,2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY,,HSD17B10,3-hydroxyacyl-CoA dehydrogenase type II,1.1.1.35/1.1.1.51/1.1.1.178,tazobactam sodium,,DB01606,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,Abnormal inflammatory response,,HP:0012647,https://www.semanticscholar.org/paper/Clinical-Diagnosis-and-Treatment-of-Dehydrogenase-A-Cui-Wang/f6e88d647f2e2c7df2897e939ec33f9d86899b37,,,,,,,,,,
43,,# 300438,2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY,,HSD17B10,3-hydroxyacyl-CoA dehydrogenase type II,1.1.1.35/1.1.1.51/1.1.1.178,B vitamins,,,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,Abnormality of the nervous system,,HP:0000707,https://www.semanticscholar.org/paper/Clinical-Diagnosis-and-Treatment-of-Dehydrogenase-A-Cui-Wang/f6e88d647f2e2c7df2897e939ec33f9d86899b37,,,,,,,,,,
44,,# 300438,2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY,,HSD17B10,3-hydroxyacyl-CoA dehydrogenase type II,1.1.1.35/1.1.1.51/1.1.1.178,creatine phosphate sodium,,DB13191,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,Abnormality of cardiovascular system physiology,,HP:0011025,,,,,,,,,,,
45,,# 300438,2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY,,HSD17B10,3-hydroxyacyl-CoA dehydrogenase type II,1.1.1.35/1.1.1.51/1.1.1.178,Carbamazepine,,,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,,seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/22132097,,,,,,,,,,
46,,# 300438,2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY,,HSD17B10,3-hydroxyacyl-CoA dehydrogenase type II,1.1.1.35/1.1.1.51/1.1.1.178,Carnitine,The drug was accompained by mild protein restriction (1.5–2.0 g/kg/day),DB00583,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,Abnormal muscle physiology,,HP:0011804,https://www.ncbi.nlm.nih.gov/pubmed/22132097,,,,,,,,,,
47,,# 300438,2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY,,HSD17B10,3-hydroxyacyl-CoA dehydrogenase type II,1.1.1.35/1.1.1.51/1.1.1.178,,,,,,,,,,,,,,,,,,,,,,,,,,,
48,,# 300438,2-METHYL-3-HYDROXYBUTYRYL-CoA DEHYDROGENASE DEFICIENCY,,HSD17B10,3-hydroxyacyl-CoA dehydrogenase type II,1.1.1.35/1.1.1.51/1.1.1.178,,,,,,,,,,,,,,,,,,,,,,,,,,,
49,4,# 610006,2-methylbutyryl-CoA dehydrogenase deficiency,,ACADSB gene,3-hydroxy-2-methylbutyryl-CoA dehydrogenase,1.1.1.178,L-Carnitine,,DB00583,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,Abnormality of muscle physiology,,HP:0011804,http://www.babysfirsttest.org/newborn-screening/conditions/2-methylbutyrylglycinuria,,https://www.newbornscreening.info/Parents/organicaciddisorders/2MBC.html#4,,,,,,,,
50,,# 610006,2-methylbutyryl-CoA dehydrogenase deficiency,,ACADSB gene,3-hydroxy-2-methylbutyryl-CoA dehydrogenase,1.1.1.178,,,,,,,,,,,,,,Elevated serum toxic intermediates in isoleucine pathway,,HP:0001939,,,,,,,,,,,
51,5,210200,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,3 Methylcrotonyl-CoA carboxylase,6.4.1.4,Biotin,"Drug works for heterozygot mutations rather than homozygous ones.
It is possible that biotin treatment might falsely normalize the results of the lymphocyte enzyme assay in biotin-responsive individuals, thus a biotin trial would best be considered after enzyme assay. There is no data suggesting continuing biotin is helpful in nonresponders. https://www.ncbi.nlm.nih.gov/pubmed/18155630",DB00121,ECO:0000352,MCCA-R385S(heterozygote mutation),https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1182108/,MCCB-(IVS16þ1G>A)/ MCCB-missense mutation E99Q Homozygous mutation,,Functional interaction(Mechanistic B),B,activity modification of a genetically defective protein,,,seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1182108/,https://www.ncbi.nlm.nih.gov/pubmed/18155630,https://www.ncbi.nlm.nih.gov/pubmed/15877210,https://www.ncbi.nlm.nih.gov/pubmed/15877210,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4470948/,https://www.sciencedirect.com/science/article/pii/S0378378210006055,https://www.orpha.net/data/patho/GB/uk-MCC.pdf,,,,
52,,210200,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,3 Methylcrotonyl-CoA carboxylase,6.4.1.4,,,,,"heterozygote missense mutation, MCCA-R385S",https://www.ncbi.nlm.nih.gov/pubmed/16773504,,,,,,,,Organic aciduria,,HP:0001992,,,,,,,,,,,
53,,210200,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,3 Methylcrotonyl-CoA carboxylase,6.4.1.4,,,,,,,,,,,,,,EEG abnormality,,HP:0002353,,,,,,,,,,,
54,,210200,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,3 Methylcrotonyl-CoA carboxylase,6.4.1.4,,,,,,,,,,,,,,Hypsarrhythmia,,HP:0002521,https://www.ncbi.nlm.nih.gov/pubmed/16773504,,,,,,,,,,
55,,210200,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,3 Methylcrotonyl-CoA carboxylase,6.4.1.4,vigabatrin,,DB01080,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/16773504,,,,,,,,,,
56,,210200,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,3 Methylcrotonyl-CoA carboxylase,6.4.1.4,,,,,,,,,,,,,,Increased 3-hydroxyisovaleric acid excretion,,NA,,,,,,,,,,,
57,,210200,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,3 Methylcrotonyl-CoA carboxylase,6.4.1.4,,,,,,,,,,,,,,Increased 3-methylcrotonylglycine excretion,,NA,,,,,,,,,,,
58,,210200,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,3 Methylcrotonyl-CoA carboxylase,6.4.1.4,,,,,,,,,,,,,,abnormal Biotinidase activity in plasma,,NA,,,,,,,,,,,
59,,210200,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,3 Methylcrotonyl-CoA carboxylase,6.4.1.4,,,,,,,,,,,,,,EEG abnormality,,HP:0002353,,,,,,,,,,,
60,,210200,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,3 Methylcrotonyl-CoA carboxylase,6.4.1.4,L-Carnitine,,DB00583,ECO:0000352,,,,,Supportive (C),C,symptomatic treatment procedure,functional complementation of a genetically defective protein,,Abnormality of muscle physiology,,HP:0011804,https://www.ncbi.nlm.nih.gov/pubmed/10485305,https://www.ncbi.nlm.nih.gov/pubmed/18155631,https://www.ncbi.nlm.nih.gov/pubmed/17968484,https://www.ncbi.nlm.nih.gov/pubmed/16835865,https://www.babysfirsttest.org/newborn-screening/conditions/3-methylcrotonyl-coa-carboxylase-deficiency,https://www.sciencedirect.com/science/article/pii/S0378378210006055,,,,,
61,,210200,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,3 Methylcrotonyl-CoA carboxylase,6.4.1.4,,,,,,,,,,,,,,secondary carnitine deficiency,,HP:0003234*,https://www.ncbi.nlm.nih.gov/pubmed/8831079,,,,,,,,,,
62,,210200,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,3 Methylcrotonyl-CoA carboxylase,6.4.1.4,,,,,,,,,,,,,,elevated serum toxic intermediates (,,HP:0001939,,,,,,,,,,,
63,,210200,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,3 Methylcrotonyl-CoA carboxylase,6.4.1.4,Glycine,"Effect of glycine in treating the condition is variable among literatures.  ""Case reports have noted variable results regarding the effect of glycine administration. Some studies have found that supplemental glycine results in increased excretion of 3-methylcrotonyl glycine, while others have not found a persistent effect; no studies have observed clinical improvement of symptoms on treatment and no randomized clinical trials have been published"" https://www.sciencedirect.com/science/article/pii/S1096719207005975?via%3Dihub#bib11
https://www.ncbi.nlm.nih.gov/pubmed/8831079
https://www.ncbi.nlm.nih.gov/pubmed/7474896",DB00145,ECO:0000352,,,,,Supportive (C),C,symptomatic treatment procedure,functional complementation of a genetically defective protein,Drug name: controversial results,defected excertion of 3- MCG,,NA,https://www.ncbi.nlm.nih.gov/pubmed/7474896,https://www.ncbi.nlm.nih.gov/pubmed/18155630,https://www.ncbi.nlm.nih.gov/pubmed/8831079,,,,,,,,
64,,210200,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,3 Methylcrotonyl-CoA carboxylase,6.4.1.4,,,,,,,,,,,,,,Accumulation of 3-methylcrotonyl-CoA metabolite level ( Metabolism abnormality)*,,HP:0001939 *,,,,,,,,,,,
65,,210200,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,3 Methylcrotonyl-CoA carboxylase,6.4.1.4,Glycine +L-Carnitine,,DB00145 +DB00583,ECO:0000352,,,,,,,symptomatic treatment procedure,functional complementation of a genetically defective protein,,Acute metabolic crisis ( Metabolism abnormality)*,,HP:0001939 *,https://link.springer.com/article/10.1007/BF00710419,,,,,,,,,,
66,,210200,3-methylcrotonyl-CoA carboxylase deficiency,,MCCC1/MCCC2,3 Methylcrotonyl-CoA carboxylase,6.4.1.4,,,,,,,,,,,,,,Accumulation of 3-methylcrotonyl-CoA metabolite level ( Metabolism abnormality)*,,HP:0001939 *,https://link.springer.com/article/10.1007/BF00710419,https://www.orpha.net/data/patho/GB/uk-MCC.pdf,https://www.jci.org/articles/view/11948,,,,,,,,
67,6,# 231530,3-alpha hydroxyacyl-CoA dehydrogenase deficiency,,HADH,3-hydroxylacyl-CoA dehydrogenase,1.1.1.35,L-carnitine,,DB00583,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Drug name: Use is controverial. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388644/?otool=igbcambulib,secondary carnitine deficiency,,HP:0003119,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388644/,https://www.orpha.net/data/patho/GB/uk-MCC.pdf,https://www.jci.org/articles/view/11948,,,,,,,,
68,,# 231530,3-alpha hydroxyacyl-CoA dehydrogenase deficiency,,HADH,3-hydroxylacyl-CoA dehydrogenase,1.1.1.35,,,,,,,,,,,,,,high  short chain acyl-carnitine metabolite level,,HP:0001939,,,,,,,,,,,
69,,# 231530,3-alpha hydroxyacyl-CoA dehydrogenase deficiency,,HADH,3-hydroxylacyl-CoA dehydrogenase,1.1.1.35,,,,,,,,,,,,,,Muscle weakness,,HP:0001324,https://link.springer.com/article/10.1023%2FA%3A1024031714659?LI=true,,,,,,,,,,
70,,# 231530,3-alpha hydroxyacyl-CoA dehydrogenase deficiency,,HADH,3-hydroxylacyl-CoA dehydrogenase,1.1.1.35,vitamin E supplements,,DB00163,ECO:0000352,,,,,Supportive (C),C,symptomatic treatment procedure,functional complementation of a genetically defective protein,,Abnormality of peripheral nerves,,HP:0045010,https://clinicaltrials.gov/ct2/show/study/NCT00840112?show_desc=Y#desc,,,,,,,,,,
71,,# 231530,3-alpha hydroxyacyl-CoA dehydrogenase deficiency,,HADH,3-hydroxylacyl-CoA dehydrogenase,1.1.1.35,,,,,,,,,,,,,,Neuropathy,,HP:0009830,,,,,,,,,,,
72,,# 231530,3-alpha hydroxyacyl-CoA dehydrogenase deficiency,,HADH,3-hydroxylacyl-CoA dehydrogenase,1.1.1.35,Triheptanoin,,DB11677,ECO:0000352,,,,,Supportive (C),C,functional complementation of a genetically defective protein,symptomatic treatment procedure,,Myalgia,,HP:0003326,https://clinicaltrials.gov/ct2/show/study/NCT01379625,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5388644/,,,,,,,,,
73,,# 231530,3-alpha hydroxyacyl-CoA dehydrogenase deficiency,,HADH,3-hydroxylacyl-CoA dehydrogenase,1.1.1.35,,,,,,,,,,,,,,Abnormal cardiac function,,HP:0011025,,,,,,,,,,,
74,,# 231530,3-alpha hydroxyacyl-CoA dehydrogenase deficiency,,HADH,3-hydroxylacyl-CoA dehydrogenase,1.1.1.35,,,,,,,,,,,,,,Fatigue,,HP:0011025,,,,,,,,,,,
75,,# 231530,3-alpha hydroxyacyl-CoA dehydrogenase deficiency,,HADH,3-hydroxylacyl-CoA dehydrogenase,1.1.1.35,Prednisone,,DB00635,ECO:0000352,,,,,,,symptomatic treatment procedure,,,Fatigue,,HP:0011025,https://www.ncbi.nlm.nih.gov/pubmed/7748366,https://www.sciencedirect.com/science/article/pii/088789949400109F,,,,,,,,,
76,,# 231530,3-alpha hydroxyacyl-CoA dehydrogenase deficiency,,HADH,3-hydroxylacyl-CoA dehydrogenase,1.1.1.35,,,,,,,,,,,,,,Impaired nerve conduction,,HP:0040129,,,,,,,,,,,
77,,# 231530,3-alpha hydroxyacyl-CoA dehydrogenase deficiency,,HADH,3-hydroxylacyl-CoA dehydrogenase,1.1.1.35,,,,,,,,,,,,,,Defected mucle plasma membrane,,,,,,,,,,,,,
78,,# 231530,3-alpha hydroxyacyl-CoA dehydrogenase deficiency,,HADH,3-hydroxylacyl-CoA dehydrogenase,1.1.1.35,,,,,,,,,,,,,,Defected neuronal plasma membrane,,,,,,,,,,,,,
79,7,% 236795,3-Hydroxyisobutyric aciduria,,ALDH6A1 gene,3-hydroxyisobutyrate dehydrogenase,1.1.1.31,Carnitine,,DB00583,ECO:0000352,,,,,Supportive (C),C,symptomatic treatment procedure,,,acidemia,,HP:0001941,http://eknygos.lsmuni.lt/springer/365/81-92.pdf,,,,,,,,,,
80,8,250950,3-methylglutaconyl-CoA hydratase deficiency (AUH defect),,AUH gene,Methylglutaconyl-CoA hydratase,4.2.1.18,L-carnitine,,DB00583,ECO:0000352,,,,,Supportive (C),C,symptomatic treatment procedure,,,Muscle weakness,,HP:0001324,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5358122/,https://www.researchgate.net/publication/46821474_The_3-methylglutaconic_acidurias_What%27s_new,,,,,,,,,
81,,250950,3-methylglutaconyl-CoA hydratase deficiency (AUH defect),,AUH gene,Methylglutaconyl-CoA hydratase,4.2.1.18,,,,,,,,,,,,,,Abnormality of movement,,HP:0100022,,,,,,,,,,,
82,,250950,3-methylglutaconyl-CoA hydratase deficiency (AUH defect),,AUH gene,Methylglutaconyl-CoA hydratase,4.2.1.18,,,,,,,,,,,,,,Metabolic Decompensation,,HP:0001939,https://www.ncbi.nlm.nih.gov/pubmed/11400757/,,,,,,,,,,
83,,250950,3-methylglutaconyl-CoA hydratase deficiency (AUH defect),,AUH gene,Methylglutaconyl-CoA hydratase,4.2.1.18,,,,,,,,,,,,,,Delayed Growth,,HP:0001510,,,,,,,,,,,
84,9,261640,6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,6-pyruvoyl-tetrahydropterin synthase,4.2.3.12,Sapropterin,,DB00360,ECO:0007121/ECO:0000352,,,,,Functional interaction( Mechanistic B),B,metabolite replacement,,,Behavioral abnormality,,HP:0000708,https://www.ncbi.nlm.nih.gov/pubmed/19323589,,,,,,,,,,
85,,261640,6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,6-pyruvoyl-tetrahydropterin synthase,4.2.3.12,,,,,,,,,,,,,,Personality disorder,,HP:0012075,,,,,,,,,,,
86,,261640,6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,6-pyruvoyl-tetrahydropterin synthase,4.2.3.12,,,,,,,,,,,,,,Hyperphenylalaninemia,,HP:0004923,https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/,,,,,,,,,,
87,,261640,6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,6-pyruvoyl-tetrahydropterin synthase,4.2.3.12,Antisense morpholino oligonucleotides (AMOs),,NA,ECO:0001565,"c.84−322A>T, c.163 + 695_163 + 751del57, or c.164−712A>T",,,,Direct interaction (Mechanistic A),A,direct complementation of genetically defective protein,,,pseudoexon activation,,NA,https://www.ncbi.nlm.nih.gov/pubmed/21542064,,,,,,,,,,
88,,261640,6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,6-pyruvoyl-tetrahydropterin synthase,4.2.3.12,BH4+L-Dopa+5HTP,,DB00360+DB01235+DB02959,ECO:0000352,,,,,Functional interaction(Mechanistic B),B,metabolite replacement,functional complementation of a genetically defective protein,,Hyperphenylalaninemia,,HP:0004923,https://www.ncbi.nlm.nih.gov/pubmed/25304915,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724/,,,,,,,,,
89,,261640,6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,6-pyruvoyl-tetrahydropterin synthase,4.2.3.12,,,,,,,,,,,,,,Abnormality of neurotransmitter metabolism,,HP:0012535,https://www.ncbi.nlm.nih.gov/pubmed/25304915,,,,,,,,,,
90,,261640,6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,6-pyruvoyl-tetrahydropterin synthase,4.2.3.12,,,,,,,,,,,,,,Neurological abnormality,,HP:0000707,https://www.ncbi.nlm.nih.gov/pubmed/25304915,,,,,,,,,,
91,,261640,6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,6-pyruvoyl-tetrahydropterin synthase,4.2.3.12,,,,,,,,,,,,,,Neurodevelopmental abnormality,,HP:0012759,https://www.ncbi.nlm.nih.gov/pubmed/25304915,,,,,,,,,,
92,,261640,6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,6-pyruvoyl-tetrahydropterin synthase,4.2.3.12,,,,,,,,,,,,,,Intellectual disability,,HP:0001249,https://www.ncbi.nlm.nih.gov/pubmed/25304915,,,,,,,,,,
93,,261640,6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,6-pyruvoyl-tetrahydropterin synthase,4.2.3.12,,,,,,,,,,,,,,Delayed CNS mylinaton,"The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879",HP:0002188,https://www.ncbi.nlm.nih.gov/pubmed/16601879,,,,,,,,,,
94,,261640,6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,6-pyruvoyl-tetrahydropterin synthase,4.2.3.12,Oxitriptan,The patients should receive combination treatment with BH4 and neurotransmitter precursors as soon as possible to reduce neurological deterioration https://www.ncbi.nlm.nih.gov/pubmed/16601879,DB02959,ECO:0000352,,,,,Functional interaction( Mechanistic B),B,metabolite replacement,,,Abnormality of neurotransmitter metabolism,"The finding of abnormalities inMRImerits further exploration of metabolites in the brainby MR spectroscopy for optimization of dosages of BH4,levodopa and 5-HTP. https://www.ncbi.nlm.nih.gov/pubmed/16601879",HP:0012535,https://www.ncbi.nlm.nih.gov/pubmed/25304915,https://www.ncbi.nlm.nih.gov/pubmed/16601879,,,,,,,,,
95,,261640,6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,6-pyruvoyl-tetrahydropterin synthase,4.2.3.12,,,,,,,,,,,,,,Abnormality in serotonin turnover (Abnormality of circulating hormone level),,HP:0003117,,,,,,,,,,,
96,,261640,6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,6-pyruvoyl-tetrahydropterin synthase,4.2.3.12,levodopa (L-dopa),"The patients should receive combination treatment with BH4 and neurotransmitter precursors as soon as possible to reduce neurological deterioration. https://www.ncbi.nlm.nih.gov/pubmed/16601879
In general, l‐dopa is used with DCIs like as carbidopa or benserazide to block the peripheral conversion to dopamine. This coadministration not only increases bioavailability but also reduces peripheral side effects. 
Clinicians should be cautious, because Levodopa-Induced Dyskinesia "" LIDs can occur commonly in patients with DRD‐plus, especially because of SR, TH, and PTPS deficiencies. The current study showed that LIDs were reported in  44.4% of patients who had PTPS deficiencies. In such patients, a very low starting dose of l‐dopa with from 0.5 to 1 mg/kg daily divided into 4 to 6 doses is recommended https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724/",DB01235,ECO:0000352,,,,,Functional interaction( Mechanistic B),B,metabolite replacement,,,Abnormality of neurotransmitter metabolism,,HP:0012535,https://www.ncbi.nlm.nih.gov/pubmed/25304915,https://www.ncbi.nlm.nih.gov/pubmed/16601879,,,,,,,,,
97,,261640,6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,6-pyruvoyl-tetrahydropterin synthase,4.2.3.12,,,,,,,,,,,,,,Paroxysmal movements,,HP:0007166,,,,,,,,,,,
98,,261640,6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,6-pyruvoyl-tetrahydropterin synthase,4.2.3.12,,,,,,,,,,,,,,Movement disorder,,HP:0100022,,,,,,,,,,,
99,,261640,6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,6-pyruvoyl-tetrahydropterin synthase,4.2.3.12,carbidopa,"The patients should receive combination treatment with BH4 and neurotransmitter precursors as soon as possible to reduce neurological deterioration. https://www.ncbi.nlm.nih.gov/pubmed/16601879
In general, l‐dopa is used with DCIs like as carbidopa or benserazide to block the peripheral conversion to dopamine. This coadministration not only increases bioavailability but also reduces peripheral side effectshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178724/",DB00190,ECO:0000352,,,,,Functional interaction( Mechanistic B),B,functional complementation of a defective protein by inhibition,,,Abnormality of neurotransmitter metabolism,,HP:0012535,https://www.ncbi.nlm.nih.gov/pubmed/25304915,https://www.ncbi.nlm.nih.gov/pubmed/16601879,,,,,,,,,
100,,261640,6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,6-pyruvoyl-tetrahydropterin synthase,4.2.3.12,pramipexole + L- dopa,"The addition of pramipexole to the treatment of 6-pyruvoyl tetrahydropterin synthase deficiency improves the results of l-3,4 dihydroxyphenylalanine therapy.https://www.ncbi.nlm.nih.gov/pubmed/19704083",DB00413+DB01235,ECO:0007121,,,,,Functional interaction( Mechanistic B),B,functional complementation of a defective protein by stimulation,metabolite replacement,"Drug name: The addition of  pramipexole to the treatment of 6-pyruvoyl tetrahydropterin synthase deficiency improves the results of l-3,4 dihydroxyphenylalanine therapy. Similar benefits may be expected in other forms of inherited tetrahydrobiopterin deficiency. https://www.ncbi.nlm.nih.gov/pubmed/19704083",Movement Disability,,HP:0100022,https://www.ncbi.nlm.nih.gov/pubmed/19704083,https://www.ncbi.nlm.nih.gov/pubmed/16601879,,,,,,,,,
101,,261640,6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,6-pyruvoyl-tetrahydropterin synthase,4.2.3.12,,,,,,,,,,,,,,High prolactin level,,HP:0000870,,,,,,,,,,,
102,,261640,6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,6-pyruvoyl-tetrahydropterin synthase,4.2.3.12,,,,,,,,,,,,,,Behavioural Disability,,HP:0000708,,,,,,,,,,,
103,,261640,6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,6-pyruvoyl-tetrahydropterin synthase,4.2.3.12,,,,,,,,,,,,,,Abnormal Unified Parkinson's Disease Rating Scale (UPDRS )score(Abnormality of neurotransmitter metabolism)*,,NA,,,,,,,,,,,
104,,261640,6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,6-pyruvoyl-tetrahydropterin synthase,4.2.3.12,selective monoamine oxidase (MAO) B inhibitor,"It's an investigational therapy where Positive results from using a selective monoamine oxidase (MAO) B inhibitor or non-ergot dopamine agonist pramipexole as an adjunct therapy have been described in the medical literature. This use of such an inhibitor can allow for lower doses of neurotransmitter precursor to be used. However, the long-term safety (e.g. effects on neonatal brain development) and effectiveness of this therapy is unknown and more research is required to determine what role, if any, selective monoamine oxidase B inhibitors play in the treatment of individuals with tetrahydrobiopterin deficiency. https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/. https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency. https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf",DB01247,ECO:0000352,,,,,Supportive (C),C,functional complementation of a genetically defective protein,symptomatic treatment procedure,,allows for lower doses of neurotransmitter precursor to avoid their side effects.,,NA,https://www.degruyter.com/downloadpdf/j/pteridines.1995.6.issue-3/pteridines.1995.6.3.144/pteridines.1995.6.3.144.pdf,https://www.researchgate.net/publication/233414693_Deprenyl_in_6-Pyruvoyl_Tetrahydropterin_Synthase_Deficiency,https://rarediseases.org/rare-diseases/tetrahydrobiopterin-deficiency/,,,,,,,,
105,,261640,6-pyruvoyl-tetrahydropterin synthase (PTPS) deficiency,,PTPS,6-pyruvoyl-tetrahydropterin synthase,4.2.3.12,folinic acid,,DB03256,ECO:0000352,,,,,Functional interaction( Mechanistic B),B,compensatory complementation of a genetically defective protein,metabolite replacement,,Abnormal serum folate,,HP:0040087,,,,,,,,,,,
106,,# 261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C",,QDPR,Dihydropteridine reductase,1.5.1.34,BH4,,DB00360,,,,,,,,metabolite replacement,,,Elevated Phe level in blood,,HP:0004923,https://www.ncbi.nlm.nih.gov/pubmed/7110811/,https://www.ncbi.nlm.nih.gov/pubmed/8433887/,,,,,,,,,
107,,# 261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C",,QDPR,Dihydropteridine reductase,1.5.1.34,,,,,,,,,,,,,,Neurological abnormality,,HP:0000707,,,,,,,,,,,
108,,# 261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C",,QDPR,Dihydropteridine reductase,1.5.1.34,BH4+L-dopa+5-hydroxytryptophan,,DB00360+DB01235+DB02959,ECO:0000352,,,,,Functional interaction(Mechanistic B),B,metabolite replacement,,,Elevated blood phenylalanine concentration,,HP:0004923,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.ncbi.nlm.nih.gov/pubmed/7110811/,https://www.ncbi.nlm.nih.gov/pubmed/23138986,,,,,,,,
109,,# 261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C",,QDPR,Dihydropteridine reductase,1.5.1.34,,,,,,,,,,,,,,Abnormality of neurotransmitter metabolism,,HP:0012535,,,,,,,,,,,
110,,# 261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C",,QDPR,Dihydropteridine reductase,1.5.1.34,,,,,,,,,,,,,,Neurological abnormality,,HP:0000707,,,,,,,,,,,
111,,# 261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C",,QDPR,Dihydropteridine reductase,1.5.1.34,BH4+L-dopa/carbidopa+5-hydroxytryptophan+Folinic acid,,DB00360+DB01235+DB02959+DB03256,ECO:0000352,,,,,Functional interaction(Mechanistic B),B,metabolite replacement,,,Developmental delay,,HP:0001263,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755580/,,,,,,,,,,
112,,# 261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C",,QDPR,Dihydropteridine reductase,1.5.1.34,,,,,,,,,,,,,,Delayed receptive language,,HP:0010863,,,,,,,,,,,
113,,# 261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C",,QDPR,Dihydropteridine reductase,1.5.1.34,,,,,,,,,,,,,,Neurological impairment,,HP:0000707,,,,,,,,,,,
114,,# 261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C",,QDPR,Dihydropteridine reductase,1.5.1.34,,,,,,,,,,,,,,Hyperphenylalaninemia,,HP:0004923,,,,,,,,,,,
115,,# 261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C",,QDPR,Dihydropteridine reductase,1.5.1.34,folinic acid,,DB03256,ECO:0000352,,,,,Functional interaction( Mechanistic B),B,compensatory complementation of a genetically defective protein,,,Progressive basal ganglia calcification,,HP:0002135,https://www.ncbi.nlm.nih.gov/pubmed/2785251,https://www.ncbi.nlm.nih.gov/pubmed/12003346,,,,,,,,,
116,,# 261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C",,QDPR,Dihydropteridine reductase,1.5.1.34,,,,,,,,,,,,,,Subcortical calcification,,HP:0007346,,,,,,,,,,,
117,,# 261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C",,QDPR,Dihydropteridine reductase,1.5.1.34,,,,,,,,,,,,,,Seizure,,HP:0001250,,,,,,,,,,,
118,,# 261630,"HYPERPHENYLALANINEMIA, BH4-DEFICIENT, C; HPABH4C",,QDPR,Dihydropteridine reductase,1.5.1.34,,,,,,,,,,,,,,,,,,,,,,,,,,,
119,10,# 200100,Abetalipoproteinemia,"The mainstays of treatment include adherence to a low-fat diet, and supplementation with essential fatty acids and high oral doses of fat soluble vitamins. https://www.ncbi.nlm.nih.gov/pubmed/24288038",MTTP gene,microsomal triglyceride transfer protein,P55157,vitamin E therapy,,DB00163,ECO:0000352,,,,,Supportive (C),C,metabolite replacement,,,nervous system abnormalities,,HP:0002011,https://www.ncbi.nlm.nih.gov/pubmed/30358967,https://www.ncbi.nlm.nih.gov/pubmed/26086616,https://www.ncbi.nlm.nih.gov/pubmed/25488886,https://ojrd.biomedcentral.com/articles/10.1186/1750-1172-3-20,https://www.ncbi.nlm.nih.gov/pubmed/24288038,,,,,,
120,,# 200100,Abetalipoproteinemia,,MTTP gene,microsomal triglyceride transfer protein,P55157,,,,,,,,,,,,,,neurologic dysfunction,,HP:0000707,,,,,,,,,,,
121,,# 200100,Abetalipoproteinemia,,MTTP gene,microsomal triglyceride transfer protein,P55157,,,,,,,,,,,,,,Retinopathy,,HP:0000488,https://www.ncbi.nlm.nih.gov/pubmed/3954973/,,,,,,,,,,
122,,# 200100,Abetalipoproteinemia,,MTTP gene,microsomal triglyceride transfer protein,P55157,medium-chain fatty acid supplements,,DB13959,ECO:0000352,,,,,Supportive (C),C,metabolite replacement,,,Growth impairment,,HP:0008897,https://www.ncbi.nlm.nih.gov/pubmed/3954973/,,,,,,,,,,
123,,# 200100,Abetalipoproteinemia,,MTTP gene,microsomal triglyceride transfer protein,P55157,Vitamin K,,CHEBI:28384,ECO:0000352,,,,,Supportive (C),C,metabolite replacement,,,Malabsorption of lipid-soluble vitamins (Fat malabsorption)*,,HP:0002630,https://www.ncbi.nlm.nih.gov/pubmed/26396722,,,,,,,,,,
124,,# 200100,Abetalipoproteinemia,,MTTP gene,microsomal triglyceride transfer protein,P55157,Vitamin D,,DB11094,ECO:0000352,,,,,Supportive (C),C,metabolite replacement,,,Malabsorption of lipid-soluble vitamins (Fat malabsorption)*,,HP:0002630,,,,,,,,,,,
125,,# 200100,Abetalipoproteinemia,,MTTP gene,microsomal triglyceride transfer protein,P55157,vitamin A+ Vitamin E,"Mixed therapy can markedly attenuate the severe retinal degeneration that is associated with untreated ABL or homozygous HBL. Yet, fundoscopic and functional retinal changes do occur despite early initiation of vitamin treatment. Therefore, the adequacy of the present treatment protocol for ABL and homozygous HBL should be re-evaluated.https://www.ncbi.nlm.nih.gov/pubmed/11767031",DB00162+DB00163,ECO:0000352,,,,,Supportive (C),C,metabolite replacement,,,Retinal degeneration,,HP:0000546,https://www.ncbi.nlm.nih.gov/pubmed/11767031,https://www.ncbi.nlm.nih.gov/pubmed/30731125,,,,,,,,,
126,,# 200100,Abetalipoproteinemia,,MTTP gene,microsomal triglyceride transfer protein,P55157,,,,,,,,,,,,,,Oxidative stress,,HP:0025464,https://www.ncbi.nlm.nih.gov/pubmed/14749227,,,,,,,,,,
127,,# 200100,Abetalipoproteinemia,,MTTP gene,microsomal triglyceride transfer protein,P55157,Medium-chain fatty acid supplements+Vitamin A+Vitamin D+Vitamin E+Vitamin K,,DB13959+DB00162+DB11094+DB00163+CHEBI:28384,ECO:0000352,,,,,Supportive (C),,metabolite replacement,,,Neurological abnormalities,,HP:0000707,https://www.ncbi.nlm.nih.gov/pubmed/24288038,,,,,,,,,,
128,,# 200100,Abetalipoproteinemia,,MTTP gene,microsomal triglyceride transfer protein,P55157,,,,,,,,,,,,,,Disease progression (Progressive),,HP:0003676,,,,,,,,,,,
129,,# 200100,Abetalipoproteinemia,,MTTP gene,microsomal triglyceride transfer protein,P55157,Progesteron,"Investigational ""Infertility investigation Abetalipoproteinaemia patients might benefit from progesterone supplementation, and further studies on this and hormonal profiles would benefit this pool of patients. Optimising the nutritional profile and body mass index of female patients will undoubtedly contribute to better chances at conception.:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4265040/",DB00396,ECO:0000352,,,,,Supportive (C),C,symptomatic treatment procedure,,,Female infertility,,HP:0008222,,,,,,,,,,,
130,,# 200100,Abetalipoproteinemia,,MTTP gene,microsomal triglyceride transfer protein,P55157,Vitamin B12+iron,,DB00115+DB01592,ECO:0000352,,,,,,,symptomatic treatment procedure,,,Anemia,,HP:0001903,,,,,,,,,,,
131,,# 200100,Abetalipoproteinemia,,MTTP gene,microsomal triglyceride transfer protein,P55157,levothyroxine,,DB00451,ECO:0000352,,,,,,,symptomatic treatment procedure,,,subclinical hypothyroidism,,HP:0000821,https://www.ncbi.nlm.nih.gov/pubmed/26396722,https://www.ncbi.nlm.nih.gov/pubmed/17132287/,,,,,,,,,
132,11,# 604290,Aceruloplasminemia,,CP gene,Ferroxidase,1.16.3.1,Deferasirox,,DB01609,ECO:0000352,,,,,Functional interaction (B),B,functional complementation of a defective protein by inhibition,,,high serum ferritin concentration,,HP:0003281,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789/,https://www.ncbi.nlm.nih.gov/books/NBK1493/,https://www.ncbi.nlm.nih.gov/pubmed/12044538,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3415789/,,,,,,,
133,,# 604290,Aceruloplasminemia,,CP gene,Ferroxidase,1.16.3.1,,,,,,,,,,,,,,high brain and liver iron stores,,HP:0003281*,,,,,,,,,,,
134,,# 604290,Aceruloplasminemia,,CP gene,Ferroxidase,1.16.3.1,vitamin E+ Zinc,,DB00163 +DB01593,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,tissue damage,,NA,,,,,,,,,,,
135,,# 604290,Aceruloplasminemia,,CP gene,Ferroxidase,1.16.3.1,,,,,,,,,,,,,,Liver dysfunction,,HP:0001410,,,,,,,,,,,
136,,# 604290,Aceruloplasminemia,,CP gene,Ferroxidase,1.16.3.1,,,,,,,,,,,,,,pancreatic dysfunction,,HP:0001738,,,,,,,,,,,
137,12,606175,Acetyl-carnitine deficiency,,CRAT,Carnitine acetyltransferase,2.3.1.7,L-Carnitine,,DB00583,ECO:0000352,,,,,Functional interaction ( Mechanistic B),B,metabolite replacement,,,fasting ketogenesis,,HP:0001946/HP:0025212,,,,,,,,,,,
138,,606175,Acetyl-carnitine deficiency,,CRAT,Carnitine acetyltransferase,2.3.1.7,,,,,,,,,,,,,,cardiac dysfunction,,HP:0011025,,,,,,,,,,,
139,,606175,Acetyl-carnitine deficiency,,CRAT,Carnitine acetyltransferase,2.3.1.7,,,,,,,,,,,,,,Delayed growth,,HP:0001510,,,,,,,,,,,
140,,606175,Acetyl-carnitine deficiency,,CRAT,Carnitine acetyltransferase,2.3.1.7,,,,,,,,,,,,,,cognitive impairment,,HP:0100543,,,,,,,,,,,
141,13,# 201100,Acrodermatitis enteropathica,,SLC39A4,zinc/iron-regulated transporter-like protein,Q6P5W5,zinc,,DB01593,ECO:0000352,,,,,Functional interaction ( Mechanistic B),B,metabolite replacement,,,skin inflammation,,HP:0011123,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902399/,https://www.ncbi.nlm.nih.gov/pubmed/24718477,,,,,,,,,
142,,# 201100,Acrodermatitis enteropathica,,SLC39A4,zinc/iron-regulated transporter-like protein,Q6P5W5,,,,,,,,,,,,,,Alopecia,,HP:0001596,,,,,,,,,,,
143,,# 201100,Acrodermatitis enteropathica,,SLC39A4,zinc/iron-regulated transporter-like protein,Q6P5W5,,,,,,,,,,,,,,Agitation,,HP:0000713,,,,,,,,,,,
144,,# 201100,Acrodermatitis enteropathica,,SLC39A4,zinc/iron-regulated transporter-like protein,Q6P5W5,,,,,,,,,,,,,,irritability,,HP:0000737,,,,,,,,,,,
145,,# 201100,Acrodermatitis enteropathica,,SLC39A4,zinc/iron-regulated transporter-like protein,Q6P5W5,,,,,,,,,,,,,,diarrhea,,HP:0002014,,,,,,,,,,,
146,,# 201100,Acrodermatitis enteropathica,,SLC39A4,zinc/iron-regulated transporter-like protein,Q6P5W5,,,,,,,,,,,,,,emotional disturbances,,HP:0000712,,,,,,,,,,,
147,,# 201100,Acrodermatitis enteropathica,,SLC39A4,zinc/iron-regulated transporter-like protein,Q6P5W5,Zinc+ linoleic acid,,DB01593+DB14104,ECO:0000352,,,,,Functional interaction ( Mechanistic B),B,metabolite replacement + symptomatic treatment procedure,,,,,HP:0000712,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2779298/,,,,,,,,,,
148,,# 201100,Acrodermatitis enteropathica,,SLC39A4,zinc/iron-regulated transporter-like protein,Q6P5W5,Diiodoquinoline,"Enthusiasm for the use of this antimalarial was tempered by the subsequent recognition that irreversible retinopathy was a predictable complication of diiodoquinoline therapy. https://www.sciencedirect.com/science/article/pii/S0190962206022560#bib39
Unfortunately, the long-term treatment with 8-hydroxyquinoline preparations has serious side effects as it leads to optic nerve atrophy and blindness [13], [14]. Therefore, an alternative treatment was desperately sought. https://www.sciencedirect.com/science/article/pii/S0946672X14001837?via%3Dihub#bib0070",DB09115,ECO:0000352,,,,,Functional interaction ( Mechanistic B),B,symptomatic treatment procedure,,,Acrodermatitis (Dermatitis)*,,HP:0011123,https://www.ncbi.nlm.nih.gov/pubmed/14354277,https://www.ncbi.nlm.nih.gov/pubmed/13044560,https://www.ncbi.nlm.nih.gov/pubmed/4929571,https://www.ncbi.nlm.nih.gov/pubmed/1275520,,,,,,,
149,,# 201100,Acrodermatitis enteropathica,,SLC39A4,zinc/iron-regulated transporter-like protein,Q6P5W5,,,,,,,,,,,,,,Diarrhea,,HP:0002014,,,,,,,,,,,
150,,# 201100,Acrodermatitis enteropathica,,SLC39A4,zinc/iron-regulated transporter-like protein,Q6P5W5,,,,,,,,,,,,,,Alopecia,,HP:0001596,,,,,,,,,,,
151,,# 201100,Acrodermatitis enteropathica,,SLC39A4,zinc/iron-regulated transporter-like protein,Q6P5W5,,,,,,,,,,,,,,Perioral dermatitis,,HP:0040181,,,,,,,,,,,
152,,# 201100,Acrodermatitis enteropathica,,SLC39A4,zinc/iron-regulated transporter-like protein,Q6P5W5,Clioquinol,,DB04815,ECO:0000352,,,,,Functional interaction ( Mechanistic B),B,functional complementation of a genetically defective protein,,,Dermatitis,,HP:0011123,https://www.ncbi.nlm.nih.gov/pubmed/375935,,,,,,,,,,
153,,# 201100,Acrodermatitis enteropathica,,SLC39A4,zinc/iron-regulated transporter-like protein,Q6P5W5,,,,,,,,,,,,,,,,,,,,,,,,,,,
154,,# 201100,Acrodermatitis enteropathica,,SLC39A4,zinc/iron-regulated transporter-like protein,Q6P5W5,,,,,,,,,,,,,,,,,,,,,,,,,,,
155,,# 201100,Acrodermatitis enteropathica,,SLC39A4,zinc/iron-regulated transporter-like protein,Q6P5W5,Zn-DTSM (zinc ionophore),"A potential therapeutic options for the long-term treatment of AE.  This compound had little overall effect on zinc content in various tissues that were assessed, although further characterisation is required to more fully explore the cellular changes underlying the physiological benefit of this compound. https://www.ncbi.nlm.nih.gov/pubmed/30669644",,ECO:0001565/ ECO:0005542,,,,,Functional interaction ( Mechanistic B),B,functional complementation of a genetically defective protein,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/30669644,,,,,,,,,,
156,,# 201100,Acrodermatitis enteropathica,,SLC39A4,zinc/iron-regulated transporter-like protein,Q6P5W5,,,,,,,,,,,,,,,,,,,,,,,,,,,
157,,# 201100,Acrodermatitis enteropathica,,SLC39A4,zinc/iron-regulated transporter-like protein,Q6P5W5,,,,,,,,,,,,,,,,,,,,,,,,,,,
158,,# 201100,Acrodermatitis enteropathica,,SLC39A4,zinc/iron-regulated transporter-like protein,Q6P5W5,,,,,,,,,,,,,,,,,,,,,,,,,,,
159,14,# 176000,Acute intermittent porphyria,,HMBS gene,Hydroxymethylbilane synthase.,2.5.1.61,Glucose,"Currently, the use of glucose is limited only to mild attacks (ie, mild pain, no paresis, seizures, or hyponatremia) according to the guidelines for the treatment of an acute attack in the USA and South Africa, or if heme arginate or hematin are not available locally. https://www.ncbi.nlm.nih.gov/pubmed/15643299/ https://www.ncbi.nlm.nih.gov/pubmed/15767622/
Intravenous glucose in water solutions, such as dextrose 5% or 10%, should be avoided as they may aggravate hyponatraemia. https://www.ncbi.nlm.nih.gov/pubmed/22783787",DB09341,ECO:0000352,,,,,Supportive (C),C,functional complementation of a genetically defective protein,,,Excretion of heme precursors(Abnormality of the heme biosynthetic pathway)*,,HP:0010472,https://clinicaltrials.gov/ct2/show/NCT02180412,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,,,,,,,,
160,,# 176000,Acute intermittent porphyria,,HMBS gene,Hydroxymethylbilane synthase.,2.5.1.61,,,,,,,,,,,,,,"(abdominal pain, nausea, vomiting)",,HP:0002027/ HP:0002017,,,,,,,,,,,
161,,# 176000,Acute intermittent porphyria,,HMBS gene,Hydroxymethylbilane synthase.,2.5.1.61,,,,,,,,,,,,,,Mild attack,,HP:0012825,https://www.ncbi.nlm.nih.gov/pubmed/23605132/,,,,,,,,,,
162,,# 176000,Acute intermittent porphyria,,HMBS gene,Hydroxymethylbilane synthase.,2.5.1.61,Panhematin,,DB03404,ECO:0000352/ECO:0007121,,,,,Functional interaction(Mechanistic B),B,metabolite replacement,,,pain,,HP:0012531,https://clinicaltrials.gov/ct2/show/NCT02922413,https://clinicaltrials.gov/ct2/show/NCT02180412,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6358544/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/,https://www.ncbi.nlm.nih.gov/pubmed/15767622/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562648/#b96-tacg-8-201,,,,,
163,,# 176000,Acute intermittent porphyria,,HMBS gene,Hydroxymethylbilane synthase.,2.5.1.61,,,,,,,,,,,,,,hypertension,,HP:0000822,,,,,,,,,,,
164,,# 176000,Acute intermittent porphyria,,HMBS gene,Hydroxymethylbilane synthase.,2.5.1.61,,,,,,,,,,,,,,tachycardia,,HP:0001649,,,,,,,,,,,
165,,# 176000,Acute intermittent porphyria,,HMBS gene,Hydroxymethylbilane synthase.,2.5.1.61,,,,,,,,,,,,,,abnormal mental status,,HP:0100543,,,,,,,,,,,
166,,# 176000,Acute intermittent porphyria,,HMBS gene,Hydroxymethylbilane synthase.,2.5.1.61,,,,,,,,,,,,,,Acute attack,,HP:0011009,,,,,,,,,,,
167,,# 176000,Acute intermittent porphyria,,HMBS gene,Hydroxymethylbilane synthase.,2.5.1.61,rh-HMBS,"The rh-HMBS-enzyme replacement therapy, however, had no effect on the patients’ symptoms during acute attacks mainly due to constantly high plasma ALA levels. The potential development of rh-HMBS-enzyme replacement therapy should be focused on the delivery of an active enzyme into the liver ,the main site of ALA overproduction, restoring the normal HMBS activity and heme biosynthesis. https://www.ncbi.nlm.nih.gov/pubmed/17375984/",NA,ECO:0007121,,,,,Direct intercation (Mechanistic A),,direct complementation of genetically defective protein,,,Accumulated  plasma porphobilinogen,,HP:0011009,https://www.ncbi.nlm.nih.gov/pubmed/17375984/,,,,,,,,,,
168,,# 176000,Acute intermittent porphyria,,HMBS gene,Hydroxymethylbilane synthase.,2.5.1.61,,,,,,,,,,,,,,Accumulated  urine porphobilinogen,,HP:0012217,,,,,,,,,,,
169,,# 176000,Acute intermittent porphyria,,HMBS gene,Hydroxymethylbilane synthase.,2.5.1.61,rhPBGD,,NA,ECO:0005542,,,,,Direct intercation (Mechanistic A),,direct complementation of genetically defective protein,,,Eevated porphyrin precursors porphobilinogen,,HP:0012217,https://www.ncbi.nlm.nih.gov/pubmed/15208740/,,,,,,,,,,
170,,# 176000,Acute intermittent porphyria,,HMBS gene,Hydroxymethylbilane synthase.,2.5.1.61,rAAV8-mediated gene therapy expressing murine HMB-synthase,,NA,ECO:0005542,,,,,Direct intercation (Mechanistic A),,direct complementation of genetically defective protein by gene therapy,,,Hepatic metabolic abnormalities ( Metabolism abnormality)*,,HP:0001939*,https://www.ncbi.nlm.nih.gov/pubmed/19861948,,,,,,,,,,
171,,# 176000,Acute intermittent porphyria,,HMBS gene,Hydroxymethylbilane synthase.,2.5.1.61,,,,,,,,,,,,,,Abnormal neuromotor function,,HP:0002333,,,,,,,,,,,
172,,# 176000,Acute intermittent porphyria,,HMBS gene,Hydroxymethylbilane synthase.,2.5.1.61,AAV2/5-PBGD,"There is a study for ""Non-viral delivery of the porphobilinogen deaminase cDNA into a mouse model of acute intermittent porphyria{ ECO: 0005542} https://www.ncbi.nlm.nih.gov/pubmed/15110317",,ECO:0007121,,,,,Direct intercation (Mechanistic A),,direct complementation of genetically defective protein by gene therapy,,,Low PBGD expression in liver,,NA,https://www.ncbi.nlm.nih.gov/pubmed/24933563,https://www.ncbi.nlm.nih.gov/pubmed/24933563,,,,,,,,,
173,15,# 614723,Adenine phosphoribosyltransferase deficiency,,APRT,Adenine phosphoribosyltransferase,2.4.2.7,allopurinol,,DB00437,ECO:0007121,,,,,Functional intearction ( Mechanistic B),B,functional complementation of a genetically defective protein,,,urolithiasis,,HP:0000787,https://clinicaltrials.gov/ct2/show/NCT02752633,https://www.ncbi.nlm.nih.gov/books/NBK100238/,https://academic.oup.com/ckj/article/9/6/800/2709623,https://www.ncbi.nlm.nih.gov/pubmed/29241594,,,,,,,
174,,# 614723,Adenine phosphoribosyltransferase deficiency,,APRT,Adenine phosphoribosyltransferase,2.4.2.7,,,,,,,,,,,,,,crystalline nephropathy,,HP:0000112,,,,,,,,,,,
175,,# 614723,Adenine phosphoribosyltransferase deficiency,,APRT,Adenine phosphoribosyltransferase,2.4.2.7,,,,,,,,,,,,,,Hematuria,,HP:0000790,,,,,,,,,,,
176,,# 614723,Adenine phosphoribosyltransferase deficiency,,APRT,Adenine phosphoribosyltransferase,2.4.2.7,,,,,,,,,,,,,,Dysuria,,HP:0100518,,,,,,,,,,,
177,,# 614723,Adenine phosphoribosyltransferase deficiency,,APRT,Adenine phosphoribosyltransferase,2.4.2.7,,,,,,,,,,,,,,Recurrent urinary tract infections,,HP:0000010,,,,,,,,,,,
178,,# 614723,Adenine phosphoribosyltransferase deficiency,,APRT,Adenine phosphoribosyltransferase,2.4.2.7,,,,,,,,,,,,,,Chronic kidney disease,,HP:0012622,,,,,,,,,,,
179,,# 614723,Adenine phosphoribosyltransferase deficiency,,APRT,Adenine phosphoribosyltransferase,2.4.2.7,,,,,,,,,,,,,,Elevated Urinary DHA excretion,,,https://www.ncbi.nlm.nih.gov/pubmed/29241594,,,,,,,,,,
180,,# 614723,Adenine phosphoribosyltransferase deficiency,,APRT,Adenine phosphoribosyltransferase,2.4.2.7,,,,,,,,,,,,,,Kidney stones,,,,,,,,,,,,,
181,,# 614723,Adenine phosphoribosyltransferase deficiency,,APRT,Adenine phosphoribosyltransferase,2.4.2.7,febuxostat,"Febuxostat was, however, significantly more efficacious than allopurinol in reducing DHA excretion in the prescribed doses. This finding, which may translate into improved outcomes of patients with APRT deficiency, should be confirmed in a larger sample. https://www.ncbi.nlm.nih.gov/pubmed/29241594
The XDH inhibitor febuxostat is an alternative option for those allergic to or intolerant of allopurinol. A low purine diet and ample fluid intake are recommended.https://www.ncbi.nlm.nih.gov/books/NBK100238/",DB04854,ECO:0007121,,,,,Functional interaction( Mechanistic B),B,functional complementation of a genetically defective protein,,,urolithiasis,,HP:0000787,https://clinicaltrials.gov/ct2/show/NCT02752633,https://www.ncbi.nlm.nih.gov/books/NBK100238/,https://www.ncbi.nlm.nih.gov/pubmed/29241594,,,,,,,,
182,,# 614723,Adenine phosphoribosyltransferase deficiency,,APRT,Adenine phosphoribosyltransferase,2.4.2.7,,,,,,,,,,,,,,crystalline nephropathy,,HP:0000112,,,,,,,,,,,
183,,# 614723,Adenine phosphoribosyltransferase deficiency,,APRT,Adenine phosphoribosyltransferase,2.4.2.7,,,,,,,,,,,,,,Hematuria,,HP:0000790,,,,,,,,,,,
184,,# 614723,Adenine phosphoribosyltransferase deficiency,,APRT,Adenine phosphoribosyltransferase,2.4.2.7,,,,,,,,,,,,,,Dysuria,,HP:0100518,,,,,,,,,,,
185,,# 614723,Adenine phosphoribosyltransferase deficiency,,APRT,Adenine phosphoribosyltransferase,2.4.2.7,,,,,,,,,,,,,,Recurrent urinary tract infections,,HP:0000010,,,,,,,,,,,
186,,# 614723,Adenine phosphoribosyltransferase deficiency,,APRT,Adenine phosphoribosyltransferase,2.4.2.7,,,,,,,,,,,,,,Chronic kidney disease,,HP:0012622,,,,,,,,,,,
187,,# 614723,Adenine phosphoribosyltransferase deficiency,,APRT,Adenine phosphoribosyltransferase,2.4.2.7,,,,,,,,,,,,,,Elevated Urinary DHA excretion,,,https://www.ncbi.nlm.nih.gov/pubmed/29241594,,,,,,,,,,
188,16,# 102700,Adenosine deaminase deficiency,,ADA gene,Adenosine deaminase,3.5.4.4,Elapegademase (Polyethylene Glycol Recombinant Adenosine Deaminase/PEGylated recombinant adenosine deaminase),,DB14712,ECO:0000352,,,,,Direct interaction (Mechanistic A),A,direct complementation of genetically defective protein,,,lymphopenia,,HP:0001888,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1182205/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3488882/,https://www.asgct.org/education/disease-treatments/inherited-immunodeficiencies,,,,,,,,
189,,# 102700,Adenosine deaminase deficiency,,ADA gene,Adenosine deaminase,3.5.4.4,,,,,,,,,,,,,,hepatosplenomegaly,,HP:0001433,,,,,,,,,,,
190,,# 102700,Adenosine deaminase deficiency,,ADA gene,Adenosine deaminase,3.5.4.4,,,,,,,,,,,,,,Elevated liver enzyme levels,,HP:0002910,,,,,,,,,,,
191,,# 102700,Adenosine deaminase deficiency,,ADA gene,Adenosine deaminase,3.5.4.4,,,,,,,,,,,,,,Low weight,,HP:0004325,,,,,,,,,,,
192,,# 102700,Adenosine deaminase deficiency,,ADA gene,Adenosine deaminase,3.5.4.4,,,,,,,,,,,,,,Abnormal eosinophil counts,,HP:0001879,,,,,,,,,,,
193,,# 102700,Adenosine deaminase deficiency,,ADA gene,Adenosine deaminase,3.5.4.4,,,,,,,,,,,,,,Hemolysis,,HP:0001878,,,,,,,,,,,
194,,# 102700,Adenosine deaminase deficiency,,ADA gene,Adenosine deaminase,3.5.4.4,,,,,,,,,,,,,,Thyroid antibodies (autoimmunity)*,,HP:0002960,,,,,,,,,,,
195,,# 102700,Adenosine deaminase deficiency,,ADA gene,Adenosine deaminase,3.5.4.4,,,,,,,,,,,,,,Abnormal immune function,,HP:0010978,https://adisinsight.springer.com/trials/700243447,,https://clinicaltrials.gov/ct2/show/NCT01420627,,https://globenewswire.com/news-release/2015/03/30/720127/10126746/en/Sigma-Tau-Pharmaceuticals-Inc-Receives-Orphan-Drug-Designation-for-EZN-2279-for-Treatment-of-Adenosine-deaminase-Deficient-Severe-Combined-Immunodeficiency-Disease.html,,,,,,
196,,# 102700,Adenosine deaminase deficiency,,ADA gene,Adenosine deaminase,3.5.4.4,,,,,,,,,,,,,,dermatitis,,HP:0011123,,,,,,,,,,,
197,,# 102700,Adenosine deaminase deficiency,,ADA gene,Adenosine deaminase,3.5.4.4,Pegademase bovine ((PEG-ADA)),"Further data gathering is necessary to determine overall outcome of patients on long-term therapy ""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726071/",DB00061,ECO:0000352,,,,,Direct interaction (Mechanistic A),A,direct complementation of genetically defective protein,,,Abnormal immune function,,HP:0010978,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2726071/,,,,,,,,,,
198,,# 102700,Adenosine deaminase deficiency,,ADA gene,Adenosine deaminase,3.5.4.4,,,,,,,,,,,,,,Recurrent infection,,HP:0002719,,,,,,,,,,,
199,,# 102700,Adenosine deaminase deficiency,,ADA gene,Adenosine deaminase,3.5.4.4,,,,,,,,,,,,,,"Frequent, severe infections",,HP:0002719,,,,,,,,,,,
200,,# 102700,Adenosine deaminase deficiency,,ADA gene,Adenosine deaminase,3.5.4.4,,,,,,,,,,,,,,Abnormal lymphocyte counts,,HP:0040088,,,,,,,,,,,
201,,# 102700,Adenosine deaminase deficiency,,ADA gene,Adenosine deaminase,3.5.4.4,,,,,,,,,,,,,,Abnormal number of b cells,,HP:0010975,,,,,,,,,,,
202,,# 102700,Adenosine deaminase deficiency,,ADA gene,Adenosine deaminase,3.5.4.4,,,,,,,,,,,,,,,,,,,,,,,,,,,
203,,# 102700,Adenosine deaminase deficiency,,ADA gene,Adenosine deaminase,3.5.4.4,Immune Globulin Human,IG replacement is also indicated in infants with severe combined immunodeficiency (SCID) awaiting transplant and in those in which B cells function is not restored following transplantation. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2585601/,DB00028,ECO:0000352,,,,,Supportive (C),C,symptomatic treatment procedure,,,Recurrent infection,,HP:0002719,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2585601/,,,,,,,,,,
204,17,# 615511,Adenosine monophosphate deaminase 1 deficiency,,AMPD1,AMP deaminase,3.5.4.6,D- Ribose,,DB02053,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,Exercise-induced muscle fatigue,,HP:0009020,https://pdfs.semanticscholar.org/99dc/08fa85d5728e08f29b8c13177aac3206f4ec.pdf,,,,,,,,,,
205,,# 615511,Adenosine monophosphate deaminase 1 deficiency,,AMPD1,AMP deaminase,3.5.4.6,,,,,,,,,,,,,,Exercise-induced myalgia,,HP:0003738,,,,,,,,,,,
206,,# 615511,Adenosine monophosphate deaminase 1 deficiency,,AMPD1,AMP deaminase,3.5.4.6,,,,,,,,,,,,,,Limb muscle weakness,,HP:0003690,,,,,,,,,,,
207,,# 615511,Adenosine monophosphate deaminase 1 deficiency,,AMPD1,AMP deaminase,3.5.4.6,,,,,,,,,,,,,,Muscle cramps,,HP:0003394,,,,,,,,,,,
208,18,# 300100,Adrenomyeloneuropathy,,ABCD1,adrenoleukodystrophy protein,3.5.4.6,Lorenzo's oil(Terminated),"It is used as an investigational treatment for asymptomatic patients, however, there are other controversial studies about the significance of this treatment 1: https://www.ncbi.nlm.nih.gov/pubmed/8350883. 2: https://www.ncbi.nlm.nih.gov/pubmed/10078732",DB12528,ECO:0007121,,,,,Supportive (C),C,symptomatic treatment procedure,,,Disease progression,,HP:0003678,https://clinicaltrials.gov/ct2/show/NCT00545597,https://www.ncbi.nlm.nih.gov/pubmed/16009761,https://www.ncbi.nlm.nih.gov/pubmed/7666063,https://www.myelin.org/lorenzos-oil/,,,,,,,
209,,# 300100,Adrenomyeloneuropathy,,ABCD1,adrenoleukodystrophy protein,3.5.4.6,,,,,,,,,,,,,,Abnormal elevated level of VLCFA in plasma,,HP:0003455,,,,,,,,,,,
210,,# 300100,Adrenomyeloneuropathy,,ABCD1,adrenoleukodystrophy protein,3.5.4.6,Lenti-D gene therapy(advanced self-inactivating lentiviral vector TYF-ABCD1),,,ECO:0007121,,,,,Direct Interaction ( Mechanistic A),A,direct complementation of a genetically defective protein by gene therapy,,,Functional disability(Constitutional symptom)*,,HP:0025142,https://clinicaltrials.gov/ct2/show/NCT03727555?cond=Adrenoleukodystrophy&rank=4,https://www.myelin.org/tag/lenti-d/,https://www.ncbi.nlm.nih.gov/pubmed/28976817,,,,,,,,
211,,# 300100,Adrenomyeloneuropathy,,ABCD1,adrenoleukodystrophy protein,3.5.4.6,Sobetirome (NV1205),The ability of these agents to affect VLCFA levels in a mammalian model was not explored. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460829/,DB07425,ECO:0007121/ECO:0005542,,,,,Functional interaction (Mechanistic B),B,functional complementatoin of a defective protein by stimulation,,,Elevated long chain fatty acids,,HP:0003455,https://www.ncbi.nlm.nih.gov/pubmed/28200172,https://clinicaltrials.gov/ct2/show/NCT03196765?cond=Adrenoleukodystrophy&rank=3,https://www.ncbi.nlm.nih.gov/pubmed/28976817,,,,,,,,
212,,# 300100,Adrenomyeloneuropathy,,ABCD1,adrenoleukodystrophy protein,3.5.4.6,Lovastatin,,DB00227,ECO:0000352/ECO:0001565/ECO:0007121,,,,,Symptomatic (C),C,functional complementatoin of a defective protein,,,High plasma level of very-long-chain fatty acids,,HP:0003455,https://www.ncbi.nlm.nih.gov/pubmed/16949688,https://www.ncbi.nlm.nih.gov/pubmed/10870849,https://www.ncbi.nlm.nih.gov/pubmed/20089986,,,,,,,,
213,,# 300100,Adrenomyeloneuropathy,,ABCD1,adrenoleukodystrophy protein,3.5.4.6,,,,,,,,,,,,,,High plasma levels of hexacosanoic acid,,NA,https://www.ncbi.nlm.nih.gov/pubmed/10870849,,,,,,,,,,
214,,# 300100,Adrenomyeloneuropathy,,ABCD1,adrenoleukodystrophy protein,3.5.4.6,interferon beta + thalidomide,"All therapeutic trials conducted so far to modify the inflammatory response did not reveal a relevant clinical benefit from beta interferon, cyclophosphamide, cyclosporin, immunoglobulins, pentoxifylline, and thalidomide. https://www.sciencedirect.com/science/article/pii/S0167488906001881?via%3Dihub",DB00060+DB01041,ECO:0007121,,,,,Supportive (C),C,symptomatic treatment procedure,,,NO revealed clinical benefit,,NA,https://clinicaltrials.gov/ct2/show/NCT00004450?cond=Adrenoleukodystrophy&rank=20,,https://www.ncbi.nlm.nih.gov/pubmed/?term=X-linked+adrenoleukodystrophy%3A+Clinical%2C+biochemical+and+pathogenetic+aspects,,,,,,,,
215,,# 300100,Adrenomyeloneuropathy,,ABCD1,adrenoleukodystrophy protein,3.5.4.6,,,,,,,,,,,,,,,,,,,,,,,,,,,
216,19,# 263570,Adult polyglucosan body disease,,GBE1 gene,"Limit dextrin alpha-1,6-maltotetraose-hydrolase",3.2.1.196,Triheptanoin,,DB11677,ECO:0007121,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,muscle pain,,HP:0003326,https://clinicaltrials.gov/ct2/show/NCT00947960?cond=Adult+Polyglucosan+Body+Disease&rank=1,,,,,,,,,,
217,,# 263570,Adult polyglucosan body disease,,GBE1 gene,"Limit dextrin alpha-1,6-maltotetraose-hydrolase",3.2.1.196,,,,,,,,,,,,,,defective heart function,,HP:0011025,,,,,,,,,,,
218,,# 263570,Adult polyglucosan body disease,,GBE1 gene,"Limit dextrin alpha-1,6-maltotetraose-hydrolase",3.2.1.196,,,,,,,,,,,,,,Lack of energy,,HP:0012378,,,,,,,,,,,
219,20,# 603471,adult-onset type II citrullinemia,Liver transplantation is the only radical treatment for CTLN2 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783980/,SLC25A13,citrin ( protein),Q9UJS0,Medium-chain triglycerides,Medium-chain triglyceride (MCT) supplement therapy with a low-carbohydrate formula was effective in CTLN2 to prevent a relapse of hyperammonemic encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/29651749,DB13959,ECO:0000352,,,,,Symptomatic (C),C,functional complementation of genetically defective protein,,,High blood ammonia level,,HP:0001987,https://www.ncbi.nlm.nih.gov/pubmed/29651749,,https://www.ncbi.nlm.nih.gov/pubmed/26427088,,,,,,,,
220,,# 603471,adult-onset type II citrullinemia,,SLC25A13,citrin ( protein),Q9UJS0,,,,,,,,,,,,,,Relapse of hyperammonemic encephalopathy,,HP:0001298*,,,,,,,,,,,
221,,# 603471,adult-onset type II citrullinemia,,SLC25A13,citrin ( protein),Q9UJS0,,,,,,,,,,,,,,High plasma citrulline levels,,HP:0011966,,,,,,,,,,,
222,,# 603471,adult-onset type II citrullinemia,,SLC25A13,citrin ( protein),Q9UJS0,,,,,,,,,,,,,,low plasma glutamine levels,,HP:0010903,,,,,,,,,,,
223,,# 603471,adult-onset type II citrullinemia,,SLC25A13,citrin ( protein),Q9UJS0,L-Arginine,,DB00125,ECO:0000352,,,,,Symptomatic (C),C,functional complementation of genetically defective protein,,,hyperammonemia,,HP:0001987,https://www.ncbi.nlm.nih.gov/pubmed/18958581,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783980/,https://www.sciencedirect.com/science/article/abs/pii/S1386634602003315,,,,,,,,
224,,# 603471,adult-onset type II citrullinemia,,SLC25A13,citrin ( protein),Q9UJS0,,,,,,,,,,,,,,Disease progression (Rapidly progressive)*,,HP:0003678*,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783980/,,,,,,,,,,
225,,# 603471,adult-onset type II citrullinemia,,SLC25A13,citrin ( protein),Q9UJS0,,,,,,,,,,,,,,Encephalopathy,,HP:0001298,https://www.jstage.jst.go.jp/article/kanzo1960/43/11/43_11_492/_article,,,,,,,,,,
226,,# 603471,adult-onset type II citrullinemia,,SLC25A13,citrin ( protein),Q9UJS0,Pyruvic acid,,DB00119,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,functional complementation of a genetically defective protein,,hyperammonemia,,HP:0001987,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5783980/,https://www.ncbi.nlm.nih.gov/books/NBK1181/,,,,,,,,,
227,,# 603471,adult-onset type II citrullinemia,,SLC25A13,citrin ( protein),Q9UJS0,L-Arginine+Pyruvic acid,It is suggested that the administration of arginine and sodium pyruvate with low-carbohydrate meals may be an effective therapy in patients with citrin deficiency in order either to prolong metabolic normalcy or to provide a safer and more affordable alternative to liver transplantation. https://www.ncbi.nlm.nih.gov/pubmed/18958581/ https://www.ncbi.nlm.nih.gov/books/NBK1181/,DB00125+DB00119,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,functional complementation of a genetically defective protein,,anorexia,,HP:0002039,https://www.ncbi.nlm.nih.gov/pubmed/18958581,,,,,,,,,,
228,,# 603471,adult-onset type II citrullinemia,,SLC25A13,citrin ( protein),Q9UJS0,,,,,,,,,,,,,,lethargy,,HP:0001254,,,,,,,,,,,
229,,# 603471,adult-onset type II citrullinemia,,SLC25A13,citrin ( protein),Q9UJS0,,,,,,,,,,,,,,fatigue,,HP:0012378,,,,,,,,,,,
230,,# 603471,adult-onset type II citrullinemia,,SLC25A13,citrin ( protein),Q9UJS0,,,,,,,,,,,,,,Poor growth,,HP:0001510,,,,,,,,,,,
231,,# 603471,adult-onset type II citrullinemia,,SLC25A13,citrin ( protein),Q9UJS0,,,,,,,,,,,,,,hyperammonemia,,HP:0001987,,,,,,,,,,,
232,,# 603471,adult-onset type II citrullinemia,,SLC25A13,citrin ( protein),Q9UJS0,,,,,,,,,,,,,,Elevated plasma citrulline level,,HP:0011966,,,,,,,,,,,
233,,# 603471,adult-onset type II citrullinemia,,SLC25A13,citrin ( protein),Q9UJS0,,,,,,,,,,,,,,Elevated threonine-to-serine ratio ( Abnormality of amino acid metabolism)*,,HP:0004337*,,,,,,,,,,,
234,,# 603471,adult-onset type II citrullinemia,,SLC25A13,citrin ( protein),Q9UJS0,,,,,,,,,,,,,,Elevated serum pancreatic secretory trypsin inhibitor,,NA,,,,,,,,,,,
235,,# 603471,adult-onset type II citrullinemia,,SLC25A13,citrin ( protein),Q9UJS0,D-mannitol,"According to a retrospective study, 11 of 12 patients who received Glyceol died, whereas both of 2 patients who received D-mannitol survived.https://www.ncbi.nlm.nih.gov/pubmed/15050970 
D-mannitol is unlikely to affect cytosolic NADH production even in citrin de ciency. Therefore, it is highly recommended to administer D-mannitol but not Glyceol to treat brain edema in patients with CTLN2. https://www.ncbi.nlm.nih.gov/pubmed/16449956",DB00742,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,Brain oedema,,HP:0002181,https://www.ncbi.nlm.nih.gov/pubmed/16449956,,,,,,,,,,
236,21,# 612953,Adult-onset dystonia-parkinsonism,,PLA2G6,Phospholipase A(2),3.1.1.4,Pergolide,It was withdrawn from the U.S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction.,DB01186,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Drug name: It was withdrawn from the U.S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction.,parkinsonism,,HP:0001300,https://www.ncbi.nlm.nih.gov/pubmed/24613933,,,,,,,,,,
237,,# 612953,Adult-onset dystonia-parkinsonism,,PLA2G6,Phospholipase A(2),3.1.1.4,L- dopa,"Many studies have reported early responce to l- dopa treatment as mentioned in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/, and other pointed to "" prominent dyskinesia "" as side effect to same treatment https://www.ncbi.nlm.nih.gov/pubmed/19087156/",DB01235,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,parkinsonism,,HP:0001300,https://www.ncbi.nlm.nih.gov/pubmed/25660576/,https://www.ncbi.nlm.nih.gov/pubmed/20938027,https://www.ncbi.nlm.nih.gov/pubmed/19087156/,https://www.ncbi.nlm.nih.gov/pubmed/18570303/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4503963/,https://www.ncbi.nlm.nih.gov/pubmed/20619503,,,,,
238,22,# 615395,Combined oxidative phosphorylation deficiency 16,,MRPL44,MITOCHONDRIAL RIBOSOMAL PROTEIN L44,Q9H9J2,creatine,,DB00148,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,functional complementation of a genetically defective protein,,Low physical capacity (Constitutional symptom)*,,HP:0025142,https://www.ncbi.nlm.nih.gov/pubmed/25797485,,,,,,,,,,
239,23,# 607765,"Congenital bile acid synthesis defect, type 1",,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,1.1.1.181/Q9H2F3,cholic acid,,DB02659,ECO:0007121,,,,,Functional interaction ( Mechanistic B),B,metabolite replacement,,,Hepatic Biochemical abnormalities (Laboratory abnormality)*,,HP:0001939*,https://www.ncbi.nlm.nih.gov/pubmed/11067870,,,,,,,,,,
240,,# 607765,"Congenital bile acid synthesis defect, type 1",,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,1.1.1.181/Q9H2F3,,,,,,,,,,,,,,Histologic abnormalities in liver (Abnormal test result)*,,HP:0500014,,,,,,,,,,,
241,,# 607765,"Congenital bile acid synthesis defect, type 1",,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,1.1.1.181/Q9H2F3,,,,,,,,,,,,,,progression of the disease (Rapidly progressive)*,,HP:0003678*,,,,,,,,,,,
242,,# 607765,"Congenital bile acid synthesis defect, type 1",,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,1.1.1.181/Q9H2F3,,,,,,,,,,,,,,Bile flow defect,,HP:0001396,,,,,,,,,,,
243,,# 607765,"Congenital bile acid synthesis defect, type 1",,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,1.1.1.181/Q9H2F3,,,,,,,,,,,,,,synthesis of atypical bile acids,,NA,,,,,,,,,,,
244,,# 607765,"Congenital bile acid synthesis defect, type 1",,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,1.1.1.181/Q9H2F3,,,,,,,,,,,,,,production of toxic intermediates,,HP:0001939*,,,,,,,,,,,
245,,# 607765,"Congenital bile acid synthesis defect, type 1",,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,1.1.1.181/Q9H2F3,,,,,,,,,,,,,,fat soluble vitamin malabsorption(Fat malabsorption)*,,HP:0002630*,,,,,,,,,,,
246,,# 607765,"Congenital bile acid synthesis defect, type 1",,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,1.1.1.181/Q9H2F3,chenodeoxycholic acid,,DB06777,ECO:0007121,,,,,Functional interaction ( Mechanistic B),B,functional complementation of genetically defective protein,symptomatic treatment procedure,,Abnormal liver function tests,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/2072042,https://www.ncbi.nlm.nih.gov/pubmed/11067870,,,,,,,,,
247,,# 607765,"Congenital bile acid synthesis defect, type 1",,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,1.1.1.181/Q9H2F3,,,,,,,,,,,,,,Pruritus,,HP:0000989,https://www.ncbi.nlm.nih.gov/pubmed/11067870,,,,,,,,,,
248,,# 607765,"Congenital bile acid synthesis defect, type 1",,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,1.1.1.181/Q9H2F3,,,,,,,,,,,,,,Abnormal urinary steroids levels(Abnormality of urine hormone level)*,,HP:0012029,,,,,,,,,,,
249,,# 607765,"Congenital bile acid synthesis defect, type 1",,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,1.1.1.181/Q9H2F3,ursodeoxycholic acid,,DB01586,ECO:0000352,,,,,Functional interaction ( Mechanistic B),B,functional complementation of a genetically defective protein,,,Abnormal liver function tests,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/7915305,,,,,,,,,,
250,,# 607765,"Congenital bile acid synthesis defect, type 1",,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,1.1.1.181/Q9H2F3,Glycocholic Acid,,DB02691,ECO:0007121,,,,,,,functional complementation of a genetically defective protein,,,Failure to thrive,,HP:0001508,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4280294/,,,,,,,,,,
251,,# 607765,"Congenital bile acid synthesis defect, type 1",,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,1.1.1.181/Q9H2F3,,,,,,,,,,,,,,fat soluble vitamin malabsorption(Fat malabsorption)*,,HP:0002630*,,,,,,,,,,,
252,,# 607765,"Congenital bile acid synthesis defect, type 1",,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,1.1.1.181/Q9H2F3,VitaminA+Vitamin D+Vitamin K+Vitamin E+ursodeoxycholic acid+chenodeoxycholic acid,,DB00162+DB11094+DB01022+DB00163+DB01586+DB06777,ECO:0000352,,,,,Symptomatic (C) + Functional interaction( Mechanistis B),,functional complementation of a genetically defective protein + symptomatic treatment procedure,metabolite replacement,,fat soluble vitamin malabsorption(Fat malabsorption)*,,HP:0002630*,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3296980/,,,,,,,,,,
253,,# 607765,"Congenital bile acid synthesis defect, type 1",,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,1.1.1.181/Q9H2F3,,,,,,,,,,,,,,Abnormal gait,,HP:0001288,,,,,,,,,,,
254,,# 607765,"Congenital bile acid synthesis defect, type 1",,HSD3B7,3-BETA-HYDROXY-DELTA-5-C27-STEROID OXIDOREDUCTASE,1.1.1.181/Q9H2F3,,,,,,,,,,,,,,Muscle weakness,,HP:0001324,,,,,,,,,,,
255,24,# 235555,"Congenital bile acid synthesis defect, type 2",,AKR1D1,DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE,EC 1.3.1.3,cholic acid,,DB02659,ECO:0000352,,,,,Functional interaction ( Mechanistic B),B,metabolite replacement,,,biochemical abnormalities,,HP:0001939*,https://www.ncbi.nlm.nih.gov/pubmed/8225213,,,,,,,,,,
256,,# 235555,"Congenital bile acid synthesis defect, type 2",,AKR1D1,DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE,EC 1.3.1.3,,,,,,,,,,,,,,Histologic abnormalities in liver(Abnormal test result)*,,HP:0500014,,,,,,,,,,,
257,,# 235555,"Congenital bile acid synthesis defect, type 2",,AKR1D1,DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE,EC 1.3.1.3,,,,,,,,,,,,,,Disease progression (Rapidly progressive)*,,HP:0003678*,,,,,,,,,,,
258,,# 235555,"Congenital bile acid synthesis defect, type 2",,AKR1D1,DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE,EC 1.3.1.3,,,,,,,,,,,,,,Bile flow defect,,HP:0001396,,,,,,,,,,,
259,,# 235555,"Congenital bile acid synthesis defect, type 2",,AKR1D1,DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE,EC 1.3.1.3,,,,,,,,,,,,,,synthesis of atypical bile acids,,NA,,,,,,,,,,,
260,,# 235555,"Congenital bile acid synthesis defect, type 2",,AKR1D1,DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE,EC 1.3.1.3,,,,,,,,,,,,,,production of bile acid toxic intermediates,,HP:0001939*,,,,,,,,,,,
261,,# 235555,"Congenital bile acid synthesis defect, type 2",,AKR1D1,DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE,EC 1.3.1.3,,,,,,,,,,,,,,fat soluble vitamin malabsorption (Fat malabsorption)*,,HP:0002630*,,,,,,,,,,,
262,,# 235555,"Congenital bile acid synthesis defect, type 2",,AKR1D1,DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE,EC 1.3.1.3,Chenodeoxycholic acid + cholic acid.,"While is probably the drug of choic in treating this disease, There is an urge to take cautions in using it in patients with high plasma concentration of chenodeoxycholic acid (and thus we would not use it in a patient with secondary 5p-reductase deficiency). The reason for this is that,if the plasma concentration of chenodeoxycholic acid is increased,it is probable that the hepatocyte concentration is also increased and hydrophobic dihydroxy bile acids such as chenodeoxycholic acid are thought to contribute to the liver cell damage that occurs in cholestasis. https://www.ncbi.nlm.nih.gov/pubmed/8707100",DB06777+DB02659,ECO:0000352,,,,,Functional interaction ( Mechanistic B),,functional complementation of a genetically defective protein,metabolite replacement,,Abnormal liver function tests,,HP:0002630*,https://www.ncbi.nlm.nih.gov/pubmed/8707100,,,,,,,,,,
263,,# 235555,"Congenital bile acid synthesis defect, type 2",,AKR1D1,DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE,EC 1.3.1.3,,,,,,,,,,,,,,Liver biopsy abnormalities,,,,,,,,,,,,,
264,,# 235555,"Congenital bile acid synthesis defect, type 2",,AKR1D1,DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE,EC 1.3.1.3,,,,,,,,,,,,,,Abnormal bilirubin level,,,,,,,,,,,,,
265,,# 235555,"Congenital bile acid synthesis defect, type 2",,AKR1D1,DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE,EC 1.3.1.3,Chenodeoxycholic acid,,DB06777,ECO:0000352,,,,,Functional interaction ( Mechanistic B),,functional complementation of a genetically defective protein,,,Abnormal liver function,,,https://www.ncbi.nlm.nih.gov/pubmed/28697823,,,,,,,,,,
266,,# 235555,"Congenital bile acid synthesis defect, type 2",,AKR1D1,DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE,EC 1.3.1.3,,,,,,,,,,,,,,Hepatomegaly,,,,,,,,,,,,,
267,,# 235555,"Congenital bile acid synthesis defect, type 2",,AKR1D1,DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE,EC 1.3.1.3,,,,,,,,,,,,,,,,,,,,,,,,,,,
268,25,# 203500,Alkaptonuria,,HGD gene,"Homogentisate 1,2-dioxygenase.",1.13.11.5,Nitisinone,"Nitisonone, a triketone herbicide and high-dose vitamin C (ascorbic acid) have been prescribed, but their efficacy has not been proven , A recent study in Oct. 2018 https://www.ncbi.nlm.nih.gov/pubmed/30449931 #It should be noted that despite its potential beneficial effects, nitisinone causes a large increase in circulating tyrosine. https://www.ncbi.nlm.nih.gov/pubmed/26891864. #There are more cinical studies running about Alkaptnuria ""for more information please check http://www.developakure.eu/index.html",DB00348,ECO:0007121,,,,,Functional interaction ( Mechanistic B),B,functional complementation of a defective protein by inhibition,,,Disease progression (Rapidly progressive)*,,HP:0003678*,https://clinicaltrials.gov/ct2/show/NCT00107783?cond=Alkaptonuria&rank=4,https://clinicaltrials.gov/ct2/show/NCT01828463?cond=Alkaptonuria&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/28813744,https://www.ncbi.nlm.nih.gov/pubmed/30477028,https://www.ncbi.nlm.nih.gov/pubmed/30049652,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/,,,,,
269,,# 203500,Alkaptonuria,,HGD gene,"Homogentisate 1,2-dioxygenase.",1.13.11.5,,,,,,,,,,,,,,ochronosis,,HP:0030764,https://www.ncbi.nlm.nih.gov/pubmed/26891864,,,,,,,,,,
270,,# 203500,Alkaptonuria,,HGD gene,"Homogentisate 1,2-dioxygenase.",1.13.11.5,,,,,,,,,,,,,,High circulating HGA (homogentisic acid)level,,NA,https://www.ncbi.nlm.nih.gov/pubmed/26891864,,,,,,,,,,
271,,# 203500,Alkaptonuria,,HGD gene,"Homogentisate 1,2-dioxygenase.",1.13.11.5,,,,,,,,,,,,,,Joint disesae,,HP:0001367,,,,,,,,,,,
272,,# 203500,Alkaptonuria,,HGD gene,"Homogentisate 1,2-dioxygenase.",1.13.11.5,N-ACETYL-CYSTEINE,,DB06151,ECO:0007121,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,apoptosis induced in chondrocytes,,NA,https://www.clinicaltrialsregister.eu/ctr-search/search?query=Alkaptonuria,,,,,,,,,,
273,,# 203500,Alkaptonuria,,HGD gene,"Homogentisate 1,2-dioxygenase.",1.13.11.5,ASCORBIC ACID,"Controversial effectivness of AA  in an old study they have demonesterated that AA didn't have much effect in treating patients https://link.springer.com/content/pdf/10.1007%2Fs004310050956.pdf, In a more recent Study , It was noted that AA 's  mild antioxidant nature , helps retard the process of conversion of homogentisate to the polymeric material that is deposited in cartilaginous tissues. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/",DB00126,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,Abnormal chondrocyte growth,,NA,https://www.ncbi.nlm.nih.gov/pubmed/9718357/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/,,,,,,,,,
274,,# 203500,Alkaptonuria,,HGD gene,"Homogentisate 1,2-dioxygenase.",1.13.11.5,,,,,,,,,,,,,,Disease progression (Rapidly progressive)*,,HP:0003678*,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508465/,,,,,,,,,,
275,,# 203500,Alkaptonuria,,HGD gene,"Homogentisate 1,2-dioxygenase.",1.13.11.5,,,,,,,,,,,,,,abnormality of proteoglycan metabolism,,HP:0004355,,,,,,,,,,,
276,26,# 613490,Alpha-1 antitrypsin deficiency,,SERPINA1,alpha-1-antitrypsin (major plasma serine protease inhibitor),P01009,ARC-AAT,"The approach is (RNA interference-based, liver-targeted therapeutic), however this trial has been terminated.",NA,ECO:0007121,,,,,Direct interaction ( Mechanistic A),A,activity modification of a genetically defective protein,direct complementation of genetically defective protein,,,,HP:0004355,https://clinicaltrials.gov/ct2/show/NCT02363946?cond=Alpha-1+antitrypsin+deficiency&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/23527792,https://clinicaltrials.gov/ct2/show/NCT02900183,,,,,,,,
277,,# 613490,Alpha-1 antitrypsin deficiency,,SERPINA1,alpha-1-antitrypsin (major plasma serine protease inhibitor),P01009,Recombinant alpha 1-antitrypsin (rAAT),,DB05481,ECO:0007121,,,,,Direct interaction ( Mechanistic A),A,direct complementation of genetically defective protein,,,Progressive emphysema,,HP:0002097,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361470/,https://www.ncbi.nlm.nih.gov/pubmed/15978931/,,,,,,,,,
278,,# 613490,Alpha-1 antitrypsin deficiency,,SERPINA1,alpha-1-antitrypsin (major plasma serine protease inhibitor),P01009,,,,,,,,,,,,,,Decreased lung function,,HP:0005952,,,,,,,,,,,
279,,# 613490,Alpha-1 antitrypsin deficiency,,SERPINA1,alpha-1-antitrypsin (major plasma serine protease inhibitor),P01009,,,,,,,,,,,,,,Recurrent infection,,HP:0002719,,,,,,,,,,,
280,,# 613490,Alpha-1 antitrypsin deficiency,,SERPINA1,alpha-1-antitrypsin (major plasma serine protease inhibitor),P01009,Retinoic acid,,DB00755,ECO:0005542,,,,,Symptomatic(C),,symptomatic treatment procedure,,,Alveoli damage ( interstitial pulmonary abnormality)*,,HP:0006530,https://www.ncbi.nlm.nih.gov/pubmed/22282548/,,,,,,,,,,
281,,# 613490,Alpha-1 antitrypsin deficiency,,SERPINA1,alpha-1-antitrypsin (major plasma serine protease inhibitor),P01009,Beta2-agonists +corticosteroids + anti-cholinergics,,DB00755,ECO:0000352,,,,,Symptomatic(C),,symptomatic treatment procedure,,,Difficulty breathing,,HP:0002098,https://www.ncbi.nlm.nih.gov/pubmed/22282548/,,,,,,,,,,
282,,# 613490,Alpha-1 antitrypsin deficiency,,SERPINA1,alpha-1-antitrypsin (major plasma serine protease inhibitor),P01009,,,,,,,,,,,,,,Lung inflammation (Abnormality of respiratory system),,HP:0002086,,,,,,,,,,,
283,27,* 609458,Alpha-mannosidosis,,MAN2B1,Alpha-mannosidase,3.2.1.24,Lamazym(rhLAMAN),,DB12374,ECO:0007121,,,,,Direct interaction ( Mechanistic A),A,direct complementation of genetically defective protein,,,Reduced pulmonary function,,HP:0005952,https://clinicaltrials.gov/ct2/show/NCT01681940?cond=Alpha-mannosidosis&rank=3,https://www.ncbi.nlm.nih.gov/pubmed/26827607,https://clinicaltrials.gov/ct2/show/NCT02998879?cond=Alpha-mannosidosis&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/23494656,https://www.clinicaltrialsregister.eu/ctr-search/search?query=Alpha-mannosidosis%C2%A0,,http://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=3&Disease_Disease_Search_diseaseGroup=Alpha-mannosidosis-&Disease_Disease_Search_diseaseType=Pat&Disease(s)/group%20of%20diseases=Alpha-mannosidosis&title=Alpha-mannosidosis&search=Disease_Search_Simple,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4693626/,,,
284,,* 609458,Alpha-mannosidosis,,MAN2B1,Alpha-mannosidase,3.2.1.24,,,,,,,,,,,,,,Low FVC%,,HP:0030878*,,,,,,,,,,,
285,,* 609458,Alpha-mannosidosis,,MAN2B1,Alpha-mannosidase,3.2.1.24,,,,,,,,,,,,,,High NFL (neurofilament light signature ) in CSF,,NA,,,,,,,,,,,
286,,* 609458,Alpha-mannosidosis,,MAN2B1,Alpha-mannosidase,3.2.1.24,,,,,,,,,,,,,,Elevated GFAP(Glial fibrillary acidic protein) level in CSF,,NA,,,,,,,,,,,
287,,* 609458,Alpha-mannosidosis,,MAN2B1,Alpha-mannosidase,3.2.1.24,,,,,,,,,,,,,,Elevated Tau-p level in CSF,,NA,,,,,,,,,,,
288,,* 609458,Alpha-mannosidosis,,MAN2B1,Alpha-mannosidase,3.2.1.24,,,,,,,,,,,,,,High CSF MAN2-oligosaccharides,,,,,,,,,,,,,
289,,* 609458,Alpha-mannosidosis,,MAN2B1,Alpha-mannosidase,3.2.1.24,,,,,,,,,,,,,,cognitive deficits,,HP:0100543,,,,,,,,,,,
290,,* 609458,Alpha-mannosidosis,,MAN2B1,Alpha-mannosidase,3.2.1.24,AAV1vector expressing α-Mannosidase,,NA,ECO:0005542,,,,,Direct interaction (Mechanistic A),A,direct complementation of a genetically defective protein by gene therapy,,,Neurological abnormalities,,HP:0100543,https://www.ncbi.nlm.nih.gov/pubmed/?term=Effective+gene+therapy+for+an+inherited+CNS+disease+in+a+large+animal+mode,,,,,,,,,,
291,28,# 207800,Arginase deficiency,,ARG1,Arginase,3.5.3.1,Glycerol phenylbutyrate,The drug is used as a maintenance therapy https://www.ncbi.nlm.nih.gov/books/NBK476305/ https://www.tandfonline.com/doi/abs/10.1080/21678707.2017.1405807,DB08909,ECO:0007121,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,low quality of life(Constitutional symptom )*,,HP:0025142*,https://www.tandfonline.com/doi/abs/10.1080/21678707.2017.1405807,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017326/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4382922/,,,,,,,,
292,,# 207800,Arginase deficiency,,ARG1,Arginase,3.5.3.1,AEB1102(Pegzilarginase) – Co-ArgI-PEG modified human Arginase I,,NA,ECO:0007121,,,,,Direct interaction ( Mechanistic A),A,direct complementation of genetically defective protein,,,Elevated blood arginine levels( Abnorality in arginie metabolism)*,,HP:0010909*,https://clinicaltrials.gov/ct2/show/NCT03378531?cond=Arginase+deficiency&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/26358771,,,,,,,,,
293,,# 207800,Arginase deficiency,,ARG1,Arginase,3.5.3.1,,,,,,,,,,,,,,Unstable neurological function (Abnormality of the nervous system)*,,HP:0000707*,,,,,,,,,,,
294,,# 207800,Arginase deficiency,,ARG1,Arginase,3.5.3.1,,,,,,,,,,,,,,Disease progression (Rapidly progressive)*,,HP:0003678*,,,,,,,,,,,
295,,# 207800,Arginase deficiency,,ARG1,Arginase,3.5.3.1,sodium benzoate,Alternative pathway therapy has limited effectiveness in preventing hyperammonemia and must be combined with effective dietary management. https://www.ncbi.nlm.nih.gov/pubmed/11148549,DB03793,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,functional complementation of a genetically defective protein,,Hyperammonemia,,HP:0001987,https://www.ncbi.nlm.nih.gov/pubmed/11148549,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4052756/#S10title,,,,,,,,,
296,,# 207800,Arginase deficiency,,ARG1,Arginase,3.5.3.1,sodium phenylbutyrate,,DB06819,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,functional complementation of a genetically defective protein,,Hyperammonemia,,HP:0001987,https://www.ncbi.nlm.nih.gov/pubmed/11148549,,,,,,,,,,
297,,# 207800,Arginase deficiency,,ARG1,Arginase,3.5.3.1,AAV-based gene therapy,,NA,ECO:0005542,,,,,Direct interaction ( Mechanistic A),A,direct complementation of a genetically defective protein by gene therapy,,,neurotoxicity,,NA,https://www.ncbi.nlm.nih.gov/pubmed/25474440,,https://www.ncbi.nlm.nih.gov/pubmed/23388701,,,https://www.nature.com/scitable/content/Progress-and-problems-with-the-use-of-14813,,,,,
298,,# 207800,Arginase deficiency,,ARG1,Arginase,3.5.3.1,,,,,,,,,,,,,,neurological abnormalities,,HP:0000707,,,,,,,,,,,
299,,# 207800,Arginase deficiency,,ARG1,Arginase,3.5.3.1,,,,,,,,,,,,,,cognitive dysfunction,,HP:0100543,,,,,,,,,,,
300,29,# 207900,Argininosuccinic aciduria,,ASL gene,argininosuccinate lyase,4.3.2.1,Nitric oxide supplement,,DB00435,ECO:0005542,,,,,Symptomatic (C),C,symptomatic treatment procedure,functional complementation of a genetically defective protein,,hypertension,,HP:0000822,https://www.ncbi.nlm.nih.gov/pubmed/22541557,,https://www.sciencedirect.com/science/article/pii/S109671921200265X?via%3Dihub,,,,,,,,
301,,# 207900,Argininosuccinic aciduria,,ASL gene,argininosuccinate lyase,4.3.2.1,,,,,,,,,,,,,,absence of flow-mediated dilatation of brachial artery,,NA,,,,,,,,,,,
302,,# 207900,Argininosuccinic aciduria,,ASL gene,argininosuccinate lyase,4.3.2.1,,,,,,,,,,,,,,endothelial dysfunction,,NA,,,,,,,,,,,
303,,# 207900,Argininosuccinic aciduria,,ASL gene,argininosuccinate lyase,4.3.2.1,,,,,,,,,,,,,,Cardiac hypertrophy,,,,,,,,,,,,,
304,,# 207900,Argininosuccinic aciduria,,ASL gene,argininosuccinate lyase,4.3.2.1,,,,,,,,,,,,,,,,,,,,,,,,,,,
305,,# 207900,Argininosuccinic aciduria,,ASL gene,argininosuccinate lyase,4.3.2.1,,,,,,,,,,,,,,,,,,,,,,,,,,,
306,,# 207900,Argininosuccinic aciduria,,ASL gene,argininosuccinate lyase,4.3.2.1,Sodium citrate,,DB09154,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,functional complementation of a genetically defective protein,,Abnormal renal nitrogen elimination,,HP:0004364,https://www.ncbi.nlm.nih.gov/pubmed/8582405,,,,,,,,,,
307,,# 207900,Argininosuccinic aciduria,,ASL gene,argininosuccinate lyase,4.3.2.1,keto-analogues of essential amino acids,,NA,ECO:0000352,,,,,Supportive (C),C,symptomatic treatment procedure,functional complementation of a genetically defective protein,,seizure,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/668730,,,,,,,,,,
308,,# 207900,Argininosuccinic aciduria,,ASL gene,argininosuccinate lyase,4.3.2.1,,,,,,,,,,,,,,High blood ammonia levels,,HP:0001987,,,,,,,,,,,
309,,# 207900,Argininosuccinic aciduria,,ASL gene,argininosuccinate lyase,4.3.2.1,,,,,,,,,,,,,,Defective argininosuccinic acid excretion,,HP:0001939*,,,,,,,,,,,
310,,# 207900,Argininosuccinic aciduria,,ASL gene,argininosuccinate lyase,4.3.2.1,Sodium Phenylbutyrate +Arginin,,DB06819+DB00125,ECO:0007121,,,,,Symptomatic (C),C,symptomatic treatment procedure,functional complementation of a genetically defective protein,,Hyperammonemia,,HP:0001987,https://clinicaltrials.gov/ct2/show/NCT00345605,https://www.ncbi.nlm.nih.gov/pubmed/8582405,,,,,,,,,
311,,# 207900,Argininosuccinic aciduria,,ASL gene,argininosuccinate lyase,4.3.2.1,Arginine,,DB00125,ECO:0000352,,,,,Functional interaction ( Mechanistic B),B,metabolite replacement,,,abnormal hepatic function tests,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/19585269,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3073162/,https://www.ncbi.nlm.nih.gov/pubmed/23040521,,,,,,,,
312,,# 207900,Argininosuccinic aciduria,,ASL gene,argininosuccinate lyase,4.3.2.1,,,,,,,,,,,,,,Low plasma arginine levels,,HP:0005961,,,,,,,,,,,
313,,# 207900,Argininosuccinic aciduria,,ASL gene,argininosuccinate lyase,4.3.2.1,,,,,,,,,,,,,,Acute hyperammonemia,,HP:0008281,,,,,,,,,,,
314,30,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC gene,Aromatic-L-amino-acid decarboxylase,4.1.1.28,AAV2-hAADC ( Gene therapy),,,ECO:0007121,,,,,Direct interaction ( Mechanistic A),A,direct complementation of a genetically defective protein by gene therapy,,,motor malperformance,,HP:0002275,https://clinicaltrials.gov/ct2/show/NCT02926066?cond=Aromatic+L-amino+acid+decarboxylase+deficiency&rank=2,,https://clinicaltrials.gov/ct2/show/NCT01395641?cond=Aromatic+L-amino+acid+decarboxylase+deficiency&rank=4,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3955971/,,,,,,
315,,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC gene,Aromatic-L-amino-acid decarboxylase,4.1.1.28,,,,,,,,,,,,,,increased dopamine and serotonin levels (neurotransmitter levels),,HP:0012654,,,,,,,,,,,
316,,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC gene,Aromatic-L-amino-acid decarboxylase,4.1.1.28,Bromocriptine,,DB01200,ECO:0000352,,,,,Symptomatic (C),C,functional complementation of a genetically defective protein,symptomatic treatment procedure,,hypokinesia,,HP:0002375,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,,,,,,,,,,
317,,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC gene,Aromatic-L-amino-acid decarboxylase,4.1.1.28,,,,,,,,,,,,,,axial hypotonia,,HP:0008936,,,,,,,,,,,
318,,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC gene,Aromatic-L-amino-acid decarboxylase,4.1.1.28,,,,,,,,,,,,,,limb hypertonia,,HP:0002509,,,,,,,,,,,
319,,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC gene,Aromatic-L-amino-acid decarboxylase,4.1.1.28,,,,,,,,,,,,,,dystonia,,HP:0001332,,,,,,,,,,,
320,,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC gene,Aromatic-L-amino-acid decarboxylase,4.1.1.28,,,,,,,,,,,,,,choreoathetosis,,HP:0001266,,,,,,,,,,,
321,,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC gene,Aromatic-L-amino-acid decarboxylase,4.1.1.28,,,,,,,,,,,,,,Poor head control,,HP:0002421,,,,,,,,,,,
322,,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC gene,Aromatic-L-amino-acid decarboxylase,4.1.1.28,,,,,,,,,,,,,,Oculogyric crises,,HP:0010553,,,,,,,,,,,
323,,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC gene,Aromatic-L-amino-acid decarboxylase,4.1.1.28,,,,,,,,,,,,,,Abnormalitilty in voluntary movements(Abnormality of movement)*,,HP:0100022*,,,,,,,,,,,
324,,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC gene,Aromatic-L-amino-acid decarboxylase,4.1.1.28,,,,,,,,,,,,,,Autonomic dysfunction,,HP:0002459,,,,,,,,,,,
325,,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC gene,Aromatic-L-amino-acid decarboxylase,4.1.1.28,Pyridoxine,,DB00165,ECO:0000352,,,,,Direct interaction ( Mechanistic A),A,activity modification of a genetically defective protein,,,boost residual AADC activity with a cofactor excess,,NA,,,,,,,,,,,
326,,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC gene,Aromatic-L-amino-acid decarboxylase,4.1.1.28,Pyrodixal 5 phosphate,Consider trial if pyridoxine gives too many side effects or is not effective. Chronic use in high dose can cause severe sensorimotor polyneuropathy. https://www.ncbi.nlm.nih.gov/pubmed/25001633/,DB00114,ECO:0000352,,,,,Direct interaction ( Mechanistic A),A,activity modification of a genetically defective protein,,,boost residual AADC activity with a cofactor excess,,,https://www.ncbi.nlm.nih.gov/pubmed/25001633/,,,,,,,,,,
327,,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC gene,Aromatic-L-amino-acid decarboxylase,4.1.1.28,pramipexole,,DB12890,ECO:0000352,,,,,Consider PLP trial if pyridoxine gives too many side effects or is not effective. Chronic use in high dose can cause severe sensorimotor polyneuropathy. https://www.ncbi.nlm.nih.gov/pubmed/25001633/,C,functional complementation of a genetically defective protein,symptomatic treatment procedure,,Hypotonia,,HP:0001290,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,,,,,,,,,,
328,,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC gene,Aromatic-L-amino-acid decarboxylase,4.1.1.28,,,,,,,,,,,,,,Oculogyric crisis,,HP:0010553,,,,,,,,,,,
329,,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC gene,Aromatic-L-amino-acid decarboxylase,4.1.1.28,,,,,,,,,,,,,,Poor head control,,HP:0002421,,,,,,,,,,,
330,,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC gene,Aromatic-L-amino-acid decarboxylase,4.1.1.28,,,,,,,,,,,,,,Voluntary movement abnormalities(Abnormality of movement)*,,HP:0100022*,,,,,,,,,,,
331,,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC gene,Aromatic-L-amino-acid decarboxylase,4.1.1.28,,,,,,,,,,,,,,Autonomic dysfunction,,HP:0002459,,,,,,,,,,,
332,,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC gene,Aromatic-L-amino-acid decarboxylase,4.1.1.28,Rotigotine,"In a study done by Mastrandeleo et. al , it was mentioned that Transdermal rotigotine was efficacious in the early stages of AADC of an affected male; however, the treatment was not effective in his older, more impaired brother.",DB05271,ECO:0000352,,,,,Symptomatic (C),C,functional complementation of a genetically defective protein,symptomatic treatment procedure,,Hypotonia,,HP:0001290,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,https://www.ncbi.nlm.nih.gov/pubmed/23390030/,,,,,,,,,
333,,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC gene,Aromatic-L-amino-acid decarboxylase,4.1.1.28,,,,,,,,,,,,,,Oculogyric crisis,,HP:0010553,,,,,,,,,,,
334,,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC gene,Aromatic-L-amino-acid decarboxylase,4.1.1.28,,,,,,,,,,,,,,Poor head control,,HP:0002421,,,,,,,,,,,
335,,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC gene,Aromatic-L-amino-acid decarboxylase,4.1.1.28,,,,,,,,,,,,,,Voluntary movement abnormalities (Abnormality of movement)*,,HP:0100022*,,,,,,,,,,,
336,,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC gene,Aromatic-L-amino-acid decarboxylase,4.1.1.28,,,,,,,,,,,,,,Autonomic dysfunction,,HP:0002459,,,,,,,,,,,
337,,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC gene,Aromatic-L-amino-acid decarboxylase,4.1.1.28,Pergolide,,DB01186,ECO:0000352,,,,,Symptomatic (C),C,functional complementation of a genetically defective protein,symptomatic treatment procedure,,Hypotonia,,HP:0001290,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,,,,,,,,,,
338,,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC gene,Aromatic-L-amino-acid decarboxylase,4.1.1.28,,,,,,,,,,,,,,Oculogyric crisis,,HP:0010553,,,,,,,,,,,
339,,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC gene,Aromatic-L-amino-acid decarboxylase,4.1.1.28,,,,,,,,,,,,,,Poor head control,,HP:0002421,,,,,,,,,,,
340,,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC gene,Aromatic-L-amino-acid decarboxylase,4.1.1.28,,,,,,,,,,,,,,Voluntary movement abnormalities (Abnormality of movement)*,,HP:0100022*,,,,,,,,,,,
341,,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC gene,Aromatic-L-amino-acid decarboxylase,4.1.1.28,,,,,,,,,,,,,,Autonomic dysfunction,,HP:0002459,,,,,,,,,,,
342,,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC gene,Aromatic-L-amino-acid decarboxylase,4.1.1.28,Folinic acid,,DB00650,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,cerebral folate depletion,,HP:0012446,https://www.ncbi.nlm.nih.gov/pubmed/25001633/,,,,,,,,,,
343,,# 608643,Aromatic L-amino acid decarboxylase deficiency,,DDC gene,Aromatic-L-amino-acid decarboxylase,4.1.1.28,Pargyline,"From the biochemical viewpoint there is strong recommendation for giving patients with AADCD a trial of MAO inhibitors, although there is little evidence of clinical benefit. All patients had co-treatment with dopamine agonists and/ or pyridoxine https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/",DB01626,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,functional complementation of a genetically defective protein,,Hypotonia,,HP:0001290,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5241937/,,,,,,,,,,
344,31,# 301835,Arts Syndrome,,PRPS1 gene,Ribose-phosphate diphosphokinase,2.7.6.1,S-adenosylmethionine,,DB00118,ECO:0000352,,,,,Symptomatic (C),C,functional complementation of a genetically defective protein,symptomatic treatment procedure,,low levels of purines,,HP:0004369,https://www.sciencedirect.com/science/article/pii/S0002929707613470,https://www.ncbi.nlm.nih.gov/pubmed/20380929,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2850427/,https://www.ncbi.nlm.nih.gov/pubmed/28967191,https://www.ncbi.nlm.nih.gov/pubmed/17701896,,,,,,
345,,# 301835,Arts Syndrome,,PRPS1 gene,Ribose-phosphate diphosphokinase,2.7.6.1,,,,,,,,,,,,,,Progression of retinal degeneration ( Rapidly Progressive)*,,HP:0003678*,,,,,,,,,,,
346,,# 301835,Arts Syndrome,,PRPS1 gene,Ribose-phosphate diphosphokinase,2.7.6.1,,,,,,,,,,,,,,Ataxia Progression(Rapid progression),,HP:0002719,https://www.ncbi.nlm.nih.gov/pubmed/23190330,,,,,,,,,,
347,,# 301835,Arts Syndrome,,PRPS1 gene,Ribose-phosphate diphosphokinase,2.7.6.1,,,,,,,,,,,,,,Recurrent infection,,HP:0002719,,,,,,,,,,,
348,,# 301835,Arts Syndrome,,PRPS1 gene,Ribose-phosphate diphosphokinase,2.7.6.1,,,,,,,,,,,,,,frequent hospital admission,,NA,,,,,,,,,,,
349,,# 301835,Arts Syndrome,,PRPS1 gene,Ribose-phosphate diphosphokinase,2.7.6.1,,,,,,,,,,,,,,Hearing impairment progression(Rapid progression)*,,HP:0003678*,,,,,,,,,,,
350,,# 301835,Arts Syndrome,,PRPS1 gene,Ribose-phosphate diphosphokinase,2.7.6.1,,,,,,,,,,,,,,Noctornal difficulty breathing,,HP:0002098,,,,,,,,,,,
351,32,208400,Aspartylglycosaminuria,"As by 2016 Banning et al. mentioned ""Currently, no treatment for AGU is available, although several preclinical studies aiming at enzyme replacement (ERT) or gene therapy have been published. Neither of these treatment options is expected to be available within the next few years",AGA gene,N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase,3.5.1.26,Amlexanox,"Amlexanox, which inhibits NMD and causes a translational read-through, facilitated the synthesis of a full-length, functional AGA protein from the nonsense allele. This could be demonstrated as presence of the AGA polypeptide and increased enzyme activity upon Amlexanox treatment. Furthermore, in the Ser72Pro/Trp168X expressing cells, Amlexanox induced a synergistic increase in AGA activity and polypeptide processing due to enhanced processing of the Ser72Pro polypeptide. A potential therapy based on results of a study conducted by Banning et al. 2016 https://www.ncbi.nlm.nih.gov/pubmed/29247835 Consistently, AMX is currently under strong clinical development for rare metabolic diseases by the company Apteeus (Terence Beghyn, Apteeus, personal communication). The drug as released in Banning et al. study works by inhibiting NMD and causing a translational read-through, it facilitated the synthesis of a full-length, functional AGA protein from the nonsense allele. ""This could be demonstrated as presence of the AGA polypeptide and increased enzyme activity upon Amlexanox treatment. Furthermore, in the Ser72Pro/Trp168X expressing cells, Amlexanox induced a synergistic increase in AGA activity and polypeptide processing due to enhanced processing of the Ser72Pro polypeptide. "" It posses the ability to cross the BBB. ""Our data show for the first time that Amlexanox might provide a valid therapy for AGU."" https://www.ncbi.nlm.nih.gov/pubmed/29247835",DB01025,ECO:0001565,Ser72Pro/Trp168X,,,,Direct interaction ( Mechanistic A),A,activity modification of a genetically defective protein,,,Low AGA activity,,NA,https://www.semanticscholar.org/topic/amlexanox/510418,https://www.ncbi.nlm.nih.gov/pubmed/29247835,,,https://www.ncbi.nlm.nih.gov/pubmed/29247835,,,,,,
352,,208400,Aspartylglycosaminuria,,AGA gene,N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase,3.5.1.26,betaine,"The trial was done on cell culture not model animals, authors of this paper "" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323/"" have mentioned that "" Since betaine has already been used for pediatric patients, plenty of safety and dosage data are available, which will facilitate the therapeutic trial for AGU. However, it is not quite clear how efficiently betaine penetrates the blood-brain barrier, and it is unclear if it exerts an effect on the central nervous system"".",DB06756,ECO:0001565,T122K,"Our data show that both T122K and AGU-Fin AGA enzyme variants most likely exhibit a relatively local folding defect that neither completely impairs the structure, nor results in severe destabilization and degradation of the mutant enzyme. These findings are somewhat contradictory to what has been proposed for the AGU-Fin mutated AGA, which has been suggested to become rapidly degraded after synthesis in the ER19,28. However, these previous studies have been based on overexpression of the mutated enzyme mainly in chinese hamster ovarian cells, which may result in ER overload and unfolded protein response, facilitating the degradation of the AGU-Fin mutant precursors. We here show that endogenous T122K and AGU-Fin AGA in patient fibroblasts do not colocalize with the ER marker calnexin, whereas a high degree of colocalization was observed with lysosomal markers. However, it is likely that the misfolding induced by T122K mutation is milder than that of AGU-Fin which impairs the formation of an intramolecular disulfide bond20. This would also be consistent with the data that the PC-like compounds used here showed a higher increase of enzyme activity in the case of T122K than AGU-Fin https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323/",,,Direct interaction ( Mechanistic A),A,activity modification of a genetically defective protein,,,Low AGA activity,,NA,https://www.nature.com/articles/srep37583/figures/5,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323/,,,,,,,,,
353,,208400,Aspartylglycosaminuria,,AGA gene,N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase,3.5.1.26,,,,,,,,,,,,,,Unstable AGA enzyme,,NA,,,,,,,,,,,
354,,208400,Aspartylglycosaminuria,,AGA gene,N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase,3.5.1.26,,,,,,,,,,,,,,Misfolded AGA,,NA,,,,,,,,,,,
355,,208400,Aspartylglycosaminuria,,AGA gene,N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase,3.5.1.26,,,,,,,,,,,,,,Abnormal AGA processing,,NA,,,,,,,,,,,
356,,208400,Aspartylglycosaminuria,,AGA gene,N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase,3.5.1.26,Glycine,,DB00145,,,,,,Direct interaction ( Mechanistic A),A,activity modification of a genetically defective protein,,,Low AGA activity,,NA,https://www.nature.com/articles/srep37583/figures/5,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120323/,https://www.ncbi.nlm.nih.gov/pubmed/23601642,,,,,,,,
357,,208400,Aspartylglycosaminuria,,AGA gene,N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase,3.5.1.26,Recombinant human Aspartylglucosamidase,"There is a combined evidence demonstrates that a high dose ERT with AGA in newborn AGU mice is up to twofold more effective in reducing the amount of the accumulated storage material from the brain tissue than ERT in adult AGU animals, indicating the importance of early detection and treatment of the disease. https://www.ncbi.nlm.nih.gov/pubmed/20607610",NA,ECO:0005542,,,,,Direct interaction ( Mechanistic A),A,direct complementation of genetically defective protein,,,pathology in many somatic tissues,,HP:0000924*,https://www.ncbi.nlm.nih.gov/pubmed/10657992,https://www.ncbi.nlm.nih.gov/pubmed/20607610/,https://www.ncbi.nlm.nih.gov/pubmed/15342551/,,https://www.ncbi.nlm.nih.gov/pubmed/27906067,,,,,,
358,,208400,Aspartylglycosaminuria,,AGA gene,N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase,3.5.1.26,,,,,,,,,,,,,,accumulating substance aspartylglucosamine from ( Metaboic abnormality)*,,HP:0001939*,,,,,,,,,,,
359,,208400,Aspartylglycosaminuria,,AGA gene,N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase,3.5.1.26,,,,,,,,,,,,,,High amount of Man2GlcNAc2-Asn in in nonneuronal tissues ( Metabolism abnormality)*,,HP:0001939*,,,,,,,,,,,
360,,208400,Aspartylglycosaminuria,,AGA gene,N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase,3.5.1.26,,,,,,,,,,,,,,High amount of aspartylglucosamine in brain tissue (( Metabolism abnormality)*),,HP:0001939*,,,,,,,,,,,
361,,208400,Aspartylglycosaminuria,,AGA gene,N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase,3.5.1.26,Gene therapy (wild-type Ad-AGA),"The  injections  of  recombinant  viruses in vivo into  theAGU  mouse  brain  showed  no  inflammation  peak  orgliosis related to the viral injection, but mild periventricu-lar  microglial  activation  persisted  throughout  the  wholefollow-up  time.  The  AGA  immunostaining  prevailed  inthe  ependymal  cells  lining  the  ventricles  and  expressedAGA  was  also  found  in  the  surrounding  brain  areas.
Other reports of adenovirus-mediated gene expression inthe brain have indicated inflammation during the first 2weeks   after  injection 

https://www.sciencedirect.com/science/article/pii/030645229500068T 
https://www.ncbi.nlm.nih.gov/pubmed/9930336",NA,ECO:0005542,,,,,Direct interaction ( Mechanistic A),A,direct complementation of a genetically defective protein by gene therapy,,,Low expression of AGA enzyme,,HP:0001939*,https://www.ncbi.nlm.nih.gov/pubmed/9930336/,,,,,,,,,,
362,,208400,Aspartylglycosaminuria,,AGA gene,N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase,3.5.1.26,,,,,,,,,,,,,,Liver lysosomal storage abnormality,,,,,,,,,,,,,
363,,208400,Aspartylglycosaminuria,,AGA gene,N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase,3.5.1.26,,,,,,,,,,,,,,Brain lysosomal storage disease,,,,,,,,,,,,,
364,,208400,Aspartylglycosaminuria,,AGA gene,N(4)-(beta-N-acetylglucosaminyl)-L-asparaginase,3.5.1.26,,,,,,,,,,,,,,ipsilateral brain neuronal storage abnormalities,,,https://www.ncbi.nlm.nih.gov/pubmed/16518877/,,,,,,,,,,
365,33,# 277460,Ataxia with vitamin E deficiency,,TTPA gene,α-tocopherol transfer protein,P49638,vitamin E,"There is a common note in different reserachs refers to the importance of early managment by Vitamin E supplements since it limits disease progression and it can reverse some of the clinical manifestation (e.x ataxia and the intellectual deficit), if it was interoduced early in life. Therefore, early diagnosis is paramount.",DB00163,ECO:0000352,,,,,Symptomatic (C),C,metabolite replacement,functional complementation of a genetically defective protein,,Disease progression (Rapidly progressive)*,,HP:0003678*,https://www.ncbi.nlm.nih.gov/pubmed/20301317,https://www.ncbi.nlm.nih.gov/pubmed/20301419,https://www.ncbi.nlm.nih.gov/books/NBK1241/,https://www.ncbi.nlm.nih.gov/pubmed/15300460,,,,,,,
366,,# 277460,Ataxia with vitamin E deficiency,,TTPA gene,α-tocopherol transfer protein,P49638,,,,,,,,,,,,symptomatic treatment procedure,,Abnormal vitamin E level(Vitamin E deficiency)*,,HP:0100513*,,,,,,,,,,,
367,,# 277460,Ataxia with vitamin E deficiency,,TTPA gene,α-tocopherol transfer protein,P49638,,,,,,,,,,,,,,Ataxia,,HP:0001251,https://www.ncbi.nlm.nih.gov/pubmed/9931538,https://www.ncbi.nlm.nih.gov/pubmed/11554913,,,,,,,,,
368,,# 277460,Ataxia with vitamin E deficiency,,TTPA gene,α-tocopherol transfer protein,P49638,,,,,,,,,,,,,,Neurological abnormalitis,,HP:0000707,https://www.ncbi.nlm.nih.gov/pubmed/11554913,https://www.ncbi.nlm.nih.gov/pubmed/15300460,,,,,,,,,
369,,# 277460,Ataxia with vitamin E deficiency,,TTPA gene,α-tocopherol transfer protein,P49638,RRR-α-tocopherol,,DB14002,ECO:0000352,,,,,Functional interaction (B),B,functional complementation of a genetically defective protein,activity modification of a genetically defective protein,,High urinary LTE4 excretion (Abnormality of leukotriene metabolism)*,,HP:0030390*,https://www.sciencedirect.com/science/article/pii/S0022347699704245?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/15300460,,,,,,,,,
370,,# 277460,Ataxia with vitamin E deficiency,,TTPA gene,α-tocopherol transfer protein,P49638,,,,,,,,,,,,,,Abnormal H50 (The erythrocyte resistance to oxidative stress),,NA,,,,,,,,,,,
371,34,#208900,Ataxia Telangectesia,,ATM,ATM serine/threonine kinase,2.7.11.21,myo-inositol,,DB13178,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,neurological malfunction,,HP:0000707,https://academic.oup.com/bmb/article/81-82/1/129/283634#3543182,,,,,,,,,,
372,,#208900,Ataxia Telangectesia,,ATM,ATM serine/threonine kinase,2.7.11.21,,,,,,,,,,,,,,immune dysfunctions,,HP:0002715,,,,,,,,,,,
373,,#208900,Ataxia Telangectesia,,ATM,ATM serine/threonine kinase,2.7.11.21,Alpha lipoic acid,,DB00166,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,Neuronal death,,HP:0002529,https://academic.oup.com/bmb/article/81-82/1/129/283634#3543182,,,,,,,,,,
374,,#208900,Ataxia Telangectesia,,ATM,ATM serine/threonine kinase,2.7.11.21,,,,,,,,,,,,,,Oxidative stress,,HP:0025464,,,,,,,,,,,
375,,#208900,Ataxia Telangectesia,,ATM,ATM serine/threonine kinase,2.7.11.21,nicotinamide,,DB02701,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,Abnormal levels of urine total alkanes,,NA,https://academic.oup.com/bmb/article/81-82/1/129/283634#3543182,,,,,,,,,,
376,,#208900,Ataxia Telangectesia,,ATM,ATM serine/threonine kinase,2.7.11.21,,,,,,,,,,,,,,Oxidative stress,,HP:0025464,,,,,,,,,,,
377,,#208900,Ataxia Telangectesia,,ATM,ATM serine/threonine kinase,2.7.11.21,Alpha-lipoic acid + nicotinamide,,DB00166+DB02701,ECO:0007121,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,Abnormal serum fast ORAC(oxygen reduced absorbance capacity),,NA,,,,,,,,,,,
378,,#208900,Ataxia Telangectesia,,ATM,ATM serine/threonine kinase,2.7.11.21,,,,,,,,,,,,,,Abnormal lymphocyte counts,,HP:0040088,https://academic.oup.com/bmb/article/81-82/1/129/283634#3543182,,,,,,,,,,
379,,#208900,Ataxia Telangectesia,,ATM,ATM serine/threonine kinase,2.7.11.21,Immunoglobulin replacement therap,,DB00028,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,Recurrent infection,,HP:0002719,https://www.ncbi.nlm.nih.gov/pubmed/28318010,,,,,,,,,,
380,,#208900,Ataxia Telangectesia,,ATM,ATM serine/threonine kinase,2.7.11.21,amantadine,,DB00915,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,Ataxia,,HP:0001251,https://www.ncbi.nlm.nih.gov/pubmed/22550086/,,,,,,,,,,
381,,#208900,Ataxia Telangectesia,,ATM,ATM serine/threonine kinase,2.7.11.21,,,,,,,,,,,,,,involuntary movements,,HP:0004305,,,,,,,,,,,
382,,#208900,Ataxia Telangectesia,,ATM,ATM serine/threonine kinase,2.7.11.21,,,,,,,,,,,,,,parkinsonism,,HP:0001300,,,,,,,,,,,
383,,#208900,Ataxia Telangectesia,,ATM,ATM serine/threonine kinase,2.7.11.21,clonazepam,,DB01068,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,myoclonuic Jerk,,HP:0001336,https://www.ncbi.nlm.nih.gov/pubmed/26232052/,,,,,,,,,,
384,,#208900,Ataxia Telangectesia,,ATM,ATM serine/threonine kinase,2.7.11.21,,,,,,,,,,,,,,Poor fine motor skills,,HP:0007010,,,,,,,,,,,
385,,#208900,Ataxia Telangectesia,,ATM,ATM serine/threonine kinase,2.7.11.21,,,,,,,,,,,,,,Voice tremor,,HP:0012477,,,,,,,,,,,
386,,#208900,Ataxia Telangectesia,,ATM,ATM serine/threonine kinase,2.7.11.21,,,,,,,,,,,,,,Poor intelligibility,,HP:0001249,,,,,,,,,,,
387,35,# 208920,Ataxia-oculomotor apraxia type 1,,APTX gene,Aprataxin,3.1.12.2,CoQ10,,DB09270,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,lack of strenght,,HP:0003750,https://www.ncbi.nlm.nih.gov/pubmed/28277561,,,,,,,,,,
388,,# 208920,Ataxia-oculomotor apraxia type 1,,APTX gene,Aprataxin,3.1.12.2,,,,,,,,,,,,,,seizures,,HP:0001250,,,,,,,,,,,
389,36,# 209300,Atransferrinemia,,TF gene,transferrin,P02787,Human apotransferrin,,CHEBI:2786,ECO:0007121,,,,,Direct interaction ( Mechanistic A),A,direct complementation of genetically defective protein,,,hypochromic anemia,,HP:0001931,https://clinicaltrials.gov/ct2/results?cond=Atransferrinemia%C2%A0&term=&cntry=&state=&city=&dist=,,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1682235/,,,,,,
390,,# 209300,Atransferrinemia,,TF gene,transferrin,P02787,Deferoxamine,,DB00746,ECO:0000352,,,,,Supportive (C),C,functional complementation of a genetically defective protein,symptomatic treatment procedure,,hypochromic anemia,,HP:0001931,https://www.ncbi.nlm.nih.gov/pubmed/8187613,,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1682235/,,,,,,
391,,# 209300,Atransferrinemia,,TF gene,transferrin,P02787,Ferrous sulfate,"Oral iron is given as a supplementary treatment to improve the outcome of Plasma transufsion. ""Plasma transfusion, as a natural source of transferrin, leads to Hb synthesis. Since the excess iron is unavailable for erythropoiesis in this disease, and transferrin‐bound iron uptake by TfR1 is the only known means of iron delivery for erythropoiesis,3 iron supply during the period in which serum transferrin molecules are present may increase the amount of iron transported to marrow and augment Hb synthesis. https://www.ncbi.nlm.nih.gov/pubmed/28895280",DB13257,ECO:0000352,,,,,Supportive (C),C,symptomatic treatment procedure,functional complementation of a genetically defective protein,,Decreased hemoglobin,,HP:0001903,https://www.ncbi.nlm.nih.gov/pubmed/28895280,,,,,,,,,,
392,,# 209300,Atransferrinemia,,TF gene,transferrin,P02787,,,,,,,,,,,,,,High ferritin level,,HP:0003281,,,,,,,,,,,
393,37,162350,Autosomal dominant neuronal ceroid lipofuscinosis 4B,,DNAJC5A,DnaJ homolog subfamily C member 5(cysteine string PROTEIN),Q9H3Z4,No treatment avilable in DDIEM,"Symptomatic treatment can be successful in mitigating the manifestations of NCL. Seizures, sleep-related problems, malnutrition, gastroesophageal reflux, pneumonia, sialorrhea, hyperactivity and behavior problems, psychosis, anxiety, spasticity, Parkinsonian symptoms, and dystonia can be palliated. https://www.ncbi.nlm.nih.gov/books/NBK1428/#ncl.Management",,,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,,,HP:0003281,https://www.ncbi.nlm.nih.gov/books/NBK1428/#ncl.Management,,,,,,,,,,
394,38,256730,Infantile Neuronal Ceroid Lipofuscinosis,,PPT1,PALMITOYL-PROTEIN THIOESTERASE,3.1.2.22,Cystagon,Overall no significant clinical positive effect of Cystagon was seen in the current study involving four patients. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755542/,DB00847,ECO:0007121,,,,,Functional interaction ( Mechanistic B),B,functional complementation of a genetically defective protein,,,progression of neurodegeneration,,HP:0002344,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3755542/,,https://clinicaltrials.gov/ct2/show/NCT00028262?cond=neuronal+ceroid+lipofuscinosis&draw=2&rank=13,,,,,,,,
395,,256730,Infantile Neuronal Ceroid Lipofuscinosis,,PPT1,PALMITOYL-PROTEIN THIOESTERASE,3.1.2.22,N-Acetylcysteine+cysteamine bitartrate,"A combination therapy with cysteamine bitartrate and N-acetylcysteine is associated with delay of isoelectric EEG, depletion of GRODs, and subjective benefits as reported by parents and physicians. https://www.ncbi.nlm.nih.gov/pubmed/24997880",DB06151+DB00847,ECO:0007121,,,,,Functional interaction ( Mechanistic B),B,functional complementation of a genetically defective protein,,,granular osmiophilic deposits (GROD),,HP:0003657,https://www.ncbi.nlm.nih.gov/pubmed/24997880,,,,,,,,,,
396,,256730,Infantile Neuronal Ceroid Lipofuscinosis,,PPT1,PALMITOYL-PROTEIN THIOESTERASE,3.1.2.22,,,,,,,,,,,,,,irritability,,HP:0000737,,,,,,,,,,,
397,,256730,Infantile Neuronal Ceroid Lipofuscinosis,,PPT1,PALMITOYL-PROTEIN THIOESTERASE,3.1.2.22,,,,,,,,,,,,,,Defected alertness,,HP:0004372,,,,,,,,,,,
398,,256730,Infantile Neuronal Ceroid Lipofuscinosis,,PPT1,PALMITOYL-PROTEIN THIOESTERASE,3.1.2.22,,,,,,,,,,,,,,Isoelectric electroencephalogram,,HP:0002353,,,,,,,,,,,
399,,256730,Infantile Neuronal Ceroid Lipofuscinosis,,PPT1,PALMITOYL-PROTEIN THIOESTERASE,3.1.2.22,δ-tocopherol (DT),,DB11251,ECO:0001565,,,,,Functional interaction ( Mechanistic B),B,functional complementation of a genetically defective protein,,,cognitive deficits,,HP:0100543,https://www.ncbi.nlm.nih.gov/pubmed/29631617,,,,,,,,,,
400,,256730,Infantile Neuronal Ceroid Lipofuscinosis,,PPT1,PALMITOYL-PROTEIN THIOESTERASE,3.1.2.22,hydroxypropyl-β-cyclodextrin (HPBCD),,NA,ECO:0001565,,,,,Functional interaction ( Mechanistic B),B,functional complementation of a genetically defective protein,,,brain atrophy,,HP:0012444,,,,,,,,,,,
401,,256730,Infantile Neuronal Ceroid Lipofuscinosis,,PPT1,PALMITOYL-PROTEIN THIOESTERASE,3.1.2.22,δ-tocopherol (DT) + hydroxypropyl-β-cyclodextrin (HPBCD),A combination therapy of δ-tocopherol and HPBCD further improved the effect compared to that of either drug used as a single therapy.,DB11251,ECO:0001565,,,,,Functional interaction ( Mechanistic B),B,functional complementation of a genetically defective protein,,,Lipid accumulation( Abnorality in lipid meabolism)*,,HP:0003119*,,,,,,,,,,,
402,,256730,Infantile Neuronal Ceroid Lipofuscinosis,,PPT1,PALMITOYL-PROTEIN THIOESTERASE,3.1.2.22,,,,,,,,,,,,,,Lysosomal enlargment (Abnormality of lysosomal metabolism)*,,HP:0004356*,,,,,,,,,,,
403,,256730,Infantile Neuronal Ceroid Lipofuscinosis,,PPT1,PALMITOYL-PROTEIN THIOESTERASE,3.1.2.22,Recombinant human palmitoyl-protein thioesterase 1 ( PPT1),,NA,ECO:0001565,,,,,Direct interaction ( Mechanistic A),A,direct complementation of genetically defective protein,,,Enlarged lysosomes in NCL NSCs and fibroblasts (Abnormality of lysosomal metabolism)*,,HP:0004356*,,,,,,,,,,,
404,39,# 204200,Juvenile Neuronal Ceroid Lipofuscinosis CLN2,,CLN3,battenin,Q13286,Mycophenolate mofetil,,DB00688,ECO:0007121/ECO:0005542,,,,,Symptomatic (C),C,symptomatic treatment procedure,,"Drug name: The primary outcome of the study was to check tolaribilty to treatment. The drug was well tolarated https://link.springer.com/chapter/10.1007%2F8904_2018_113. 

However, there were no definite effects on measured autoimmunity or clinical outcomes in the setting of short-term use of CellCept(Mycophenolate mofetil).

The brief exposure to treatment was useful to study short-term safety risks and support future long-term studies, but it “did not allow clinical insights into potential efficacy,” researchers stated in https://battendiseasenews.com/2018/06/27/cellcept-safe-but-ineffective-phase-2-clinical-trial-cln3-disease/",The primary outcome of the study was to check tolaribilty to treatment. The drug was well tolarated,,HP:0004356*,,,https://clinicaltrials.gov/ct2/show/results/NCT01399047?cond=neuronal+ceroid+lipofuscinosis&rank=1&sect=X70156#outcome1,https://battendiseasenews.com/2018/06/27/cellcept-safe-but-ineffective-phase-2-clinical-trial-cln3-disease/,https://link.springer.com/chapter/10.1007%2F8904_2018_113,,,,,,
405,,# 204200,Juvenile Neuronal Ceroid Lipofuscinosis CLN2,,CLN3,battenin,Q13286,carbenoxolone,,DB02329,ECO:0005542,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Drug name: Study has been conducted invivo and invitro in mice. https://www.ncbi.nlm.nih.gov/pubmed/29660499,Blood-brain barrier (BBB) impairment,,NA,,,https://www.ncbi.nlm.nih.gov/pubmed/29660499,https://battendiseasenews.com/2018/06/27/cellcept-safe-but-ineffective-phase-2-clinical-trial-cln3-disease/,https://link.springer.com/chapter/10.1007%2F8904_2018_113,,,,,,
406,,# 204200,Juvenile Neuronal Ceroid Lipofuscinosis CLN2,,CLN3,battenin,Q13286,,,,,,,,,,,,,,Low cell autofluorescence,,NA,,,,,,,,,,,
407,,# 204200,Juvenile Neuronal Ceroid Lipofuscinosis CLN2,,CLN3,battenin,Q13286,,,,,,,,,,,,,,membrane fluidity alterations,,NA,,,,,,,,,,,
408,,# 204200,Juvenile Neuronal Ceroid Lipofuscinosis CLN2,,CLN3,battenin,Q13286,,,,,,,,,,,,,,extended G1 interval,,HP:0011018,,,,,,,,,,,
409,40,# 601780,Late infantile neuronal ceroid lipofuscinoses CLN6,,CLN6,"CLN6, transmembrane ER protein",NO Human id,scAVV9.CB.CLN6,,NA,ECO:0007121,,,,,Direct interaction ( Mechanistic A),A,direct complementation of a genetically defective protein by gene therapy,,Drug name: under investgation/ aim is to slow the neurodegeneration progression HP:0002344,,,HP:0011018,,,http://www.orpha.net/consor/cgi-bin/OC_Exp.php?lng=EN&Expert=168491,,https://clinicaltrials.gov/ct2/show/NCT02725580?cond=neuronal+ceroid+lipofuscinosis&draw=2&rank=14,,,,,,
410,41,# 204500,Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TRIPEPTIDYL PEPTIDASE I,EC 3.4.14.9,cerliponase alfa,,DB13173,ECO:0007121/ECO:0000352,,,,,Functional interaction ( Mechanistic B),B,functional complementation of a genetically defective protein,,,neurologic deficits,,HP:0000707,https://clinicaltrials.gov/ct2/show/NCT01907087,https://www.ncbi.nlm.nih.gov/pubmed/28589525/,https://www.ncbi.nlm.nih.gov/pubmed/29688815/,https://emedicine.medscape.com/article/1178391-treatment,https://www.ncbi.nlm.nih.gov/pubmed/24938720,,,,,,
411,,# 204500,Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TRIPEPTIDYL PEPTIDASE I,EC 3.4.14.9,,,,,,,,,,,,,,cognitive dysfunction,,HP:0100543,,,,,,,,,,,
412,,# 204500,Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TRIPEPTIDYL PEPTIDASE I,EC 3.4.14.9,,,,,,,,,,,,,,brain atrophy,,HP:0012444,,,,,,,,,,,
413,,# 204500,Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TRIPEPTIDYL PEPTIDASE I,EC 3.4.14.9,,,,,,,,,,,,,,loss of ambulation,,HP:0002540,,,,,,,,,,,
414,,# 204500,Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TRIPEPTIDYL PEPTIDASE I,EC 3.4.14.9,,,,,,,,,,,,,,,,,,,,,,,,,,,
415,,# 204500,Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TRIPEPTIDYL PEPTIDASE I,EC 3.4.14.9,,,,,,,,,,,,,,,,,,,,,,,,,,,
416,,# 204500,Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TRIPEPTIDYL PEPTIDASE I,EC 3.4.14.9,,,,,,,,,,,,,,,,,,,,,,,,,,,
417,,# 204500,Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TRIPEPTIDYL PEPTIDASE I,EC 3.4.14.9,,,,,,,,,,,,,,,,,,,,,,,,,,,
418,,# 204500,Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TRIPEPTIDYL PEPTIDASE I,EC 3.4.14.9,,,,,,,,,,,,,,,,,,,,,,,,,,,
419,,# 204500,Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TRIPEPTIDYL PEPTIDASE I,EC 3.4.14.9,,,,,,,,,,,,,,,,,,,,,,,,,,,
420,,# 204500,Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TRIPEPTIDYL PEPTIDASE I,EC 3.4.14.9,AAVrh.10CUhCLN2,,NA,ECO:0007121,,,,,Direct interaction ( Mechanistic A),A,direct complementation of a genetically defective protein by gene therapy,,Drug name: under investgation/ aim is to slow the neurodegeneration progression,,,,,,https://clinicaltrials.gov/ct2/show/NCT01161576?cond=neuronal+ceroid+lipofuscinosis&draw=2&rank=8,,,,,,,,
421,,# 204500,Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TRIPEPTIDYL PEPTIDASE I,EC 3.4.14.9,AAV2CUhCLN2,,NA,ECO:0007121,,,,,Direct interaction ( Mechanistic A),A,direct complementation of a genetically defective protein by gene therapy,,Drug name: under investgation/ aim is to slow the neurodegeneration progression,,,,,,https://clinicaltrials.gov/ct2/show/NCT00151216?cond=neuronal+ceroid+lipofuscinosis&draw=2&rank=9,https://emedicine.medscape.com/article/1178391-treatment,,,,,,,
422,,# 204500,Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TRIPEPTIDYL PEPTIDASE I,EC 3.4.14.9,δ-tocopherol (DT),,DB11251,ECO:0001565,,,,,Functional interaction ( Mechanistic B),B,functional complementation of a genetically defective protein,,,cognitive deficits,,HP:0100543,,,https://www.ncbi.nlm.nih.gov/pubmed/29631617,https://emedicine.medscape.com/article/1178391-treatment,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4263309/,,,,,,
423,,# 204500,Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TRIPEPTIDYL PEPTIDASE I,EC 3.4.14.9,hydroxypropyl-β-cyclodextrin (HPBCD),,NA,ECO:0001565,,,,,Functional interaction ( Mechanistic B),B,functional complementation of a genetically defective protein,,,brain atrophy,,HP:0012444,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5891977/,,,,,,,,
424,,# 204500,Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TRIPEPTIDYL PEPTIDASE I,EC 3.4.14.9,recombinant human tripeptidyl peptidase-1 (rhTPP1),,NA,ECO:0001565,,,,,Direct interaction ( Mechanistic A),A,direct complementation of genetically defective protein,,,neurological disease,,HP:0000707,,,https://www.prnewswire.com/news-releases/new-england-journal-of-medicine-published-open-label-study-showing-brineura-cerliponase-alfa-reduced-the-rate-of-clinical-decline-of-children-with-cln2-disease-a-form-of-batten-disease-300635669.html,https://www.ncbi.nlm.nih.gov/pubmed/24938720,,,,,,,
425,,# 204500,Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TRIPEPTIDYL PEPTIDASE I,EC 3.4.14.9,BMN 190 (cerliponase alfa),,DB13173,ECO:0007121,,,,,Direct interaction ( Mechanistic A),A,direct complementation of genetically defective protein,,,neurologic deficits,,HP:0000707,,,https://clinicaltrials.gov/ct2/show/NCT01907087,https://www.ncbi.nlm.nih.gov/pubmed/24938720,,,,,,,
426,,# 204500,Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TRIPEPTIDYL PEPTIDASE I,EC 3.4.14.9,,,,,,,,,,,,,,cognitive dysfunction,,HP:0100543,,,,,,,,,,,
427,,# 204500,Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TRIPEPTIDYL PEPTIDASE I,EC 3.4.14.9,,,,,,,,,,,,,,brain atrophy,,HP:0012444,,,,,,,,,,,
428,,# 204500,Late infantile neuronal ceroid lipofuscinoses CLN2,,TPP1,TRIPEPTIDYL PEPTIDASE I,EC 3.4.14.9,,,,,,,,,,,,,,loss of ambulation,,HP:0002540,,,,,,,,,,,
429,42,# 612016,Autosomal recessive spinocerebellar ataxia 9,,ADCK3,"Atypical kinase COQ8A, mitochondrial",1.3.5.1,CoQ10(ubiquinone),,DB09270,ECO:0007121,comp. htz c.[895C > T] + [1358delT] exons 7 and 11 p.[Arg299Trp] + [ Leu453Argfs*24],,,,Functional interaction ( Mechanistic B),B,functional complementation of a genetically defective protein,,"Drug name:                                 Mutation that didn't benefit the treatment:  E551K  in one patient & A compound heterozygotes for( R213W,  G272V) in another.  https://www.ncbi.nlm.nih.gov/pubmed/18319072                                                                                                                                                                                                       ; Duplication mutation on ADCK3/CABC1 https://www.ncbi.nlm.nih.gov/pubmed/27793482",tremor,,HP:0001298,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3843540/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427193/,https://www.ncbi.nlm.nih.gov/pubmed/28125198,https://www.ncbi.nlm.nih.gov/pubmed/24164873,,,,,,,
430,,# 612016,Autosomal recessive spinocerebellar ataxia 9,,ADCK3,"Atypical kinase COQ8A, mitochondrial",1.3.5.1,,,,,,,,,,,,,,Drawing inabiliity,,MP:0004144,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3843540/,,,,,,,,,,
431,,# 612016,Autosomal recessive spinocerebellar ataxia 9,,ADCK3,"Atypical kinase COQ8A, mitochondrial",1.3.5.1,,,,,comp. htz c.1523 T > C exon13 + del exons 3 to 15 p.Phe508Ser,,,,,,,,,Myoclonus,,HP:0002180,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3843540/,https://www.ncbi.nlm.nih.gov/pubmed/24164873,,,,,,,,,
432,,# 612016,Autosomal recessive spinocerebellar ataxia 9,,ADCK3,"Atypical kinase COQ8A, mitochondrial",1.3.5.1,,,,,comp. htz c.1523 T > C exon13 + del exons 3 to 15 p.Phe508Ser,,,,,,,,,Dystonia,,HP:0001332,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3843540/,https://www.ncbi.nlm.nih.gov/pubmed/24164873,,,,,,,,,
433,,# 612016,Autosomal recessive spinocerebellar ataxia 9,,ADCK3,"Atypical kinase COQ8A, mitochondrial",1.3.5.1,,,,,Hetero c.[1541A→G] + [1750_1752 delACC],,,,,,,,,exercise intolerance,,HP:0012211,https://www.ncbi.nlm.nih.gov/pubmed/18319074,,,,,,,,,,
434,,# 612016,Autosomal recessive spinocerebellar ataxia 9,,ADCK3,"Atypical kinase COQ8A, mitochondrial",1.3.5.1,,,,,G272D https://www.ncbi.nlm.nih.gov/pubmed/18319072,,,,,,,,"Phenotypes improved: Although there was a slight improvement of patient 4 on COQ10 , but a progressive cerebellar ataxia appeared 2 years later. https://www.ncbi.nlm.nih.gov/pubmed/18319072 https://www.ncbi.nlm.nih.gov/pubmed/15326254/",,,,https://www.ncbi.nlm.nih.gov/pubmed/15326254/,,,,,,,,,,
435,,# 612016,Autosomal recessive spinocerebellar ataxia 9,,ADCK3,"Atypical kinase COQ8A, mitochondrial",1.3.5.1,,,,,,,,,,,,,"Phenotypes improved: Although there was a slight improvement of patient 4 on COQ10 , but a progressive cerebellar ataxia appeared 2 years later. https://www.ncbi.nlm.nih.gov/pubmed/18319072 https://www.ncbi.nlm.nih.gov/pubmed/15326254/",hyperlactatemia,,HP:0003128,https://www.ncbi.nlm.nih.gov/pubmed/15326254/,,,,,,,,,,
436,,# 612016,Autosomal recessive spinocerebellar ataxia 9,,ADCK3,"Atypical kinase COQ8A, mitochondrial",1.3.5.1,,,,,Homozygous deletion (c.504del_CT),,,,,,,,,Speech problem,,HP:0002167,https://www.ncbi.nlm.nih.gov/pubmed/26818466,,,,,,,,,,
437,,# 612016,Autosomal recessive spinocerebellar ataxia 9,,ADCK3,"Atypical kinase COQ8A, mitochondrial",1.3.5.1,,,,,,,,,,,,,,Gait abnormality,,HP:0001288,,,,,,,,,,,
438,,# 612016,Autosomal recessive spinocerebellar ataxia 9,,ADCK3,"Atypical kinase COQ8A, mitochondrial",1.3.5.1,,,,,,,,,,,,,,Neurological abormalities,,HP:0000707,https://www.ncbi.nlm.nih.gov/pubmed/26818466,,,,,,,,,,
439,,# 612016,Autosomal recessive spinocerebellar ataxia 9,,ADCK3,"Atypical kinase COQ8A, mitochondrial",1.3.5.1,,,,,Homozygous deletion (c.1511_1512delCT) that leads to a premature truncation of the protein (p. Ala504fs),,,,,,,,,Fatigue,,HP:0012378,https://www.ncbi.nlm.nih.gov/pubmed/29159460,,,,,,,,,,
440,,# 612016,Autosomal recessive spinocerebellar ataxia 9,,ADCK3,"Atypical kinase COQ8A, mitochondrial",1.3.5.1,,,,,,,,,,,,,,High ataxia score ( Ataxia)*,,HP:0001251*,,,,,,,,,,,
441,,# 612016,Autosomal recessive spinocerebellar ataxia 9,,ADCK3,"Atypical kinase COQ8A, mitochondrial",1.3.5.1,,,,,homozygous frameshift mutation (c.1844_1845insG) in the C-terminus of mitochondrial atypical kinase COQ8A,,,,,,,,,Myoclonic abnormalities(Myoclouns)*,,HP:0001336*,https://www.ncbi.nlm.nih.gov/pubmed/29159460,https://www.ncbi.nlm.nih.gov/pubmed/24218524,,,,,,,,,
442,,# 612016,Autosomal recessive spinocerebellar ataxia 9,,ADCK3,"Atypical kinase COQ8A, mitochondrial",1.3.5.1,,,,,,,,,,,,,,ataxic gait,,HP:0002066,,,,,,,,,,,
443,,# 612016,Autosomal recessive spinocerebellar ataxia 9,,ADCK3,"Atypical kinase COQ8A, mitochondrial",1.3.5.1,,,,,,,,,,,,,,dysarthric speech,,HP:0001260,,,,,,,,,,,
444,,# 612016,Autosomal recessive spinocerebellar ataxia 9,,ADCK3,"Atypical kinase COQ8A, mitochondrial",1.3.5.1,idebenone,"Drug name: A switch to idebenone treatment resulted in clinical and metabolic worsening, which disappeared with subsequent CoQ10 treatment. https://www.ncbi.nlm.nih.gov/pubmed/15326254/                                       Drug not only failed to improve his condition but also worsened the course of the disease and was therefore discontinued after 7 months. https://www.ncbi.nlm.nih.gov/pubmed/18319072.  In another patient, the myoclonus was aggravated by idebenone. She recovered her previous status after its withdrawal. https://www.ncbi.nlm.nih.gov/pubmed/24164873",DB09081,ECO:0000352,,,,,,,,,,,,HP:0001260,https://www.ncbi.nlm.nih.gov/pubmed/15326254/,,,,,,,,,,
445,,# 612016,Autosomal recessive spinocerebellar ataxia 9,,ADCK3,"Atypical kinase COQ8A, mitochondrial",1.3.5.1,Sodium Valproate,,DB00313,,,,,,Symptomatic (C),,symptomatic treatment procedure,,,seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427298/,,,,,,,,,,
446,42,# 607091,B4GALT1-CDG (CDG-IId),,GALT1 gene,"beta-1,4-galactosyl transferase.",2.4.1.274,galactose supplementation,Drug name: Treatment is under trial.,DB11735,ECO:0007121,,,,,Symptomatic (C),C,dietary supplementation,,,,,HP:0001250,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427298/,,https://clinicaltrials.gov/ct2/show/NCT02955264,,,,,,,,
447,43,# 602579,CDG-Ib,,MPI,Mannose-6-phosphate isomerase,5.3.1.8,mannose supply,,DB12907,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein,,,Metabolism abnormality,,HP:0001939,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2427298/,,https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf,https://www.ncbi.nlm.nih.gov/pubmed/12756558,,,,,,,
448,,# 602579,CDG-Ib,,MPI,Mannose-6-phosphate isomerase,5.3.1.8,,,,,,,,,,,,,,hypoproteinemia,,MP:0005567,,,,,,,,,,,
449,,# 602579,CDG-Ib,,MPI,Mannose-6-phosphate isomerase,5.3.1.8,,,,,,,,,,,,,,blood coagulation,,HP:0001928,,,,,,,,,,,
450,,# 602579,CDG-Ib,,MPI,Mannose-6-phosphate isomerase,5.3.1.8,,,,,,,,,,,,,,protein-losing enteropathy,,HP:0002243,,,,,,,,,,,
451,,# 602579,CDG-Ib,,MPI,Mannose-6-phosphate isomerase,5.3.1.8,,,,,,,,,,,,,,hypoglycaemia,,HP:0001943,https://www.ncbi.nlm.nih.gov/pubmed/10484808,,,,,,,,,,
452,,# 602579,CDG-Ib,,MPI,Mannose-6-phosphate isomerase,5.3.1.8,,,,,,,,,,,,,,Hypoglycosylation of serum glycoproteins,,NA,https://www.ncbi.nlm.nih.gov/pubmed/9525984,,,,,,,,,,
453,,# 602579,CDG-Ib,,MPI,Mannose-6-phosphate isomerase,5.3.1.8,,,,,,,,,,,,,,urinary tract infection,,HP:0000010,,,,,,,,,,,
454,,#614921,PGM1 DEFICIENCY ( PGM1-CDG),,PGM1,Phosphoglucomutase-1,5.4.2.2,D- Galactose,,DB11735,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein,,,Abnormal aPTT level,,HP:0003645,https://www.ncbi.nlm.nih.gov/pubmed/28617415,,,,,,,,,,
455,,#614921,PGM1 DEFICIENCY ( PGM1-CDG),,PGM1,Phosphoglucomutase-1,5.4.2.2,,,,,,,,,,,,,,Abnormal AST level (Abnormal liver enzymes)*,,HP:0002910,,,,,,,,,,,
456,,#614921,PGM1 DEFICIENCY ( PGM1-CDG),,PGM1,Phosphoglucomutase-1,5.4.2.2,,,,,,,,,,,,,,Abnormal ALT level(Abnormal liver enzymes)*,,HP:0002910,,,,,,,,,,,
457,,#614921,PGM1 DEFICIENCY ( PGM1-CDG),,PGM1,Phosphoglucomutase-1,5.4.2.2,,,,,,,,,,,,,,Abnormal Antithrombin-III levels,,HP:0001976,,,,,,,,,,,
458,,#614921,PGM1 DEFICIENCY ( PGM1-CDG),,PGM1,Phosphoglucomutase-1,5.4.2.2,,,,,,,,,,,,,,,,,,,,,,,,,,,
459,44,# 266265,CDG IIc,,SLC35C1,GDP-fucose transporter 1,Q96A29,fucose therapy,,DB03485,ECO:0001565,,,,,Functional interaction (B),B,functional complementation of a genetically defective protein,,,Abnormal Golgi located fucosylation,,NA,http://www.jbc.org/content/282/14/10762.long#ref-14,,https://pdfs.semanticscholar.org/7753/abad26acee41547592d5a3a65b0483eff767.pdf,,,,"espite the successful correction of immunodeficiency-related defects in CDG IIc (LAD II), correction of the delayed psychomotor development was expected to be more difficult to achieve. However, the patient showed significant psychomotor improvement while on fucose therapy.",,,,
460,,# 266265,CDG IIc,,SLC35C1,GDP-fucose transporter 1,Q96A29,,,,,,,,,,,,,,Abnormal fucosylation state of glycoconjugates.,,NA,,,,,,,,,,,
461,,# 266265,CDG IIc,,SLC35C1,GDP-fucose transporter 1,Q96A29,,,,ECO:0005542,,,,,,,,,,Abnormal selectin ligand function,,NA,http://www.bloodjournal.org/content/94/12/3976.abstract?ijkey=201ceaaf5f2f21a180c7df639f863d067551bca5&keytype2=tf_ipsecsha,,,,,,,,,,
462,,# 266265,CDG IIc,,SLC35C1,GDP-fucose transporter 1,Q96A29,,,,ECO:0005542,,,,,,,,,,Neutropenia,,HP:0001875,http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,,,,,,,,,,
463,45,# 241510,Childhood hypophosphatasia,,ALPL gene,Alkaline phosphatase,3.1.3.1,Asfotase Alfa,,DB09105,ECO:0000352,,,,,Direct interaction ( Mechanistic A),A,direct complementation of genetically defective protein,,,Abnormal developmental milestones,,HP:0012759,http://www.bloodjournal.org/content/101/5/1705.abstract?ijkey=beed53c4a4e057b537c85d82cccb6b2438abbafa&keytype2=tf_ipsecsha&sso-checked=true,,https://www.ncbi.nlm.nih.gov/pubmed/22397652/,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4824800/,,"ENB-0040, an enzyme-replacement therapy, was associated with improved findings on skeletal radiographs and improved pulmonary and physical function in infants and young children with life-threatening hypophosphatasia. (Funded by Enobia Pharma and Shriners Hospitals for Children; ClinicalTrials.gov number, NCT00744042.).",,"Bone-targeted enzyme replacement therapy (asfotase alfa, now Strensiq™) was approved for HPP in Japan (July, 2015), and for pediatric-onset HPP in Canada (August, 2015), Europe (August, 2015), and the USA (October, 2015). Supportive treatment includes hydration and restriction of dietary calcium and perhaps administration of calciuretics for infants with hypercalcemia and hypercalciuria [35, 36]. Management of the respiratory complications of perinatal and infantile HPP may be complex as multiple factors compromise their pulmonary function [108]. Vitamin B6-dependent seizures can respond temporarily to pyridoxine administration.",,
464,,# 241510,Childhood hypophosphatasia,,ALPL gene,Alkaline phosphatase,3.1.3.1,,,,,,,,,,,,,,deteriorating pulmonary function,,HP:0005952,,,,,,,,,,,
465,,# 241510,Childhood hypophosphatasia,,ALPL gene,Alkaline phosphatase,3.1.3.1,,,,,,,,,,,,,,Decreased physical function,,HP:0025142,,,,,,,,,,,
466,,# 241510,Childhood hypophosphatasia,,ALPL gene,Alkaline phosphatase,3.1.3.1,,,,,,,,,,,,,,failure-to-thrive,,HP:0001508,,,,,,,,,,,
467,,# 241510,Childhood hypophosphatasia,,ALPL gene,Alkaline phosphatase,3.1.3.1,,,,,,,,,,,,,,Dental Defects,,HP:0000164,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3144124/,,,,,,,,
468,,# 241510,Childhood hypophosphatasia,,ALPL gene,Alkaline phosphatase,3.1.3.1,pyridoxal,,DB00147,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,epilepsy,,HP:0001250,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3316461/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096504/,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,https://www.researchgate.net/publication/8668575_A_successful_treatment_with_pyridoxal_phosphate_for_West_syndrome_in_hypophosphatasia,,,,,
469,46,# 308050,CHILD syndrome,,NSDHL gene,NAD(P) dependent steroid dehydrogenase-like,Q3US15*,simvastatin,,DB00641,ECO:0000352,,,,,Functional interaction ( Mechanistic B),B,functional complementation of a defective protein by inhibition,,,Accumulation of toxic metabolites in cholesterol biosynthetic pathway,,HP:0001939*,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487/,,,,,,,,
470,,# 308050,CHILD syndrome,,NSDHL gene,NAD(P) dependent steroid dehydrogenase-like,Q3US15*,,,,,,,,,,,,,,ichthyosiform erythematous plaques,,HP:0008064,,,,,,,,,,,
471,,# 308050,CHILD syndrome,,NSDHL gene,NAD(P) dependent steroid dehydrogenase-like,Q3US15*,,,,,,,,,,,,,,waxy scaling plaques,,HP:0040189*,,,,,,,,,,,
472,,# 308050,CHILD syndrome,,NSDHL gene,NAD(P) dependent steroid dehydrogenase-like,Q3US15*,,,,,,,,,,,,,,inflammation,,MP:0001845,,,,,,,,,,,
473,,# 308050,CHILD syndrome,,NSDHL gene,NAD(P) dependent steroid dehydrogenase-like,Q3US15*,,,,,,,,,,,,,,skin thickening,,HP:0100725,,,,,,,,,,,
474,,# 308050,CHILD syndrome,,NSDHL gene,NAD(P) dependent steroid dehydrogenase-like,Q3US15*,lovastatin+cholesterol,,DB00227+DB04540,ECO:0000352,,,,,Functional interaction (B),B,functional complementation of a defective protein by inhibition,,,Cutaneous abnormalities,,MP:00011911,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487/,,,,,,,,
475,,# 308050,CHILD syndrome,,NSDHL gene,NAD(P) dependent steroid dehydrogenase-like,Q3US15*,,,,,,,,,,,,,,Ichthyosiform erythroderma,,HP:0007431,,,,,,,,,,,
476,,# 308050,CHILD syndrome,,NSDHL gene,NAD(P) dependent steroid dehydrogenase-like,Q3US15*,ketoconazole,,DB01026,ECO:0000352,,,,,Functional interaction (B),B,functional complementation of a genetically defective protein,,,Cutaneous abnormalities,,MP:0001191,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909487/,,,,,,,,
477,,# 308050,CHILD syndrome,,NSDHL gene,NAD(P) dependent steroid dehydrogenase-like,Q3US15*,simvastatin+cholesterol,,DB00641+ DB04540,ECO:0000352,,,,,Functional interaction (B),B,functional complementation of a defective protein by inhibition,,,Ichthyosiform erythroderma,,HP:0007431,,,,,,,,,,,
478,,# 308050,CHILD syndrome,,NSDHL gene,NAD(P) dependent steroid dehydrogenase-like,Q3US15*,,,,,,,,,,,,,,Itchy skin,,HP:0000989,,,,,,,,,,,
479,,# 308050,CHILD syndrome,,NSDHL gene,NAD(P) dependent steroid dehydrogenase-like,Q3US15*,,,,,,,,,,,,,,Scaling Skin,,HP:0040189,,,,,,,,,,,
480,,# 308050,CHILD syndrome,,NSDHL gene,NAD(P) dependent steroid dehydrogenase-like,Q3US15*,,,,,,,,,,,,,,Erythema,,HP:0010783,,,,,,,,,,,
481,,# 308050,CHILD syndrome,,NSDHL gene,NAD(P) dependent steroid dehydrogenase-like,Q3US15*,,,,,,,,,,,,,,Verruciform plaques(verruciform xanthomas)*,,HP:0031517*,,,https://www.ncbi.nlm.nih.gov/pubmed/29341259,,,,,,,,
482,,# 308050,CHILD syndrome,,NSDHL gene,NAD(P) dependent steroid dehydrogenase-like,Q3US15*,,,,,,,,,,,,,,VX‐like lesions,,NA,,,,,,,,,,,
483,,# 308050,CHILD syndrome,,NSDHL gene,NAD(P) dependent steroid dehydrogenase-like,Q3US15*,Retinoids,,CHEBI:26537,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,Scaling Skin,,HP:0040189,,,https://www.ncbi.nlm.nih.gov/pubmed/29392821,,,,,,,,
484,,# 308050,CHILD syndrome,,NSDHL gene,NAD(P) dependent steroid dehydrogenase-like,Q3US15*,Glycolic acid+lovastatin+cholesterol,,DB03085+DB00227+DB04540,ECO:0000352,,,,,,,,,,verruciform xanthomas,,HP:0031517,,,,,,,,,,,
485,47,# 275630,Chanarin-Dorfman syndrome,,ABHD5 gene,adipose triglyceride lipase (ATGL),3.1.1.3,Emollients +acitretin,,A06AA+DB00459,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,Ichthyosis,,HP:0008064,,,https://www.ncbi.nlm.nih.gov/pubmed/?term=Acitretin%E2%80%90Responsive+Ichthyosis+in+Chanarin–Dorfman+Syndrome+with+a+Novel+Mutation+in+the+ABHD5%2FCGI%E2%80%9058+Gene,https://onlinelibrary.wiley.com/doi/abs/10.1111/pde.12170,,,,,,,
486,,# 275630,Chanarin-Dorfman syndrome,,ABHD5 gene,adipose triglyceride lipase (ATGL),3.1.1.3,,,,,,,,,,,,,,Erythroderma,,HP:0001019,,,https://www.ncbi.nlm.nih.gov/pubmed/21981352/,,,,,,,,
487,,# 275630,Chanarin-Dorfman syndrome,,ABHD5 gene,adipose triglyceride lipase (ATGL),3.1.1.3,,,,,,,,,,,,,,Diffuse scaling(Skin Scaling)*,,HP:0040189*,,,https://www.ncbi.nlm.nih.gov/pubmed/21981352/,,,,,,,,
488,,# 275630,Chanarin-Dorfman syndrome,,ABHD5 gene,adipose triglyceride lipase (ATGL),3.1.1.3,,,,,,,,,,,,,,Collodion membrane(Nonbullous congenital ichthyosiform erythroderma)*,,HP:0007479*,,,https://www.ncbi.nlm.nih.gov/pubmed/21981352/,,,,,,,,
489,,# 275630,Chanarin-Dorfman syndrome,,ABHD5 gene,adipose triglyceride lipase (ATGL),3.1.1.3,,,,,,,,,,,,,,Erythema,,HP:0010783,,,https://www.ncbi.nlm.nih.gov/pubmed/28979034,,,,,,,,
490,,# 275630,Chanarin-Dorfman syndrome,,ABHD5 gene,adipose triglyceride lipase (ATGL),3.1.1.3,,,,,,,,,,,,,,Scaling,,HP:0040189,,,https://www.ncbi.nlm.nih.gov/pubmed/28979034,,,,,,,,
491,,# 275630,Chanarin-Dorfman syndrome,,ABHD5 gene,adipose triglyceride lipase (ATGL),3.1.1.3,Emollients,,A06AA,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,erythema,,HP:0010783,,,https://www.ncbi.nlm.nih.gov/pubmed/?term=Dorfman-Chanarin+syndrome+in+two+female+siblings%3A+A+case+report+and+discussion+on+approach+%26+management,,,,,,,,
492,,# 275630,Chanarin-Dorfman syndrome,,ABHD5 gene,adipose triglyceride lipase (ATGL),3.1.1.3,,,,,,,,,,,,,,Ichthyosis,,HP:0008064,,,https://www.ncbi.nlm.nih.gov/pubmed/28636073,,,,,,,,
493,,# 275630,Chanarin-Dorfman syndrome,,ABHD5 gene,adipose triglyceride lipase (ATGL),3.1.1.3,,,,,,,,,,,,,,Pruritis,,HP:0000989,,,https://www.ncbi.nlm.nih.gov/pubmed/28636073,,,,,,,,
494,,# 275630,Chanarin-Dorfman syndrome,,ABHD5 gene,adipose triglyceride lipase (ATGL),3.1.1.3,,,,,,,,,,,,,,scaling,,HP:0040189,,,,,,,,,,,
495,,# 275630,Chanarin-Dorfman syndrome,,ABHD5 gene,adipose triglyceride lipase (ATGL),3.1.1.3,Ursodeoxycholic acid,,DB01586,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,steatohepatitis,,HP:0001397,,,https://www.ncbi.nlm.nih.gov/pubmed/?term=Dorfman-Chanarin+syndrome+in+two+female+siblings%3A+A+case+report+and+discussion+on+approach+%26+management,,,,,,,,
496,,# 275630,Chanarin-Dorfman syndrome,,ABHD5 gene,adipose triglyceride lipase (ATGL),3.1.1.3,vitamin E,,DB00163,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,steatohepatitis,,HP:0001397,,,https://www.ncbi.nlm.nih.gov/pubmed/?term=Dorfman-Chanarin+syndrome+in+two+female+siblings%3A+A+case+report+and+discussion+on+approach+%26+management,,,,,,,,
497,49,# 213700,Cerebrotendinous xanthomatosis,,CYP27A1,Cholestanetriol 26-monooxygenase,1.14.15.15,chenodeoxycholic acid,,DB06777,ECO:0000352,,,,,Functional interaction (B),B,metabolite replacement,,,neurological dysfunctions,,HP:0000707,,,https://www.ncbi.nlm.nih.gov/pubmed/29260356,,,,,,,,
498,,# 213700,Cerebrotendinous xanthomatosis,,CYP27A1,Cholestanetriol 26-monooxygenase,1.14.15.15,lovastatin,,DB00227,ECO:0000352,,,,,Symptomatic (C),C,functional complementation of a genetically defective protein,symptomatic treatment procedure,,cataracts,,HP:0000518,,,,,,,,,,,
499,,# 213700,Cerebrotendinous xanthomatosis,,CYP27A1,Cholestanetriol 26-monooxygenase,1.14.15.15,,,,,,,,,,,,,,chronic diarrhoea,,MP:0001665,,,,,,,,,,,
500,,# 213700,Cerebrotendinous xanthomatosis,,CYP27A1,Cholestanetriol 26-monooxygenase,1.14.15.15,,,,,,,,,,,,,,Elevated serum cholesterol,,HP:0003124,,,,,,,,,,,
501,,# 213700,Cerebrotendinous xanthomatosis,,CYP27A1,Cholestanetriol 26-monooxygenase,1.14.15.15,,,,,,,,,,,,,,EEG abnormalities,,HP:0002353,,,,,,,,,,,
502,,# 213700,Cerebrotendinous xanthomatosis,,CYP27A1,Cholestanetriol 26-monooxygenase,1.14.15.15,,,,,,,,,,,,,,abnormal gait,,HP:0001288,,,,,,,,,,,
503,,# 213700,Cerebrotendinous xanthomatosis,,CYP27A1,Cholestanetriol 26-monooxygenase,1.14.15.15,,,,,,,,,,,,,,Cognitive impairment,,HP:0100543,,,,,,,,,,,
504,,# 213700,Cerebrotendinous xanthomatosis,,CYP27A1,Cholestanetriol 26-monooxygenase,1.14.15.15,,,,,,,,,,,,,,seizure,,HP:0001250,,,,,,,,,,,
505,,# 213700,Cerebrotendinous xanthomatosis,,CYP27A1,Cholestanetriol 26-monooxygenase,1.14.15.15,coenzyme Q10,,DB09270,ECO:0000352,,,,,Symptomatic (C),C,functional complementation of a genetically defective protein,symptomatic treatment procedure,,muscle weakness,,HP:0001324,,,https://rarediseases.info.nih.gov/diseases/5622/cerebrotendinous-xanthomatosis,,,,,,,,
506,50,# 613068,Cerebral folate deficiency,,FOLR1,Folate receptor alpha,P15328,folinic acid,,DB00650,ECO:0000352,,,,,Symptomatic (C),C,functional complementation of a genetically defective protein,,,Impaired social interaction,,HP:0000735,,,,,,,,,,,
507,,# 613068,Cerebral folate deficiency,,FOLR1,Folate receptor alpha,P15328,,,,,,,,,,,,,,Movement disorder,,HP:0100022,,,,,,,,,,,
508,,# 613068,Cerebral folate deficiency,,MTHFR,Methylenetetrahydrofolate reductase,1.5.1.20,,,,,,,,,,,,,,seizure,,HP:0001250,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4727671/,,,,,,,,
509,,# 613068,Cerebral folate deficiency,,MTHFR,Methylenetetrahydrofolate reductase,1.5.1.20,,,,,,,,,,,,,,Myoclonic seizures,,HP:0002123,,,https://academic.oup.com/brain/article/135/7/2002/357230,,,,,,,,
510,,# 613068,Cerebral folate deficiency,,MTHFR,Methylenetetrahydrofolate reductase,1.5.1.20,,,,,,,,,,,,,,astatic seizures,,HP:0010819,,,,,,,,,,,
511,51,# 125700,Central diabetes insipidus,,AVP,Hormone ( Arginine vasopressin),1.5.1.20,Desmopressin,,DB00035,ECO:0007121,,,,,Direct Interaction (A),A,direct complementation of genetically defective protein,,,polyuria,,HP:0000103,,,https://clinicaltrials.gov/ct2/show/NCT01280188?cond=Central+diabetes+insipidus&rank=1,,,,,,,,
512,,# 125700,Central diabetes insipidus,,AVP,Hormone ( Arginine vasopressin),1.5.1.20,Vasopressin,,DB00067,,,,,,Direct Interaction (A),A,direct complementation of genetically defective protein,,,polydipsia,,MP:0001426,,,https://academic.oup.com/jcem/article/98/10/3958/2833930,,,,,,,,
513,,# 125700,Central diabetes insipidus,,AVP,Hormone ( Arginine vasopressin),1.5.1.20,,,,,,,,,,,,,,thirst,,HP:0001959,,,,,,,,,,,
514,,# 125700,Central diabetes insipidus,,AVP,Hormone ( Arginine vasopressin),1.5.1.20,chlorpropamide,,DB00672,ECO:0007121,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,Polyurea,,HP:0000103,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1517999/,,,,,,,,
515,,# 125700,Central diabetes insipidus,,AVP,Hormone ( Arginine vasopressin),1.5.1.20,Chlorpropamide + carbamazepine,This combined drug therapy proved effective in all three cases: the good antidiuretic effect of chlorpropamide at high dosage is impaired by hypoglycaemia; the combination of carbamazepine allowed the dosage of chlorpropamide to be decreased without impairment of the obtained antidiuretic effect and with avoidance of hypoglycaemia and other side effects. https://www.ncbi.nlm.nih.gov/pubmed/1220254,DB00672+DB00564,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Drug name: This combined drug therapy proved effective in all three cases: the good antidiuretic effect of chlorpropamide at high dosage is impaired by hypoglycaemia; the combination of carbamazepine allowed the dosage of chlorpropamide to be decreased without impairment of the obtained antidiuretic effect and with avoidance of hypoglycaemia and other side effects. https://www.ncbi.nlm.nih.gov/pubmed/1220254,chlorpropamide-induced hypoglycaemia (Hypoglycemia)*,,HP:0001943*,,,https://www.ncbi.nlm.nih.gov/pubmed/1220254,,,,,,,,
516,,# 125700,Central diabetes insipidus,,AVP,Hormone ( Arginine vasopressin),1.5.1.20,,,,,,,,,,,,,,Polyuria,,HP:0000103,,,,,,,,,,,
517,,# 125700,Central diabetes insipidus,,AVP,Hormone ( Arginine vasopressin),1.5.1.20,chlorpropamide+Hydrochlorothiazide,Some patients could only be fully controlled by the combination of chlorpropamide and hydrochlorothiazide.,DB00672+DB00999,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Drug name: Some patients could only be fully controlled by the combination of chlorpropamide and hydrochlorothiazide.,Ployuria,,HP:0000103,,,,,,,,,,,
518,,# 125700,Central diabetes insipidus,,AVP,Hormone ( Arginine vasopressin),1.5.1.20,,,,,,,,,,,,,,,,,,,,,,,,,,,
519,,# 125700,Central diabetes insipidus,,AVP,Hormone ( Arginine vasopressin),1.5.1.20,,,,,,,,,,,,,,,,,,,,,,,,,,,
520,,# 125700,Central diabetes insipidus,,AVP,Hormone ( Arginine vasopressin),1.5.1.20,Pitressin tannate in oil,,NA,ECO:0000352,,,,,Direct Interaction (A),A,direct complementation of genetically defective protein,,Drug name: The study was withdrawn.,Ployuria,,HP:0000103,,,https://www.ncbi.nlm.nih.gov/pubmed/3940717,,,,,,,,
521,,# 125700,Central diabetes insipidus,,AVP,Hormone ( Arginine vasopressin),1.5.1.20,Clofibrate,,DB00636,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,Ployuria,,HP:0000103,,,https://academic.oup.com/jcem/article/98/10/3958/2833930,,,,,,,,
522,,# 125700,Central diabetes insipidus,,AVP,Hormone ( Arginine vasopressin),1.5.1.20,,,,,,,,,,,,,,Hyposthenuria,,HP:0003158,,,,,,,,,,,
523,,# 125700,Central diabetes insipidus,,AVP,Hormone ( Arginine vasopressin),1.5.1.20,Indapamide,,DB00808,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,High serum osmolality,,NA,,,https://www.ncbi.nlm.nih.gov/pubmed/10510995,https://www.ncbi.nlm.nih.gov/pubmed/12016800,,,,,,,
524,,# 125700,Central diabetes insipidus,,AVP,Hormone ( Arginine vasopressin),1.5.1.20,,,,,,,,,,,,,,Ployuria,,HP:0000103,,,,,,,,,,,
525,,# 125700,Central diabetes insipidus,,AVP,Hormone ( Arginine vasopressin),1.5.1.20,,,,,,,,,,,,,,Reduced urinary osmolality,,HP:0003158,,,,,,,,,,,
526,,# 125700,Central diabetes insipidus,,AVP,Hormone ( Arginine vasopressin),1.5.1.20,dDAVP (1-Desamino-8-D Arginine Vasopressin),"Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447",DB00035,ECO:0000352,,,,,Direct interaction ( Mechanistic A),A,direct complementation of genetically defective protein,,"Drug name: Intranasal dDAVP, because of efficacy, long duration of action, and infrequent side effects, is the preferred treatment of neurogenic diabetes insipidus in children and adults.https://www.ncbi.nlm.nih.gov/pubmed/626447",Increased urine output,,HP:0000103,,,https://www.ncbi.nlm.nih.gov/pubmed/626447,,,,,,,,
527,,# 125700,Central diabetes insipidus,,AVP,Hormone ( Arginine vasopressin),1.5.1.20,,,,,,,,,,,,,,,,,,,,,,,,,,,
528,,# 125700,Central diabetes insipidus,,AVP,Hormone ( Arginine vasopressin),1.5.1.20,,,,,,,,,,,,,,,,,,,,,,,,,,,
529,52,# 212138,Carnitine-acylcarnitine translocase deficiency,,SLC25A20,carnitine-acylcarnitine translocase,1.5.1.20,Medium-chain triglycerides,,DB13959,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,functional complementation of a genetically defective protein,,developmental delay,,HP:0001263,,,https://rarediseases.info.nih.gov/diseases/1123/carnitine-acylcarnitine-translocase-deficiency,,,,,,,,
530,,# 212138,Carnitine-acylcarnitine translocase deficiency,,SLC25A20,carnitine-acylcarnitine translocase,1.5.1.20,carnitine,,DB00583,ECO:0000352,,,,,Functional interaction (B),B,metabolite replacement,functional complementation of a genetically defective protein,,epilepsy,,HP:0001250,,,https://www.ncbi.nlm.nih.gov/pubmed/17508264,Abstract,,,,,,,
531,53,* 601987,"Carnitine palmitoyltransferase I deficiency , muscle",,CPT1B gene,"carnitine O-palmitoyltransferase 1, muscle isoform",2.3.1.21,Medium-chain triglycerides,,DB13959,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,functional complementation of a genetically defective protein,,neurological damage,,HP:0000707,,,https://rarediseases.info.nih.gov/diseases/10325/carnitine-palmitoyltransferase-i-deficiency-muscle,,,,,,,,
532,,* 601987,"Carnitine palmitoyltransferase I deficiency , muscle",,CPT1B gene,"carnitine O-palmitoyltransferase 1, muscle isoform",2.3.1.21,,,,,,,,,,,,,,hypoglycemia,,HP:0001943,,,,,,,,,,,
533,54,# 255120,Carnitine palmitoyl transferase 1 deficiency,,CPT1A gene,carnitine palmitoyltransferase 1A,2.3.1.21,Triheptanoin,,DB11677,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,functional complementation of a genetically defective protein,,muscle pain,,HP:0003326,,,http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2015/08/WC500192013.pdf,,,,,,,,
534,,# 255120,Carnitine palmitoyl transferase 1 deficiency,,CPT1A gene,carnitine palmitoyltransferase 1A,2.3.1.21,,,,,,,,,,,,,,rhabdomyolysis,,HP:0003201,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2676979/,PMC2676979,,,,,,,
535,,# 255120,Carnitine palmitoyl transferase 1 deficiency,,CPT1A gene,carnitine palmitoyltransferase 1A,2.3.1.21,,,,,,,,,,,,,,abnormal SF-36 physical composite scores,,NA,,,,,,,,,,,
536,,# 255120,Carnitine palmitoyl transferase 1 deficiency,,CPT1A gene,carnitine palmitoyltransferase 1A,2.3.1.21,cornstarch,,DB11599,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,dietary regime modification,,Hypoglycemia,,HP:0001943,,,https://www.ncbi.nlm.nih.gov/pubmed/15669684,,,,,,,,
537,,# 255120,Carnitine palmitoyl transferase 1 deficiency,,CPT1A gene,carnitine palmitoyltransferase 1A,2.3.1.21,,,,,,,,,,,,,,Low growth rate (Abnormal growth)*,,HP:0001507*,,,,,,,,,,,
538,55,# 237300,Carbamoyl phosphate synthetase 1 deficiency,,CPS1 gene,Carbamoyl-phosphate synthase (ammonia,6.3.4.16,N-Carbamylglutamate,,DB06775,,,,,,Direct Interaction (A),A,activity modification of a genetically defective protein,,Active,hyperammonaemia,,MP:0005309,,,https://www.ncbi.nlm.nih.gov/pubmed/28281899,,,,,,,,
539,,# 237300,Carbamoyl phosphate synthetase 1 deficiency,,CPS1 gene,Carbamoyl-phosphate synthase (ammonia,6.3.4.16,N-acetyl-l-glutamate,,DB04075,,,,,,Direct Interaction (A),A,activity modification of a genetically defective protein,,,Acidemia,,HP:0001941,,,https://www.ncbi.nlm.nih.gov/pubmed/23649895,,,,,,,,
540,,# 237300,Carbamoyl phosphate synthetase 1 deficiency,,CPS1 gene,Carbamoyl-phosphate synthase (ammonia,6.3.4.16,Gene Therapy ??,,DB04075,,,,,,Direct Interaction (A),A,direct complementation of genetically defective protein by gene therapy,,Under trial,hyperammonaemia,,MP:0005309,,,http://medcraveonline.com/JPNC/JPNC-07-00273.php,,,,,,,,
541,56,# 253260,Biotinidase deficiency,,BTD gene,biotinidase,3.5.1.12,ORL-1B,,DB00121,,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Active,seizure,,HP:0001250,,,https://trialbulletin.com/lib/entry/ct-03269045,,,,,,,,
542,,# 253260,Biotinidase deficiency,,BTD gene,biotinidase,3.5.1.12,baclofen,,DB00181,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Active,dystonia,,HP:0001332,,,https://emedicine.medscape.com/article/942055-treatment,,,,,,,,
543,,# 253260,Biotinidase deficiency,,BTD gene,biotinidase,3.5.1.12,,,,,,,,,,,,,,Spasticity,,HP:0001257,,,,,,,,,,,
544,57,# 607483,Biotin-thiamine-responsive basal ganglia disease,,SLC19A3 gene,thiamine transporter,not available,Biotin+thiamine,,DB00121+DB00152,ECO:0000352,,,,,Symptomatic (C),C,functional complementation of a genetically defective protein,symptomatic treatment procedure,Active,seizures,,HP:0001250,,,https://www.ncbi.nlm.nih.gov/pubmed/27749535,https://www.ncbi.nlm.nih.gov/pubmed/31061755,,http://www.neurologyindia.com/article.asp?issn=0028-3886;year=2016;volume=64;issue=6;spage=1328;epage=1331;aulast=Muthusamy,,,,,
545,,# 607483,Biotin-thiamine-responsive basal ganglia disease,,SLC19A3 gene,thiamine transporter,not available,,,,,,,,,Symptomatic (C),C,,,,encephalopathy,,HP:0001298,,,https://www.ncbi.nlm.nih.gov/pubmed/27749535,https://www.ncbi.nlm.nih.gov/pubmed/31061755,https://www.ncbi.nlm.nih.gov/pubmed/24260777,,,,,,
546,,# 607483,Biotin-thiamine-responsive basal ganglia disease,,SLC19A3 gene,thiamine transporter,not available,,,,,,,,,,,,,,signal abnormality of the cortex,,HP:0030178,,,https://www.ncbi.nlm.nih.gov/pubmed/27749535,,,,,,,,
547,,# 607483,Biotin-thiamine-responsive basal ganglia disease,,SLC19A3 gene,thiamine transporter,not available,,,,,,,,,,,,,,Abnormal movement,,HP:0100022,,,https://www.ncbi.nlm.nih.gov/pubmed/27749535,,,,,,,,
548,,# 607483,Biotin-thiamine-responsive basal ganglia disease,,SLC19A3 gene,thiamine transporter,not available,,,,,,,,,,,,,,Dystonia,,HP:0001332,,,https://www.ncbi.nlm.nih.gov/pubmed/27749535,,,,,,,,
549,,# 607483,Biotin-thiamine-responsive basal ganglia disease,,SLC19A3 gene,thiamine transporter,not available,,,,,,,,,,,,,,Abnormal reflexes,,HP:0001347,,,https://www.ncbi.nlm.nih.gov/pubmed/27749535,,,,,,,,
550,,# 607483,Biotin-thiamine-responsive basal ganglia disease,,SLC19A3 gene,thiamine transporter,not available,L-dopa,,DB01235,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,dystonia,,HP:0001332,,,https://www.ncbi.nlm.nih.gov/pubmed/24260777,Abstract,,,,,,,
551,58,# 203750,Beta ketothiolase deficiency,,ACAT1 gene,Acetyl-CoA C-acetyltransferase.,2.3.1.9,glucose,,DB09341,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,functional complementation of a genetically defective protein,Active,Ketosis,,HP:0001946,,,https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1552-6569.2012.00772.x,,,,,,,,
552,,# 203750,Beta ketothiolase deficiency,,ACAT1 gene,Acetyl-CoA C-acetyltransferase.,2.3.1.9,carnitine,,DB00583,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,functional complementation of a genetically defective protein,,Organic aciduria,,HP:0001992,,,https://www.sciencedirect.com/science/article/pii/S1110863016300763,,,,,,,,
553,,# 203750,Beta ketothiolase deficiency,,ACAT1 gene,Acetyl-CoA C-acetyltransferase.,2.3.1.9,Bicitra,,DB09154,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,Acidosis,,HP:0001941,,,http://www.babysfirsttest.org/newborn-screening/conditions/beta-ketothiolase-deficiency,,,,,,,,
554,59,# 601678,Bartter Syndrome 1,,SLC12A1,Solute carrier family 12 member 1,Q13621,spironolactone+potassium+ACE-inhibitor,,DB00421+DB14500+C09A,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Active,electrolyte disturbances,,HP:0003111,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6233707/,,https://www.orpha.net/data/patho/GB/uk-Bartter.pdf,https://www.ncbi.nlm.nih.gov/pubmed/2646391,,,,,,,
555,,# 601678,Bartter Syndrome 1,,SLC12A1,Solute carrier family 12 member 1,Q13621,Acetazolamide,,DB00819,EC:0007121,,,,,Symptomatic (C),,symptomatic treatment procedure,,,Metabolic alkalosis,,HP:0200114,https://clinicaltrials.gov/ct2/results?cond=%22Bartter+syndrome%22,,https://www.orpha.net/data/patho/GB/uk-Bartter.pdf,https://www.ncbi.nlm.nih.gov/pubmed/2646391,,,,,,,
556,,# 601678,Bartter Syndrome 1,,SLC12A1,Solute carrier family 12 member 1,Q13621,,,,,,,,,,,,,,Hypokalemia Metabolic Alkalosis,,HP:0002900,,,,,,,,,,,
557,60,# 241200,Bartter Syndrome 2,,KCNJ1,ATP-sensitive inward rectifier potassium channel 1,P48048,,,,,,,,,,,,,,hypomagnesemia,,HP:0002917,https://www.ncbi.nlm.nih.gov/pubmed/2646391,,,,,,,,,,
558,61,# 602522,Bartter Syndrome 4,,BSND,barttin,Q8WZ55,Tanespimycin,,DB05134,ECO:0005542,,,,,Functional interaction ( Mechanistic B),B,activity modification of a genetically defective protein,,,Low plasma membrane expression of R8Lin kidney,,NA,https://www.ncbi.nlm.nih.gov/pubmed/24189473,,,,,,,,,,
559,,# 602522,Bartter Syndrome 4,,BSND,barttin,Q8WZ55,,,,,,,,,,,,,,Hypokalemia,,HP:0002900,,,,,,,,,,,
560,,# 602522,Bartter Syndrome 4,,BSND,barttin,Q8WZ55,,,,,,,,,,,,,,Metabolic alkalosis,,HP:0200114,,,,,,,,,,,
561,,# 602522,Bartter Syndrome 4,,BSND,barttin,Q8WZ55,,,,,,,,,,,,,,Sensorineural hearing impairment,,HP:0000407,,,,,,,,,,,
562,,# 602522,Bartter Syndrome 4,,BSND,barttin,Q8WZ55,,,,,,,,,,,,,,ER-associated degradation of R8L,,NA,,,,,,,,,,,
563,,# 602522,Bartter Syndrome 4,,BSND,barttin,Q8WZ55,,,,,,,,,,,,,,Mislocalization of R8L,,NA,,,,,,,,,,,
564,,# 602522,Bartter Syndrome 4,,BSND,barttin,Q8WZ55,Potassium Chloride,,DB00761,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,hypokalemia,,HP:0002900,https://www.ncbi.nlm.nih.gov/books/NBK442019/,,,,,,,,,,
565,,# 602522,Bartter Syndrome 4,,BSND,barttin,Q8WZ55,Naproxen,,DB00788,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,hypokalemia,,HP:0002900,https://www.nejm.org/doi/full/10.1056/NEJM197807132990214,,,,,,,,,,
566,,# 602522,Bartter Syndrome 4,,BSND,barttin,Q8WZ55,Niflumic acid,,DB04552,ECO:0001565,L155/ G345/ A349,"Those three mutants are localized in two different protein regions that, based on the crystal structure of bacterial CLC homologs, are expected to be exposed to the extracellular side of the channel, relatively close to each other, and are thus good candidates for being part of the potentiating NFA binding site",G167A / F213A,These two. mutations drastically altered general gating properties and are unlikely to be involved in NFA binding,Functional interaction (Mechanistic B),B,functional complementation of a genetically defective protein,,,Abnormal ClC-Ka function,,NA,https://www.ncbi.nlm.nih.gov/pubmed/20649569/,,,,,,,,,,
567,,# 602522,Bartter Syndrome 4,,BSND,barttin,Q8WZ55,,,,,"L155A, G345S and A349E",,,,,,,,,,,,,,,,,,,,,,
568,,# 602522,Bartter Syndrome 4,,BSND,barttin,Q8WZ55,,,,,,,,,,,,,,,,,,,,,,,,,,,
569,,# 602522,Bartter Syndrome 4,,BSND,barttin,Q8WZ55,,,,,,,,,,,,,,,,,,,,,,,,,,,
570,,# 607364,"BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,Chloride channel protein ClC-Kb,P51801,POTASSIUM-SPARING AGENTS,,C03D,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,,Deleterious prognosis,,NA,https://www.ncbi.nlm.nih.gov/pubmed/30387909,,,,,,,,,,
571,,# 607364,"BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,Chloride channel protein ClC-Kb,P51801,,,,,,,,,,,,,,Decreased life expectancy,,NA,,,,,,,,,,,
572,,# 607364,"BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,Chloride channel protein ClC-Kb,P51801,,,,,,,,,,,,,,Salt wasting,,HP:0000127,,,,,,,,,,,
573,,# 607364,"BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,Chloride channel protein ClC-Kb,P51801,,,,,,,,,,,,,,Growth retardation,,HP:0001510,,,,,,,,,,,
574,,# 607364,"BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,Chloride channel protein ClC-Kb,P51801,Indomethacin,,DB00328,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,,Deleterious prognosis,,NA,https://www.ncbi.nlm.nih.gov/pubmed/30387909,https://www.ncbi.nlm.nih.gov/pubmed/17185149?dopt=Abstract,,,,,,,,,
575,,# 607364,"BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,Chloride channel protein ClC-Kb,P51801,,,,,,,,,,,,,,Decreased life expectancy (Mortality)*,,HP:0040006*,,,,,,,,,,,
576,,# 607364,"BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,Chloride channel protein ClC-Kb,P51801,,,,,,,,,,,,,,Salt wasting,,HP:0000127,,,,,,,,,,,
577,,# 607364,"BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,Chloride channel protein ClC-Kb,P51801,Growth hormone,,DB00052,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,,Short stature,,HP:0004322,https://www.ncbi.nlm.nih.gov/pubmed/30387909,https://www.ncbi.nlm.nih.gov/pubmed/?term=Classic+Bartter+syndrome+complicated+with+profound+growth+hormone+deficiency%3A+a+case+report,,,,,,,,,
578,,# 607364,"BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,Chloride channel protein ClC-Kb,P51801,,,,,,,,,,,,,,Decreased serum IGF‐1,,HP:0030353,,,,,,,,,,,
579,,# 607364,"BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,Chloride channel protein ClC-Kb,P51801,,,,,,,,,,,,,,Failure to thrive,,HP:0001508,,,,,,,,,,,
580,,# 607364,"BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,Chloride channel protein ClC-Kb,P51801,Potassium,,DB14500,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,,Hypokalemia,,HP:0002900,https://www.ncbi.nlm.nih.gov/pubmed/17185149?dopt=Abstract,,,,,,,,,,
581,,# 607364,"BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,Chloride channel protein ClC-Kb,P51801,Magnesium,,DB14513,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,,Hypomagnesemia,,HP:0002917,https://www.sciencedirect.com/science/article/abs/pii/S0002962915356895?via%3Dihub,,,,,,,,,,
582,,# 607364,"BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,Chloride channel protein ClC-Kb,P51801,Sodium,,DB09395,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,,Hyponatremia,,HP:0002902,https://www.ncbi.nlm.nih.gov/pubmed/17185149?dopt=Abstract,,,,,,,,,,
583,,# 607364,"BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,Chloride channel protein ClC-Kb,P51801,Aminoglycoside (Geneticin),,DB04263,ECO:0001565,W610X,,,,Direct Interaction,A,direct complementation of genetically defective protein,,,Defected ClC-Kb expression,,NA,https://www.ncbi.nlm.nih.gov/pubmed/23772144?dopt=Abstract,,,,,,,,,,
584,,# 607364,"BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,Chloride channel protein ClC-Kb,P51801,Potassium+Indomethacin±Spironolactone,,DB14500+DB00328+ DB00421,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,,Short stature,,HP:0004322,https://www.ncbi.nlm.nih.gov/pubmed/28288174,,,,,,,,,,
585,,# 607364,"BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,Chloride channel protein ClC-Kb,P51801,Nonsteroidal anti-inflammatory drugs,,M01AX,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,,Elevated prostaglandin E2,,HP:0003566,https://www.ncbi.nlm.nih.gov/pubmed/24189473/,,,,,,,,,,
586,,# 607364,"BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,Chloride channel protein ClC-Kb,P51801,,,,,,,,,,,,,,Hypokalemia,,HP:0002900,,,,,,,,,,,
587,,# 607364,"BARTTER SYNDROME, TYPE 3; BARTS3",,CLCNKB,Chloride channel protein ClC-Kb,P51801,,,,,,,,,,,,,,High calcium excretion in urine,,HP:0002150,,,,,,,,,,,
588,,# 300971,"BARTTER SYNDROME, TYPE 5, ANTENATAL, TRANSIENT; BARTS5","Among antenatal Bartter syndrome, the transient form was defined as a regression of clinical symptoms and normalization of biologic parameters allowing the arrest of treatment. https://www.ncbi.nlm.nih.gov/pubmed/29146702
This condition can be successfully treated with close monitoring and fluid and electrolyte replacement, avoiding the potential harmful effects of indomethacin. This diagnosis is important for clinical management and parental counseling regarding overall patient prognosis. https://www.ncbi.nlm.nih.gov/pubmed/29594084",MAGED2,Melanoma-associated antigen D2,Q9UNF1,Electrolytes,,B05BB01,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,,Renal salt wasting,,HP:0000127,https://www.ncbi.nlm.nih.gov/pubmed/27120771,,,,,,,,,,
589,,# 300971,"BARTTER SYNDROME, TYPE 5, ANTENATAL, TRANSIENT; BARTS5",,MAGED2,Melanoma-associated antigen D2,Q9UNF1,Indomethacin,,DB00328,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,,,,,,,,,,,,,,,
590,62,302060,Barth syndrome,,TAZ gene,tafazzin ( Protein),Not available,Elamipretide,,DB11981,ECO:0007121,,,,,Functional interaction(Mechanistic B),B,functional complementation of a genetically defective protein,,,oxidative stress,,HP:0025464,https://mitochondrialdiseasenews.com/2018/03/09/stealth-biotherapeutics-completes-enrollment-elamipretide-trial-barth-syndrome/,https://clinicaltrials.gov/ct2/show/NCT03098797?cond=Elamipretide+in+Barth+syndrome&rank=1,,,,,,,,,
591,,302060,Barth syndrome,,TAZ gene,tafazzin ( Protein),Not available,,,,,,,,,,,,,,abnormal energy production in damaged mitochondria,,HP:0003287,https://clinicaltrials.gov/ct2/show/NCT03098797?cond=Barth+syndrome&rank=1,,,,,,,,,,
592,,302060,Barth syndrome,,TAZ gene,tafazzin ( Protein),Not available,,,,,,,,,,,,,,Fatigue,,HP:0012378,,,,,,,,,,,
593,,302060,Barth syndrome,,TAZ gene,tafazzin ( Protein),Not available,Granulocyte colony stimulating factor (G‐CSF),,DB00020,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,Neutropenia,,HP:0001875,https://www.ncbi.nlm.nih.gov/pubmed/15098233/,https://www.ncbi.nlm.nih.gov/pubmed/18632498/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3249181/,https://www.ncbi.nlm.nih.gov/pubmed/18632498/,https://www.ncbi.nlm.nih.gov/pubmed/31239752,https://www.ncbi.nlm.nih.gov/pubmed/23432031,,,,,
594,,302060,Barth syndrome,,TAZ gene,tafazzin ( Protein),Not available,,,,,,,,,,,,,,Recurrent infection,,HP:0002719,https://www.ncbi.nlm.nih.gov/pubmed/23432031,,,,,,,,,,
595,,302060,Barth syndrome,,TAZ gene,tafazzin ( Protein),Not available,Digoxin,,DB00390,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Drug name: Temporary improvemnet,Low ejection fraction,,HP:0012664,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1025545/,,,,,,,,,,
596,,302060,Barth syndrome,,TAZ gene,tafazzin ( Protein),Not available,,,,,,,,,,,,,,Tricusped incompetence,,HP:0005180,,,,,,,,,,,
597,,302060,Barth syndrome,,TAZ gene,tafazzin ( Protein),Not available,,,,,,,,,,,,,,Mitral incomptence,,HP:0001653,,,,,,,,,,,
598,,302060,Barth syndrome,,TAZ gene,tafazzin ( Protein),Not available,Pantothenic acid,,DB01783,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,Low myocardial function,,HP:0001638,https://www.ncbi.nlm.nih.gov/pubmed/7833193,,,,,,,,,,
599,,302060,Barth syndrome,,TAZ gene,tafazzin ( Protein),Not available,,,,,,,,,,,,,,T wave abnormalities,,HP:0005135,,,,,,,,,,,
600,,302060,Barth syndrome,,TAZ gene,tafazzin ( Protein),Not available,,,,,,,,,,,,,,Delayed Growth,,HP:0001510,,,,,,,,,,,
601,,302060,Barth syndrome,,TAZ gene,tafazzin ( Protein),Not available,,,,,,,,,,,,,,hypocholesterolaemia,,HP:0003146,,,,,,,,,,,
602,,302060,Barth syndrome,,TAZ gene,tafazzin ( Protein),Not available,,,,,,,,,,,,,,hyperuricaemia,,HP:0002149,,,,,,,,,,,
603,,302060,Barth syndrome,,TAZ gene,tafazzin ( Protein),Not available,,,,,,,,,,,,,,Neutropenia,,HP:0001875,,,,,,,,,,,
604,,302060,Barth syndrome,,TAZ gene,tafazzin ( Protein),Not available,Angiotensin-converting enzyme inhibitors / angiotensin II receptor blockers/ beta-blockers/ diuretics,,C09A/C09CA/C07/C03,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,Heart failure,,HP:0001635,https://www.ncbi.nlm.nih.gov/pubmed/31239752,,,,,,,,,,
605,,302060,Barth syndrome,,TAZ gene,tafazzin ( Protein),Not available,Angiotensin-converting enzyme inhibitors / angiotensin II receptor blockers/ beta-blockers/ diuretics + anticoagulate,,C09A/C09CA/C07/C04+B01A,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,,Atrial fibrillation,,HP:0005110,https://www.ncbi.nlm.nih.gov/pubmed/31239752,,,,,,,,,,
606,,302060,Barth syndrome,,TAZ gene,tafazzin ( Protein),Not available,Bezafibrate,,DB01393,ECO:0005542,,,,,,,symptomatic treatment procedure,,,Cardiac dysfunction,,HP:0001635,https://www.ncbi.nlm.nih.gov/pubmed/29695963/,https://www.ncbi.nlm.nih.gov/pubmed/28279226/,,,,,,,,,
607,,302060,Barth syndrome,,TAZ gene,tafazzin ( Protein),Not available,,,,,,,,,,,,,,Exercise intolerance,,HP:0003546,https://www.ncbi.nlm.nih.gov/pubmed/29695963/,,,,,,,,,,
608,,302060,Barth syndrome,,TAZ gene,tafazzin ( Protein),Not available,AAV9-TAZ,,NA,ECO:0005542,,,,,Direct Interaction ( Mechanistic A),A,direct complementatoin of a genetically defective protein by gene therapy,,,Abnormal cardiac protein (TAZ) expression,,NA,https://www.ncbi.nlm.nih.gov/pubmed/30788385/,https://www.ncbi.nlm.nih.gov/pubmed/30070157/,,,,,,,,,
609,,302060,Barth syndrome,,TAZ gene,tafazzin ( Protein),Not available,,,,,,,,,,,,,,Mitochondrial dysfunction,,HP:0003287,https://www.ncbi.nlm.nih.gov/pubmed/30070157/,,,,,,,,,,
610,,302060,Barth syndrome,,TAZ gene,tafazzin ( Protein),Not available,,,,,,,,,,,,,,Mueculoskeletal dysfunction,,HP:0001324,https://www.ncbi.nlm.nih.gov/pubmed/30070157/,,,,,,,,,,
611,,302060,Barth syndrome,,TAZ gene,tafazzin ( Protein),Not available,Digoxin+furosemide+captopril,,DB00390+DB00695+DB01197,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,,Cardiomegaly,,HP:0001640,https://www.ncbi.nlm.nih.gov/pubmed/20981509,,,,,,,,,,
612,,302060,Barth syndrome,,TAZ gene,tafazzin ( Protein),Not available,,,,,,,,,,,,,,Reduced ejection fraction,,HP:0012664,https://www.ncbi.nlm.nih.gov/pubmed/20981509,,,,,,,,,,
613,,302060,Barth syndrome,,TAZ gene,tafazzin ( Protein),Not available,,,,,,,,,,,,,,Developmetal delay,,HP:0001263,https://www.ncbi.nlm.nih.gov/pubmed/20981509,,,,,,,,,,
614,,302060,Barth syndrome,,TAZ gene,tafazzin ( Protein),Not available,,,,,,,,,,,,,,Abormal liver size,,HP:0002240,https://www.ncbi.nlm.nih.gov/pubmed/20981509,,,,,,,,,,
615,,302060,Barth syndrome,,TAZ gene,tafazzin ( Protein),Not available,,,,,,,,,,,,,,,,,,,,,,,,,,,
616,63,# 278000,Cholesteryl ester storage disease (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA gene,lysosomal acid lipase,P38571,sebelipase alfa,,DB11563,ECO:0000352/ECO:0005542,,,,,Direct Interaction ( Mechanistic A),A,direct complementation of genetically defective protein,,,High plasma cholesterol level*,,HP:0003107,https://rarediseases.org/rare-diseases/cholesteryl-ester-storage-disease/,https://www.ncbi.nlm.nih.gov/pubmed/27878737,,,,,,,,,
617,,# 278000,Cholesteryl ester storage disease (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA gene,lysosomal acid lipase,P38571,,,,,,,,,,,,,,hypertriglycemia,,HP:0002155,https://clinicaltrials.gov/ct2/show/NCT02376751?cond=Cholesteryl+ester+storage+disease&rank=4,,,,,,,,,,
618,,# 278000,Cholesteryl ester storage disease (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA gene,lysosomal acid lipase,P38571,,,,,,,,,,,,,,Abnormal liver function,,HP:0002910,,,,,,,,,,,
619,,# 278000,Cholesteryl ester storage disease (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA gene,lysosomal acid lipase,P38571,,,,,,,,,,,,,,Dyslipidemia,,HP:0003119,,,,,,,,,,,
620,,# 278000,Cholesteryl ester storage disease (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA gene,lysosomal acid lipase,P38571,,,,,,,,,,,,,,,,,,,,,,,,,,,
621,,# 278000,Cholesteryl ester storage disease (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA gene,lysosomal acid lipase,P38571,fenofibrate,,DB01039,ECO:0005542,,,,,Symptomatic (C),C,symptomatic treatment procedure,functional complementation of a genetcially defective protein,,Increased plasma triglycerides,,HP:0002155,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930475/,,,,,,,,,,
622,,# 278000,Cholesteryl ester storage disease (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA gene,lysosomal acid lipase,P38571,Simvastatin,,DB00641,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,functional complementation of a genetcially defective protein,,Hyperlipidemia,,HP:0003077,https://www.ncbi.nlm.nih.gov/pubmed/16848116,,,,,,,,,,
623,,# 278000,Cholesteryl ester storage disease (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA gene,lysosomal acid lipase,P38571,Lovastatin,Treatment success with statins has been mixed.,DB00227,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,functional complementation of a genetcially defective protein,,Increased LDL cholesterol,,HP:0003141,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC442441/,,,,,,,,,,
624,,# 278000,Cholesteryl ester storage disease (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA gene,lysosomal acid lipase,P38571,,,,,,,,,,,,,,Increased plasma triglycerides,,HP:0002155,,,,,,,,,,,
625,,# 278000,Cholesteryl ester storage disease (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA gene,lysosomal acid lipase,P38571,,,,,,,,,,,,,,Increased total cholesterol,,HP:0003124,,,,,,,,,,,
626,,# 278000,Cholesteryl ester storage disease (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA gene,lysosomal acid lipase,P38571,,,,,,,,,,,,,,Elevated urine mevalonate levels,,NA,,,,,,,,,,,
627,,# 278000,Cholesteryl ester storage disease (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA gene,lysosomal acid lipase,P38571,Colestyramine+Simivastatin,,DB01432+DB00641,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,functional complementation of a genetcially defective protein,,Dyslipidemia,,HP:0003119,https://www.ncbi.nlm.nih.gov/pubmed/1801793,https://www.sciencedirect.com/science/article/pii/S1521691810001101,,,,,,,,,
628,,# 278000,Cholesteryl ester storage disease (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA gene,lysosomal acid lipase,P38571,,,,,,,,,,,,,,Abnormal liver function,,HP:0002910,,,,,,,,,,,
629,,# 278000,Cholesteryl ester storage disease (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA gene,lysosomal acid lipase,P38571,Ezetimibe,,DB00973,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,functional complementation of a genetcially defective protein,,Dyslipidemia,,HP:0003119,https://www.ncbi.nlm.nih.gov/pubmed/29374495,,,,,,,,,,
630,,# 278000,Cholesteryl ester storage disease (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA gene,lysosomal acid lipase,P38571,,,,,,,,,,,,,,Abnormal liver function,,HP:0002910,,,,,,,,,,,
631,,# 278000,Cholesteryl ester storage disease (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA gene,lysosomal acid lipase,P38571,,,,,,,,,,,,,,,,,,,,,,,,,,,
632,,# 278000,Cholesteryl ester storage disease (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA gene,lysosomal acid lipase,P38571,,,,,,,,,,,,,,,,,,,,,,,,,,,
633,,# 278000,Cholesteryl ester storage disease (LYSOSOMAL ACID LIPASE DEFICIENCY),,LIPA gene,lysosomal acid lipase,P38571,,,,,,,,,,,,,,,,,,,,,,,,,,,
634,64,# 118600,Chondrocalcinosis 2,,ANKH gene,Progressive ankylosis protein homolog,Q9HCJ1,Colchicine(COL),"Effective in flares when used in combination with NSAIDs. It is also beneficial as prophylaxis for preventing recurrent flares. Oral COL should be preferred over the intravenous form. If contraindications present to use oral COL, then intravenous COL solution should be pre-diluted with 0.9% NaCl prior to infusion.",DB01394,ECO:0007121,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,Arthritis,,HP:0001369,https://clinicaltrials.gov/ct2/show/NCT03128905?cond=Chondrocalcinosis&draw=2&rank=2,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045115/,,,,,,,,,
635,,# 118600,Chondrocalcinosis 2,,ANKH gene,Progressive ankylosis protein homolog,Q9HCJ1,,,,,,,,,,,,,,Arthralgia,,HP:0002829,,,,,,,,,,,
636,,# 118600,Chondrocalcinosis 2,,ANKH gene,Progressive ankylosis protein homolog,Q9HCJ1,prednisone,Effective only in flares. Oral steroids should be preferred when joint involvement is polyarticular; intra-muscular steroids when contraindication to use oral steroids and joint involvement is polyarticular; intra-articular steroids when joint involvement is mono- or oligoarticular.  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/,DB00635,ECO:0000352/ECO:0007121,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,Arthritis,,HP:0001369,https://clinicaltrials.gov/ct2/show/NCT03128905?cond=Chondrocalcinosis&draw=2&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/27790033/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045115/,https://acrabstracts.org/abstract/anakinra-compared-to-prednisone-on-the-treatment-of-acute-cppd-crystal-arthritis-a-randomized-controlled-double-blind-study/,,,,,,,
637,,# 118600,Chondrocalcinosis 2,,ANKH gene,Progressive ankylosis protein homolog,Q9HCJ1,naproxen sodium,,DB00788,,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,Arthralgia,,HP:0002829,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045115/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045115/,https://acrabstracts.org/abstract/anakinra-compared-to-prednisone-on-the-treatment-of-acute-cppd-crystal-arthritis-a-randomized-controlled-double-blind-study/,,,,,,,
638,,# 118600,Chondrocalcinosis 2,,ANKH gene,Progressive ankylosis protein homolog,Q9HCJ1,,,,,,,,,,,,,,Recurrent repisode of flares (Recurrent)*,,HP:0025303,,,,,,,,,,,
639,,# 118600,Chondrocalcinosis 2,,ANKH gene,Progressive ankylosis protein homolog,Q9HCJ1,Anakinra/canakinuma,"Anakinra was administered as preventive therapy in one study"" https://www.ncbi.nlm.nih.gov/pubmed/19289295"". In another one, it was documented that the drug may be helpful to control flares in patients having CPP crystal-induced arthritis for which conventional therapies are ineffective or contra-indicated. https://www.ncbi.nlm.nih.gov/pubmed/23022422. 
The acute/subacute pseudogout or acute hydroxyapatite deposition arthritis should require extended duration of treatment with anakinra than in gouty arthritis . Moreover, adding anakinra to conventional drugs could show better efficacy than each drug alone. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4398911/
There have been case reports and case series of success with interleukin-1β inhibitors for both prophylaxis and treatment in patients with ESRD.15 16 However, there are no randomised controlled clinical studies to support efficacy. Furthermore, these therapies are only administered parenterally (which excludes our patient from treatment given her aversion to needles), and the cost of therapy can exceed US$100 000 annually. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/",DB00026/DB06168,ECO:0007121/ ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,Recurrent repisode of flares (Recurrent)*,,HP:0025303,https://www.ncbi.nlm.nih.gov/pubmed/29675606,https://www.ncbi.nlm.nih.gov/pubmed/19289295,https://acrabstracts.org/abstract/anakinra-compared-to-prednisone-on-the-treatment-of-acute-cppd-crystal-arthritis-a-randomized-controlled-double-blind-study/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6368924/,https://www.ncbi.nlm.nih.gov/pubmed/23022422?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/22832289,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/,,,,
640,,# 118600,Chondrocalcinosis 2,,ANKH gene,Progressive ankylosis protein homolog,Q9HCJ1,,,,,,,,,,,,,,Arthritis,,HP:0001369,https://www.ncbi.nlm.nih.gov/pubmed/23022422,https://www.ncbi.nlm.nih.gov/pubmed/25922564?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/18240249?dopt=Abstract,,,,,,,,
641,,# 118600,Chondrocalcinosis 2,,ANKH gene,Progressive ankylosis protein homolog,Q9HCJ1,,,,,,,,,,,,,,Refractory Arthritis,,HP:0031375,https://www.ncbi.nlm.nih.gov/pubmed/22658375,,,,,,,,,,
642,,# 118600,Chondrocalcinosis 2,,ANKH gene,Progressive ankylosis protein homolog,Q9HCJ1,,,,,,,,,,,,,,Synovitis,,HP:0100769,https://www.ncbi.nlm.nih.gov/pubmed/22341584?dopt=Abstract,,,,,,,,,,
643,,# 118600,Chondrocalcinosis 2,,ANKH gene,Progressive ankylosis protein homolog,Q9HCJ1,rilonacept,,DB06372,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,Recurrent repisode of flares (Recurrent)*,,HP:0025303,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6169684/,,,,,,,,,,
644,,# 118600,Chondrocalcinosis 2,,ANKH gene,Progressive ankylosis protein homolog,Q9HCJ1,methotrexate,"There is a contraversy about effectivness of methotrexate in treating ""Condrocalcinosis 2"" .. Details are in https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/ and https://www.ncbi.nlm.nih.gov/pubmed/22832286/",DB00563,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,swollen joint,,HP:0001386,https://www.ncbi.nlm.nih.gov/pubmed/29675606,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4379613/,https://www.ncbi.nlm.nih.gov/pubmed/25315665,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223155/,https://www.nature.com/articles/nrrheum.2010.182,,,,,,
645,,# 118600,Chondrocalcinosis 2,,ANKH gene,Progressive ankylosis protein homolog,Q9HCJ1,,,,,,,,,,,,,,Arthralgia,,HP:0002829,,,,,,,,,,,
646,,# 118600,Chondrocalcinosis 2,,ANKH gene,Progressive ankylosis protein homolog,Q9HCJ1,Hydroxychloroquine,,DB01611,ECO:0007121,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,swollen joint,,HP:0001386,https://www.ncbi.nlm.nih.gov/pubmed/9195122/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/,https://www.nature.com/articles/nrrheum.2010.182,,,,,,,,
647,,# 118600,Chondrocalcinosis 2,,ANKH gene,Progressive ankylosis protein homolog,Q9HCJ1,,,,,,,,,,,,,,Arthralgia,,HP:0002829,,,,,,,,,,,
648,,# 118600,Chondrocalcinosis 2,,ANKH gene,Progressive ankylosis protein homolog,Q9HCJ1,,,,,,,,,,,,,,Arthropathy,,HP:0003040,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/,,,,,,,,
649,,# 118600,Chondrocalcinosis 2,,ANKH gene,Progressive ankylosis protein homolog,Q9HCJ1,Probenecid,,DB01032,ECO:0001565,,,,,Functional interaction( Mechanistic B),,functional complementation of a genetically defective protein,,,Abnormality of phosphate homeostasis,,HP:0100529,https://www.ncbi.nlm.nih.gov/pubmed/7520501,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6411330/,,,,,,,,
650,,# 118600,Chondrocalcinosis 2,,ANKH gene,Progressive ankylosis protein homolog,Q9HCJ1,,,,,,,,,,,,,,,,,,,,,,,,,,,
651,65,118610,Chondrocalcinosis due to apatite crystal deposition,,ANKH gene,Progressive ankylosis protein homolog,Q9HCJ1,NSAIDs,,DB00788,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,acute arthritis,,HP:0001369,https://www.ncbi.nlm.nih.gov/pubmed/17541659,,,,,,,,,,
652,67,# 246700,Chylomicron retention disease,,SAR1B,Sar1b protein,Q9HCJ1,vitamin E,,DB00163,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,neurological abnormalities,,HP:0012638,https://rarediseases.info.nih.gov/diseases/9683/chylomicron-retention-disease,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915691/,https://www.ncbi.nlm.nih.gov/pubmed/23329770,,,,,,,,
653,,# 246700,Chylomicron retention disease,,SAR1B,Sar1b protein,Q9HCJ1,Alpha-tocopherol,,DB11251,,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,neurological abnormalities,,HP:0012638,https://rarediseases.info.nih.gov/diseases/9683/chylomicron-retention-disease,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5915691/,https://www.ncbi.nlm.nih.gov/pubmed/23329770,,,,,,,,
654,,# 246700,Chylomicron retention disease,,SAR1B,Sar1b protein,Q9HCJ1,,,,,,,,,,,,,,Abnormal Adipose tissue tocopherol level.,,NA,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4982212/,,,,,,,,,,
655,,# 246700,Chylomicron retention disease,,SAR1B,Sar1b protein,Q9HCJ1,Tocofersolan,"""Oral tocofersolan was more bio available than the water-soluble formulation in children with chronic cholestasis and similarly bio available in CF. This suggests that water-soluble vitamin E may represent an alternative to painful intramuscular vitamin E injections in chronic cholestasis, or other oral formulations in CF. However, the mechanism responsible for fat malabsorption in CRD concerns the absorptive phase as opposed to the digestive phase in CF and cholestatic syndromes. To our knowledge, no specific studies with these new vitamin E preparations have been conducted in CRD."" https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/",DB11635,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,No Studies were done on this drug.,,NA,https://www.ncbi.nlm.nih.gov/pubmed/27520363,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,,,,,,,,,
656,,# 246700,Chylomicron retention disease,,SAR1B,Sar1b protein,Q9HCJ1,Vitamin A+ Vitamin E,,DB00162+DB00163,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,Minor visual abnormalities,,HP:0000505,https://www.ncbi.nlm.nih.gov/pubmed/19285442/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,,,,,,,,,
657,,# 246700,Chylomicron retention disease,,SAR1B,Sar1b protein,Q9HCJ1,,,,,,,,,,,,,,Neurological abnormality,,HP:0012638,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,,,,,,,,,,
658,,# 246700,Chylomicron retention disease,,SAR1B,Sar1b protein,Q9HCJ1,,,,,,,,,,,,,,Muscular abnormality,,HP:0012638,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,,,,,,,,,,
659,,# 246700,Chylomicron retention disease,,SAR1B,Sar1b protein,Q9HCJ1,vitamin D,,DB11094,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,osteopenia,,HP:0000938,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,,,,,,,,,,
660,,# 246700,Chylomicron retention disease,,SAR1B,Sar1b protein,Q9HCJ1,,,,,,,,,,,,,,Vitamin D insufficiency,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,,,,,,,,,,
661,,# 246700,Chylomicron retention disease,,SAR1B,Sar1b protein,Q9HCJ1,vitamin K,,DB01022,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,Bleeding tendency,,HP:0001892,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,,,,,,,,,,
662,,# 246700,Chylomicron retention disease,,SAR1B,Sar1b protein,Q9HCJ1,,,,,,,,,,,,,,Vitamin K insufficiency,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,,,,,,,,,,
663,,# 246700,Chylomicron retention disease,,SAR1B,Sar1b protein,Q9HCJ1,medium-chain triglycerides,,DB13959,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,Low weight/growth,,HP:0004325,https://www.sciencedirect.com/science/article/pii/S0929693X16302044?via%3Dihub,,,,,,,,,,
664,,# 246700,Chylomicron retention disease,,SAR1B,Sar1b protein,Q9HCJ1,,,,,,,,,,,,,,Diarrhea,,HP:0002014,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,,,,,,,,,,
665,,# 246700,Chylomicron retention disease,,SAR1B,Sar1b protein,Q9HCJ1,,,,,,,,,,,,,,Malnutrition,,HP:0004395,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,,,,,,,,,,
666,,# 246700,Chylomicron retention disease,,SAR1B,Sar1b protein,Q9HCJ1,fat emulsion,,DB09422,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,Fat malabsorption,,HP:0001324,https://www.ncbi.nlm.nih.gov/pubmed/2596948/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,,,,,,,,,
667,68,#215720,Citrulline transport defect,,SAR1B,Sar1b protein,Q9HCJ1,No Treatment available in DDIEM,,DB09422,,,,,,,,,,,,,HP:0001324,https://www.ncbi.nlm.nih.gov/pubmed/2596948/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,,,,,,,,,
668,69,# 611209,COG1-CDG (CDG-IIg),,COG1,component of oligomeric golgi complex 1,Q9HCJ1,No Treatment available in DDIEM,,DB09422,,,,,,,,,,,,,HP:0001324,https://nyaspubs.onlinelibrary.wiley.com/doi/full/10.1111/j.1749-6632.2010.05840.x,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956717/,,,,,,,,,
669,70,# 615395,Combined oxidative phosphorylation deficiency 16,,MRPL44,mitochondrial ribosomal protein L44,Q9H9J2,l-carnitine +propranolol,,DB00583+DB00571,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,low physical capacity,,HP:0012378,https://link.springer.com/article/10.1007%2Fs10048-015-0444-2,https://www.ncbi.nlm.nih.gov/pubmed/25797485,,,,,,,,,
670,71,# 607765,"Congenital bile acid synthesis defect, type 1",,HSD3B7,3-beta-hydroxy-delta-5-C27 steroid oxidoreductase,Q9H9J2,Cholic acid,,DB02659,ECO:0000352,,,,,Functional interaction (B),B,functional complementation of a genetically defective protein,metabolite replacement,,Atypical bile acids,,NA,https://rarediseases.info.nih.gov/diseases/9813/congenital-bile-acid-synthesis-defect-type-1,https://www.ncbi.nlm.nih.gov/pubmed/16819396?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/8225213?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/11067870,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,https://www.ncbi.nlm.nih.gov/pubmed/19622360,,,,,
671,,# 607765,"Congenital bile acid synthesis defect, type 1",,HSD3B7,3-beta-hydroxy-delta-5-C27 steroid oxidoreductase,Q9H9J2,,,,,,,,,,,,,,Defected bile flow,,HP:0001396,https://rarediseases.info.nih.gov/diseases/9813/congenital-bile-acid-synthesis-defect-type-2,,,,,,,,,,
672,,# 607765,"Congenital bile acid synthesis defect, type 1",,HSD3B7,3-beta-hydroxy-delta-5-C27 steroid oxidoreductase,Q9H9J2,,,,,,,,,,,,,,Cirrhosis,,HP:0001394,https://www.ncbi.nlm.nih.gov/pubmed/30373615,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,,,,,,,,,
673,,# 607765,"Congenital bile acid synthesis defect, type 1",,HSD3B7,3-beta-hydroxy-delta-5-C27 steroid oxidoreductase,Q9H9J2,chenodeoxycholic acid,,DB06777,ECO:0000352,,,,,Functional interaction (B),B,functional complementation of a genetically defective protein,metabolite replacement,,Pruritus,,HP:0000989,https://www.ncbi.nlm.nih.gov/pubmed/2072042,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206929/,,,,,,,,,
674,,# 607765,"Congenital bile acid synthesis defect, type 1",,HSD3B7,3-beta-hydroxy-delta-5-C27 steroid oxidoreductase,Q9H9J2,,,,,,,,,,,,,,Abnormal urinary steroid level,,HP:0012030,https://www.ncbi.nlm.nih.gov/pubmed/2072042,,,,,,,,,,
675,,# 607765,"Congenital bile acid synthesis defect, type 1",,HSD3B7,3-beta-hydroxy-delta-5-C27 steroid oxidoreductase,Q9H9J2,,,,,,,,,,,,,,Ill-being (Constitutional symptoms)*,,HP:0025142*,,,,,,,,,,,
676,,# 607765,"Congenital bile acid synthesis defect, type 1",,HSD3B7,3-beta-hydroxy-delta-5-C27 steroid oxidoreductase,Q9H9J2,Ursodeoxycholic acid,,DB01586,ECO:0000352,,,,,,,functional complementation of a genetically defective protein,,,,,HP:0025142*,,,,,,,,,,,
677,72,# 235555,"Congenital bile acid synthesis defect, type 2",,AKR1D1,Aldo-keto reductase family 1 member D1,1.3.1.3,Cholic acid,,DB02659,ECO:0000352,,,,,Functional interaction (B),B,functional complementation of a genetically defective protein,metabolite replacement,,Liver biochemical abnormalities (Laboratory abnormalities)*,,HP:0001939,https://rarediseases.info.nih.gov/diseases/10045/congenital-bile-acid-synthesis-defect-type-2,,,,,,,,,,
678,,# 235555,"Congenital bile acid synthesis defect, type 2",,AKR1D1,Aldo-keto reductase family 1 member D1,1.3.1.3,,,,,,,,,,,,,,Histological abnormalities (Abnormal test result)*,,HP:0500014,,,,,,,,,,,
679,,# 235555,"Congenital bile acid synthesis defect, type 2",,AKR1D1,Aldo-keto reductase family 1 member D1,1.3.1.3,,,,,,,,,,,,,,Disease progression (Rapidly progressive)*,,HP:0003678*,,,,,,,,,,,
680,,# 235555,"Congenital bile acid synthesis defect, type 2",,AKR1D1,Aldo-keto reductase family 1 member D1,1.3.1.3,,,,,,,,,,,,,,Defected bile flow(Cholestasis)*,,HP:0001396,,,,,,,,,,,
681,,# 235555,"Congenital bile acid synthesis defect, type 2",,AKR1D1,Aldo-keto reductase family 1 member D1,1.3.1.3,,,,,,,,,,,,,,fat soluble vitamin malabsorption*,,HP:0002630,,,,,,,,,,,
682,,# 235555,"Congenital bile acid synthesis defect, type 2",,AKR1D1,Aldo-keto reductase family 1 member D1,1.3.1.3,,,,,,,,,,,,,,Atypical bile acid synthesis,,NA,,,,,,,,,,,
683,,# 235555,"Congenital bile acid synthesis defect, type 2",,AKR1D1,Aldo-keto reductase family 1 member D1,1.3.1.3,,,,,,,,,,,,,,production of toxic bile acid metabolic intermediates,,NA,,,,,,,,,,,
684,,# 235555,"Congenital bile acid synthesis defect, type 2",,AKR1D1,Aldo-keto reductase family 1 member D1,1.3.1.3,chenodeoxycholic acid,,DB06777,ECO:0000352,,,,,Functional interaction (B),B,functional complementation of a genetically defective protein,metabolite replacement,,abnormal liver function,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/28697823,,,,,,,,,,
685,,# 235555,"Congenital bile acid synthesis defect, type 2",,AKR1D1,Aldo-keto reductase family 1 member D1,1.3.1.3,,,,,,,,,,,,,,hepatomegaly,,HP:0002240,,,,,,,,,,,
686,73,# 224120,Congenital dyserythropoietic anemia type 1,,CDAN1,codanin 1,1.3.1.3,interferon α-2a,,DB00034,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,controversial,low hemoglobin concentration,,HP:0001931,https://www.ncbi.nlm.nih.gov/pubmed/16141353,https://www.ncbi.nlm.nih.gov/pubmed/16141353?dopt=Abstract,http://www.ncbi.nlm.nih.gov/pubmed/15804998?dopt=Abstract,,,,,,,,
687,,# 224120,Congenital dyserythropoietic anemia type 1,,CDAN1,codanin 1,1.3.1.3,,,,,,,,,,,,,,Abnormal upregulated enteral iron uptake (Abnormality of iron homeostasis)*,,HP:0011031*,,,,,,,,,,,
688,,# 224120,Congenital dyserythropoietic anemia type 1,,CDAN1,codanin 1,1.3.1.3,deferoxamine,,DB00746,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,high plasma ferritin,,HP:0003281,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925531/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925531/,,,,,,,,,
689,,# 224120,Congenital dyserythropoietic anemia type 1,,CDAN1,codanin 1,1.3.1.3,deferiprone,,DB08826,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,Elevated serum ferritin concentrations,,HP:0003281,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4925531/,https://www.ncbi.nlm.nih.gov/pubmed/16141353,,,,,,,,,
690,74,# 220120,D-glycericacidemia,,GLYCTK,d-glycerate kinase,2.7.1.31,Sodium bicarbonate,,DB01390,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Active,Metabolic acidosis,,HP:0001942,https://www.ncbi.nlm.nih.gov/pubmed/26247153,http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0001-37652015005050021&lng=en&nrm=iso&tlng=en,https://www.ncbi.nlm.nih.gov/pubmed/971536?dopt=Abstract,,,,,,,,
691,75,# 261515,D-bifunctional protein deficiency,"No proven treatments exist to address the underlying biochemical defect in this disorder, although dietary phytanic acid restriction and/or bile acid supplementation may warrant further study.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001/",HSD17B4,17β-hydroxysteroid dehydrogenase type 4,2.7.1.31,chenodeoxycholic acid+cholic acid,,DB06777+DB02659,ECO:0007121,,,,,Supportive (C),C,functional complementation of a genetically defective protein,metabolite replacement,,The study was terminated,,HP:0001942,https://clinicaltrials.gov/ct2/show/NCT00004442?cond=D-bifunctional+protein+deficiency&rank=1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963001/,https://www.ncbi.nlm.nih.gov/pubmed/971536?dopt=Abstract,,,,,,,,
692,,# 261515,D-bifunctional protein deficiency,,HSD17B4,17β-hydroxysteroid dehydrogenase type 4,2.7.1.31,cholic acid+ursodiol,,DB02659 +DB14555,ECO:0007121,,,,,Supportive (C),C,functional complementation of a genetically defective protein,metabolite replacement,,The study was terminated,,,,,,,,,,,,,
693,76,# 600721,D-2-hydroxyglutaric aciduria,,D2HGDH,D-2-hydroxyglutarate dehydrogenase,2.7.1.31,L- carnitine,,DB00583,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,DNA damage (Abnormality of DNA repair)*,,HP:0003254*,https://www.ncbi.nlm.nih.gov/pubmed/28396261?dopt=Abstract,,,,,,,,,,
694,,# 600721,D-2-hydroxyglutaric aciduria,,D2HGDH,D-2-hydroxyglutarate dehydrogenase,2.7.1.31,,,,,,,,,,,,,,oxidative injury*,,HP:0025463,,,,,,,,,,,
695,,# 600721,D-2-hydroxyglutaric aciduria,,D2HGDH,D-2-hydroxyglutarate dehydrogenase,2.7.1.31,,,,,,,,,,,,,,Protein oxidation,,NA,,,,,,,,,,,
696,,# 600721,D-2-hydroxyglutaric aciduria,,D2HGDH,D-2-hydroxyglutarate dehydrogenase,2.7.1.31,,,,,,,,,,,,,,lipid peroxidation,,NA,,,,,,,,,,,
697,77,# 220110,"MITOCHONDRIAL COMPLEX IV DEFICIENCY (CYTOCHROME c OXIDASE DEFICIENCY
COX DEFICIENCY)",,D2HGDH,cytochrome c oxidase assembly factor,1.9.3.1,Valproic acid,,DB00313,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,better to be avoided,Seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/22149023,,,,,,,,,,
698,,# 220110,"MITOCHONDRIAL COMPLEX IV DEFICIENCY (CYTOCHROME c OXIDASE DEFICIENCY
COX DEFICIENCY)",,D2HGDH,cytochrome c oxidase assembly factor,1.9.3.1,carbamazepine,,DB00593,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,Seizures,,HP:0001250,,,,,,,,,,,
699,,# 220110,"MITOCHONDRIAL COMPLEX IV DEFICIENCY (CYTOCHROME c OXIDASE DEFICIENCY
COX DEFICIENCY)",,D2HGDH,cytochrome c oxidase assembly factor,1.9.3.1,phenobarbital,,DB01174,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,Seizures,,HP:0001250,,,,,,,,,,,
700,,# 220110,"MITOCHONDRIAL COMPLEX IV DEFICIENCY (CYTOCHROME c OXIDASE DEFICIENCY
COX DEFICIENCY)",,D2HGDH,cytochrome c oxidase assembly factor,1.9.3.1,phenytoin,,DB00252,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,Seizures,,HP:0001250,,,,,,,,,,,
701,,# 220110,"MITOCHONDRIAL COMPLEX IV DEFICIENCY (CYTOCHROME c OXIDASE DEFICIENCY
COX DEFICIENCY)",,D2HGDH,cytochrome c oxidase assembly factor,1.9.3.1,oxcarbazepine,,DB00776,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,Seizures,,HP:0001250,,,,,,,,,,,
702,,# 220110,"MITOCHONDRIAL COMPLEX IV DEFICIENCY (CYTOCHROME c OXIDASE DEFICIENCY
COX DEFICIENCY)",,D2HGDH,cytochrome c oxidase assembly factor,1.9.3.1,vigabatrin,,DB01080,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,Seizures,,HP:0001250,,,,,,,,,,,
703,,# 220110,"MITOCHONDRIAL COMPLEX IV DEFICIENCY (CYTOCHROME c OXIDASE DEFICIENCY
COX DEFICIENCY)",,D2HGDH,cytochrome c oxidase assembly factor,1.9.3.1,gabapentin,,DB00996,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,Seizures,,HP:0001250,,,,,,,,,,,
704,,# 220110,"MITOCHONDRIAL COMPLEX IV DEFICIENCY (CYTOCHROME c OXIDASE DEFICIENCY
COX DEFICIENCY)",,D2HGDH,cytochrome c oxidase assembly factor,1.9.3.1,topiramate,,DB00273,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,Seizures,,HP:0001250,,,,,,,,,,,
705,,# 220110,"MITOCHONDRIAL COMPLEX IV DEFICIENCY (CYTOCHROME c OXIDASE DEFICIENCY
COX DEFICIENCY)",,D2HGDH,cytochrome c oxidase assembly factor,1.9.3.1,zonisamide,,DB00909,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,Seizures,,HP:0001250,,,,,,,,,,,
706,,# 220110,"MITOCHONDRIAL COMPLEX IV DEFICIENCY (CYTOCHROME c OXIDASE DEFICIENCY
COX DEFICIENCY)",,D2HGDH,cytochrome c oxidase assembly factor,1.9.3.1,ethosuximide,,DB00593,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,Seizures,,HP:0001250,,,,,,,,,,,
707,78,# 219750,"Cystinosis, ocular nonnephropathic",,CTNS,cystinosin,O60931,cysteamine,,DB00847,ECO:0005542/ECO:0007121,,,,,Functional interaction ( Mechanistic B),B,functional complementation of a genetically defective protein,,,corneal crystals,,HP:0000531,https://www.ncbi.nlm.nih.gov/pubmed/12370309/,,http://www.ncbi.nlm.nih.gov/pubmed/21897743?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/12488257/,https://www.ncbi.nlm.nih.gov/pubmed/1929112/,,,,,,
708,79,# 219800,Cystinosis,,CTNS,cystinosin,O60931,cysteamine,"Non-compliance is frequent and is secondary to the acrid sulfur body and breath smell, gastrointestinal upset and tight administration schedules (every 6 h) [49]. Strategies to reduce foul odor include oral supplements of vitamin B2 (riboflavin) or the use of chlorophyll tablets to mask the odor produced by dimethyl sulfide, the culprit metabolite of cysteamine that causes bad smell. However, the benefits of these compounds have not been proved and are particularly difficult to monitor in the clinical practice; therefore, their use is purely based on subjective assessment from patients. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/ Cysteamine currently represents the mainstay of therapy, allowing depletion of lysosomal cystine in most tissues. It should be initiated as early as possible and continued lifelong. Although cysteamine does not cure the disease, it dramatically improves the overall prognosis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/ Phenotypes improved: Because systemic cysteamine treatment has no effect on corneal cystine crystals, topical 0.5 % cysteamine eye drops are indicated. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/",DB00847,ECO:0000352/ECO:0005542,,,,,Functional interaction ( Mechanistic B),B,functional complementation of a genetically defective protein,,"Drug name: Non-compliance is frequent and is secondary to the acrid sulfur body and breath smell, gastrointestinal upset and tight administration schedules (every 6 h) [49]. Strategies to reduce foul odor include oral supplements of vitamin B2 (riboflavin) or the use of chlorophyll tablets to mask the odor produced by dimethyl sulfide, the culprit metabolite of cysteamine that causes bad smell. However, the benefits of these compounds have not been proved and are particularly difficult to monitor in the clinical practice; therefore, their use is purely based on subjective assessment from patients.    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/                                                                                                                                                                                                                                                                                                                                          Cysteamine currently represents the mainstay of therapy, allowing depletion of lysosomal cystine in most tissues. It should be initiated as early as possible and continued lifelong. Although cysteamine does not cure the disease, it dramatically improves the overall prognosis https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/ Phenotypes improved: Because systemic cysteamine treatment has no effect on corneal cystine crystals, topical 0.5 % cysteamine eye drops are indicated. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/",corneal crystals,,HP:0000531,https://www.ncbi.nlm.nih.gov/pubmed/11001803,https://www.ncbi.nlm.nih.gov/pubmed/9758713,http://www.ncbi.nlm.nih.gov/pubmed/21897743?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3016220/,,,,,,
709,,# 219800,Cystinosis,,CTNS,cystinosin,O60931,,,,,,,,,,,,,,Photophobia,,HP:0000613,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,,,,,,,,,,
710,,# 219800,Cystinosis,,CTNS,cystinosin,O60931,,,,,,,,,,,,,,Kidney disease progression ( Progressive disorder)*,,HP:0003678*,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,,,,,,,,,
711,,# 219800,Cystinosis,,CTNS,cystinosin,O60931,,,,,,,,,,,,,"Phenotypes improved : lifelong and diligent cysteamine therapy prevents 
hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, 
and prevents a host of nonrenal complications",development of extra-renal pathologies ( Progressive disorder)*,"lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications",HP:0003678*,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,,,,,,,,,
712,,# 219800,Cystinosis,,CTNS,cystinosin,O60931,,,,,,,,,,,,,"Phenotypes improved : lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications",hypothyroidism,"lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications",HP:0000821,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,,,,,,,,,,
713,,# 219800,Cystinosis,,CTNS,cystinosin,O60931,,,,,,,,,,,,,"Phenotypes improved : lifelong and diligent cysteamine therapy prevents 
hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, 
and prevents a host of nonrenal complications",Delayed growth,"lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications",HP:0001510,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,https://www.ncbi.nlm.nih.gov/pubmed/3550461/,https://www.ncbi.nlm.nih.gov/pubmed/8444253,,,,,,,,
714,,# 219800,Cystinosis,,CTNS,cystinosin,O60931,,,,,,,,,,,,,"Phenotypes improved : lifelong and diligent cysteamine therapy prevents 
hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, 
and prevents a host of nonrenal complications",cystine accumulation in muscle parenchyma,"lifelong and diligent cysteamine therapy prevents hypothyroidism, enhances growth, depletes muscle parenchyma of cystine, and prevents a host of nonrenal complications",HP:0003358,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3505515/,,,,,,,,,,
715,,# 219800,Cystinosis,,CTNS,cystinosin,O60931,,,,,,,,,,,,,,shorter life expectancy,,NA,,,,,,,,,,,
716,,# 219800,Cystinosis,,CTNS,cystinosin,O60931,,,,,,,,,,,,,,Reduction of WBC cystine levels,,NA,,,,,,,,,,,
717,,# 219800,Cystinosis,,CTNS,cystinosin,O60931,,,,,,,,,,,,,,renal function declines,,HP:0012622,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,,,,,,,,,,
718,,# 219800,Cystinosis,,CTNS,cystinosin,O60931,,,,,,,,,,,,,,Elevated intralysosomal cystine accumulation( abnormality of cysteine metabolism),,HP:0010918*,https://www.ncbi.nlm.nih.gov/pubmed/23416144,,,,,,,,,,
719,,# 219800,Cystinosis,,CTNS,cystinosin,O60931,,,,,,,,,,,,,,glomerular damage,,HP:0000095*,,,,,,,,,,,
720,,# 219800,Cystinosis,,CTNS,cystinosin,O60931,indomethacin,Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,DB00328,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Drug name: Controversial benefits https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,polyuria,,HP:0000103,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,,,,,,,,,,
721,,# 219800,Cystinosis,,CTNS,cystinosin,O60931,,,,,,,,,,,,,,weight gain,,HP:0004324,,,,,,,,,,,
722,,# 219800,Cystinosis,,CTNS,cystinosin,O60931,,,,,,,,,,,,,,proximal tubule salt losses (Proximal tubular defect),,HP:0000114,,,,,,,,,,,
723,,# 219800,Cystinosis,,CTNS,cystinosin,O60931,,,,,,,,,,,,,,renal salt wasting,,HP:0000127,,,,,,,,,,,
724,,# 219800,Cystinosis,,CTNS,cystinosin,O60931,Bicarbonate+potassium supplements,,DB01390+DB01345,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,acidosis,,HP:0001941,,,,,,,,,,,
725,,# 219800,Cystinosis,,CTNS,cystinosin,O60931,neutral phosphate+Vitamin D,,DB14502 orDB09449 +DB11094,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Drug name: Substitution with sodium or potassium phosphate and 1–25-(OH)2 cholecalciferol should be initiated from early childhood to compensate for the phosphate imbal- ance and to prevent rickets in patients with preserved GFR https://www.ncbi.nlm.nih.gov/pubmed/27102039,Phosphate imbalance (Abnormality of phosphate homeostasis),,HP:0100529,https://www.ncbi.nlm.nih.gov/pubmed/27102039,,,,,,,,,,
726,,# 219800,Cystinosis,,CTNS,cystinosin,O60931,Thiazide,,DB01324,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,"Drug name: Usage of Diutics like thiazide to avoid volume expansion, could aggrevate Potassium loss and augments the need for potassium supplements https://emedicine.medscape.com/article/981774-treatment not benefical",low proximal tubular reabsorption of bicarbonates,,HP:0004910*,,,,,,,,,,,
727,,# 219800,Cystinosis,,CTNS,cystinosin,O60931,growth hormone,,DB00052,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,retarded growth,,HP:0001510,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4158338/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4841061/,,,,,,,,,
728,,# 219800,Cystinosis,,CTNS,cystinosin,O60931,,,,,,,,,,,,,,low phosphate reabsorption,,HP:0000117,,,,,,,,,,,
729,,# 219800,Cystinosis,,CTNS,cystinosin,O60931,Thyroxine,,DB00451,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,hypothyroidism,,HP:0000821,,,,,,,,,,,
730,,# 219800,Cystinosis,,CTNS,cystinosin,O60931,ACE inhibitors,,DB01348,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Drug name: Effectivness of the drug is controversial.                                                                                                                                                                                                                     ACE inhibitors must be used with caution in patients with extracellular volume and sodium depletion https://www.ncbi.nlm.nih.gov/pubmed/14690254/,glomerular proteinuria,,HP:0000100,,,,,,,,,,,
731,,# 219800,Cystinosis,,CTNS,cystinosin,O60931,,,,,,,,,,,,,,Albuminuria,,HP:0012592,https://www.ncbi.nlm.nih.gov/pubmed/14690254/,,,,,,,,,,
732,,# 219800,Cystinosis,,CTNS,cystinosin,O60931,Testosterone,,,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,"Drug name:  Currently, insufficient data is available on the pathophysiology of the azoospermia observed in male cystinosis patients. Testosterone supplementation is indicated in patients with a primary testicular failure and low plasma testosterone levels https://www.ncbi.nlm.nih.gov/pubmed/19217094/",Low serum testosterone levels,,HP:004017,https://www.ncbi.nlm.nih.gov/pubmed/19217094/,,,,,,,,,,
733,80,# 606785,"Crigler Najjar syndrome, type 2","Treatment of CNS type 2 is usually conservative with avoidance of drugs that displace bilirubin from albumin like penicillin, sulphonamides, salicylates, ceftriaxone and furosemide. https://www.ncbi.nlm.nih.gov/pubmed/23162302/
Affected patients should also avoid drugs that displace bilirubin from albumin such as penicillines, sulphonamides, salicylates, ceftriaxone and furosemide.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/",UGT1A1,UDP glucuronosyltransferase family 1 member A1,O60931,phenobarbital,,DB01174,ECO:0000352,,,,,Direct Interaction (A),A,activity modification of a genetically defective protein,,,high serum bilirubin level,,HP:0002904,https://www.ncbi.nlm.nih.gov/pubmed/23162302/,,https://www.ncbi.nlm.nih.gov/pubmed?Db=pubmed&Cmd=Retrieve&list_uids=27264814&dopt=abstractplus,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788912/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/,,,,
734,,# 606785,"Crigler Najjar syndrome, type 2",,UGT1A1,UDP glucuronosyltransferase family 1 member A1,O60931,orlistat,,DB01083,ECO:0007121,,,,,Symptomatic (C),C,symptomatic treatment procedure,functional complementation of a genetically defective protein,,high plasma level of unconjugated bilirubin concentration,,HP:0008282,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/,,https://clinicaltrials.gov/ct2/show/NCT00461799?cond=Crigler+Najjar+syndrome&rank=4,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4788912/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5583863/,https://www.ncbi.nlm.nih.gov/pubmed/3306242,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3491300/,,,,
735,,# 606785,"Crigler Najjar syndrome, type 2",,UGT1A1,UDP glucuronosyltransferase family 1 member A1,O60931,,,,,,,,,,,,,,increased fecal fat excretion,,HP:0002570,,,,,,,,,,,
736,,# 606785,"Crigler Najjar syndrome, type 2",,UGT1A1,UDP glucuronosyltransferase family 1 member A1,O60931,,,,,,,,,,,,,,low fecal excretion of unconjugated bilirubin (Unconjugated hyperbilirubinemia)*,,HP:0008282*,,,,,,,,,,,
737,,# 606785,"Crigler Najjar syndrome, type 2",,UGT1A1,UDP glucuronosyltransferase family 1 member A1,O60931,AT342,,NA,ECO:0007121,,,,,Direct Interaction (A),A,direct complementation of a genetically defective protein by gene therapy,,,High serum  bilirubin concentration,,HP:0002904,,,https://clinicaltrials.gov/ct2/show/NCT03223194?cond=Crigler+Najjar+syndrome&rank=3,,,,,,,,
738,,# 606785,"Crigler Najjar syndrome, type 2",,UGT1A1,UDP glucuronosyltransferase family 1 member A1,O60931,GNT0003,,NA,ECO:0007121,,,,,Direct Interaction (A),A,direct complementation of a genetically defective protein by gene therapy,,,High serum  bilirubin concentration,,HP:0002904,,,https://clinicaltrials.gov/ct2/show/NCT03466463?cond=Crigler+Najjar+syndrome&rank=1,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099/,,,,,,,
739,,# 606785,"Crigler Najjar syndrome, type 2",,UGT1A1,UDP glucuronosyltransferase family 1 member A1,O60931,hypericum extract,,DB01323,ECO:0000352,,,,,Direct Interaction (A),A,activity modification of a genetically defective protein,,,,,HP:0002904,,,https://www.ncbi.nlm.nih.gov/pubmed/26692114?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099/,,,,,,,
740,,# 606785,"Crigler Najjar syndrome, type 2",,UGT1A1,UDP glucuronosyltransferase family 1 member A1,O60931,AAV-mediated gene therapy,Coupling AAV-mediated promoterless gene targeting to SaCas9 nuclease to efficiently correct liver metabolic diseases,NA,ECO:0005542,,,,,Direct Interaction (A),,direct complementation of a genetically defective protein by gene therapy,,,Abnormal liver function,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/15753292,https://www.ncbi.nlm.nih.gov/pubmed/10603107/,https://www.ncbi.nlm.nih.gov/pubmed/26692114?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282099/,,,,,,,
741,,# 606785,"Crigler Najjar syndrome, type 2",,UGT1A1,UDP glucuronosyltransferase family 1 member A1,O60931,,,,,,,,,,,,,,High serum  bilirubin concentration,,HP:0002904,,,,,,,,,,,
742,,# 606785,"Crigler Najjar syndrome, type 2",,UGT1A1,UDP glucuronosyltransferase family 1 member A1,O60931,,,,,,,,,,,,,,Increased inflammatory response,,HP:0012649,,,,,,,,,,,
743,,# 606785,"Crigler Najjar syndrome, type 2",,UGT1A1,UDP glucuronosyltransferase family 1 member A1,O60931,,,,,,,,,,,,,,Abnormality of metabolism,,HP:0001939,,,,,,,,,,,
744,,# 606785,"Crigler Najjar syndrome, type 2",,UGT1A1,UDP glucuronosyltransferase family 1 member A1,O60931,Chlofibrate,,DB00636,ECO:0000352,,,,,Symptomatic (C),,activity modification of a genetically defective protein,,,High serum  bilirubin concentration,,HP:0002904,https://www.ncbi.nlm.nih.gov/pubmed/7483726,https://www.ncbi.nlm.nih.gov/pubmed/19752526/,,,,,,,,,
745,,# 606785,"Crigler Najjar syndrome, type 2",,UGT1A1,UDP glucuronosyltransferase family 1 member A1,O60931,Fenofibrate,,DB01039,ECO:0000352,,,,,Symptomatic (C),,activity modification of a genetically defective protein,,,Drug wasn't effective (Insignificant effect),,,https://www.ncbi.nlm.nih.gov/pubmed/16830281,,,,,,,,,,
746,,# 606785,"Crigler Najjar syndrome, type 2",,UGT1A1,UDP glucuronosyltransferase family 1 member A1,O60931,Calcium,,DB01373,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,functional complementation of a genetically defective protein,,Calcium makes phototherapy more efficient,,,https://www.ncbi.nlm.nih.gov/pubmed/10603107/,,,,,,,,,,
747,,# 606785,"Crigler Najjar syndrome, type 2",,UGT1A1,UDP glucuronosyltransferase family 1 member A1,O60931,,,,,,,,,,,,,,,,,,,,,,,,,,,
748,81,# 218800,"Crigler Najjar syndrome, type 1",,UGT1A1,uridine diphosphate–glucuronyl transferase,O60931,Tin-protoporphyrin,The drug is effective in conjuction with phototherapy,DB02285,ECO:0000352,,,,,Functional interaction (B),B,functional complementation of a genetically defective protein,,,High serum bilirubin level,,HP:0002904,https://www.nature.com/articles/pr1989488,,http://pediatrics.aappublications.org/content/86/1/152,https://www.sciencedirect.com/topics/medicine-and-dentistry/crigler-najjar-syndrome,,,,,,,
749,,# 218800,"Crigler Najjar syndrome, type 1",,UGT1A1,uridine diphosphate–glucuronyl transferase,O60931,orlistat,"Clinically relevant response to orlistat treatment was not correlated with age, sex, CN type, BMI, or co-treatment with phototherapy or phenobarbital, but appeared correlated with a relatively lower dietary fat intake.https://www.ncbi.nlm.nih.gov/pubmed/17957158. The Drug works through increasing fecal fat excretion so dietary fat intake may determine the responsiveness to orlistat treatment.",DB01083,ECO:0007121/ECO:0005542,,,,,Symptomatic (C),C,symptomatic treatment procedure,functional complementation of a genetically defective protein,,high plasma level of unconjugated bilirubin concentration,,HP:0008282,https://www.ncbi.nlm.nih.gov/pubmed/17957158,https://clinicaltrials.gov/ct2/show/NCT00461799,https://www.ncbi.nlm.nih.gov/pubmed/14517515?dopt=Abstract&holding=npg,https://www.ncbi.nlm.nih.gov/pubmed/15726662,,,,,,,
750,,# 218800,"Crigler Najjar syndrome, type 1",,UGT1A1,uridine diphosphate–glucuronyl transferase,O60931,AT342,,NA,ECO:0007121,,,,,Direct Interaction (A),A,direct complementation of a genetically defective protein by gene therapy,,,Study was suspended based on Sponsor Decision.,,HP:0002904,https://clinicaltrials.gov/ct2/show/NCT03223194,https://clinicaltrials.gov/ct2/show/NCT00461799,https://www.ncbi.nlm.nih.gov/pubmed/14517515?dopt=Abstract&holding=npg,https://www.ncbi.nlm.nih.gov/pubmed/15726662,,,,,,,
751,,# 218800,"Crigler Najjar syndrome, type 1",,UGT1A1,uridine diphosphate–glucuronyl transferase,O60931,GNT0003,Information about the Study can be ound in https://gmoinfo.jrc.ec.europa.eu/bsnifs-gmo/B-NL-17-001.pdf,,ECO:0007121,,,,,Direct Interaction (A),,direct complementation of a genetically defective protein by gene therapy,,,Study is still recruiting,,,https://clinicaltrials.gov/ct2/show/NCT03466463,,,,,,,,,,
752,,# 218800,"Crigler Najjar syndrome, type 1",,UGT1A1,uridine diphosphate–glucuronyl transferase,O60931,Ad5/CMV/hUG-Br1,,NA,ECO:0005542,,,,,Direct Interaction (A),A,direct complementation of a genetically defective protein by gene therapy,,,Hyperbilirubinemia,,HP:0002904,https://www.ncbi.nlm.nih.gov/pubmed/9525311/,https://www.ncbi.nlm.nih.gov/pubmed/9156798/,https://www.ncbi.nlm.nih.gov/pubmed/15753292,,,,,,,,
753,,# 218800,"Crigler Najjar syndrome, type 1",,UGT1A1,uridine diphosphate–glucuronyl transferase,O60931,Chimeric oligonucleotide(oligonucleotide-based gene therapy),,NA,ECO:0005542,,,,,Direct Interaction (A),,direct complementation of a genetically defective protein by gene therapy,,,UDP-glucuronosyltransferase gene defect,,NA,https://www.ncbi.nlm.nih.gov/pubmed/10468611/,,,,,,,,,,
754,,# 218800,"Crigler Najjar syndrome, type 1",,UGT1A1,uridine diphosphate–glucuronyl transferase,O60931,Retrovirus,,,ECO:0005542,,,,,Direct Interaction (A),,direct complementation of a genetically defective protein by gene therapy,,,Hyperbilirubinemia,,HP:0002904,https://www.ncbi.nlm.nih.gov/pubmed/9457971/,,,,,,,,,,
755,,# 218800,"Crigler Najjar syndrome, type 1",,UGT1A1,uridine diphosphate–glucuronyl transferase,O60931,Ad-hBUGT1,,NA,ECO:0005542,,,,,Direct Interaction (A),,direct complementation of a genetically defective protein by gene therapy,,,Hyperbilirubinemia,,HP:0002904,https://www.ncbi.nlm.nih.gov/pubmed/8900123/,,,,,,,,,,
756,82,% 608158,CoQ-responsive OXPHOS deficiency,,UGT1A1,uridine diphosphate–glucuronyl transferase,O60931,sodium benzoate,"Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744",DB03793,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Not Active,hyperammonemia,,HP:0001987,https://www.ncbi.nlm.nih.gov/pubmed/12948744,,https://www.sciencedirect.com/science/article/pii/S1096719215300895?via%3Dihub,,,,,,,,
757,,% 608158,CoQ-responsive OXPHOS deficiency,,UGT1A1,uridine diphosphate–glucuronyl transferase,O60931,sodium phenylacetate,"Treatment was stopped three days later because of lack of improvement and severe respiratory alkalosis with lactic acidosis (serum lactic acid 70 mg/dl, normal 4–20 mg/dl). https://www.ncbi.nlm.nih.gov/pubmed/12948744",DB09269,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,Not Active,hyperammonemia,,HP:0001987,https://www.ncbi.nlm.nih.gov/pubmed/12948744,,,,,,,,,,
758,,% 608158,CoQ-responsive OXPHOS deficiency,,UGT1A1,uridine diphosphate–glucuronyl transferase,O60931,CoQ,,DB09270,ECO:0000352,,,,,Functional interaction (B),B,functional complementation of a genetically defective protein,,,Abnormal liver function,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/12948744,,,,,,,,,,
759,83,121270,"Copper deficiency, familial benign",,UGT1A1,uridine diphosphate–glucuronyl transferase,O60931,copper,,DB09130,ECO:0000352,,,,,Functional interaction (B),B,functional complementation of a genetically defective protein,,,hypocupraemia,,HP:0010836,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1627787/,,,,,,,,,,
760,,121270,"Copper deficiency, familial benign",,UGT1A1,uridine diphosphate–glucuronyl transferase,O60931,,,,,,,,,,,,,,seizures,,HP:0001250,,,,,,,,,,,
761,84,# 263700,Congenital erythropoietic porphyria,,UROS gene,uroporphyrinogen III synthase,4.2.1.75,bortezomib,,DB00188,ECO:0005542/ECO:0001565,,,,,Functional interaction (B),B,activity modification of a genetically defective protein,,,high porphyrin accumulation in circulating RBCs,,HP:0012187,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3831495/,https://www.ncbi.nlm.nih.gov/pubmed/24145442,,,,,,,,,
762,,# 263700,Congenital erythropoietic porphyria,,UROS gene,uroporphyrinogen III synthase,4.2.1.75,,,,,,,,,,,,,,skin photosensitivity,,HP:0000992,,,,,,,,,,,
763,,# 263700,Congenital erythropoietic porphyria,,UROS gene,uroporphyrinogen III synthase,4.2.1.75,,,,,,,,,,,,,,premature degradation of misfolded UROS mutants,,NA,https://www.ncbi.nlm.nih.gov/pubmed/28334762,,,,,,,,,,
764,,# 263700,Congenital erythropoietic porphyria,,UROS gene,uroporphyrinogen III synthase,4.2.1.75,,,,,,,,,,,,,,abnormal porphyrin accumulation in urine,,HP:0010473,,,,,,,,,,,
765,85,# 610198,"DCMA syndrome (3-methylglutaconic aciduria, type V)",,DNAJC19,DnaJ heat shock protein family (Hsp40) member C19,Q96DA6,Angiotensin-converting enzyme (ACE) inhibitors+digoxin+furosemide,,C09C+DB00390+DB00695,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,Low ejection fraction,,HP:0010473,https://www.ncbi.nlm.nih.gov/pubmed/27928778,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511/,,,,,,,,
766,86,261750,GLYCOGEN STORAGE DISEASE IXb; GSD9B,,PHKB,Phosphorylase b kinase regulatory subunit beta,Q93100,Dextrothyroxine,,DB00509,ECO:0007121,,,,,,,symptomatic treatment procedure,,,Hepatomegaly,,HP:0002240,https://www.ncbi.nlm.nih.gov/pubmed/280544,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC324959/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2564511/,,,,,,,,
767,,261750,GLYCOGEN STORAGE DISEASE IXb; GSD9B,,PHKB,Phosphorylase b kinase regulatory subunit beta,Q93100,,,,,,,,,,,,,,Elevated hepatic transaminases,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/280544,,,,,,,,,,
768,,261750,GLYCOGEN STORAGE DISEASE IXb; GSD9B,,PHKB,Phosphorylase b kinase regulatory subunit beta,Q93100,,,,,,,,,,,,,,Hypertriglyceridemia,,HP:0002155,https://www.ncbi.nlm.nih.gov/pubmed/280544,,,,,,,,,,
769,,261750,GLYCOGEN STORAGE DISEASE IXb; GSD9B,,PHKB,Phosphorylase b kinase regulatory subunit beta,Q93100,,,,,,,,,,,,,,Mild asymptomatic hypoglycemia,,HP:0001943,https://www.ncbi.nlm.nih.gov/pubmed/280544,,,,,,,,,,
770,,261750,GLYCOGEN STORAGE DISEASE IXb; GSD9B,,PHKB,Phosphorylase b kinase regulatory subunit beta,Q93100,Complex Carbohydrates,,,ECO:0000352,,,,,,,dietary supplementation,,,Elevated hepatic transaminases,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/25266922,,,,,,,,,,
771,,261750,GLYCOGEN STORAGE DISEASE IXb; GSD9B,,PHKB,Phosphorylase b kinase regulatory subunit beta,Q93100,,,,,,,,,,,,,,Short Stature,,HP:0004322,https://www.ncbi.nlm.nih.gov/pubmed/25266922,,,,,,,,,,
772,,261750,GLYCOGEN STORAGE DISEASE IXb; GSD9B,,PHKB,Phosphorylase b kinase regulatory subunit beta,Q93100,Complex carbohydrates+Beneprotein+Low fats,,,ECO:0000352,,,,,,,dietary supplementation,,,Elevated hepatic transaminases,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/25266922,,,,,,,,,,
773,,306000,GLYCOGEN STORAGE DISEASE IXa1 (Formally Glycogen storage disease 8 ),,PHKA2,"Phosphorylase b kinase regulatory subunit alpha, liver isoform",P46019,Uncooked cornstarch+ Beneprotein+Low fats diet,,,ECO:0000352,,,,,,,dietary supplementation,,,Elevated hepatic transaminases,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/25266922,,,,,,,,,,
774,,306000,GLYCOGEN STORAGE DISEASE IXa1 (Formally Glycogen storage disease 8 ),,PHKA2,"Phosphorylase b kinase regulatory subunit alpha, liver isoform",P46019,Uncooked cornstarch+ Beneprotein,,,ECO:0000352,,,,,,,dietary supplementation,,,Elevated hepatic transaminases,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/25266922,,,,,,,,,,
775,,306000,GLYCOGEN STORAGE DISEASE IXa1 (Formally Glycogen storage disease 8 ),,PHKA2,"Phosphorylase b kinase regulatory subunit alpha, liver isoform",P46019,,,,,,,,,,,,,,Failure to thrive,,HP:0001508,https://www.ncbi.nlm.nih.gov/pubmed/25266922,,,,,,,,,,
776,,306000,GLYCOGEN STORAGE DISEASE IXa1 (Formally Glycogen storage disease 8 ),,PHKA2,"Phosphorylase b kinase regulatory subunit alpha, liver isoform",P46019,Uncooked cornstarch,,,ECO:0000352,,,,,,,dietary supplementation,,,Elevated hepatic transaminases,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/25266922,,,,,,,,,,
777,,306000,GLYCOGEN STORAGE DISEASE IXa1 (Formally Glycogen storage disease 8 ),,PHKA2,"Phosphorylase b kinase regulatory subunit alpha, liver isoform",P46019,,,,,,,,,,,,,,Failure to thrive,,HP:0001508,https://www.ncbi.nlm.nih.gov/pubmed/25266922,,,,,,,,,,
778,,306000,GLYCOGEN STORAGE DISEASE IXa1 (Formally Glycogen storage disease 8 ),,PHKA2,"Phosphorylase b kinase regulatory subunit alpha, liver isoform",P46019,Uncooked cornstarch+ Beneprotein+CoCarbs(Complex carbohydrate),,,ECO:0000352,,,,,,,dietary supplementation,,,Elevated hepatic transaminases,"On this regimen, one patient had the enlevated liver enxymes stabilized while the other had mild improvement.",HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/25266922,,,,,,,,,,
779,,306000,GLYCOGEN STORAGE DISEASE IXa1 (Formally Glycogen storage disease 8 ),,PHKA2,"Phosphorylase b kinase regulatory subunit alpha, liver isoform",P46019,CoCarbs + HPro,,,ECO:0000352,,,,,,,dietary supplementation,,,Elevated hepatic transaminases,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/25266922,,,,,,,,,,
780,,# 613027,GLYCOGEN STORAGE DISEASE IXc; GSD9C,,PHKG2,"Phosphorylase b kinase gamma catalytic chain, liver/testis isoform",P15735,Uncooked cornstarch+ Beneprotein,,,ECO:0000352,,,,,,,dietary supplementation,,,Elevated hepatic transaminases,Patient transaminases  slowly decreased with time in https://www.ncbi.nlm.nih.gov/pubmed/12930917,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/25266922,https://www.ncbi.nlm.nih.gov/pubmed/12930917,,,,,,,,,
781,,# 613027,GLYCOGEN STORAGE DISEASE IXc; GSD9C,,PHKG2,"Phosphorylase b kinase gamma catalytic chain, liver/testis isoform",P15735,,,,,,,,,,,,,,Hypoglycemia,,HP:0001943,https://www.ncbi.nlm.nih.gov/pubmed/12930917,,,,,,,,,,
782,,# 613027,GLYCOGEN STORAGE DISEASE IXc; GSD9C,,PHKG2,"Phosphorylase b kinase gamma catalytic chain, liver/testis isoform",P15735,,,,,,,,,,,,,,,,,,,,,,,,,,,
783,,# 613027,GLYCOGEN STORAGE DISEASE IXc; GSD9C,,PHKG2,"Phosphorylase b kinase gamma catalytic chain, liver/testis isoform",P15735,,,,,,,,,,,,,,,,,,,,,,,,,,,
784,87,# 240600,"Glycogen storage disease type 0, liver","GS deficiency has a good long term prognosis: it is usually associated with a normal intellectual outcome, symptoms can be prevented if the condition is recognized and treated by avoidance of prolonged fasting and tolerance to fasting improves with age. https://www.ncbi.nlm.nih.gov/pubmed/12794686
Patients are treated with a diet high in protein with complex, low glycemic index carbohydrates. Since gluconeogenesis is intact, protein supplementation provides gluconeogenic precursors that can be used for endogenous glucose production. In turn, there is also less dependence upon fatty acid oxidation, and accumulation of free fatty acids and ketones is prevented. This not only reduces systemic acidosis, but prevention of hyperketonemia also enhances gluconeogenesis since more alanine can be released from skeletal muscle. https://www.ncbi.nlm.nih.gov/pubmed/106027
Simple carbohydrates should be limited since they can increase blood lactate concentrations. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/",GYS2,glycogen synthase 2,2.4.1.11,Glycosade,,NA,ECO:0007121,,,,,Symptomatic (C),C,dietary supplementation,symptomatic treatment procedure,,Nocturnal Hypoglycemia(Hypoglycemia)*,,HP:0001943*,https://clinicaltrials.gov/ct2/show/NCT02054832?cond=Glycogen+Storage+Disease+Type+0&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/29223626,,,,,,,,,
785,,# 240600,"Glycogen storage disease type 0, liver",,GYS2,glycogen synthase 2,2.4.1.11,,,,,,,,,,,,,,Poor sleep quality(Sleep disturbance)*,,HP:0002360*,https://www.ncbi.nlm.nih.gov/pubmed/29223626,,,,,,,,,,
786,,# 240600,"Glycogen storage disease type 0, liver",,GYS2,glycogen synthase 2,2.4.1.11,Cornstarch,"Uncooked Cornstarch usually is administered at bedtime, and every 6 hours during illness, to prevent morning hypoglycemia and ketosis. In children who are particularly active, a dose of cornstarch in the morning or 1 hour before strenuous or prolonged physical activity can improve stamina. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1474809/",DB11599,ECO:0000352,,,,,,,dietary supplementation,symptomatic treatment procedure,,MorningHypoglycemia (Hypoglycemia)*,,HP:0012051,https://www.ncbi.nlm.nih.gov/pubmed/12794686,,,,,,,,,,
787,,# 240600,"Glycogen storage disease type 0, liver",,GYS2,glycogen synthase 2,2.4.1.11,,,,,,,,,,,,,,Ketosis,,HP:0001946,,,,,,,,,,,
788,,# 240600,"Glycogen storage disease type 0, liver",,GYS2,glycogen synthase 2,2.4.1.11,,,,,,,,,,,,,,,,,,,,,,,,,,,
789,,# 240600,"Glycogen storage disease type 0, liver",,GYS2,glycogen synthase 2,2.4.1.11,,,,,,,,,,,,,,,,,,,,,,,,,,,
790,88,#611881,Glycogen storage disease type 12,,ALDOA,"aldolase, fructose-bisphosphate A",4.1.2.13,No treatment available,,,,,,,,,,,,,,,done,https://link.springer.com/article/10.1007%2Fs11940-017-0473-2,,,,,,,,,,
791,89,#612932,Glycogen storage disease type 13,,ENO3,enolase 3,4.2.1.11,No treatment available,,,,,,,,,,,,,,,done,https://link.springer.com/article/10.1007%2Fs11940-017-0473-2,,,,,,,,,,
792,90,# 232200,Glycogen storage disease type 1A,,G6PC,Glucose 6-phophatase,3.1.3.9,DTX401,,NA,ECO:0007121,,,,,Direct Interaction (A),A,direct complementation of a genetically defective protein by gene therapy,,,"The study is still recruting. The primary objective of the study is to determine the safety of single doses of DTX401, including the incidence of dose-limiting toxicities (DLTs) at each dose level.",,done,https://clinicaltrials.gov/ct2/show/NCT03517085?cond=von+Gierke&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/20163245,,,,,,,,,
793,,# 232200,Glycogen storage disease type 1A,,G6PC,Glucose 6-phophatase,3.1.3.9,FIV-hAAT-G6Pase,,NA,ECO:0005542,,,,,Direct Interaction (A),A,direct complementation of a genetically defective protein by gene therapy,,,Hypoglycemia,,done,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956916/,https://www.ncbi.nlm.nih.gov/pubmed/20163245,,,,,,,,,
794,,# 232200,Glycogen storage disease type 1A,,G6PC,Glucose 6-phophatase,3.1.3.9,Ad-mG6Pase,,NA,ECO:0005542,,,,,Direct Interaction (A),A,direct complementation of a genetically defective protein by gene therapy,,,Growth retardation,,,https://www.ncbi.nlm.nih.gov/pubmed/10625614,,,,,,,,,,
795,,# 232200,Glycogen storage disease type 1A,,G6PC,Glucose 6-phophatase,3.1.3.9,,,,,,,,,,,,,,Hypoglycemia,,,https://www.ncbi.nlm.nih.gov/pubmed/10625614,,,,,,,,,,
796,,# 232200,Glycogen storage disease type 1A,,G6PC,Glucose 6-phophatase,3.1.3.9,,,,,,,,,,,,,,Hyperuricemia,,,https://www.ncbi.nlm.nih.gov/pubmed/10625614,,,,,,,,,,
797,,# 232200,Glycogen storage disease type 1A,,G6PC,Glucose 6-phophatase,3.1.3.9,,,,,,,,,,,,,,Hyperlipidemia,,,https://www.ncbi.nlm.nih.gov/pubmed/10625614,,,,,,,,,,
798,,# 232200,Glycogen storage disease type 1A,,G6PC,Glucose 6-phophatase,3.1.3.9,,,,,,,,,,,,,,Enlarged kidney,,HP:0000105,https://www.ncbi.nlm.nih.gov/pubmed/10625614,,,,,,,,,,
799,,# 232200,Glycogen storage disease type 1A,,G6PC,Glucose 6-phophatase,3.1.3.9,,,,,,,,,,,,,,Hepatomegaly,,HP:0002240,https://www.ncbi.nlm.nih.gov/pubmed/10625614,,,,,,,,,,
800,,# 232200,Glycogen storage disease type 1A,,G6PC,Glucose 6-phophatase,3.1.3.9,AAV-cG6PGH,,NA,ECO:0005542,,,,,Direct Interaction (A),A,direct complementation of a genetically defective protein by gene therapy,,,Growth Failure,,HP:0002240,https://www.ncbi.nlm.nih.gov/pubmed/16672983,,,,,,,,,,
801,,# 232200,Glycogen storage disease type 1A,,G6PC,Glucose 6-phophatase,3.1.3.9,,,,,,,,,,,,,,Hyperlipidemia,,,https://www.ncbi.nlm.nih.gov/pubmed/16672983,https://www.ncbi.nlm.nih.gov/pubmed/17430128,,,,,,,,,
802,,# 232200,Glycogen storage disease type 1A,,G6PC,Glucose 6-phophatase,3.1.3.9,,,,,,,,,,,,,,Hypoglycemia,,,https://www.ncbi.nlm.nih.gov/pubmed/16672983,https://www.ncbi.nlm.nih.gov/pubmed/17430128,,,,,,,,,
803,,# 232200,Glycogen storage disease type 1A,,G6PC,Glucose 6-phophatase,3.1.3.9,HDAd-G6Pase,"Ad vectors, HDAd is completely devoid of all viral protein genes and has been shown to display markedly reduced toxicity in mice.https://www.ncbi.nlm.nih.gov/pubmed/15753292",NA,ECO:0005542,,,,,Direct Interaction (A),A,direct complementation of a genetically defective protein by gene therapy,,,Hypoglycemia,,,https://www.ncbi.nlm.nih.gov/pubmed/17505475,https://www.ncbi.nlm.nih.gov/pubmed/17430128,,,,,,,,,
804,,# 232200,Glycogen storage disease type 1A,,G6PC,Glucose 6-phophatase,3.1.3.9,Glycosade,,NA,ECO:0007121,,,,,Functional interaction (B),B,dietary supplementation,,,Fasting hypoglycemia,,HP:0003162,https://clinicaltrials.gov/ct2/show/NCT02054832?cond=von+Gierke&rank=6,https://www.ncbi.nlm.nih.gov/pubmed/29223626,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/17514432,,,,,,,
805,,# 232200,Glycogen storage disease type 1A,,G6PC,Glucose 6-phophatase,3.1.3.9,,,,,,,,,,,,,,Sleep disturbance/Poor sleep quality,The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862,HP:0002360,https://www.ncbi.nlm.nih.gov/pubmed/29223626,https://www.ncbi.nlm.nih.gov/pubmed/18996862,,,,,,,,,
806,,# 232200,Glycogen storage disease type 1A,,G6PC,Glucose 6-phophatase,3.1.3.9,,,,,,,,,,,,,,Low quality of life(Constitutional symptoms)*,,HP:0025142*,,,,,,,,,,,
807,,# 232200,Glycogen storage disease type 1A,,G6PC,Glucose 6-phophatase,3.1.3.9,l-carnitine,,DB00583,ECO:0007764,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,mitochondrial dysfunction,,HP:0003287,http://www.ncbi.nlm.nih.gov/pubmed/28317891?dopt=Abstract,https://www.nature.com/articles/srep44408,,,,,,,,,
808,,# 232200,Glycogen storage disease type 1A,,G6PC,Glucose 6-phophatase,3.1.3.9,Tempol,,DB12449,ECO:0005242,,,,,Symptomatic (C),,symptomatic treatment procedure,,,Abnormal renal function,,HP:0012211,https://www.ncbi.nlm.nih.gov/pubmed/20195241,https://www.nature.com/articles/srep44408,,,,,,,,,
809,,# 232200,Glycogen storage disease type 1A,,G6PC,Glucose 6-phophatase,3.1.3.9,,,,,,,,,,,,,,Renal disease progression( Progressive disorder)*,,HP:0003676*,https://www.ncbi.nlm.nih.gov/pubmed/20195241,,,,,,,,,,
810,,# 232200,Glycogen storage disease type 1A,,G6PC,Glucose 6-phophatase,3.1.3.9,,,,,,,,,,,,,,Nephropathy,,HP:0000112,https://www.ncbi.nlm.nih.gov/pubmed/20195241,,,,,,,,,,
811,,# 232200,Glycogen storage disease type 1A,,G6PC,Glucose 6-phophatase,3.1.3.9,ACE‐inhibitors,,C09C,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,,Glomerular hyperfilteration (Abnormal glomerular filtration rate),,HP:0012212,https://www.ncbi.nlm.nih.gov/pubmed/15963056,https://content.iospress.com/articles/translational-science-of-rare-diseases/trd006,,,,,,,,,
812,,# 232200,Glycogen storage disease type 1A,,G6PC,Glucose 6-phophatase,3.1.3.9,Antioxidant + ACE inhibitors,,DB12449+C09C,ECO:0007764,,,,,Symptomatic (C),,symptomatic treatment procedure,,,Nephropathy,,HP:0000112,https://www.ncbi.nlm.nih.gov/pubmed/15963056,https://content.iospress.com/articles/translational-science-of-rare-diseases/trd006,,,,,,,,,
813,,# 232200,Glycogen storage disease type 1A,,G6PC,Glucose 6-phophatase,3.1.3.9,Glucose,,DB01914,ECO:0000352,,,,,Functional interaction (B),B,metabolite replacement,,,Hypoglycemia,,HP:0001943,https://www.ncbi.nlm.nih.gov/pubmed/26835382,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2956916/,,,,,,,,,
814,,# 232200,Glycogen storage disease type 1A,,G6PC,Glucose 6-phophatase,3.1.3.9,Uncooked cornstarch,,,ECO:0000352,,,,,Functional interaction (B),,dietary supplementation,,,Hypoglycemia,,HP:0001943,https://www.researchgate.net/publication/307584174_Glycogen_storage_diseases_Diagnosis_treatment_and_outcome,https://content.iospress.com/articles/translational-science-of-rare-diseases/trd006,https://www.ncbi.nlm.nih.gov/pubmed/20975743/,,,,,,,,
815,,# 232200,Glycogen storage disease type 1A,,G6PC,Glucose 6-phophatase,3.1.3.9,Allopurinol,,DB00437,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,High plasma uric acid levels,,HP:0002149,https://www.ncbi.nlm.nih.gov/pubmed/26835382,,,,,,,,,,
816,,# 232200,Glycogen storage disease type 1A,,G6PC,Glucose 6-phophatase,3.1.3.9,Calcium+ vitamin D3,Preventive calcium and vitamin D3 supplementation is also recommended to prevent osteoporosis.,DB01373+DB00169,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,,Osteoporosis,Preventive calcium and vitamin D3 supplementation is also recommended to prevent osteoporosis.,HP:0000939,https://content.iospress.com/articles/translational-science-of-rare-diseases/trd006,,,,,,,,,,
817,,# 232200,Glycogen storage disease type 1A,,G6PC,Glucose 6-phophatase,3.1.3.9,medium chain triglycerides,,DB13959,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,Hyperuricemia,,HP:0002149,https://www.ncbi.nlm.nih.gov/pubmed/20357432,,,,,,,,,,
818,,# 232200,Glycogen storage disease type 1A,,G6PC,Glucose 6-phophatase,3.1.3.9,,,,,,,,,,,,,,Hypertriglyceridemia,,HP:0002155,https://www.ncbi.nlm.nih.gov/pubmed/20357432,,,,,,,,,,
819,,# 232200,Glycogen storage disease type 1A,,G6PC,Glucose 6-phophatase,3.1.3.9,,,,,,,,,,,,,,Growth failure,,HP:0001510,https://www.ncbi.nlm.nih.gov/pubmed/20357432,,,,,,,,,,
820,,# 232200,Glycogen storage disease type 1A,,G6PC,Glucose 6-phophatase,3.1.3.9,,,,,,,,,,,,,,,,,,,,,,,,,,,
821,91,# 232220,Glycogen storage disease type 1b,,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),O43826,Human granulocyte-colony-stimulating-factor,Long-term use of GCSF is associated with complications such as hypersplenism and malignancy. https://www.ncbi.nlm.nih.gov/pubmed/26835382,DB00099,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,,,Neutropenia,,HP:0001875,https://www.ncbi.nlm.nih.gov/pubmed/26835382,https://www.ncbi.nlm.nih.gov/pubmed/25288127,https://www.ncbi.nlm.nih.gov/pubmed/8447561,https://www.ncbi.nlm.nih.gov/pubmed/19066956,,,,,,,
822,,# 232220,Glycogen storage disease type 1b,,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),O43826,,,,,,,,,,,,,,Recurrent bacterial infection,,HP:0002718,https://www.ncbi.nlm.nih.gov/pubmed/1709246,https://www.sciencedirect.com/science/article/abs/pii/S0022347605802902,,,,,,,,,
823,,# 232220,Glycogen storage disease type 1b,,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),O43826,,,,,,,,,,,,,,"Frequent, severe infections",,HP:0002719,https://www.ncbi.nlm.nih.gov/pubmed/1709246,https://www.sciencedirect.com/science/article/abs/pii/S0022347605802902,,,,,,,,,
824,,# 232220,Glycogen storage disease type 1b,,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),O43826,G‐CSF + 5‐aminosalicylic acid,"Anti-inflammatory medications, including derivatives of 5-aminosalicylic acid (5-ASA), might be a helpful adjunct for treating gastrointestinal complaints in GSD Ib patients, if renal function is carefully monitored . https://www.ncbi.nlm.nih.gov/pubmed/12373585",DB00099+DB00244,ECO:0000352,,,,,,,symptomatic treatment procedure,,,Neutropenia with IBD,,HP:0001875+HP:0002037,https://www.ncbi.nlm.nih.gov/pubmed/12373585,https://www.ncbi.nlm.nih.gov/pubmed/25288127,https://www.ncbi.nlm.nih.gov/pubmed/19541498,,,,,,,,
825,,# 232220,Glycogen storage disease type 1b,,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),O43826,Adalimumab,,,ECO:0000352,,,,,,,symptomatic treatment procedure,,,GSD-associated enterocolitis(enterocolitis),,HP:0004387,https://www.ncbi.nlm.nih.gov/pubmed/18172743,,,,,,,,,,
826,,# 232220,Glycogen storage disease type 1b,,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),O43826,Glycosade,,NA,ECO:0007121,,,,,Functional interaction (B),B,dietary supplementation,,,Fasting hypoglycemia,,HP:0003162,https://clinicaltrials.gov/ct2/show/NCT02054832?cond=von+Gierke&rank=6,https://www.ncbi.nlm.nih.gov/pubmed/29223626,https://www.ncbi.nlm.nih.gov/pubmed/18996862,https://www.ncbi.nlm.nih.gov/pubmed/17514432,,,,,,,
827,,# 232220,Glycogen storage disease type 1b,,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),O43826,,,,,,,,,,,,,,Sleep disturbance/Poor sleep qaulity,The therapy may allow patients with GSD to sleep through the night without awakening for therapy https://www.ncbi.nlm.nih.gov/pubmed/18996862,HP:0002360,https://www.ncbi.nlm.nih.gov/pubmed/29223626,https://www.ncbi.nlm.nih.gov/pubmed/18996862,,,,,,,,,
828,,# 232220,Glycogen storage disease type 1b,,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),O43826,,,,,,,,,,,,,,Low quality of life(Constitutional symptoms)*,,HP:0025142*,,,,,,,,,,,
829,,# 232220,Glycogen storage disease type 1b,,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),O43826,rAAV-GPE-G6PT,,NA,ECO:0007121,,,,,Direct Interaction (A),A,direct complementation of a genetically defective protein by gene therapy,,,hyperlipidemia,,HP:0003077,http://www.ncbi.nlm.nih.gov/pubmed/28973635?dopt=Abstract,,,,,,,,,,
830,,# 232220,Glycogen storage disease type 1b,,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),O43826,,,,,,,,,,,,,,hypoglycemia,,HP:0001943,http://www.ncbi.nlm.nih.gov/pubmed/28973635?dopt=Abstract,,,,,,,,,,
831,,# 232220,Glycogen storage disease type 1b,,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),O43826,,,,,,,,,,,,,,hyperuricemia,,HP:0002149,http://www.ncbi.nlm.nih.gov/pubmed/28973635?dopt=Abstract,,,,,,,,,,
832,,# 232220,Glycogen storage disease type 1b,,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),O43826,,,,,,,,,,,,,,lactic acidemia,,HP:0003128,http://www.ncbi.nlm.nih.gov/pubmed/28973635?dopt=Abstract,,,,,,,,,,
833,,# 232220,Glycogen storage disease type 1b,,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),O43826,,,,,,,,,,,,,,age-related insulin resistance(Insulin resistance)*,,HP:0000855*,http://www.ncbi.nlm.nih.gov/pubmed/28973635?dopt=Abstract,,,,,,,,,,
834,,# 232220,Glycogen storage disease type 1b,,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),O43826,,,,,,,,,,,,,,obesity,,HP:0001513,http://www.ncbi.nlm.nih.gov/pubmed/28973635?dopt=Abstract,,,,,,,,,,
835,,# 232220,Glycogen storage disease type 1b,,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),O43826,galactose+Uridine,"To exclude a lack of uridine as a limiting factor, uridine was added for the
 last 9 weeks of treatment.",DB11735+DB02745,ECO:0007121,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,Partial correction of neutrophil dysfunction,"In this study, the amount of oral galactose and uridine sufficient to correct PGM1-deficiency, 322 could not improve the hypoglycosylation of neutrophils in a GSD-Ib patient.https://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract",HP:0011990,http://www.ncbi.nlm.nih.gov/pubmed/28126686?dopt=Abstract,,,,,,,,,,
836,,# 232220,Glycogen storage disease type 1b,,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),O43826,vitamin E,,DB00163,ECO:0007121,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,neutropenia,,HP:0001875,https://www.ncbi.nlm.nih.gov/pubmed/19066956,,,,,,,,,,
837,,# 232220,Glycogen storage disease type 1b,,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),O43826,,,,,,,,,,,,,,"Frequent, severe infections",,HP:0002719,https://www.ncbi.nlm.nih.gov/pubmed/19066956,,,,,,,,,,
838,,# 232220,Glycogen storage disease type 1b,,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),O43826,testosterone,"Testosterone therapy needs to be carefully considered because of the risk of hepatic adenomas.https://www.ncbi.nlm.nih.gov/pubmed/28160246
Androgen receptors are expressed in the liver, and androgens can stimulate hepatocyte proliferation. Although rare, androgens have been shown in observational studies to induce adenoma development (Giannitrapani et al. 2006). Testosterone levels should be assessed for response 2–3 months after therapy is initiated.",DB00624,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,decreased male libido,,HP:0040306,https://www.ncbi.nlm.nih.gov/pubmed/28160246,,,,,,,,,,
839,,# 232220,Glycogen storage disease type 1b,,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),O43826,,,,,,,,,,,,,,low physical activity,,HP:0025142,,,,,,,,,,,
840,,# 232220,Glycogen storage disease type 1b,,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),O43826,,,,,,,,,,,,,,decrease muscle strenght,,HP:0001324,,,,,,,,,,,
841,,# 232220,Glycogen storage disease type 1b,,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),O43826,medium chain triglycerides,,DB13959,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,Hyperurecemia,,done,https://www.ncbi.nlm.nih.gov/pubmed/20357432,,,,,,,,,,
842,,# 232220,Glycogen storage disease type 1b,,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),O43826,,,,,,,,,,,,,,Hypertriglycerdemia,,,,,,,,,,,,,
843,,# 232220,Glycogen storage disease type 1b,,SLC37A4,Glucose-6-phosphate exchanger SLC37A4 (glucose 6-phosphate translocase),O43826,,,,,,,,,,,,,,Growth failure,,,,,,,,,,,,,
844,92,# 232400,Glycogen storage disease type 3,Managment guidelines for treating GSD3 can be accessed through https://www.ncbi.nlm.nih.gov/pubmed/20631546,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",2.4.1.25 +3.2.1.33,Cornstarch,,DB11599,ECO:0000352,,,,,Symptomatic (C),C,dietary supplementation,,,linear growth velocity(Abnormality of body height)*,,HP:0000002*,https://www.nature.com/articles/gim201069,https://www.ncbi.nlm.nih.gov/pubmed/20631546,https://www.ncbi.nlm.nih.gov/pubmed/25153581,https://www.ncbi.nlm.nih.gov/pubmed/24613482,,,,,,,
845,,# 232400,Glycogen storage disease type 3,,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",2.4.1.25 +3.2.1.33,,,,,,,,,,,,,,hypoglycemic seizures,,HP:0002173,,,,,,,,,,,
846,,# 232400,Glycogen storage disease type 3,,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",2.4.1.25 +3.2.1.33,,,,,,,,,,,,,,Enlarged size of the liver,,HP:0002240,,,,,,,,,,,
847,,# 232400,Glycogen storage disease type 3,,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",2.4.1.25 +3.2.1.33,calcium and vitamin D,,DB01373 + DB11094,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,Osteoporosis,,HP:0000939,,,,,,,,,,,
848,,# 232400,Glycogen storage disease type 3,,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",2.4.1.25 +3.2.1.33,Glycosade,,NA,ECO:0007121,,,,,Functional interaction (B),B,dietary supplementation,,,Fasting hypoglycemia,,HP:0003162,https://clinicaltrials.gov/ct2/show/NCT02054832?cond=von+Gierke&rank=6,https://www.ncbi.nlm.nih.gov/pubmed/29223626,https://www.ncbi.nlm.nih.gov/pubmed/17514432,,,,,,,,
849,,# 232400,Glycogen storage disease type 3,,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",2.4.1.25 +3.2.1.33,,,,,,,,,,,,,,Sleep disturbance,,HP:0002360,https://www.ncbi.nlm.nih.gov/pubmed/29223626,,,,,,,,,,
850,,# 232400,Glycogen storage disease type IIIa,,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",2.4.1.25 +3.2.1.33,Rapamycin,,DB00877,ECO:0005542,,,,,functional complementation of a defective protein by inhibition,B,functional complementation of a defective protein by inhibition,,Drug name:   Study was done in a canine model.,high glycogen levels in muscles,,HP:0009051,https://www.ncbi.nlm.nih.gov/pubmed/24509886,,,,,,,,,,
851,,# 232400,Glycogen storage disease type IIIa,,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",2.4.1.25 +3.2.1.33,,,,,,,,,,,,,,liver fibrosis progression,,HP:0001395,https://www.ncbi.nlm.nih.gov/pubmed/24509886,,,,,,,,,,
852,,# 232400,Glycogen storage disease type IIIa,,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",2.4.1.25 +3.2.1.33,fructose,,DB04173,ECO:0007121,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,exercise intolerance,,HP:0003546,https://www.ncbi.nlm.nih.gov/pubmed/25832663,,,,,,,,,,
853,,# 232400,Glycogen storage disease type IIIa,,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",2.4.1.25 +3.2.1.33,high protein diet,,NA,,,,,,Symptomatic (C),C,dietary regime modification,,Drug name: A dietary tretament,delayed growth,,HP:0001510,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571/,https://www.ncbi.nlm.nih.gov/pubmed/8245377,,,,,,,,,
854,,# 232400,Glycogen storage disease type IIIa,,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",2.4.1.25 +3.2.1.33,,,,,,,,,,,,,,myopathy,,HP:0003198,,,,,,,,,,,
855,,# 232400,Glycogen storage disease type IIIa,,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",2.4.1.25 +3.2.1.33,,,,,,,,,,,,,,cardiomyopathy,,HP:0001638,,,,,,,,,,,
856,,# 232400,Glycogen storage disease type IIIa,,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",2.4.1.25 +3.2.1.33,Modified Atkins diet,,NA,ECO:0000352,,,,,Symptomatic (C),C,dietary regime modification,,Drug name: A dietary tretament,abnormal blood levels of ketone bodies,,HP:0001939,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4302571/,https://www.ncbi.nlm.nih.gov/pubmed/20631546/,,,,,,,,,
857,,# 232400,Glycogen storage disease type IIIa,,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",2.4.1.25 +3.2.1.33,,,,,,,,,,,,,,Abnormal blood levels of  fatty acids,,HP:0004359,,,,,,,,,,,
858,,# 232400,Glycogen storage disease type IIIa,,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",2.4.1.25 +3.2.1.33,,,,,,,,,,,,,,high creatine kinase,,HP:0003236,,,,,,,,,,,
859,,# 232400,Glycogen storage disease type IIIa,,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",2.4.1.25 +3.2.1.33,,,,,,,,,,,,,,cardiomyopathy,,HP:0001638,,,,,,,,,,,
860,,# 232400,Glycogen storage disease type IIIa,,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",2.4.1.25 +3.2.1.33,,,,,,,,,,,,,,low energetic state of heart(Abnormality of cardiovascular system physiology)*,,HP:0011025*,,,,,,,,,,,
861,,# 232400,Glycogen storage disease type IIIa,,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",2.4.1.25 +3.2.1.33,,,,,,,,,,,,,,low energetic state of skeletal muscle,,HP:0011804,,,,,,,,,,,
862,,# 232400,Glycogen storage disease type IIIa,,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",2.4.1.25 +3.2.1.33,,,,,,,,,,,,,,Increased creatine kinase activity,,HP:0003236,,,,,,,,,,,
863,,# 232400,Glycogen storage disease type IIIa,,AGL,"Glycogen debranching enzyme (4-alpha-glucanotransferase+Amylo-1,6-glucosidase)",2.4.1.25 +3.2.1.33,,,,,,,,,,,,,,,,,,,,,,,,,,,
864,93,# 232600,Glycogen storage disease type 5,,PYGM,"Glycogen phosphorylase, Muscle form",2.4.1.1,Sodium Valproate,,DB00313,ECO:0007121,,,,,Functional interaction(Mechanistic B),B,functional complementation of a defective protein by stimulation,,Drug name:,,,done,http://euromacregistry.eu/portal1/content.asp?contentid=1207,https://clinicaltrials.gov/ct2/show/NCT03112889?cond=McArdle+Disease&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/25455802?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/25762569,,,,,,,
865,,# 232600,Glycogen storage disease type 5,,PYGM,"Glycogen phosphorylase, Muscle form",2.4.1.1,Triheptanoin,,DB11677,ECO:0007121,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,abnormal fat metabolism,,HP:0004359,https://link.springer.com/article/10.1007%2Fs11940-017-0473-2,https://clinicaltrials.gov/ct2/show/NCT02432768?cond=Glycogen+Storage+Disease+Type+V&rank=1,,,,,,,,,
866,,# 232600,Glycogen storage disease type 5,,PYGM,"Glycogen phosphorylase, Muscle form",2.4.1.1,,,,,,,,,,,,,,abnormal carbohydrate metabolism*,,HP:0011013,,,,,,,,,,,
867,,# 232600,Glycogen storage disease type 5,,PYGM,"Glycogen phosphorylase, Muscle form",2.4.1.1,creatine,,DB00148,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,exercise intolerance,,HP:0003546,https://www.ncbi.nlm.nih.gov/pubmed/25391139,http://www.ncbi.nlm.nih.gov/pubmed/28932990?dopt=Abstract,https://www.sciencedirect.com/science/article/pii/S096089660700082X,https://www.ncbi.nlm.nih.gov/pubmed/24493026,https://link.springer.com/content/pdf/10.1016%2Fj.nurt.2008.08.006.pdf,,,,,,
868,,# 232600,Glycogen storage disease type 5,,PYGM,"Glycogen phosphorylase, Muscle form",2.4.1.1,sucrose,,DB02772,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,exercise intolerance,,HP:0003547,http://www.ncbi.nlm.nih.gov/pubmed/28932990?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/25391139,https://www.sciencedirect.com/science/article/pii/S096089660700082X,https://www.ncbi.nlm.nih.gov/pubmed/24493026,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,,,https://www.ncbi.nlm.nih.gov/pubmed/14695410?dopt=Abstract,,,
869,,# 232600,Glycogen storage disease type 5,,PYGM,"Glycogen phosphorylase, Muscle form",2.4.1.1,vitamin B6,,DB00165,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,insufficient anaerobic glycolysis of skeletal muscle,,,https://www.ncbi.nlm.nih.gov/pubmed/?term=Confirmation+of+the+efficacy+of+vitamin+B6+supplementation+for+McArdle+disease+by+follow‐up+muscle+biops,https://www.sciencedirect.com/science/article/pii/S096089660700082X,https://www.ncbi.nlm.nih.gov/pubmed/24493026,https://link.springer.com/content/pdf/10.1016%2Fj.nurt.2008.08.006.pdf,,,,,,,
870,,# 232600,Glycogen storage disease type 5,,PYGM,"Glycogen phosphorylase, Muscle form",2.4.1.1,,,,,,,,,,,,,,exercise intolerance,,HP:0003546,,,,,,,,,,,
871,,# 232600,Glycogen storage disease type 5,,PYGM,"Glycogen phosphorylase, Muscle form",2.4.1.1,,,,,,,,,,,,,,abnormal muscle phosphorylase activity,,NA,,,,,,,,,,,
872,,# 232600,Glycogen storage disease type 5,,PYGM,"Glycogen phosphorylase, Muscle form",2.4.1.1,ramipril,,DB00178,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,disability(Functional motor problems)*,,HP:0004302*,https://www.ncbi.nlm.nih.gov/pubmed/18098237,https://www.ncbi.nlm.nih.gov/pubmed/24493026,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,,,,,,,,
873,,# 232600,Glycogen storage disease type 5,,PYGM,"Glycogen phosphorylase, Muscle form",2.4.1.1,,,,,,,,,,,,,,Abnormal exercise physiology,,HP:0009020,,,,,,,,,,,
874,,# 232600,Glycogen storage disease type 5,,PYGM,"Glycogen phosphorylase, Muscle form",2.4.1.1,GENTAMICIN,,DB04729,ECO:0000352,,,,,Symptomatic (C),C,,,Drug name: ineffective/ further study is needed,,,HP:0009020,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514707/,https://link.springer.com/content/pdf/10.1016%2Fj.nurt.2008.08.006.pdf,https://www.ncbi.nlm.nih.gov/pubmed/16434679?dopt=Abstract,,,,,,,,
875,94,# 232700,Glycogen storage disease type 6,,PYGL,"Glycogen phosphorylase, liver form",2.4.1.1,Cornstarch(Uncooked),,DB11599,ECO:0000352,,,,,Functional interaction (B),B,dietary supplementation,,"Drug name: Uncooked cornstarch administartion can result in avoidance of ketosis, hypoglycemia and hepatomegaly. https://www.ncbi.nlm.nih.gov/pubmed/20301760",short stature,,HP:0004322,https://www.ncbi.nlm.nih.gov/pubmed/25266922,https://www.sciencedirect.com/science/article/pii/S1096719214002959?via%3Dihub,,,,,,,,,
876,,# 232700,Glycogen storage disease type 6,,PYGL,"Glycogen phosphorylase, liver form",2.4.1.1,,,,,,,,,,,,,,Abnormal blood glucose concentration,,HP:0011015,https://www.ncbi.nlm.nih.gov/pubmed/20301760,,,,,,,,,,
877,,# 232700,Glycogen storage disease type 6,,PYGL,"Glycogen phosphorylase, liver form",2.4.1.1,,,,,,,,,,,,,,Low energy level(Tiredness)*,,HP:0012378,https://www.ncbi.nlm.nih.gov/pubmed/20301760,,,,,,,,,,
878,,# 232700,Glycogen storage disease type 6,,PYGL,"Glycogen phosphorylase, liver form",2.4.1.1,,,,,,,,,,,,,,Failure to thrive,,HP:0001508,https://www.ncbi.nlm.nih.gov/pubmed/25266922,,,,,,,,,,
879,,# 232700,Glycogen storage disease type 6,,PYGL,"Glycogen phosphorylase, liver form",2.4.1.1,,,,,,,,,,,,,,Elevated Hepatic transaminases,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/25266922,,,,,,,,,,
880,,# 232700,Glycogen storage disease type 6,,PYGL,"Glycogen phosphorylase, liver form",2.4.1.1,Beneprotein,,NA,ECO:0000352,,,,,Functional interaction (B),B,,,,short stature,,HP:0004322,https://www.ncbi.nlm.nih.gov/pubmed/25266922,,https://www.ncbi.nlm.nih.gov/pubmed/25266922,https://m.ufhealth.org/sites/default/files/media/GSD/General-Nutrition-Guidelines-For-Glycogen-Storage-Disease-Type-VI.pdf,,,,,,,
881,,# 232700,Glycogen storage disease type 6,,PYGL,"Glycogen phosphorylase, liver form",2.4.1.1,Uncooked cornstarch+Beneprotein,,DB11599+NA,ECO:0000352,,,,,Functional interaction (B),,,,,Elevated Hepatic transaminases,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/25266922,,,,,,,,,,
882,,# 232700,Glycogen storage disease type 6,,PYGL,"Glycogen phosphorylase, liver form",2.4.1.1,D-Thyroxine,,DB00509,ECO:0000352,,,,,Functional interaction (B),,,,,Hepatomeglay,,HP:0002240,https://www.ncbi.nlm.nih.gov/pubmed/3483883,https://www.nature.com/articles/pr19842087,,,,,,,,,
883,,# 232700,Glycogen storage disease type 6,,PYGL,"Glycogen phosphorylase, liver form",2.4.1.1,,,,,,,,,,,,,,Elevated Hepatic transaminases,,HP:0002910,,,,,,,,,,,
884,,# 232700,Glycogen storage disease type 6,,PYGL,"Glycogen phosphorylase, liver form",2.4.1.1,,,,,,,,,,,,,,Failure to thrive,,HP:0001508,,,,,,,,,,,
885,,# 232700,Glycogen storage disease type 6,,PYGL,"Glycogen phosphorylase, liver form",2.4.1.1,,,,,,,,,,,,,,Increased erythrocyte glycogen content,,HP:0001939,,,,,,,,,,,
886,,# 232700,Glycogen storage disease type 6,,PYGL,"Glycogen phosphorylase, liver form",2.4.1.1,,,,,,,,,,,,,,Hypertriglyceridemia,,HP:0002155,,,,,,,,,,,
887,,# 232700,Glycogen storage disease type 6,,PYGL,"Glycogen phosphorylase, liver form",2.4.1.1,,,,,,,,,,,,,,,,,,,,,,,,,,,
888,,# 232700,Glycogen storage disease type 6,,PYGL,"Glycogen phosphorylase, liver form",2.4.1.1,,,,,,,,,,,,,,,,,,,,,,,,,,,
889,95,# 232800,Glycogen storage disease type 7,"The infantile form of PFK deficiency is characterized by the early onset of muscle weakness and multisystem involvement, which often leads to death in infancy or early childhood. Early diagnosis and improved understanding would enable clinicians to provide better clinical care. https://www.ncbi.nlm.nih.gov/pubmed/26108272",PFKM,"ATP-dependent 6-phosphofructokinase, muscle type",2.7.1.11,Triheptanoin,"A clinical trail studying the effect of Triheptanoin on excersise intolerance and fat metabolism, is currently under process. https://clinicaltrials.gov/ct2/show/NCT03642860?cond=Glycogen+Storage+Disease+VII&rank=1",,ECO:0007121,,,,,,,,,,Trial is still in the Recruiting stage.,,,https://clinicaltrials.gov/ct2/show/NCT03642860?cond=Glycogen+Storage+Disease+VII&rank=1,,,,,,,,,,
890,,# 232800,Glycogen storage disease type 7,,PFKM,"ATP-dependent 6-phosphofructokinase, muscle type",2.7.1.11,,,,,,,,,,,,,,,,,,,,,,,,,,,
891,96,# 606664,Glycine N-methyltransferase deficiency,"Treatment recommendations could be regular monitoring and low-methionine diet if symptoms appear or if methionine is very high. https://www.ncbi.nlm.nih.gov/pubmed/27207470.                                                                                                                                                                                                                                                                                            The necessity for treatment of this asymptomatic seemingly benign disorder is presently questionable, careful follow-up being the main parameter for optimal care. https://www.ncbi.nlm.nih.gov/pubmed/27671891. No treatment needed in most cases.",GNMT,glycine N-methyltransferase,2.1.1.20,Nicotinamide,An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/,DB02701,ECO:0005542,,,,,Functional interaction(Mechanistic B),B,,,"Disease name: Treatment recommendations could be regular monitoring and low-methionine diet if symptoms appear or if methionine is very high.

https://www.ncbi.nlm.nih.gov/pubmed/27207470.                                                                                                                                                                                                                                                                                            The necessity for treatment of this asymptomatic seemingly benign disorder is presently questionable, careful follow-up being the main parameter for optimal care. https://www.ncbi.nlm.nih.gov/pubmed/27671891. No treatment needed in most cases.  Drug name: An experimental study done on a mice with GMNT knocked out. suggesting considering Nicotinamide as atreatment option in patients with GNMT deficiency.  https://www.ncbi.nlm.nih.gov/pubmed/20578266/",Liver steatosis,,HP:0001397,https://www.ncbi.nlm.nih.gov/pubmed/20578266/,https://www.ncbi.nlm.nih.gov/pubmed/27207470,https://www.ncbi.nlm.nih.gov/pubmed/19585268,,,,,,,,
892,,# 606664,Glycine N-methyltransferase deficiency,,GNMT,glycine N-methyltransferase,2.1.1.20,,,,,,,,,,,,,,Fatty liver,,HP:0001397,,,,,,,,,,,
893,,# 606664,Glycine N-methyltransferase deficiency,,GNMT,glycine N-methyltransferase,2.1.1.20,,,,,,,,,,,,,,Liver fibrosis,,HP:0001395,,,,,,,,,,,
894,,# 606664,Glycine N-methyltransferase deficiency,,GNMT,glycine N-methyltransferase,2.1.1.20,,,,,,,,,,,,,,DNA hypermethylation,,NA,,,,,,,,,,,
895,96,# 231950,Glutathionuria,,GGT1,Glutathione hydrolase 1 proenzyme/Gamma-glutamyltranspeptidase,3.4.19.13/2.3.2.2,OTZ (L-2-oxothiazoline-4-carboxylic acid,,NA,ECO:0005542,,,,,Functional interaction (B),B,,,Disease name : In 2007 Ristoff et al.   mentioned in their paper  that there is no treatment that has been recommended. https://www.ncbi.nlm.nih.gov/pubmed/17397529?dopt=Abstract. Drug name: These drugs have been tested on mice.,low intracellular cysteine*,,HP:0010918,,,http://www.ncbi.nlm.nih.gov/pubmed/12757858?dopt=Abstract,,,,,,,,
896,,# 231950,Glutathionuria,,GGT1,Glutathione hydrolase 1 proenzyme/Gamma-glutamyltranspeptidase,3.4.19.13/2.3.2.2,,,,,,,,,,,,,,behavioral abnormalities,,HP:0000708,,,,,,,,,,,
897,,# 231950,Glutathionuria,,GGT1,Glutathione hydrolase 1 proenzyme/Gamma-glutamyltranspeptidase,3.4.19.13/2.3.2.2,,,,,,,,,,,,,,GSH deficiency,,HP:0003343,,,,,,,,,,,
898,,# 231950,Glutathionuria,,GGT1,Glutathione hydrolase 1 proenzyme/Gamma-glutamyltranspeptidase,3.4.19.13/2.3.2.2,N-acetylcysteine,,DB06151,ECO:0005542,,,,,Functional interaction (B),B,,,Drug name: These drugs have been tested on mice.,Delayed growth,,HP:0001510,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC38850/,,https://www.ncbi.nlm.nih.gov/pubmed/20868666,,,,,,,,
899,,# 231950,Glutathionuria,,GGT1,Glutathione hydrolase 1 proenzyme/Gamma-glutamyltranspeptidase,3.4.19.13/2.3.2.2,,,,,,,,,,,,,,Cataract,,HP:0000518,https://www.ncbi.nlm.nih.gov/pubmed/11095909,,,,,,,,,,
900,,# 231950,Glutathionuria,,GGT1,Glutathione hydrolase 1 proenzyme/Gamma-glutamyltranspeptidase,3.4.19.13/2.3.2.2,,,,,,,,,,,,,,low reproductive capacity (infertility),,HP:0000144,https://www.ncbi.nlm.nih.gov/pubmed/11089562,,,,,,,,,,
901,97,# 266130,Glutathione synthetase deficiency,,GSS,glutathione synthetase,6.3.2.3,ascorbic acid,,DB00126,ECO:0000352,,,,,Symptomatic (C),C,,,,oxidative stress,,HP:0025464,https://www.ncbi.nlm.nih.gov/pubmed/8301428/,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1852094/,,,,,,,,
902,,# 266130,Glutathione synthetase deficiency,,GSS,glutathione synthetase,6.3.2.3,Ascorbate + N-acetylcysteine,,DB00126+DB06151,ECO:0000352,,,,,,,,,,High erythrocyte turnover(Abnormality of erythrocytes)*,,HP:0001877*,https://www.ncbi.nlm.nih.gov/pubmed/8301428/,,,,,,,,,,
903,,# 266130,Glutathione synthetase deficiency,,GSS,glutathione synthetase,6.3.2.3,Polycitra (citric acid +potassium citrate + sodium citrate)+vitamin C+vitamin E+selenium,,DB11135,ECO:0000352,,,,,Symptomatic (C),C,,,,oxidative stress,,HP:0025464,http://www.ncbi.nlm.nih.gov/pubmed/26984560?dopt=Abstract,,,,,,,,,,
904,,# 266130,Glutathione synthetase deficiency,,GSS,glutathione synthetase,6.3.2.3,alpha-tocopherol,,DB00163,ECO:0000352,,,,,Symptomatic (C),C,,,,abnormal microtubule assembly,,NA,,,https://books.google.com.sa/books?id=s5LmBwSwwGsC&pg=PA555&lpg=PA555&dq=alpha-tocopherol+in+treating+abnormal+microtubule+assembly%C2%A0&source=bl&ots=4aMlvmEp6z&sig=4RJAuvv04-5ZSQQWo2OOGLf5LYg&hl=en&sa=X&ved=2ahUKEwjrut3GkqHeAhUJJ1AKHUwSBiYQ6AEwBXoECAQQAQ#v=onepage&q=alpha-tocopherol%20in%20treating%20abnormal%20microtubule%20assembly%C2%A0&f=false,,,,,,,,
905,,# 266130,Glutathione synthetase deficiency,,GSS,glutathione synthetase,6.3.2.3,,,,,,,,,,,,,,Short erythrocyte survival (Abnormality of erythrocytes)*,,HP:0001877*,https://www.ncbi.nlm.nih.gov/pubmed/29340523,,,,,,,,,,
906,,# 266130,Glutathione synthetase deficiency,,GSS,glutathione synthetase,6.3.2.3,,,,,,,,,,,,,,abnormal polymorphonuclear leukocyte function,,HP:0001874,,,,,,,,,,,
907,,# 266130,Glutathione synthetase deficiency,,GSS,glutathione synthetase,6.3.2.3,,,,,,,,,,,,,,Neutropenia,,HP:0001875,,,,,,,,,,,
908,,# 266130,Glutathione synthetase deficiency,,GSS,glutathione synthetase,6.3.2.3,,,,,,,,,,,,,,Susceptibility to Bacterial infection,,HP:0002718,,,,,,,,,,,
909,,# 266130,Glutathione synthetase deficiency,,GSS,glutathione synthetase,6.3.2.3,,,,,,,,,,,,,,retinal dystrophy,,HP:0000556,https://www.ncbi.nlm.nih.gov/pubmed/17206463?dopt=Abstract,,,,,,,,,,
910,,# 266130,Glutathione synthetase deficiency,,GSS,glutathione synthetase,6.3.2.3,,,,,,,,,,,,,,CNS damage progression,,HP:0007367,,,,,,,,,,,
911,,# 266130,Glutathione synthetase deficiency,,GSS,glutathione synthetase,6.3.2.3,L-carnitine+vitamin E+vitamin B1+ cobalamin,,DB00583+DB00163+DB00152+DB14098+DB01390,ECO:0000352,,,,,Symptomatic (C),,,,,Hypersomnia,,HP:0100786,https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract,,,,,,,,,,
912,,# 266130,Glutathione synthetase deficiency,,GSS,glutathione synthetase,6.3.2.3,,,,,,,,,,,,,,Jaundice,,HP:0000952,https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract,,,,,,,,,,
913,,# 266130,Glutathione synthetase deficiency,,GSS,glutathione synthetase,6.3.2.3,,,,,,,,,,,,,,Carnitine deficiency,,HP:0003234,https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract,,,,,,,,,,
914,,# 266130,Glutathione synthetase deficiency,,GSS,glutathione synthetase,6.3.2.3,,,,,,,,,,,,,,Hypotonia,,HP:0001290,https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract,,,,,,,,,,
915,,# 266130,Glutathione synthetase deficiency,,GSS,glutathione synthetase,6.3.2.3,L-carnitine+vitamin B1+B2+ B12+ C+E + sodium bicarbonate,,DB00583+DB00163+DB00152+DB00140 +DB01390+DB00126+DB00115,ECO:0000352,,,,,Symptomatic (C),,,,,Metabolic acidosis,,HP:0001942,https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract,,,,,,,,,,
916,,# 266130,Glutathione synthetase deficiency,,GSS,glutathione synthetase,6.3.2.3,,,,,,,,,,,,,,Hypoglycemia,,HP:0001943,https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract,,,,,,,,,,
917,,# 266130,Glutathione synthetase deficiency,,GSS,glutathione synthetase,6.3.2.3,,,,,,,,,,,,,,Elevated urine 5-oxoproline,,NA,https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract,,,,,,,,,,
918,,# 266130,Glutathione synthetase deficiency,,GSS,glutathione synthetase,6.3.2.3,,,,,,,,,,,,,,Decreased blood free carnitine,,HP:0008315,https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract,,,,,,,,,,
919,,# 266130,Glutathione synthetase deficiency,,GSS,glutathione synthetase,6.3.2.3,L-carnitine+ vitamin B1+B12+C + E,,DB00583+DB00152+DB00115+DB00126+DB00163,ECO:0000352,,,,,Symptomatic (C),,,,,Elevated urine 5-oxoproline,,NA,https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract,,,,,,,,,,
920,,# 266130,Glutathione synthetase deficiency,,GSS,glutathione synthetase,6.3.2.3,,,,,,,,,,,,,,Decreased blood free carnitine,,HP:0008315,https://www.ncbi.nlm.nih.gov/pubmed/25851806?dopt=Abstract,,,,,,,,,,
921,,# 266130,Glutathione synthetase deficiency,,GSS,glutathione synthetase,6.3.2.3,Sodium Bicarbonate,,DB01390,ECO:0000352,,,,,,,,,,Metabolic acidosis,,HP:0001942,https://www.ncbi.nlm.nih.gov/pubmed/29340523,https://www.ncbi.nlm.nih.gov/pubmed/26669244/,,,,,,,,,
922,,# 266130,Glutathione synthetase deficiency,,GSS,glutathione synthetase,6.3.2.3,coenzyme Q10,,DB09270,ECO:0000352,,,,,Symptomatic (C),C,,,,high-anion gap acidosis,,HP:0001941*,http://www.ncbi.nlm.nih.gov/pubmed/26669244?dopt=Abstract,,,,,,,,,,
923,,# 266130,Glutathione synthetase deficiency,,GSS,glutathione synthetase,6.3.2.3,dorzolamide+acetazolamide,,DB00869+DB00819,ECO:0000352,,,,,Symptomatic (C),C,,,,cystoid macular edema,,HP:0011505,https://www.ncbi.nlm.nih.gov/pubmed/29395598?dopt=Abstract,,,,,,,,,,
924,,# 266130,Glutathione synthetase deficiency,,GSS,glutathione synthetase,6.3.2.3,erythropoietin + iron+folic acid + vitamin B12,,DB00016+DB01592+DB00158+DB00165,ECO:0000352,,,,,Symptomatic (C),C,,,,anaemia,,HP:0001903,http://www.ncbi.nlm.nih.gov/pubmed/16435214?dopt=Abstract,https://link.springer.com/content/pdf/10.1007%2Fs10545-005-0156-0.pdf,,,,,,,,,
925,98,# 231670,Glutaric acidemia type I,"It has been shown that in the majority of neonatally diagnosed patients striatal injury can be prevented by combined metabolic treatment. Metabolic treatment that includes a low lysine diet, carnitine supplementation and intensified emergency treatment during acute episodes of intercurrent illness should be introduced and monitored by an experienced interdisciplinary team. https://www.ncbi.nlm.nih.gov/pubmed/21431622",GCDH,"glutaryl-CoA dehydrogenase, mitochondrial",1.3.8.6,Carnitine +anti-catabolic drugs(eg.Glutamine)+ Amino Acid supplements,"This combination therapy should be accompained with low lysin diet that is often combined with the use of lysine-free, tryptophan-reduced amino acids (AA) supplements. These supplements are given with the aim of preventing malnutrition by providing essential amino acids and (depending on the product) also minerals, trace elements and vitamins. https://www.ncbi.nlm.nih.gov/pubmed/10630918",DB00583+DB00130+DB09393,ECO:0000352,,,,,Symptomatic (C),C,,,,Brain damage,Initiation of treatment after the onset of symptoms is generally not effective in preventing permanent damage. The combination is suggested to given in presymptomatic patients to prevent brain damage.https://www.ncbi.nlm.nih.gov/pubmed/21431622,HP:0001298,https://www.ncbi.nlm.nih.gov/pubmed/23326493,,,,,,,,,,
926,,# 231670,Glutaric acidemia type I,,GCDH,"glutaryl-CoA dehydrogenase, mitochondrial",1.3.8.6,,,,,,,,,,,,,,Cerebral palsy,"Early diagnosis can prevent the phenotype, Initiation of treatment after the onset of symptoms is generally not effective in preventing permanent damage. https://www.ncbi.nlm.nih.gov/pubmed/21431622. https://www.ncbi.nlm.nih.gov/pubmed/10630918",HP:0100021,https://www.ncbi.nlm.nih.gov/pubmed/10630918,,,,,,,,,,
927,,# 231670,Glutaric acidemia type I,,GCDH,"glutaryl-CoA dehydrogenase, mitochondrial",1.3.8.6,,,,,,,,,,,,,,Secondary Carnitine deficiency( Carnitine deficiency)*,,HP:0003234*,,,,,,,,,,,
928,,# 231670,Glutaric acidemia type I,,GCDH,"glutaryl-CoA dehydrogenase, mitochondrial",1.3.8.6,Carnitine+ Riboflavin+baclofen,,DB00583+DB00130+DB00181,ECO:0000352,,,,,Symptomatic (C),C,,,,Disease progression,,HP:0003676,https://www.ncbi.nlm.nih.gov/pubmed/3335963,http://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract,,,,,,,,,
929,,# 231670,Glutaric acidemia type I,,GCDH,"glutaryl-CoA dehydrogenase, mitochondrial",1.3.8.6,,,,,,,,,Symptomatic (C),C,,,,Secondary Carnitine deficiency( Carnitine deficiency)*,,HP:0003234*,,,,https://www.sciencedirect.com/science/article/pii/S0387760405001439?via%3Dihub,,,,,,,
930,,# 231670,Glutaric acidemia type I,,GCDH,"glutaryl-CoA dehydrogenase, mitochondrial",1.3.8.6,,,,,,,,,,,,,,Metabolic acidosis,,HP:0001942,,,,,,,,,,,
931,,# 231670,Glutaric acidemia type I,,GCDH,"glutaryl-CoA dehydrogenase, mitochondrial",1.3.8.6,Carnitine+Thioridazine Hcl+Chloral hydrate+Baclofen,,DB00583+DB00679+DB01563+DB00181,ECO:0000352,,,,,Symptomatic (C),,,,,Dystonia,The phenotype has been reported in association to treatment with baclofen as,HP:0001332,https://www.ncbi.nlm.nih.gov/pubmed/8881997,,,,,,,,,,
932,,# 231670,Glutaric acidemia type I,,GCDH,"glutaryl-CoA dehydrogenase, mitochondrial",1.3.8.6,chlorpromazine,,DB00477,ECO:0000352,,,,,Symptomatic (C),C,,,,hyperpyrexia in case of acute encephalopathic crises(Fever)*,,HP:0001945*,https://www.ncbi.nlm.nih.gov/pubmed/10222465,,,,,,,,,,
933,,# 231670,Glutaric acidemia type I,,GCDH,"glutaryl-CoA dehydrogenase, mitochondrial",1.3.8.6,Carnitine+Riboflavin+L-Arginine+clofibrate,The combination was accompanied by Low L-lysine diet,DB00583+DB00130+DB00125+DB00636,ECO:0005542,,,,,Functional interaction (B),B,,,,Glutaric acidemia,Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787,HP:0003530,https://www.ncbi.nlm.nih.gov/pubmed/20923787,,,,,,,,,,
934,99,# 231680,Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",1.3.8.6,Carnitine+ riboflavin,Synergism inmproves results,DB00583+DB00140,ECO:0000352,,,,,Functional interaction (B)+Direct Interaction (A),B,,,,High serum creatine kinase,Treatment with clofibrate decreased cerebral and hepatic concentrations of glutaric acid in glutaryl-coenzyme A dehydrogenase-deficient mice. This finding opens new therapeutic perspectives such as pharmacological stimulation of alternative L-lysine oxidation in peroxisomes.https://www.ncbi.nlm.nih.gov/pubmed/20923787,HP:0003236,https://www.ncbi.nlm.nih.gov/pubmed/10723193,https://www.ncbi.nlm.nih.gov/pubmed/19249206,https://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract,,,,,,,,
935,,# 231680,Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",1.3.8.6,,,,,,,,,,,,,synergism inmproves results,Muscle weakness,,HP:0001324,https://www.ncbi.nlm.nih.gov/pubmed/10723193,,,,,,,,,,
936,,# 231680,Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",1.3.8.6,,,,,,,,,,,,,,Secondary Carnitine deficiency( Carnitine deficiency)*,,HP:0003234,https://www.ncbi.nlm.nih.gov/pubmed/10723193,,,,,,,,,,
937,,# 231680,Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",1.3.8.6,Carnitine+ riboflavin+Coenzyme Q,,DB00583+DB00140+DB09270,ECO:0000352,,,,,Functional interaction (B)+Direct Interaction (A)+symptomatic,A,,,,Dysphagia,,HP:0002015,https://www.ncbi.nlm.nih.gov/pubmed/26236614,,,,,,,,,,
938,,# 231680,Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",1.3.8.6,,,,,,,,,,,,,,Difficulty walking,,HP:0002355,,,,,,,,,,,
939,,# 231680,Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",1.3.8.6,,,,,,,,,,,,,,Secondary Carnitine deficiency( Carnitine deficiency)*,,HP:0003234,https://www.ncbi.nlm.nih.gov/pubmed/10723193,,,,,,,,,,
940,,# 231680,Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",1.3.8.6,Glycine+Riboflavin+Carnitine,,DB00145+DB00140+DB00583,ECO:0000352,,,,,Symptomatic (C)+Direct Interaction (A)+Functional interaction (B),C,,,,Muscle weakness,,HP:0001324,https://www.ncbi.nlm.nih.gov/pubmed/3229565,,,,,,,,,,
941,,# 231680,Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",1.3.8.6,"sodium-d,l-3-hydroxybutyrate",,CHEBI:113373,ECO:0000352,,,,,Symptomatic (C),C,,,,progressive leukodystrophy,,HP:0002415,https://www.ncbi.nlm.nih.gov/pubmed/12727399,http://www.ncbi.nlm.nih.gov/pubmed/16368216?dopt=Abstract,,,,,,,,,
942,,# 231680,Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",1.3.8.6,,,,,,,,,,,,,,paralysis,,HP:0003470,https://www.ncbi.nlm.nih.gov/pubmed/12727399,,,,,,,,,,
943,,# 231680,Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",1.3.8.6,,,,,,,,,,,,,,cardiomyopathy,,HP:0001638,https://www.ncbi.nlm.nih.gov/pubmed/12727399,,,,,,,,,,
944,,# 231680,Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",1.3.8.6,,,,,,,,,,,,,,Impaired myocardial contractility,,HP:0006670,https://www.ncbi.nlm.nih.gov/pubmed/12727399,,,,,,,,,,
945,,# 231680,Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",1.3.8.6,Riboflavin,,DB00140,ECO:0000352,,,,,Direct Intercation (activity modification)*,,,,,,,HP:0006670,https://www.ncbi.nlm.nih.gov/pubmed/10581232,,,,,,,,,,
946,,# 231680,Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",1.3.8.6,,,,,,,,,,,,,,,,,,,,,,,,,,,
947,,# 231680,Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",1.3.8.6,,,,,,,,,,,,,,,,,,,,,,,,,,,
948,,# 231680,Glutaric acidemia type II,,"ETFA,ETFB,ETFDH","electron transfer flavoprotein (Alpha subunit), electron transfer flavoprotein (Beta subunit), electron transfer flavoprotein dehydrogenase",1.3.8.6,,,,,,,,,,,,,,,,,,,,,,,,,,,
949,100,# 231690,Glutaric acidemia type III,,SUGCT,succinate-hydroxymethylglutarate coA-transferase,2.8.3.13,Metronidazole,,DB00140,ECO:00007121,,,,,Functional intercation ( Mechanistic B),C,,,,Cyclic vomiting (Vomiting)*,,HP:0002013,https://www.ncbi.nlm.nih.gov/pubmed/28766179,,,,,,,,,,
950,,# 231690,Glutaric acidemia type III,,SUGCT,succinate-hydroxymethylglutarate coA-transferase,2.8.3.13,,,,,,,,,,,,,,Bacterial glutric acid production,,NA,,,,,,,,,,,
951,101,# 266130,Glutathione synthetase deficiency,,GLUL,Glutamine synthetase,6.3.1.2,l-glutamine,,DB00130,ECO:0007121,,,,,Functional intercation ( Mechanistic B),B,,,,Abnormal plasma glutamine levels,,HP:0010903,https://www.ncbi.nlm.nih.gov/pubmed/22830360,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5192420/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3495849/,,,,,,,
952,,# 266130,Glutathione synthetase deficiency,,GLUL,Glutamine synthetase,6.3.1.2,,,,,,,,,,,,,,Low CSF glutamine level,,HP:0030980*,,,,,,,,,,,
953,,# 266130,Glutathione synthetase deficiency,,GLUL,Glutamine synthetase,6.3.1.2,,,,,,,,,,,,,,unalertness,,HP:0002329,,,,,,,,,,,
954,,# 266130,Glutathione synthetase deficiency,,GLUL,Glutamine synthetase,6.3.1.2,,,,,,,,,,,,,,Lack of emotional expressions,,HP:0030213,,,,,,,,,,,
955,,# 266130,Glutathione synthetase deficiency,,GLUL,Glutamine synthetase,6.3.1.2,,,,,,,,,,,,,,Abnormal EEG results,,HP:0002353,,,,,,,,,,,
956,,# 266130,Glutathione synthetase deficiency,,GLUL,Glutamine synthetase,6.3.1.2,,,,,,,,,,,,,,Low brain glutamine concentration,,HP:0030980,,,,,,,,,,,
957,,# 266130,Glutathione synthetase deficiency,,GLUL,Glutamine synthetase,6.3.1.2,,,,,,,,,Symptomatic (C),,,,,Secondary NAD+ deficiency in leucocytes,,NA,https://www.ncbi.nlm.nih.gov/pubmed/22830360,https://www.ncbi.nlm.nih.gov/pubmed/25896882/,,,,,,,,,
958,,# 266130,Glutathione synthetase deficiency,,GLUL,Glutamine synthetase,6.3.1.2,Nicotinamide,,DB02701,ECO:0001565,,,,,Symptomatic (C),C,,,,Secondary NAD+ deficiency in leucocytes,,NA,https://www.ncbi.nlm.nih.gov/pubmed/25896882/,https://www.ncbi.nlm.nih.gov/pubmed/25896882/,,,,,,,,,
959,,# 266130,Glutathione synthetase deficiency,,GLUL,Glutamine synthetase,6.3.1.2,Vitamin C+Vitamin E+Selenium,,DB02701,ECO:0000352,,,,,Symptomatic (C),,,,,Oxidative stress,,HP:0025464,https://www.ncbi.nlm.nih.gov/pubmed/26984560,https://www.ncbi.nlm.nih.gov/pubmed/25896882/,,,,,,,,,
960,,# 266130,Glutathione synthetase deficiency,,GLUL,Glutamine synthetase,6.3.1.2,Citric acid+Sodium citrate+ Potassium citrate,,,ECO:0000352,,,,,Symptomatic (C),,,,,Metabolic acidosis,,HP:0001942,https://www.ncbi.nlm.nih.gov/pubmed/26984560,,,,,,,,,,
961,102,# 229100,Glutamate formiminotransferase deficiency,The majority of individuals with FTCD deficiency detected by newborn screening are asymptomatic. https://www.ncbi.nlm.nih.gov/pubmed/30740726,FTCD,formiminotransferase cyclodeaminase,6.3.1.2,pyridoxine +folic acid,,DB00165+DB00158,ECO:0000352,,,,,Functional interaction (B),B,,,,Megaloblastic anemia,,HP:0001889,https://www.ncbi.nlm.nih.gov/pubmed/5301410,,,,,,,,,,
962,103,# 606824,Glucose-galactose malabsorption,Treatment rests with the avoidance of Glucse and galactose dietary sugars.https://www.ncbi.nlm.nih.gov/pubmed/28283348.  https://www.ncbi.nlm.nih.gov/pubmed/28753187,SLC5A1,sodium/glucose cotransporter protein called SGLT1,6.3.1.2,Fractose +Carbohydrate free formula,The enteric carbohydrate‐free formula with or without fructose addition seems a very effective and safe measures for the rehydration. https://www.ncbi.nlm.nih.gov/pubmed/10404446. https://www.ncbi.nlm.nih.gov/pubmed/20486940,,ECO:0000352,,,,,Symptomatic (C),,,,,Watery Diarrhea,,HP:0002014,https://www.ncbi.nlm.nih.gov/pubmed/10404446,https://www.ncbi.nlm.nih.gov/pubmed/20486940,,https://www.ncbi.nlm.nih.gov/pubmed/28283348,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4808885/,,,,,,
963,,# 606824,Glucose-galactose malabsorption,,SLC5A1,sodium/glucose cotransporter protein called SGLT1,6.3.1.2,,,,,,,,,,,,,,Dehydration,,HP:0001944,,,,,,,,,,,
964,104,# 606777,Glucose transporter type 1 deficiency syndrome,"The currently established or investigated precision medicine treatments include the ketogenic diet in patients with GLUT1 deficiency. https://www.ncbi.nlm.nih.gov/pubmed/27781560/ https://www.ncbi.nlm.nih.gov/pubmed/22812641/ https://www.ncbi.nlm.nih.gov/pubmed/12029447?dopt=Abstract
Clinical exacerbation in Glut 1 DS could happen with certain AEDs based on their mechanism of action or effects on the Glut 1 transporter. Common AEDs known to inhibit the Glut 1 transporter in vitro, for example, 1) phenobarbital https://www.ncbi.nlm.nih.gov/pubmed/12029447?dopt=Abstract , 2) Valporate https://www.ncbi.nlm.nih.gov/pubmed/16149077?dopt=Abstract 3) Benzodiazepines https://www.ncbi.nlm.nih.gov/pubmed/12029447?dopt=Abstract are relatively contraindicated in Glut 1 DS. https://www.ncbi.nlm.nih.gov/pubmed/22812641/
In addition, combination therapy of KD and carbonic anhydrase inhibitors—for example, topiramate, zonisamide, and acetazolamide—may increase risk of non–anion gap metabolic acidosis and urolithiasis, and should be avoided if possible https://www.ncbi.nlm.nih.gov/pubmed/20466520?dopt=Abstract",SLC2A1,glucose transporter protein type 1 (GLUT1),6.3.1.2,UX007 (triheptanoin),,DB11677,ECO:0007121/ECO:0005542,,,,,Symptomatic (C),C,,,,seizures,,HP:0001250,https://clinicaltrials.gov/ct2/show/NCT01993186?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=1,https://clinicaltrials.gov/ct2/show/NCT02960217?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=2,https://clinicaltrials.gov/ct2/show/NCT02036853?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=3,https://clinicaltrials.gov/ct2/show/NCT02000960?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=5,https://www.ncbi.nlm.nih.gov/pubmed/29303961,https://clinicaltrials.gov/ct2/show/NCT02014883?cond=Glucose+transporter+type+1+deficiency+syndrome&rank=9,https://www.ncbi.nlm.nih.gov/pubmed/23196212/,ECO:0007121/ECO:0005542,,,
965,,# 606777,Glucose transporter type 1 deficiency syndrome,,SLC2A1,glucose transporter protein type 1 (GLUT1),6.3.1.2,,,,,,,,,,,,,,EEG with focal spike waves,,HP:0011197,,,,,,,,,,,
966,,# 606777,Glucose transporter type 1 deficiency syndrome,,SLC2A1,glucose transporter protein type 1 (GLUT1),6.3.1.2,,,,,,,,,,,,,,Nonepileptic paroxysmal abnormalities,,NA,,,,,,,,,,,
967,,# 606777,Glucose transporter type 1 deficiency syndrome,,SLC2A1,glucose transporter protein type 1 (GLUT1),6.3.1.2,,,,,,,,,,C,,,,Seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/22812641/,https://www.ncbi.nlm.nih.gov/pubmed/23196212/,https://www.ncbi.nlm.nih.gov/pubmed/22812641/,,,,,,,,
968,,# 606777,Glucose transporter type 1 deficiency syndrome,,SLC2A1,glucose transporter protein type 1 (GLUT1),6.3.1.2,,,,,,,,,,C,,,,movement disorders,,HP:0100022,,,,,,,,,,,
969,,# 606777,Glucose transporter type 1 deficiency syndrome,,SLC2A1,glucose transporter protein type 1 (GLUT1),6.3.1.2,,,,,,,,,,,,,,Dyskinesia,,HP:0100660,,,http://medwiekurozwoj.pl/articles/2015-4-7.pdf,,,,,,,,
970,,# 606777,Glucose transporter type 1 deficiency syndrome,,SLC2A1,glucose transporter protein type 1 (GLUT1),6.3.1.2,AAV-GLUT1,,NA,ECO:0005542,,,,,Direct interaction ( Mechanistic A),A,,,,Abnormal CSF glucose levels,,HP:0031884,,,https://www.ncbi.nlm.nih.gov/pubmed/29624790,,,,,,,,
971,,# 606777,Glucose transporter type 1 deficiency syndrome,,SLC2A1,glucose transporter protein type 1 (GLUT1),6.3.1.2,,,,,,,,,,,,,,Abnormal motor function,,HP:0004302,,,,,,,,,,,
972,,# 606777,Glucose transporter type 1 deficiency syndrome,,SLC2A1,glucose transporter protein type 1 (GLUT1),6.3.1.2,,,,,,,,,,,,,,Paroxysmal exertion-induced dyskinesia (Paroxysmal dyskinesia),,HP:0007166,,,,,,,,,,,
973,105,# 263800,Gitelman syndrome,,SLC12A3 / CLCNKB,sodium chloride co-transporter/ chloride channel called ClC-Kb,P51801,Rofecoxib,The use of the drug is limited by its long-term cardiovascular adverse effects. https://www.ncbi.nlm.nih.gov/pubmed/12141411,DB00533,ECO:0000352,,,,,Symptomatic (C),C,,,,Refractory hypokalemia,,HP:0002900*,https://www.ncbi.nlm.nih.gov/pubmed/12141411,,,,https://www.sciencedirect.com/science/article/pii/S0085253816306020?via%3Dihub,,,,,,
974,,# 263800,Gitelman syndrome,,SLC12A3 / CLCNKB,sodium chloride co-transporter/ chloride channel called ClC-Kb,P51801,,,,,,,,,,,,,,Abnormally reduced levels of aldosterone,,HP:0004319,,,,,,,,,,,
975,,# 263800,Gitelman syndrome,,SLC12A3 / CLCNKB,sodium chloride co-transporter/ chloride channel called ClC-Kb,P51801,,,,,,,,,,,,,,Abnormal serum renin level,,HP:0040084,,,,,,,,,,,
976,,# 263800,Gitelman syndrome,,SLC12A3 / CLCNKB,sodium chloride co-transporter/ chloride channel called ClC-Kb,P51801,,,,,,,,,,,,,,,,,,,,,,,,,,,
977,,# 263800,Gitelman syndrome,,SLC12A3 / CLCNKB,sodium chloride co-transporter/ chloride channel called ClC-Kb,P51801,Indometacin/Amiloride/Eplerenone+Potassium,"Indomethacin was the most effective but can cause gastrointestinal intolerance and decreased eGFR. Amiloride and eplerenone have similar but lower efficacies and increase sodium depletion. The benefit/risk ratio of each drug should be carefully evaluated for each patient.          https://www.ncbi.nlm.nih.gov/pubmed/25012174
Despite a documented effect on hypokalemia, indomethacin and other nonsteroidal anti-inflammatory drugs should be used with caution due to their short- and long-term gastrointestinal side effects and nephrotoxicity.https://www.ncbi.nlm.nih.gov/pubmed/28003083",(DB00328/DB00594/DB00700)+DB00761,ECO:0000352,,,,,Symptomatic (C),C,,,,Refractory hypokalemia,,HP:0002900*,https://www.ncbi.nlm.nih.gov/pubmed/25012174,,https://clinicaltrials.gov/ct2/show/NCT01146197?cond=Gitelman+syndrome&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/25012174,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263/,https://www.ncbi.nlm.nih.gov/pubmed/21503667/,https://www.ncbi.nlm.nih.gov/pubmed/28381550/,,,,
978,,# 263800,Gitelman syndrome,,SLC12A3 / CLCNKB,sodium chloride co-transporter/ chloride channel called ClC-Kb,P51801,Indometacin,,(DB00328/DB00594/DB00700)+DB00761,,,,,,,,,,,developmental delay,,HP:0001263,https://www.ncbi.nlm.nih.gov/pubmed/25852896/,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263/,https://www.ncbi.nlm.nih.gov/pubmed/25012174,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5507263/,https://www.ncbi.nlm.nih.gov/pubmed/21503667/,https://www.ncbi.nlm.nih.gov/pubmed/28381550/,,,,
979,,# 263800,Gitelman syndrome,,SLC12A3 / CLCNKB,sodium chloride co-transporter/ chloride channel called ClC-Kb,P51801,,,,,,,,,,,,,,high plasma RAAS activity,,HP:0000847*,,,,,,,,,,,
980,,# 263800,Gitelman syndrome,,SLC12A3 / CLCNKB,sodium chloride co-transporter/ chloride channel called ClC-Kb,P51801,,,,,,,,,Symptomatic (C),C,,,,Abnormally reduced levels of aldosterone,,HP:0004319,https://www.ncbi.nlm.nih.gov/pubmed/25012174,,,,,,,,,,
981,,# 263800,Gitelman syndrome,,SLC12A3 / CLCNKB,sodium chloride co-transporter/ chloride channel called ClC-Kb,P51801,,,,,,,,,Symptomatic (C),C,,,,Abnormal serum renin level,,HP:0040084,https://www.ncbi.nlm.nih.gov/pubmed/25012174,,,,,,,,,,
982,,# 263800,Gitelman syndrome,,SLC12A3 / CLCNKB,sodium chloride co-transporter/ chloride channel called ClC-Kb,P51801,Magnesium,,DB14513,ECO:0000352,,,,,Supportive (C),C,,,,hypomagnesemia,"In the presence of hypomagnesemia, magnesium supplementation should be considered first, because magnesium repletion will facilitate potassium repletion and reduce the risk of tetany and other complications",HP:0002917,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2518128/,,,,,,,,,,
983,,# 263800,Gitelman syndrome,,SLC12A3 / CLCNKB,sodium chloride co-transporter/ chloride channel called ClC-Kb,P51801,,,,,,,,,,,,,,chondrocalcinosis,,HP:0000934,,,,,,,,,,,
984,,# 263800,Gitelman syndrome,,SLC12A3 / CLCNKB,sodium chloride co-transporter/ chloride channel called ClC-Kb,P51801,Potassium chloride,,DB00761,ECO:0000352,,,,,Supportive (C),C,,,,hypokalemia,,HP:0002900,,,,,,,,,,,
985,106,# 230800,Gaucher disease,,GBA,beta-glucocerebrosidase,3.2.1.45,Taliglucerase alfa,,DB08876,ECO:0007121,,,,,Direct interaction ( Mechanistic A),A,,,,Hepatomegaly,,HP:0002240,https://clinicaltrials.gov/ct2/show/results/NCT01422187?cond=Gaucher+disease&draw=3&rank=23&sect=X01256#all,https://www.ncbi.nlm.nih.gov/pubmed/29471850,https://www.ncbi.nlm.nih.gov/pubmed/29388611,https://www.ncbi.nlm.nih.gov/pubmed/27839981,,,,,,,
986,,# 230800,Gaucher disease,,GBA,beta-glucocerebrosidase,3.2.1.45,,,,,,,,,,,,,,Splenomegaly,,HP:0001744,https://www.ncbi.nlm.nih.gov/pubmed/28131618,,,https://www.ncbi.nlm.nih.gov/pubmed/27102949,https://www.ncbi.nlm.nih.gov/pubmed/27499018,,,,,,
987,,# 230800,Gaucher disease,,GBA,beta-glucocerebrosidase,3.2.1.45,,,,,,,,,,,,,,thrombocytopenia,,HP:0001873,,,,,,,,,,,
988,,# 230800,Gaucher disease,,GBA,beta-glucocerebrosidase,3.2.1.45,,,,,,,,,,,,,,low mean hemoglobin concentration,,HP:0025547,,,,,,,,,,,
989,,# 230800,Gaucher disease,,GBA,beta-glucocerebrosidase,3.2.1.45,,,,,,,,,,,,,,low bone marrow fat fraction value,,NA,,,https://www.ncbi.nlm.nih.gov/pubmed/30066229,,,,,,,,
990,,# 230800,Gaucher disease,,GBA,beta-glucocerebrosidase,3.2.1.45,Imiglucérase (ISU302),,DB00053,ECO:0007121,,,,,Direct interaction ( Mechanistic A),A,,,,primary low heamoglobin level,,HP:0001903*,https://clinicaltrials.gov/ct2/show/results/NCT02770625?cond=Gaucher+disease&draw=3&rank=24&sect=X4301256#othr,,https://www.ncbi.nlm.nih.gov/pubmed/30066229,,,,,,,,
991,,# 230800,Gaucher disease,,GBA,beta-glucocerebrosidase,3.2.1.45,,,,,,,,,,,,,,thrombocytopenia,,HP:0001873,,,,,,,,,,,
992,,# 230800,Gaucher disease,,GBA,beta-glucocerebrosidase,3.2.1.45,,,,,,,,,,,,,,splenomegaly,,HP:0001744,,,,,,,,,,,
993,,# 230800,Gaucher disease,,GBA,beta-glucocerebrosidase,3.2.1.45,,,,,,,,,,,,,,Hepatomegaly,,HP:0002240,,,,,,,,,,,
994,,# 230800,Gaucher disease,,GBA,beta-glucocerebrosidase,3.2.1.45,,,,,,,,,,,,,,high angiotensin- converting enzyme,,HP:0000841,,,,,,,,,,,
995,,# 230800,Gaucher disease,,GBA,beta-glucocerebrosidase,3.2.1.45,,,,,,,,,,,,,,high  Chitotriosidase Level(Abnormality of lysosomal metabolism)*,,HP:0004356,,,,,,,,,,,
996,,# 230800,Gaucher disease,,GBA,beta-glucocerebrosidase,3.2.1.45,,,,,,,,,,,,,,elevated Chemokine Ligand (CCL-18) Level [ng/mL],,NA,,,,,,,,,,,
997,,# 230800,Gaucher disease,,GBA,beta-glucocerebrosidase,3.2.1.45,prGCD,,DB06667,ECO:0007121,,,,,Direct interaction ( Mechanistic A),A,,,Study is no longer available,Trial is no longer available,,NA,https://clinicaltrials.gov/ct2/show/NCT00705939,,https://clinicaltrials.gov/ct2/show/NCT00962260?cond=Gaucher+disease&draw=4&rank=25,https://clinicaltrials.gov/ct2/show/results/NCT00376168?cond=Gaucher+disease&draw=5&rank=39&sect=X30156#evnt,,,,,,,
998,,# 230800,Gaucher disease,,GBA,beta-glucocerebrosidase,3.2.1.45,,,,,,,,,,,,,,,,,,,,,,,,,,,
999,,# 230800,Gaucher disease,,GBA,beta-glucocerebrosidase,3.2.1.45,Eliglustat tartrate,,DB09039,ECO:0007121,,,,,Functional interaction(Mechanistic B),B,,,,Low mean hemoglobin level,,HP:0001903,https://clinicaltrials.gov/ct2/show/NCT01074944?cond=Gaucher+disease&draw=4&rank=26,https://www.ncbi.nlm.nih.gov/pubmed/20439622,,,,,,,,,
1000,107,# 608013,Gaucher disease perinatal lethal,,GBA,beta-glucocerebrosidase,3.2.1.45,,,,,,,,,,,,,,Thrombocytopenia,,HP:0001873,,,,,,,,,,,
1001,,# 608013,Gaucher disease perinatal lethal,,GBA,beta-glucocerebrosidase,3.2.1.45,,,,,,,,,,,,,,Hepatomegaly,,HP:0002240,,,,,,,,,,,
1002,,# 608013,Gaucher disease perinatal lethal,,GBA,beta-glucocerebrosidase,3.2.1.45,,,,,,,,,,,,,,Splenomegaly,,HP:0001744,,,,,,,,,,,
1003,,# 608013,Gaucher disease perinatal lethal,,GBA,beta-glucocerebrosidase,3.2.1.45,,,,,,,,,,,,,,Low lumbar spine bone mineral density(bnormality of bone mineral density)*,,HP:0004348,,,,,,,,,,,
1004,108,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,N-acetylcysteine,,DB06151,ECO:0007121,,,,,Symptomatic (C),C,,,,Oxidative stress,,HP:0025464,https://clinicaltrials.gov/ct2/show/NCT01427517,https://clinicaltrials.gov/ct2/show/NCT02583672?cond=Gaucher+disease&rank=9,,https://www.ncbi.nlm.nih.gov/pubmed/?term=N-acetylcysteine+in+treating+Gauchers,,,,,,,
1005,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,,,,,,,,,,,,Low blood glutathione redox ratios,,MP:0012604*,,,,,,,,,,,
1006,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,,,,,,,,,,,,Inflammation,,HP:0012649,https://www.ncbi.nlm.nih.gov/pubmed/23860343,,,,,,,,,,
1007,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,,,,,,,,,,,,concentration of myo-inositol in brain,,HP:0025460,,,,,,,,,,,
1008,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,,,,,,,,,,,,concentration of TNF-alpha in plasma,,HP:0011118*,,,,,,,,,,,
1009,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,Elelyso,,DB08876,ECO:0000352/ ECO:0007121,,,,,Direct interaction ( Mechanistic A),A,,,,Hepatomegaly,,HP:0002240,https://www.ncbi.nlm.nih.gov/pubmed/22916340,https://www.ncbi.nlm.nih.gov/pubmed/29471850,https://clinicaltrials.gov/ct2/show/NCT03021941?cond=Gaucher+disease&rank=7,,,,,,,,
1010,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,,,,,,,,,,,,Splenomegaly,,HP:0001744,,,,,,,,,,,
1011,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,,,,,,,,,,,,thrombocytopenia,,HP:0001873,,,,,,,,,,,
1012,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,,,,,,,,,,,,anaemia,,HP:0001903,,,,,,,,,,,
1013,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,Velaglucerase alfa,,DB06720,ECO:0007121,,,,,Direct interaction ( Mechanistic A),A,,,,changes in lumbar spine (LS),,HP:0100712,https://www.ncbi.nlm.nih.gov/pubmed/29503270,,https://clinicaltrials.gov/ct2/show/NCT00391625?cond=Gaucher+disease&draw=2&rank=14,https://clinicaltrials.gov/ct2/show/NCT02574286?cond=Gaucher+disease&draw=2&rank=15,https://www.ncbi.nlm.nih.gov/pubmed/25801797,,,,,,
1014,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,,,,,,,,,,,,abnormality in bone mineral density,,HP:0004348,,,,,,,,,,,
1015,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,,,,,,,,,,,,anaemia,,HP:0001903,,,,,,,,,,,
1016,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,,,,,,,,,,,,thrombocytopenia,,HP:0001873,,,,,,,,,,,
1017,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,,,,,,,,,,,,hepatosplenomegaly,,HP:0001433,,,,,,,,,,,
1018,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,,,,,,,,,,,,growth faliure,,HP:0001510,,,,,,,,,,,
1019,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,,,,,,,,,,,,avascular osteonecrosis,,HP:0010885,https://www.ncbi.nlm.nih.gov/pubmed/29503270,,,,,,,,,,
1020,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,,,,,,,,,,,,Bone pain,,HP:0002653,https://www.ncbi.nlm.nih.gov/pubmed/29503270,,,,,,,,,,
1021,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,Ambroxol,The drug was used in a pilot study.,DB06742,ECO:0007121,,,,,Direct interaction (A),A,,,Suspended study,Anemia,,done,https://clinicaltrials.gov/ct2/show/NCT01463215?cond=Gaucher+disease&draw=2&rank=17,https://www.ncbi.nlm.nih.gov/pubmed/23085429,,,,,,,,,
1022,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,,,,,,,,,,,,Splenomegaly,,HP:0001744,https://www.ncbi.nlm.nih.gov/pubmed/23085429,,,,,,,,,,
1023,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,,,,,,,,,,,,Thrombocytpenia,,HP:0001873,https://www.ncbi.nlm.nih.gov/pubmed/23085429,,,,,,,,,,
1024,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,,,,,,,,,,,,Hepatomegaly,,HP:0002240,https://www.ncbi.nlm.nih.gov/pubmed/23085429,,,,,,,,,,
1025,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,Miglustat (NB-DNJ)(OGT 918),,,ECO:0007121/ECO:0005542,,,,,Functional interaction(Mechanistic B),B,,,,Splenomegly,,HP:0001744,https://www.ncbi.nlm.nih.gov/pubmed/23085429,,https://www.ncbi.nlm.nih.gov/pubmed/11227045,https://www.ncbi.nlm.nih.gov/pubmed/12064906,,https://www.ncbi.nlm.nih.gov/pubmed/15505381,https://www.ncbi.nlm.nih.gov/pubmed/15895716,,,,
1026,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,,,,,,,,,,,,hepatomegly,,HP:0002240,,,https://www.ncbi.nlm.nih.gov/pubmed/16199246,https://www.ncbi.nlm.nih.gov/pubmed/16285070,,,,,,,
1027,,# 230800,Gaucher disease type 1,,GBA,beta-glucocerebrosidase,3.2.1.45,,,,,,,,,,,,,,High chitotriosidase level,,NA,,,,,,,,,,,
1028,109,# 230900,Gaucher disease type 2,"By Knocking out RIPK3, we show that modulating the receptor-interacting protein kinase-3 (Ripk3) pathway markedly improves neurological and systemic disease in a mouse model of GD. https://www.ncbi.nlm.nih.gov/pubmed/24441827
Notably, Ripk3 deficiency substantially improved the clinical course of GD mice, with increased survival and motor coordination and salutary effects on cerebral as well as hepatic injury.",GBA,beta-glucocerebrosidase,3.2.1.45,Glucocerebrosidase+ gadolinium-diethylenetriamine penta-acetic acid,The treatment was done via convection-enhanced delivery,DB06667,ECO:0007121/ ECO:0000352,,,,,Direct interaction ( Mechanistic A) ERT,A,,,,No result is  added,,NA,https://www.ncbi.nlm.nih.gov/pubmed/18952590,,https://clinicaltrials.gov/ct2/show/NCT00244582?cond=Gaucher+disease+type+II&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/24441827,https://www.ncbi.nlm.nih.gov/pubmed/18952590,https://www.ncbi.nlm.nih.gov/pubmed/7814809,,,,,
1029,,# 230900,Gaucher disease type 2,,GBA,beta-glucocerebrosidase,3.2.1.45,,,,,,,,,,,,,,,,done,,,https://link.springer.com/article/10.1007%2Fs11011-018-0236-1,,,,,,,,
1030,110,# 231005,Gaucher disease type 3,,GBA,beta-glucocerebrosidase,3.2.1.45,Miglustat (Substrate reduction therapy)+imiglucerase,,DB00419+DB00053,ECO:0007121,,,,,Functional interaction(Mechanistic B)+Direct interaction (Mechanistic A),B,,,,neuropathy,,HP:0009830,https://www.ncbi.nlm.nih.gov/pubmed/17433057,https://clinicaltrials.gov/ct2/show/NCT02520934?cond=Gaucher+disease&rank=2,https://link.springer.com/article/10.1007%2Fs11011-018-0236-1,,,,,,,,
1031,,# 231005,Gaucher disease type 3,,GBA,beta-glucocerebrosidase,3.2.1.45,,,,,,,,,,,,,,generalized tonic-clonic seizures,,HP:0002069,,,,,,,,,,,
1032,,# 231005,Gaucher disease type 3,,GBA,beta-glucocerebrosidase,3.2.1.45,,,,,,,,,,,,,,speech impairment,,HP:0002167,,,,,,,,,,,
1033,,# 231005,Gaucher disease type 3,,GBA,beta-glucocerebrosidase,3.2.1.45,Eliglustat(Substrate reduction therapy),,DB09039,ECO:0007121,CYP2D6,,,,Functional interaction(Mechanistic B),B,,,,abnormal glucocerebroside level,,HP:0003656,https://www.ncbi.nlm.nih.gov/pubmed/29680197,https://www.ncbi.nlm.nih.gov/pubmed/30264864,http://clinicaltrials.gov/show/NCT00358150,https://www.ncbi.nlm.nih.gov/pubmed/30247105,https://www.ncbi.nlm.nih.gov/pubmed/29358012,,,,,,
1034,,# 231005,Gaucher disease type 3,,GBA,beta-glucocerebrosidase,3.2.1.45,,,,,,,,,,,,,,Hepatosplenomegaly,,HP:0001433,https://www.ncbi.nlm.nih.gov/pubmed/28935503,,,,,,,,,,
1035,,# 231005,Gaucher disease type 3,,GBA,beta-glucocerebrosidase,3.2.1.45,,,,,,,,,,,,,,thrombocytopenia,,HP:0001873,,,,,,,,,,,
1036,,# 231005,Gaucher disease type 3,,GBA,beta-glucocerebrosidase,3.2.1.45,,,,,,,,,,,,,,low mean hemoglobin concentration,,HP:0025547,,,,,,,,,,,
1037,,# 231005,Gaucher disease type 3,,GBA,beta-glucocerebrosidase,3.2.1.45,velaglucerase alfa,,DB06720,ECO:0007121,,,,,Direct interaction ( Mechanistic A),A,,,,Decreased hemoglobin,,HP:0001903,https://clinicaltrials.gov/ct2/show/NCT03519646?cond=Gaucher+disease&draw=2&rank=18,https://clinicaltrials.gov/ct2/show/results/NCT01685216?cond=Gaucher+disease&draw=5&rank=35&sect=X01256#all,,,,,,,,,
1038,,# 231005,Gaucher disease type 3,,GBA,beta-glucocerebrosidase,3.2.1.45,,,,,,,,,,,,,,thrombocytopenia,,HP:0001873,,,,,,,,,,,
1039,,# 231005,Gaucher disease type 3,,GBA,beta-glucocerebrosidase,3.2.1.45,,,,,,,,,,,,,,High spleen volume,,HP:0001744,,,,,,,,,,,
1040,,# 231005,Gaucher disease type 3,,GBA,beta-glucocerebrosidase,3.2.1.45,,,,,,,,,,,,,,high liver volume,,HP:0002240,,,,,,,,,,,
1041,111,# 219500,Gamma-cystathionase deficiency,Cystathioninuria not associated with vitamin B6 dependency is an evidence of genetic heterogeneity in primary cystathioninuria. https://www.ncbi.nlm.nih.gov/pubmed/417288        https://www.ncbi.nlm.nih.gov/pubmed/5707897,CTH,cystathionine gamma-lyase,4.4.1.1,pyridoxine,,DB00165,ECO:0000352,,,,,Functional interaction(Mechanistic B),B,,,,Cystathioninuria,,HP:0003153,http://www.ncbi.nlm.nih.gov/pubmed/20584029?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/19428278?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/417288,https://www.ncbi.nlm.nih.gov/pubmed/5707897,,,,,,,
1042,,# 219500,Gamma-cystathionase deficiency,,CTH,cystathionine gamma-lyase,4.4.1.1,,,,,,,,,,,,,,Tremor,,HP:0001337,,,,,,,,,,,
1043,,# 219500,Gamma-cystathionase deficiency,,CTH,cystathionine gamma-lyase,4.4.1.1,,,,,,,,,,,,,,Impaired fine motor skillls,,HP:0007010,,,,,,,,,,,
1044,,# 219500,Gamma-cystathionase deficiency,,CTH,cystathionine gamma-lyase,4.4.1.1,,,,,,,,,,,,,,EEG abnormality,,HP:0002353,,,,,,,,,,,
1045,,# 219500,Gamma-cystathionase deficiency,,CTH,cystathionine gamma-lyase,4.4.1.1,,,,,,,,,,,,,,High total homocysteine level,,HP:0010919,,,,,,,,,,,
1046,112,# 613163,Gamma aminobutyric acid transaminase deficiency,,ABAT,GABA-transaminase,2.6.1.19,flumazenil,,DB01205,ECO:0007121/ECO:0000352,,,,,Symptomatic (C),C,,,,unalertness,,HP:0002329,http://www.ncbi.nlm.nih.gov/pubmed/28411234?dopt=Abstract,,https://www.ncbi.nlm.nih.gov/pubmed/29480352,,,,,,,,
1047,,# 613163,Gamma aminobutyric acid transaminase deficiency,,ABAT,GABA-transaminase,2.6.1.19,,,,,,,,,,,,,,EEG abnormality,,HP:0002353,http://www.ncbi.nlm.nih.gov/pubmed/28411234?dopt=Abstract,,,,,,,,,,
1048,,# 613163,Gamma aminobutyric acid transaminase deficiency,,ABAT,GABA-transaminase,2.6.1.19,,,,,,,,,,,,,,Functional motor deficit,,HP:0004302,http://www.ncbi.nlm.nih.gov/pubmed/28411234?dopt=Abstract,,,,,,,,,,
1049,,# 613163,Gamma aminobutyric acid transaminase deficiency,,ABAT,GABA-transaminase,2.6.1.19,,,,,,,,,,,,,,excessive adventitious movements,,HP:0100022*,http://www.ncbi.nlm.nih.gov/pubmed/28411234?dopt=Abstract,,,,,,,,,,
1050,,# 613163,Gamma aminobutyric acid transaminase deficiency,,ABAT,GABA-transaminase,2.6.1.19,,,,,,,,,,,,,,hypersomnolence,,HP:0100786,http://www.ncbi.nlm.nih.gov/pubmed/28411234?dopt=Abstract,,,,,,,,,,
1051,,# 613163,Gamma aminobutyric acid transaminase deficiency,,ABAT,GABA-transaminase,2.6.1.19,,,,,,,,,,,,,,Oculomotor apraxia,,HP:0000657,https://www.ncbi.nlm.nih.gov/pubmed/29480352,,,,,,,,,,
1052,,# 613163,Gamma aminobutyric acid transaminase deficiency,,ABAT,GABA-transaminase,2.6.1.19,,,,,,,,,,,,,,Developmental delay,,HP:0012758,https://www.ncbi.nlm.nih.gov/pubmed/29480352,,,,,,,,,,
1053,,# 613163,Gamma aminobutyric acid transaminase deficiency,,ABAT,GABA-transaminase,2.6.1.19,Phenobarbital/clonazepam/valproate/ midazolam,"Phenobarbital, clonazepam, valproate, and midazolam could not completely control seizures. https://www.ncbi.nlm.nih.gov/pubmed/20052547/",DB01174/DB01068/DB00313/DB00683,ECO:0000352,,,,,Symptomatic (C),,,,,Seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/29480352,,,,,,,,,,
1054,,# 613163,Gamma aminobutyric acid transaminase deficiency,,ABAT,GABA-transaminase,2.6.1.19,rapamycin,,DB00877,ECO:0007764/ECO:0005542,,,,,Symptomatic (C),C,,,,elevated CSF GHB levels,,NA,https://www.ncbi.nlm.nih.gov/pubmed/25485164,https://www.ncbi.nlm.nih.gov/pubmed/24578415/,,,,,,,,,
1055,,# 613163,Gamma aminobutyric acid transaminase deficiency,,ABAT,GABA-transaminase,2.6.1.19,,,,,,,,,,,,,,oxidative stress,,HP:0025464,,,,,,,,,,,
1056,113,# 256540,Galactosialidosis,,CTSA,Lysosomal protective protein protein/cathepsin A or PPCA/β-galactosidase/ neuraminidase,3.4.16.5,rAAV-PPCR,,NA,ECO:0005542,,,,,Direct interaction ( Mechanistic A),A,,,,edematous,,HP:0000969,,https://www.ncbi.nlm.nih.gov/pubmed/22008912/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5461780/,https://www.ncbi.nlm.nih.gov/pubmed/15084520/,,,,,,,
1057,,# 256540,Galactosialidosis,,CTSA,Lysosomal protective protein protein/cathepsin A or PPCA/β-galactosidase/ neuraminidase,3.4.16.5,,,,,,,,,,,,,,infertility,,HP:0000789,,,,,,,,,,,
1058,,# 256540,Galactosialidosis,,CTSA,Lysosomal protective protein protein/cathepsin A or PPCA/β-galactosidase/ neuraminidase,3.4.16.5,,,,,,,,,,,,,,incoordination,,HP:0002311,,,,,,,,,,,
1059,,# 256540,Galactosialidosis,,CTSA,Lysosomal protective protein protein/cathepsin A or PPCA/β-galactosidase/ neuraminidase,3.4.16.5,,,,,,,,,,,,,,gait abnormality,,HP:0001288,,,,,,,,,,,
1060,,# 256540,Galactosialidosis,,CTSA,Lysosomal protective protein protein/cathepsin A or PPCA/β-galactosidase/ neuraminidase,3.4.16.5,,,,,,,,,,,,,,,,,,,,,,,,,,,
1061,,# 256540,Galactosialidosis,,CTSA,Lysosomal protective protein protein/cathepsin A or PPCA/β-galactosidase/ neuraminidase,3.4.16.5,N-octyl-4-epi-β-valienamine (NOEV),,NA,ECO:0001565,SpDEx7];/p.[Q49R;Y395C]/c.[478_480delTTC];[?]* no mutation was in the second all,,,,Functional interaction(Mechanistic B),B,,,,Low β-gal activity (Abnormal enzyme/coenzyme activity )*,,,,,https://www.ncbi.nlm.nih.gov/pubmed/26259553,,,,,,,,
1062,114,# 230200,Galactokinase deficiency,,GALK1,galactokinase 1,2.7.1.6,No treatment is available in DDIEM,,NA,,,,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/26259553,,,,,,,,
1063,115,# 606812,Fumarase deficiency,"The high fat, low carbohydrate diet may has a possible disease modifying effect. https://www.ncbi.nlm.nih.gov/pubmed/29052812",FH,"Fumarate hydratase, mitochondrial",4.2.1.2,No treatment is available in DDIEM,,NA,,,,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/26259553,,,,,,,,
1064,116,253800,Fukuyama type muscular dystrophy,,FKTN,fukutin,O75072,antisense oligonucleotide (VMO AED cocktail),,NA,ECO:0005542/ECO:0001565,,,,,Direct interaction ( Mechanistic A),A,,,,Abnormal fukutin mRNA expression,,HP:0030098,https://www.nature.com/articles/nature10456,https://www.ncbi.nlm.nih.gov/pubmed/27421908,https://www.ncbi.nlm.nih.gov/pubmed/26259553,,,,,,,,
1065,,253800,Fukuyama type muscular dystrophy,,FKTN,fukutin,O75072,,,,,,,,,,,,,,pathogenic exon trapping,,NA,,,,,,,,,,,
1066,,253800,Fukuyama type muscular dystrophy,,FKTN,fukutin,O75072,AAV9-MCK-fukutin,,NA,ECO:0005542,,,,,Direct interaction ( Mechanistic A),A,,,,Imapired muscle function,,HP:0011804,https://academic.oup.com/hmg/article/22/15/3003/652530,,,,,,,,,,
1067,,253800,Fukuyama type muscular dystrophy,,FKTN,fukutin,O75072,Corticosteroid,,DB00288,ECO:0000352,,,,,Symptomatic (C),C,,,,Muscle weakness,,HP:0001324,https://www.ncbi.nlm.nih.gov/pubmed/21726969,,,,,,,,,,
1068,,253800,Fukuyama type muscular dystrophy,,FKTN,fukutin,O75072,,,,,,,,,,,,,,Muscle necrosis,,HP:0003713,,,,,,,,,,,
1069,,253800,Fukuyama type muscular dystrophy,,FKTN,fukutin,O75072,,,,,,,,,,,,,,Muscle inflammation,,HP:0100614,,,,,,,,,,,
1070,117,# 230000,Fucosidosis,,FUCA1,a-L-fucosidase,3.2.1.51,recombinant canine α-l-fucosidase enzyme,,NA,ECO:0005542,,,,,Direct interaction ( Mechanistic A),A,,,,High level of fucosyl-linked oligosaccharide accumulation,,HP:0100614,https://www.ncbi.nlm.nih.gov/pubmed/21575633,https://www.ncbi.nlm.nih.gov/pubmed/27491218,https://www.ncbi.nlm.nih.gov/pubmed/26537923,,,,,,,,
1071,,# 230000,Fucosidosis,,FUCA1,a-L-fucosidase,3.2.1.51,,,,,,,,,,,,,,Neuronal vacuolation,,NA,,,,,,,,,,,
1072,,# 230000,Fucosidosis,,FUCA1,a-L-fucosidase,3.2.1.51,,,,,,,,,,,,,,Pyramidal neuron loss,,HP:0002062*,,,,,,,,,,,
1073,,# 230000,Fucosidosis,,FUCA1,a-L-fucosidase,3.2.1.51,,,,,,,,,,,,,,Astrocytosis,,MP:0003354,,,,,,,,,,,
1074,,# 230000,Fucosidosis,,FUCA1,a-L-fucosidase,3.2.1.51,,,,,,,,,,,,,,Microgliosis,,HP:0100708,,,,,,,,,,,
1075,,# 230000,Fucosidosis,,FUCA1,a-L-fucosidase,3.2.1.51,,,,,,,,,,,,,,Purkinji cells apoptosis,,MP:0000880,,,,,,,,,,,
1076,,# 230000,Fucosidosis,,FUCA1,a-L-fucosidase,3.2.1.51,,,,,,,,,,,,,,Oligodendrocyte loss,,HP:0100709,,,,,,,,,,,
1077,,# 230000,Fucosidosis,,FUCA1,a-L-fucosidase,3.2.1.51,,,,,,,,,,,,,,Hypomyelination,,MP:0013438,,,,,,,,,,,
1078,,# 230000,Fucosidosis,,FUCA1,a-L-fucosidase,3.2.1.51,,,,,,,,,,,,,,Lysosomal expansion in neurons of deep cortex,,HP:0004356*,,,,,,,,,,,
1079,,# 230000,Fucosidosis,,FUCA1,a-L-fucosidase,3.2.1.51,,,,,,,,,,,,,,Astrocytosis in cerebral cortex,,HP:0002446,,,,,,,,,,,
1080,,# 230000,Fucosidosis,,FUCA1,a-L-fucosidase,3.2.1.51,,,,,,,,,,,,,,Abnormal lysosomal membrane associated protein-1 (LAMP-1) gene expression,,NA,,,,,,,,,,,
1081,,# 230000,Fucosidosis,,FUCA1,a-L-fucosidase,3.2.1.51,,,,,,,,,,,,,,Abnormal neurololgical function,,HP:0000707,,,,,,,,,,,
1082,,# 230000,Fucosidosis,,FUCA1,a-L-fucosidase,3.2.1.51,Tocilizumab,,DB06273,ECO:0000352,,,,,Symptomatic (C),,,,,Arthritis,,HP:0001369,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6649943/,,,,,,,,,,
1083,118,# 229700,"Fructose-1,6-bisphosphatase deficiency","The therapy is based on avoiding prolonged fasts, glucose infusion, and a specific diet, rich in glucose without fructose intake. https://www.ncbi.nlm.nih.gov/pubmed?Db=pubmed&Cmd=Retrieve&list_uids=29390242&dopt=abstractplus
Fructose, glycerol and oral medicines that may contain sucrose and sorbitol should not be given during acute illness. https://link.springer.com/chapter/10.1007/978-3-642-15720-2_9",FBP1,"Fructose-1,6-bisphosphatase 1",3.1.3.11,Glucose,"Sodium bicarbonate is not given routinely as any acidosis usually corrects quickly, but sodium bicarbonate may be needed if, after the initial bolus of glucose, the pH remains <7.1 or the pH is deteriorating rapidly. https://www.ncbi.nlm.nih.gov/pubmed/29203193",DB01914,ECO:0000352,,,,,Functional interaction( Mechanistic B),B,,,,Hypoglycemia,,HP:0001943,https://www.ncbi.nlm.nih.gov/pubmed/29203193,,https://www.ncbi.nlm.nih.gov/pubmed?Db=pubmed&Cmd=Retrieve&list_uids=29390242&dopt=abstractplus,,,,,,,,
1084,119,# 136120,Fish-eye disease,"Fat restriction is recommended as it leads to progressive mesangial and glomerular sclerosis.https://www.ncbi.nlm.nih.gov/pubmed/2068059. 
and as well another author have suggested that low fat/calorie diet mainly consisting of vegetables may inhibit the progression of the renal disease.https://www.ncbi.nlm.nih.gov/pubmed/2634146",LCAT,lecithin-cholesterol acyltransferase,2.3.1.43,statin,,DB00175,ECO:0000352,,,,,Functional interaction( Mechanistic B),B,,,,decreased cholesterol absorption,,MP:0002647,https://www.ncbi.nlm.nih.gov/pubmed/24636183,,,,,,,,,,
1085,,# 136120,Fish-eye disease,,LCAT,lecithin-cholesterol acyltransferase,2.3.1.43,ANGIOTENSIN II RECEPTOR BLOCKERS (ARBs),The drug was accomapined with fat-restricted diet,C09C,ECO:0000352,,,,,,,,,,Abnormal lipoprotein profile,,HP:0010979,https://www.ncbi.nlm.nih.gov/pubmed/23522979,,,,,,,,,,
1086,,# 136120,Fish-eye disease,,LCAT,lecithin-cholesterol acyltransferase,2.3.1.43,,,,,,,,,,,,,,Abnormal renal function,,HP:0012211,https://www.ncbi.nlm.nih.gov/pubmed/23522979,,,,,,,,,,
1087,,# 136120,Fish-eye disease,,LCAT,lecithin-cholesterol acyltransferase,2.3.1.43,,,,,,,,,,,,,,Proteinuria,,HP:0000093,https://www.ncbi.nlm.nih.gov/pubmed/23522979,,,,,,,,,,
1088,,# 136120,Fish-eye disease,,LCAT,lecithin-cholesterol acyltransferase,2.3.1.43,,,,,,,,,,,,,,Low serum HDL-cholesterol,,HP:0003233,https://www.ncbi.nlm.nih.gov/pubmed/23522979,,,,,,,,,,
1089,,# 136120,Fish-eye disease,,LCAT,lecithin-cholesterol acyltransferase,2.3.1.43,r LCAT,rhLCAT was used in atrial and it has been found to increase the HDL-C and it was safe. https://www.ncbi.nlm.nih.gov/pubmed/24385512,NA,ECO:0005542,,,,,,,,,,Abnormal lipoprotein profile,,HP:0010979,https://www.ncbi.nlm.nih.gov/pubmed/20605907,,,,,,,,,,
1090,,# 136120,Fish-eye disease,,LCAT,lecithin-cholesterol acyltransferase,2.3.1.43,,,,,,,,,,,,,,Low HDL-C  level,,HP:0003233,https://www.ncbi.nlm.nih.gov/pubmed/20605907,,,,,,,,,,
1091,120,# 612319,Fatty acid hydroxylase-associated neurodegeneration,,FA2H,fatty acid 2-hydroxylase,2.3.1.43,baclofen/tizanidine/trihexyphenidyl/benzodiazepine/dantrolene,,DB00182/DB00697/DB00376/DB12537/DB01219,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,dystonia,,HP:0001332,https://www.ncbi.nlm.nih.gov/pubmed/21735565,,,,,,,,,,
1092,,# 612319,Fatty acid hydroxylase-associated neurodegeneration,,FA2H,fatty acid 2-hydroxylase,2.3.1.43,,,,,,,,,,,,,,spasticity,,HP:0001257,https://www.ncbi.nlm.nih.gov/pubmed/21735565,,,,,,,,,,
1093,,# 612319,Fatty acid hydroxylase-associated neurodegeneration,,FA2H,fatty acid 2-hydroxylase,2.3.1.43,botulinum toxin,,DB00083,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,abnormal muscular co-contraction,,HP:0001257,https://www.ncbi.nlm.nih.gov/pubmed/21735565,,,,,,,,,,
1094,,# 612319,Fatty acid hydroxylase-associated neurodegeneration,,FA2H,fatty acid 2-hydroxylase,2.3.1.43,Nimodipine,,DB00393,ECO:0000305/ECO:0001565,,,,,Direct interaction ( Mechanistic A),,activity modification of a genetically defective protein,,,Abnormality of circulating enzyme level,,HP:0011021,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454877/,,,,,,,,,,
1095,121,# 616896,Fatal infantile encephalomyopathy,,OPA1,mitochondrial dynamin like GTPase,2.3.1.43,No treatment is available in DDIEM,,DB00393,,,,,,,,,,,,,HP:0011021,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454877/,,,,,,,,,,
1096,122,# 228000,Farber's disease,,ASAH1,acid ceramidase,3.5.1.23,human recombinant acid ceramidase/human ACDase-encoding lentivector,,NA,ECO:0005542/ECO:0001565,,,,,Direct interaction ( Mechanistic A) ERT,A,Direct complementation,,,Delayed growth,,HP:0001510,https://www.ncbi.nlm.nih.gov/pubmed/23681708/,https://www.ncbi.nlm.nih.gov/pubmed/28275553,https://www.ncbi.nlm.nih.gov/pubmed/27155573,,,,,,,,
1097,,# 228000,Farber's disease,,ASAH1,acid ceramidase,3.5.1.23,,,,,,,,,,,,,,High cermaide level,,MP:0020582,https://www.ncbi.nlm.nih.gov/pubmed/23681708/,https://www.ncbi.nlm.nih.gov/pubmed/28275553,https://www.ncbi.nlm.nih.gov/pubmed/27155573,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5338723/,,,,,,,
1098,,# 228000,Farber's disease,,ASAH1,acid ceramidase,3.5.1.23,,,,,,,,,,,,,,High intracellular cermaid level,,MP:0020582*,https://www.ncbi.nlm.nih.gov/pubmed/23681708/,https://www.ncbi.nlm.nih.gov/pubmed/28275553,https://www.ncbi.nlm.nih.gov/pubmed/27155573,,,,,,,,
1099,,# 228000,Farber's disease,,ASAH1,acid ceramidase,3.5.1.23,,,,,,,,,,,,,,Abnormal spleen size,,HP:0001744,https://www.ncbi.nlm.nih.gov/pubmed/23681708/,https://www.ncbi.nlm.nih.gov/pubmed/28275553,https://www.ncbi.nlm.nih.gov/pubmed/27155573,,,,,,,,
1100,,# 228000,Farber's disease,,ASAH1,acid ceramidase,3.5.1.23,,,,,,,,,,,,,,abnormal sphingosine level(Abnormality of lipid metabolism)*,,MP:0009587,https://www.ncbi.nlm.nih.gov/pubmed/23681708/,https://www.ncbi.nlm.nih.gov/pubmed/28275553,https://www.ncbi.nlm.nih.gov/pubmed/27155573,,,,,,,,
1101,,# 228000,Farber's disease,,ASAH1,acid ceramidase,3.5.1.23,,,,,,,,,,,,,,high plasma MCP-1,,NA,https://www.ncbi.nlm.nih.gov/pubmed/23681708/,https://www.ncbi.nlm.nih.gov/pubmed/28275553,https://www.ncbi.nlm.nih.gov/pubmed/27155573,,,,,,,,
1102,,# 228000,Farber's disease,,ASAH1,acid ceramidase,3.5.1.23,,,,,,,,,,,,,,High macrophage infiltration into tissues(Abnormal inflammatory response)*,,HP:0012647*,https://www.ncbi.nlm.nih.gov/pubmed/23681708/,https://www.ncbi.nlm.nih.gov/pubmed/28275553,https://www.ncbi.nlm.nih.gov/pubmed/27155573,,,,,,,,
1103,,# 228000,Farber's disease,,ASAH1,acid ceramidase,3.5.1.23,,,,,,,,,,,,,,Abnormal tissue lipid profiles(Abnormality of lipid metabolism)*,,HP:0003119,https://www.ncbi.nlm.nih.gov/pubmed/23681708/,https://www.ncbi.nlm.nih.gov/pubmed/28275553,https://www.ncbi.nlm.nih.gov/pubmed/27155573,,,,,,,,
1104,,# 228000,Farber's disease,,ASAH1,acid ceramidase,3.5.1.23,,,,,,,,,,,,,,Joint inflammation,,HP:0001369,https://www.ncbi.nlm.nih.gov/pubmed/23681708/,https://www.ncbi.nlm.nih.gov/pubmed/28275553,https://www.ncbi.nlm.nih.gov/pubmed/27155573,,,,,,,,
1105,,# 228000,Farber's disease,,ASAH1,acid ceramidase,3.5.1.23,Amitriptyline,"The drug wasn't tried in animal model of Farber's disease, however, it seems to have an effect on ceraminde level in lungs.",,ECO:0000305/ECO:0005542,,,,,,,Functional complementation by inhibition,,,Abnormal pulmonary ceramide level,,NA,https://www.ncbi.nlm.nih.gov/pubmed/18376404,https://www.ncbi.nlm.nih.gov/pubmed/28275553,https://www.ncbi.nlm.nih.gov/pubmed/27155573,,,,,,,,
1106,,# 228000,Farber's disease,,ASAH1,acid ceramidase,3.5.1.23,,,,,,,,,,,,,,,,,,,,,,,,,,,
1107,123,# 227810,Fanconi Bickel syndrome,,SLC2A2,"Solute carrier family 2, facilitated glucose transporter member 2",P11168,Uncooked Cornstarch,Uncoooked cornstrach was introduced in small frequent meal and was accomapined with elimination of lactose in diet,DB11599,ECO:0000352,,,,,Symptomatic (C),C,Dietary supplementation,,,Failure to thrive,,HP:0001508,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4353876/,https://www.ncbi.nlm.nih.gov/pubmed/7564233/,,,,,,,,,
1108,,# 227810,Fanconi Bickel syndrome,,SLC2A2,"Solute carrier family 2, facilitated glucose transporter member 2",P11168,Vitamin D,,DB11094,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,Short stature,,HP:0004322,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4353876/,,,,,,,,,,
1109,,# 227810,Fanconi Bickel syndrome,,SLC2A2,"Solute carrier family 2, facilitated glucose transporter member 2",P11168,phosphorus,,DB14151,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,Rickets,,HP:0002748,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4353876/,,,,,,,,,,
1110,,# 227810,Fanconi Bickel syndrome,,SLC2A2,"Solute carrier family 2, facilitated glucose transporter member 2",P11168,bicarbonate,,DB01390,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,Renal tubular acidosis,,HP:0001947,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4353876/,,,,,,,,,,
1111,,# 227810,Fanconi Bickel syndrome,,SLC2A2,"Solute carrier family 2, facilitated glucose transporter member 2",P11168,Insulin,,DB00030,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,Diabetes mellitus,,HP:0000819,http://www.ncbi.nlm.nih.gov/pubmed/29116606?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/23456528,,,,,,,,,
1112,124,151660,Familial partial lipodystrophy type 2,Data regarding TZD therapy and the restoration of adipose tissue in lipoatrophic areas has been conflicting; it appears as though TZDs do not improve lipoatrophy in patients with FPLD2. https://www.ncbi.nlm.nih.gov/pubmed/19040647/,LMNA,lamins ( Lamins A and C),P02545,ISIS 703802 (AKCEA-ANGPTL3-LRx),,NA,ECO:0007121,,,,,Symptomatic(C),C,,,,high fasting triglycerides,,HP:0002155*,https://clinicaltrials.gov/ct2/show/NCT03514420?cond=Familial+partial+lipodystrophy+type+2&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/23456528,,,,,,,,,
1113,,151660,Familial partial lipodystrophy type 2,,LMNA,lamins ( Lamins A and C),P02545,Metreleptin(A-100),,DB09046,ECO:0007121/ECO:0000352,,,,,Symptomatic(C),C,,,,abnormal free fatty acid levels,,HP:0040300,https://clinicaltrials.gov/ct2/show/NCT00025883?cond=Familial+partial+lipodystrophy+type+2&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/25734254,,,,,,,,,
1114,,151660,Familial partial lipodystrophy type 2,,LMNA,lamins ( Lamins A and C),P02545,,,,,,,,,,,,,,high facial soft tissue volume,,HP:0000287,https://www.ncbi.nlm.nih.gov/pubmed/28993984,,,,,,,,,,
1115,,151660,Familial partial lipodystrophy type 2,,LMNA,lamins ( Lamins A and C),P02545,,,,,,,,,,,,,,abnormal fasting glucose,,MP:0013277,https://www.ncbi.nlm.nih.gov/pubmed/29044799,https://www.ncbi.nlm.nih.gov/pubmed/26584826,,,,,,,,,
1116,,151660,Familial partial lipodystrophy type 2,,LMNA,lamins ( Lamins A and C),P02545,,,,,,,,,,,,,,high  HbA1c levels,,HP:0040217,,,,,,,,,,,
1117,,151660,Familial partial lipodystrophy type 2,,LMNA,lamins ( Lamins A and C),P02545,Albiglutide (glucagon-like peptide-1 receptor agonist),,DB09043,,,,,,Symptomatic (C),C,,,,abnormal fasting glucose,,MP:0013277,,,,,,,,,,,
1118,,151660,Familial partial lipodystrophy type 2,,LMNA,lamins ( Lamins A and C),P02545,,,,,,,,,,,,,,high  HbA1c levels,,HP:0040217,,,,,,,,,,,
1119,,151660,Familial partial lipodystrophy type 2,,LMNA,lamins ( Lamins A and C),P02545,volanesorsen (IONIS-APOCIIIRx),,NA,ECO:0007121,,,,,Symptomatic (C),C,,,,Abnormal fasting triglycerides,,HP:0002155*,https://clinicaltrials.gov/ct2/show/NCT02300233,https://clinicaltrials.gov/ct2/show/NCT02211209,https://clinicaltrials.gov/ct2/show/NCT02527343?cond=%22familial+partial+lipodystrophy%22&rank=2,,,,,,,,
1120,,151660,Familial partial lipodystrophy type 2,,LMNA,lamins ( Lamins A and C),P02545,Obeticholic Acid,,DB05990,ECO:0007121,,,,,Symptomatic (C),C,,,,Hepatic steatosis,,HP:0001397,https://clinicaltrials.gov/ct2/show/NCT02430077?cond=%22familial+partial+lipodystrophy%22&rank=3,,,,,,,,,,
1121,,151660,Familial partial lipodystrophy type 2,,LMNA,lamins ( Lamins A and C),P02545,,,,,,,,,,,,,,High liver triglyceride level(hyperlipidemia)*,,HP:0003077*,,,,,,,,,,,
1122,,151660,Familial partial lipodystrophy type 2,,LMNA,lamins ( Lamins A and C),P02545,Gemcabene,,DB05123,ECO:0007121,,,,,Symptomatic (C),C,,,,Hypertriglyceridemia,,HP:0002155,https://clinicaltrials.gov/ct2/show/NCT03508687?cond=%22familial+partial+lipodystrophy%22&rank=6,,,,,,,,,,
1123,,151660,Familial partial lipodystrophy type 2,,LMNA,lamins ( Lamins A and C),P02545,,,,,,,,,,,,,,Hepatic steatosis,,HP:0001397,,,,,,,,,,,
1124,,151660,Familial partial lipodystrophy type 2,,LMNA,lamins ( Lamins A and C),P02545,fibrates + omega-3 fatty acids (OMG-3),Niacin DB00627 occasionally can be used with Fibrate and omega 3 fatty acid in treating hypertriglyceridiemia. https://www.ncbi.nlm.nih.gov/pubmed/21079616,DB00636 +DB11133,ECO:0000352,,,,,Symptomatic (C),C,,,,Hypertriglyceridemia,,HP:0002155,https://www.ncbi.nlm.nih.gov/pubmed/27710244,,,,,,,,,,
1125,,151660,Familial partial lipodystrophy type 2,,LMNA,lamins ( Lamins A and C),P02545,,,,,,,,,,,,,,,,,,,,,,,,,,,
1126,125,# 245900,Familial LCAT deficiency,,LCAT,lecithin-cholesterol acyltransferase,2.3.1.43,recombinant human LCAT (ACP-501),,NA,ECO:0007121,,,,,Direct interaction ( Mechanistic A),A,activity modification of a genetically defective protein,,,anemia,,HP:0001903,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826469/,https://www.clinicaltrials.gov/ct2/show/NCT01554800?term=ACP-501&rank=1,,,,,,,,,
1127,,# 245900,Familial LCAT deficiency,,LCAT,lecithin-cholesterol acyltransferase,2.3.1.43,,,,,,,,,,,,,,Abnormal lecithin:cholesterol acyltransferase activity,,MP:0011598,,,,,,,,,,,
1128,,# 245900,Familial LCAT deficiency,,LCAT,lecithin-cholesterol acyltransferase,2.3.1.43,,,,,,,,,,,,,,abnormal plasma lipids levels,,HP:0003119,,,,,,,,,,,
1129,,# 245900,Familial LCAT deficiency,,LCAT,lecithin-cholesterol acyltransferase,2.3.1.43,,,,,,,,,,,,,,low HDL level,,HP:0003233,,,,,,,,,,,
1130,,# 245900,Familial LCAT deficiency,,LCAT,lecithin-cholesterol acyltransferase,2.3.1.43,,,,,,,,,,,,,,low HDL-C level,,HP:0003233,,,,,,,,,,,
1131,,# 245900,Familial LCAT deficiency,,LCAT,lecithin-cholesterol acyltransferase,2.3.1.43,,,,,,,,,,,,,,Abnormal cholesterol efflux from cells,,MP:0003193,,,,,,,,,,,
1132,,# 245900,Familial LCAT deficiency,,LCAT,lecithin-cholesterol acyltransferase,2.3.1.43,,,,,,,,,,,,,,dyslipidemia,,MP:0003949,,,,,,,,,,,
1133,,# 245900,Familial LCAT deficiency,,LCAT,lecithin-cholesterol acyltransferase,2.3.1.43,,,,,,,,,,,,,,low APO A level,,HP:0025201*,,,,,,,,,,,
1134,,# 245900,Familial LCAT deficiency,,LCAT,lecithin-cholesterol acyltransferase,2.3.1.43,,,,,,,,,,,,,,Low Apo B protein level,,HP:0025201*,,,,,,,,,,,
1135,,# 245900,Familial LCAT deficiency,,LCAT,lecithin-cholesterol acyltransferase,2.3.1.43,,,,,,,,,,,,,,proteinuria,,HP:0000093,,,,,,,,,,,
1136,,# 245900,Familial LCAT deficiency,,LCAT,lecithin-cholesterol acyltransferase,2.3.1.43,Captopril,,DB01197,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,Hypertension,,HP:0000822,https://www.ncbi.nlm.nih.gov/pubmed/23391322,,,,,,,,,,
1137,,# 245900,Familial LCAT deficiency,,LCAT,lecithin-cholesterol acyltransferase,2.3.1.43,Thiazide,,DB01324,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,Oedema,,HP:0000969,,,,,,,,,,,
1138,126,# 162000,Familial juvenile hyperuricaemic nephropathy,,UMOD,uromodulin,P07911,Probenecid,,DB01032,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,functional complementation of a defective protein by inhibition,,Hyperurecemia,,HP:0002149,https://www.ncbi.nlm.nih.gov/pubmed?Db=pubmed&Cmd=Retrieve&list_uids=20301530&dopt=abstractplus,https://www.ncbi.nlm.nih.gov/pubmed/8842764,,,,,,,,,
1139,,# 162000,Familial juvenile hyperuricaemic nephropathy,,UMOD,uromodulin,P07911,Probenecid+Allopurinol,,DB01032+DB00437,ECO:0000352,,,,,Symptomatic (C),,symptomatic treatment procedure,functional complementation of a defective protein by inhibition,,Hyperurecemia,,HP:0002149,https://www.ncbi.nlm.nih.gov/pubmed/8842764,,,,,,,,,,
1140,,# 162000,Familial juvenile hyperuricaemic nephropathy,,UMOD,uromodulin,P07911,Allopurinol,"In individuals with allergies or intolerance to allopurinol, febuxostat may be considered; however, no data on the use of this medication in UMOD-associated kidney disease are available at present.",DB00437,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,functional complementation of a defective protein by inhibition,,Hyperurecemia,,HP:0002149,https://www.ncbi.nlm.nih.gov/pubmed/12205338,https://www.ncbi.nlm.nih.gov/pubmed/11068651,,,,,,,,,
1141,,# 162000,Familial juvenile hyperuricaemic nephropathy,,UMOD,uromodulin,P07911,,,,,,,,,,,,,,Mortality,,HP:0040006,https://www.ncbi.nlm.nih.gov/pubmed/12205338,,,,,,,,,,
1142,,# 162000,Familial juvenile hyperuricaemic nephropathy,,UMOD,uromodulin,P07911,,,,,,,,,,,,,,Disaess progression(Progressive)*,,HP:0003676,https://www.ncbi.nlm.nih.gov/pubmed?Db=pubmed&Cmd=Retrieve&list_uids=20301530&dopt=abstractplus,,,,,,,,,,
1143,,# 162000,Familial juvenile hyperuricaemic nephropathy,,UMOD,uromodulin,P07911,Allopurinal+Benzbromarone,,DB00437+DB12319,ECO:0000352,,,,,,,symptomatic treatment procedure,functional complementation of a defective protein by inhibition,,Hyperurecemia,,HP:0002149,https://www.ncbi.nlm.nih.gov/pubmed/9678437,,,,,,,,,,
1144,127,# 145980,Familial hypocalciuric hypercalcemia type 1,"In majority of cases, there is no need for treatment until thecalcium level is very high, it becomes necessary to treat FHH.https://www.ncbi.nlm.nih.gov/pubmed/21986511",CASR,calcium-sensing receptor,P41180,Cinacalcet,,DB01012,ECO:0000352,,,,,,,activity modification of a genetically defective protein,,,Hypercalcemia,,HP:0003072,https://www.ncbi.nlm.nih.gov/pubmed/28459040,https://www.ncbi.nlm.nih.gov/pubmed/16882283/,https://www.ncbi.nlm.nih.gov/pubmed/17803689/,https://www.ncbi.nlm.nih.gov/pubmed/22142470/,https://www.ncbi.nlm.nih.gov/pubmed/21289269/,https://www.ncbi.nlm.nih.gov/pubmed/20495831/,,,,,
1145,,# 145980,Familial hypocalciuric hypercalcemia type 1,,CASR,calcium-sensing receptor,P41180,,,,,,,,,,,,,,Elevated circulating parathyroid hormone level,,HP:0003165,https://www.ncbi.nlm.nih.gov/pubmed/20495831/,https://www.ncbi.nlm.nih.gov/pubmed/21289269/,,,,,,,,,
1146,,# 145980,Familial hypocalciuric hypercalcemia type 1,,CASR,calcium-sensing receptor,P41180,,,,,,,,,,,,,,Impaired renal uric acid clearance,,HP:0004732,https://www.ncbi.nlm.nih.gov/pubmed/28459040,,,,,,,,,,
1147,,# 145980,Familial hypocalciuric hypercalcemia type 1,,CASR,calcium-sensing receptor,P41180,,,,,,,,,,,,,,Polydipsia,,HP:0001959,https://www.ncbi.nlm.nih.gov/pubmed/28459040,,,,,,,,,,
1148,128,# 145981,Familial hypocalciuric hypercalcemia type 2,,GNA11,guanine nucleotide-binding protein (Gα11),P21278,Cinacalcet,,DB01012,ECO:0000352,,,,,Functional interaction(Mechanistic B),B,activity modification of a genetically defective protein,,,high serum ionized calcium concentrations,,HP:0003072*,https://www.ncbi.nlm.nih.gov/pubmed/22142470/,,https://www.ncbi.nlm.nih.gov/pubmed/28833550,,,,,,,,
1149,,# 145981,Familial hypocalciuric hypercalcemia type 2,,GNA11,guanine nucleotide-binding protein (Gα11),P21278,,,,,,,,,,,,,,abnormal parathyroid hormone level,,HP:0003165,,,,,,,,,,,
1150,129,# 600740,Familial hypocalciuric hypercalcemia type 3,,AP2S1,adaptor protein-2 σ-subunit,P53680,Cinacalcet,,DB01012,ECO:0000352,,,,,Functional interaction(Mechanistic B),B,activity modification of a genetically defective protein,,,high serum ionized calcium concentrations,,HP:0003072*,https://www.ncbi.nlm.nih.gov/pubmed/27050234/,https://www.ncbi.nlm.nih.gov/pubmed/22142470/,https://academic.oup.com/jcem/article/100/7/2515/2829587,,,,,,,,
1151,,# 600740,Familial hypocalciuric hypercalcemia type 3,,AP2S1,adaptor protein-2 σ-subunit,P53680,,,,,,,,,,,,,,abnormal parathyroid hormone level,,HP:0003165,,,,,,,,,,,
1152,,# 600740,Familial hypocalciuric hypercalcemia type 3,,AP2S1,adaptor protein-2 σ-subunit,P53680,,,,,,,,,,,,,,low calcium urine excretion,,HP:0003127,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367245/,,,,,,,,,,
1153,,# 145750,"HYPERTRIGLYCERIDEMIA, FAMILIAL",,APOA5,Apolipoprotein A-V,Q6Q788,Gemfibrozil,,,,,,,,,,,,,,,HP:0003127,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5367245/,,,,,,,,,,
1154,,# 145750,"HYPERTRIGLYCERIDEMIA, FAMILIAL",,APOA5,Apolipoprotein A-V,Q6Q788,,,,,,,,,,,,,,,,,,,,,,,,,,,
1155,,# 145750,"HYPERTRIGLYCERIDEMIA, FAMILIAL",,APOA5,Apolipoprotein A-V,Q6Q788,fenofibrate,,,,,,,,,,,,,,,,,,,,,,,,,,
1156,,# 145750,"HYPERTRIGLYCERIDEMIA, FAMILIAL",,APOA5,Apolipoprotein A-V,Q6Q788,,,,,,,,,,,,,,,,,,,,,,,,,,,
1157,130,# 604091,Familial HDL deficiency,,ABCA1,Phospholipid-transporting ATPase ABCA1,7.6.2.1,Niacin,,DB00627,ECO:0007121,,,,,Direct interaction (Mechanistic A),A,activity modification of a genetically defective protein,,,hypoalphalipoproteinemia,,HP:0003233,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2988622/,https://www.clinicaltrials.gov/ct2/show/NCT01942291?cond=%22Hypolipoproteinemia%22&rank=10,,,,,,,,,
1158,,# 604091,Familial HDL deficiency,,ABCA1,Phospholipid-transporting ATPase ABCA1,7.6.2.1,Gemfibrozil,,DB01241,ECO:0005542,,,,,Direct interaction ( Mechanistic A),A,activity modification of a genetically defective protein,,,Low HDL cholesterol concentration,,HP:0003233,https://www.ncbi.nlm.nih.gov/pubmed/9493705,https://www.clinicaltrials.gov/ct2/show/NCT01942291?cond=%22Hypolipoproteinemia%22&rank=10,,,,,,,,,
1159,,# 604091,Familial HDL deficiency,,ABCA1,Phospholipid-transporting ATPase ABCA1,7.6.2.1,fenofibrate,,DB01039,,,,,,Direct interaction ( Mechanistic A),A,,,,,,done,https://www.ncbi.nlm.nih.gov/pubmed/9493705,https://www.clinicaltrials.gov/ct2/show/NCT01942291?cond=%22Hypolipoproteinemia%22&rank=10,,,,,,,,,
1160,,# 604091,Familial HDL deficiency,,ABCA1,Phospholipid-transporting ATPase ABCA1,7.6.2.1,Atorvastatin,,DB01076,,,,,,Direct interaction ( Mechanistic A),A,,,,,,done,https://www.ncbi.nlm.nih.gov/pubmed/9493705,https://www.clinicaltrials.gov/ct2/show/NCT01942291?cond=%22Hypolipoproteinemia%22&rank=10,https://www.clinicaltrials.gov/ct2/show/NCT00458055?cond=%22Hypolipoproteinemia%22&rank=3,,,,,,,,
1161,,# 604091,Familial HDL deficiency,,ABCA1,Phospholipid-transporting ATPase ABCA1,7.6.2.1,"CER 001, a recombinant high-density lipoprotein (HDL)",,NA,ECO:0007121,,,,,Direct interaction ( Mechanistic A),A,,,,low  plasma cholesterol,,HP:0003146,https://www.ncbi.nlm.nih.gov/pubmed/9493705,https://www.clinicaltrials.gov/ct2/show/NCT01942291?cond=%22Hypolipoproteinemia%22&rank=10,https://www.ncbi.nlm.nih.gov/pubmed/28213743,https://www.clinicaltrials.gov/ct2/show/NCT02697136?cond=%22Hypolipoproteinemia%22&draw=2&rank=8,,,,,,,
1162,,# 604091,Familial HDL deficiency,,ABCA1,Phospholipid-transporting ATPase ABCA1,7.6.2.1,,,,,,,,,,,,,,low unesterified cholesterol,,HP:0003107*,,,,,,,,,,,
1163,131,# 301500,Fabry disease,,GLA,alpha-galactosidase A,7.6.2.1,Fabrazyme ( agalsidase beta),,DB00103,,,,,,Direct interaction (Mechanistic A),A,,,,Abnormal kidney function,,HP:0012211,,,https://fabrydiseasenews.com/prx-102-pegunigalsidase-alfa/,https://clinicaltrials.gov/ct2/show/NCT02930655?cond=fabry+disease&rank=2,https://clinicaltrials.gov/ct2/show/NCT03180840?cond=fabry+disease&rank=4,https://clinicaltrials.gov/ct2/show/NCT03018730?cond=fabry+disease&rank=7,https://clinicaltrials.gov/ct2/show/NCT01218659?cond=fabry+disease&rank=8,,,,
1164,,# 301500,Fabry disease,,GLA,alpha-galactosidase A,7.6.2.1,REPLAGAL (Agalsidase Alfa),,DB00103,,,,,,Direct interaction (Mechanistic A),A,,,,cardiomegaly,,HP:0001640,,,https://fabrydiseasenews.com/prx-102-pegunigalsidase-alfa/,https://clinicaltrials.gov/ct2/show/NCT02930655?cond=fabry+disease&rank=2,https://clinicaltrials.gov/ct2/show/NCT03180840?cond=fabry+disease&rank=4,https://clinicaltrials.gov/ct2/show/NCT03018730?cond=fabry+disease&rank=7,https://clinicaltrials.gov/ct2/show/NCT01218659?cond=fabry+disease&rank=8,,,,
1165,,# 301500,Fabry disease,,GLA,alpha-galactosidase A,7.6.2.1,,,,,,,,,,,,,,low renal glomerular filtration rate,,HP:0012213,,,,,,,,,,,
1166,,# 301500,Fabry disease,,GLA,alpha-galactosidase A,7.6.2.1,,,,,,,,,,,,,,pain,,HP:0012531,,,,,,,,,,,
1167,,# 301500,Fabry disease,,GLA,alpha-galactosidase A,7.6.2.1,pegunigalsidase alfa ( PRX-102),,NA,,,,,,Direct interaction (Mechanistic A),A,,,,,,done,,,,,,,,,,,
1168,,# 301500,Fabry disease,,GLA,alpha-galactosidase A,7.6.2.1,migalastat hydrochloride (AT1001),,DB05018,,,,,,Direct interaction (Mechanistic A),A,,,,,,done,,,,,,,,,,,
1169,132,# 612073,MITOCHONDRIAL DNA DEPLETION SYNDROME 5,,SUCLA2,Succinyl-CoA synthetase ( beta subunit),7.6.2.1,Carbamazepine,,DB00564,,,,,,Symptomatic (C),C,,,,seizures,,HP:0001250,,,https://www.ncbi.nlm.nih.gov/books/NBK6803/,,,,,,,,
1170,133,# 249900,Encephalopathy due to prosaposin deficiency,,PSAP,prosaposin,7.6.2.1,NA,,DB00564,,,,,,,,,,,,,done,,,https://www.ncbi.nlm.nih.gov/pubmed/8370580,https://www.omim.org/entry/611721,,,,,,,
1171,134,# 177000,Erythropoietic protoporphyria,,FECH,ferrochelatase,7.6.2.1,vitamin D,,DB11094,,,,,,Symptomatic (C),C,,,,concommitant low vit D level,,HP:0100512*,,,https://www.ncbi.nlm.nih.gov/pubmed?Db=pubmed&Cmd=Retrieve&list_uids=24137761&dopt=abstractplus,https://www.omim.org/entry/611721,,,,,,,
1172,,# 177000,Erythropoietic protoporphyria,,FECH,ferrochelatase,7.6.2.1,Afamelanotide (Scenesse),,DB04931,,,,,,Symptomatic (C),C,,,,Erythema,,HP:0010783,,,https://www.karger.com/Article/Abstract/362174,https://www.omim.org/entry/611721,,,,,,,
1173,,# 177000,Erythropoietic protoporphyria,,FECH,ferrochelatase,7.6.2.1,,,,,,,,,,,,,,Cutaneous photosensitivity,,HP:0000992,,,,,,,,,,,
1174,,# 177000,Erythropoietic protoporphyria,,FECH,ferrochelatase,7.6.2.1,corticosteroids,,DB00288,,,,,,Symptomatic (C),C,,,,Pain,,HP:0012531,,,https://www.medicaljournals.se/acta/content/abstract/10.2340/00015555-2444,,,,,,,,
1175,,# 177000,Erythropoietic protoporphyria,,FECH,ferrochelatase,7.6.2.1,,,,,,,,,,,,,,Pruritus,,HP:0000989,,,,,,,,,,,
1176,,# 177000,Erythropoietic protoporphyria,,FECH,ferrochelatase,7.6.2.1,zinc,,DB01593,,,,,,Symptomatic (C),C,,,,Increased ROS formation,,HP:0025464,,,http://www.ncbi.nlm.nih.gov/pubmed/22092997?dopt=Abstract,https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1600-0846.2011.00586.x,,,,,,,
1177,,# 177000,Erythropoietic protoporphyria,,FECH,ferrochelatase,7.6.2.1,β-carotene,,DB06755,,,,,,Symptomatic (C),C,,,,intolerance to sunlight,,HP:0000992,,,http://www.bloodjournal.org/content/120/23/4496.long?sso-checked=true,https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1600-0846.2011.00586.x,,,,,,,
1178,,# 177000,Erythropoietic protoporphyria,,FECH,ferrochelatase,7.6.2.1,,,,,,,,,,,,,,Pain in the skin,,HP:0025280*,,,,,,,,,,,
1179,,# 177000,Erythropoietic protoporphyria,,FECH,ferrochelatase,7.6.2.1,Cholestyramine,,DB01432,,,,,,Symptomatic (C),C,,,,Abnormal  protoporphyrin enterhepatic circulation,,HP:0012187,,,,,,,,,,,
1180,,# 177000,Erythropoietic protoporphyria,,FECH,ferrochelatase,7.6.2.1,activated charcoal,,DB09278,,,,,,Symptomatic (C),C,,,,Hepatic involvement,,HP:0001410,,,,,,,,,,,
1181,,# 177000,Erythropoietic protoporphyria,,FECH,ferrochelatase,7.6.2.1,hemin,,DB03404,,,,,,Functional interaction (B),B,,,,Hepatic prophyria(Abnormality of the heme biosynthetic pathway)*,,HP:0010472*,,,,,,,,,,,
1182,,# 177000,Erythropoietic protoporphyria,,FECH,ferrochelatase,7.6.2.1,cysteine hydrochloride,,DB00151,,,,,,Symptomatic (C),C,,,,photosensitivity,,HP:0000992,,,https://clinicaltrials.gov/ct2/show/NCT00004831,,,,,,,,
1183,,# 177000,Erythropoietic protoporphyria,,FECH,ferrochelatase,7.6.2.1,Isoniazid,,DB00951,,,,,,Symptomatic (C),C,,,Terminated,,,done,,,https://clinicaltrials.gov/ct2/show/NCT01550705,,,,,,,,
1184,,# 177000,Erythropoietic protoporphyria,,FECH,ferrochelatase,7.6.2.1,Iron,,DB01592,,,,,,Symptomatic (C),C,,,,high erythrocyte protoporphyrin levels,,HP:0012187,,,https://clinicaltrials.gov/ct2/show/NCT02979249?cond=Erythropoietic+protoporphyria&draw=1&rank=10,,,,,,,,
1185,135,# 177000,Erythropoietic uroporphyria associated with myeloid malignancy,,FECH,ferrochelatase,7.6.2.1,NA,,DB01592,,,,,,,,,,,,,done,,,https://www.sciencedirect.com/science/article/pii/S0022202X15352507?via%3Dihub,,,,,,,,
1186,136,# 602473,Ethylmalonic encephalopathy,,ETHE1,persulfide dioxygenase,7.6.2.1,Acetylcysteine,,DB06151,,,,,,Functional interaction (Mechanistic B),B,,,,high Lactic acid,,HP:0003648,,,https://www.sciencedirect.com/science/article/pii/S0387760405002081?via%3Dihub,http://www.ncbi.nlm.nih.gov/pubmed/16376514?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/29526615,https://www.sciencedirect.com/science/article/pii/S1096719217307096?via%3Dihub,,,,,
1187,,# 602473,Ethylmalonic encephalopathy,,ETHE1,persulfide dioxygenase,7.6.2.1,neomycin,,DB00994,,,,,,Functional interaction (Mechanistic B),B,,,,abnormal thiosulfates level,,HP:0011943,,,https://www.sciencedirect.com/science/article/pii/S0387760405002081?via%3Dihub,http://www.ncbi.nlm.nih.gov/pubmed/16376514?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/29526615,https://www.sciencedirect.com/science/article/pii/S1096719217307096?via%3Dihub,,,,,
1188,,# 602473,Ethylmalonic encephalopathy,,ETHE1,persulfide dioxygenase,7.6.2.1,Metronidazole,,DB00916,,,,,,Functional interaction (Mechanistic B),B,,,,Hypotonia,,MP:0004144,,,https://www.sciencedirect.com/science/article/pii/S0387760405002081?via%3Dihub,http://www.ncbi.nlm.nih.gov/pubmed/16376514?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/29526615,https://www.sciencedirect.com/science/article/pii/S1096719217307096?via%3Dihub,,,,,
1189,,# 602473,Ethylmalonic encephalopathy,,ETHE1,persulfide dioxygenase,7.6.2.1,,,,,,,,,,,,,,diarrhea,,HP:0002014,,,,,,,,,,,
1190,,# 602473,Ethylmalonic encephalopathy,,ETHE1,persulfide dioxygenase,7.6.2.1,,,,,,,,,,,,,,high EMA levels,,HP:0003219,,,,,,,,,,,
1191,,# 602473,Ethylmalonic encephalopathy,,ETHE1,persulfide dioxygenase,7.6.2.1,Ascorbic acid,,DB00126,,,,,,Supportive (C),C,,,,Decreased activity of cytochrome C oxidase in muscle tissue,,HP:0003688,,,,,,,,,,,
1192,,# 602473,Ethylmalonic encephalopathy,,ETHE1,persulfide dioxygenase,7.6.2.1,carnitine,,DB00583,,,,,,Supportive (C),C,,,,,,done,,,,,,,,,,,
1193,137,# 237500,Dubin-Johnson syndrome,,ABCC2,Multidrug resistance protein-2,7.6.2.1,rifampicin,,DB01045,,,,,,Symptomatic (C),C,,,,pruritus,,HP:0000989,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4533671/,https://emedicine.medscape.com/article/173517-treatment,,,,,,,
1194,,# 237500,Dubin-Johnson syndrome,,ABCC2,Multidrug resistance protein-2,7.6.2.1,,,,,,,,,,,,,,hyperbilirunbinemia,,HP:0002904,,,,,,,,,,,
1195,,# 237500,Dubin-Johnson syndrome,,ABCC2,Multidrug resistance protein-2,7.6.2.1,,,,,,,,,,,,,,elevated serum concentrations of bile acids,,HP:0012202,,,,,,,,,,,
1196,,# 237500,Dubin-Johnson syndrome,,ABCC2,Multidrug resistance protein-2,7.6.2.1,UDCA,,DB01586,,,,,,Symptomatic (C),C,,,,high serum alkaline phosphatase,,HP:0003155,,,,,,,,,,,
1197,,# 237500,Dubin-Johnson syndrome,,ABCC2,Multidrug resistance protein-2,7.6.2.1,,,,,,,,,,,,,,hyperbilirunbinemia,,HP:0002904,,,,,,,,,,,
1198,,# 237500,Dubin-Johnson syndrome,,ABCC2,Multidrug resistance protein-2,7.6.2.1,,,,,,,,,,,,,,elevated serum concentrations of bile acids,,HP:0012202,,,,,,,,,,,
1199,,# 237500,Dubin-Johnson syndrome,,ABCC2,Multidrug resistance protein-2,7.6.2.1,,,,,,,,,,,,,,High biliary cholesterol saturation index,,NA,,,,,,,,,,,
1200,138,# 608799,DPM1-CDG (CDG-Ie),,DPM1,dolichol-P-mannose synthase 1,7.6.2.1,,,,,,,,,,,,,,,,done,,,https://rarediseases.org/rare-diseases/congenital-disorders-of-glycosylation/,,,,,,,,
1201,139,# 615042,DPM2-CDG,,DPM2,dolichyl-phosphate mannosyltransferase subunit 2,7.6.2.1,,,,,,,,,,,,,,,,done,,,,,,,,,,,
1202,140,# 612937,DPM3-CDG (CDG-Io),,DPM3,dolichyl-phosphate mannosyltransferase subunit 3,7.6.2.1,,,,,,,,,,,,,,,,done,,,,,,,,,,,
1203,141,# 179850,Dowling-Degos disease,,KRT5/POGLUT1,keratin 5/protein O-glucosyltransferase,7.6.2.1,hydroquinone,,DB09526,,,,,,Symptomatic (C),C,,,,,,done,,,https://rarediseases.info.nih.gov/diseases/9775/dowling-degos-disease,https://onlinelibrary.wiley.com/doi/full/10.1111/ced.13649,https://emedicine.medscape.com/article/1118586-treatment#d8,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418989/,,,,,
1204,,# 179850,Dowling-Degos disease,,KRT5/POGLUT1,keratin 5/protein O-glucosyltransferase,7.6.2.1,retinoids,,DB02699,,,,,,Symptomatic (C),C,,,,,,done,,,https://rarediseases.info.nih.gov/diseases/9775/dowling-degos-disease,https://onlinelibrary.wiley.com/doi/full/10.1111/ced.13649,https://emedicine.medscape.com/article/1118586-treatment#d8,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418989/,,,,,
1205,,# 179850,Dowling-Degos disease,,KRT5/POGLUT1,keratin 5/protein O-glucosyltransferase,7.6.2.1,steroids,,DB14657,,,,,,Symptomatic (C),C,,,,,,done,,,https://rarediseases.info.nih.gov/diseases/9775/dowling-degos-disease,https://onlinelibrary.wiley.com/doi/full/10.1111/ced.13649,https://emedicine.medscape.com/article/1118586-treatment#d8,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418989/,,,,,
1206,,# 179850,Dowling-Degos disease,,KRT5/POGLUT1,keratin 5/protein O-glucosyltransferase,7.6.2.1,"tretinoin,",,DB00755,,,,,,Symptomatic (C),C,,,,,,done,,,https://rarediseases.info.nih.gov/diseases/9775/dowling-degos-disease,https://onlinelibrary.wiley.com/doi/full/10.1111/ced.13649,https://emedicine.medscape.com/article/1118586-treatment#d8,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418989/,,,,,
1207,142,# 223360,Dopamine beta hydroxylase deficiency,,DBH,dopamine beta (β)-hydroxylase,7.6.2.1,droxidopa,,DB06262,,,,,,Functional interaction (Mechanistic B),B,,,,orthostatic hypotension,,HP:0001278,,,https://clinicaltrials.gov/ct2/show/NCT00889135?cond=Dopamine+beta+hydroxylase+deficiency&rank=10,https://onlinelibrary.wiley.com/doi/full/10.1111/ced.13649,https://emedicine.medscape.com/article/1118586-treatment#d8,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418989/,,,,,
1208,143,# 128230,Dopa-responsive dystonia,,GCH1/TH/SPR,GTP cyclohydrolase 1/ tyrosine hydroxylase/sepiapterin reductase,7.6.2.1,levedopa,,DB01235,,,,,,Functional interaction (Mechanistic B),B,,,,Dystonia,,HP:0001332,,,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://onlinelibrary.wiley.com/doi/full/10.1111/ced.13649,https://emedicine.medscape.com/article/1118586-treatment#d8,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418989/,,,,,
1209,,# 128230,Dopa-responsive dystonia,,GCH1/TH/SPR,GTP cyclohydrolase 1/ tyrosine hydroxylase/sepiapterin reductase,7.6.2.1,carbidopa,,DB00190,,,,,,Functional interaction (Mechanistic B),B,,,,,,done,,,https://www.ncbi.nlm.nih.gov/pubmed/16891685,https://onlinelibrary.wiley.com/doi/full/10.1111/ced.13649,https://emedicine.medscape.com/article/1118586-treatment#d8,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418989/,,,,,
1210,,# 128230,Dopa-responsive dystonia,,GCH1/TH/SPR,GTP cyclohydrolase 1/ tyrosine hydroxylase/sepiapterin reductase,7.6.2.1,selegiline+L-dopa,,DB01037+DB01235,,,,,,Functional interaction (Mechanistic B),B,,,,Dystonia,,HP:0001332,,,https://www.ncbi.nlm.nih.gov/pubmed/20399390,https://www.sciencedirect.com/science/article/pii/S0887899410000287?via%3Dihub,https://emedicine.medscape.com/article/1118586-treatment#d8,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5418989/,,,,,
1211,,# 128230,Dopa-responsive dystonia,,GCH1/TH/SPR,GTP cyclohydrolase 1/ tyrosine hydroxylase/sepiapterin reductase,7.6.2.1,,,,,,,,,,,,,,lack of eye contact,,HP:0000817,,,,,,,,,,,
1212,,# 128230,Dopa-responsive dystonia,,GCH1/TH/SPR,GTP cyclohydrolase 1/ tyrosine hydroxylase/sepiapterin reductase,7.6.2.1,,,,,,,,,,,,,,Delayed motor skills,,HP:0002194,,,,,,,,,,,
1213,,# 128230,Dopa-responsive dystonia,,GCH1/TH/SPR,GTP cyclohydrolase 1/ tyrosine hydroxylase/sepiapterin reductase,7.6.2.1,,,,,,,,,,,,,,Lack of head suuport,,,,,,,,,,,,,
1214,,# 128230,Dopa-responsive dystonia,,GCH1/TH/SPR,GTP cyclohydrolase 1/ tyrosine hydroxylase/sepiapterin reductase,7.6.2.1,,,,,,,,,,,,,,Delayed mental development,,HP:0001263,,,,,,,,,,,
1215,,# 128230,Dopa-responsive dystonia,,GCH1/TH/SPR,GTP cyclohydrolase 1/ tyrosine hydroxylase/sepiapterin reductase,7.6.2.1,,,,,,,,,,,,,,lack of gross motor function,,HP:0002194,,,,,,,,,,,
1216,,# 128230,Dopa-responsive dystonia,,GCH1/TH/SPR,GTP cyclohydrolase 1/ tyrosine hydroxylase/sepiapterin reductase,7.6.2.1,5‐hydroxytryptophan,,DB02959,,,,,,Functional interaction (Mechanistic B),B,,,,Depression,,HP:0000716,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2117403/,,,,,,,,
1217,,# 128230,Dopa-responsive dystonia,,GCH1/TH/SPR,GTP cyclohydrolase 1/ tyrosine hydroxylase/sepiapterin reductase,7.6.2.1,,,,,,,,,,,,,,Serotonin deficiency,,HP:0003117*,,,,,,,,,,,
1218,144,# 614921,PGM1-CDG,,PGM1,Phosphoglucomutase-1,5.4.2.2,D-galactose,,DB11735,,,,,,Functional interaction (Mechanistic B),B,,,,"abnormal alanine transaminase,",,HP:0002910,,,https://www.ncbi.nlm.nih.gov/pubmed/28617415,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5675745/,,,,,,,
1219,,# 614921,PGM1-CDG,,PGM1,Phosphoglucomutase-1,5.4.2.2,,,,,,,,,,,,,,abnormal aspartate transaminase,,HP:0002910,,,,,,,,,,,
1220,,# 614921,PGM1-CDG,,PGM1,Phosphoglucomutase-1,5.4.2.2,,,,,,,,,,,,,,abnormal activated partial thromboplastin time,,HP:0003645,,,,,,,,,,,
1221,,# 614921,PGM1-CDG,,PGM1,Phosphoglucomutase-1,5.4.2.2,,,,,,,,,,,,,,abnormal Antithrombin-III levels,,HP:0001976,,,,,,,,,,,
1222,,# 614921,PGM1-CDG,,PGM1,Phosphoglucomutase-1,5.4.2.2,,,,,,,,,,,,,,abnormal nucleotide sugars,,,,,,,,,,,,,
1223,145,# 266265,SLC35C1-CDG (CDG-IIc),,SLC35C1,guanosine 5'-diphosphate (GDP)-fucose transporter,Q96A29,Fucose,,DB03485,,,,,,Functional interaction (Mechanistic B),B,,,,defected phagocytic function,,HP:0010977,,,,,,,,,,,
1224,,# 266265,SLC35C1-CDG (CDG-IIc),,SLC35C1,guanosine 5'-diphosphate (GDP)-fucose transporter,Q96A29,,,,,,,,,,,,,,low neutrophil count,,HP:0001875,,,,,,,,,,,
1225,,# 266265,SLC35C1-CDG (CDG-IIc),,SLC35C1,guanosine 5'-diphosphate (GDP)-fucose transporter,Q96A29,,,,,,,,,,,,,,recurrent infection,,HP:0002719,,,,,,,,,,,
1226,,# 266265,SLC35C1-CDG (CDG-IIc),,SLC35C1,guanosine 5'-diphosphate (GDP)-fucose transporter,Q96A29,,,,,,,,,,,,,,abnormal expression of E- and P-selectin ligands,,NA,,,,,,,,,,,
1227,,# 266265,SLC35C1-CDG (CDG-IIc),,SLC35C1,guanosine 5'-diphosphate (GDP)-fucose transporter,Q96A29,,,,,,,,,,,,,,atypical psychomotor development,,HP:0001263*,,,,,,,,,,,
1228,146,# 610768,DOLK-CDG,,DOLK,dolichol kinase,Q96A29,vigabatrin,,DB01080,,,,,,Symptomatic (C),C,,,,seizures,,HP:0001250,,,https://www.sciencedirect.com/science/article/pii/S1096719213002278?via%3Dihub,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5983582/,,,,,,,
1229,,# 610768,DOLK-CDG,,DOLK,dolichol kinase,Q96A29,clonazepam,,DB01068,,,,,,Symptomatic (C),C,,,,,,done,,,https://www.sciencedirect.com/science/article/pii/S1096719213002278?via%3Dihub,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5983582/,,,,,,,
1230,147,# 610768,Dipsogenic diabetes insipidus,,???,??,Q96A29,desmopressin,,DB00035,,,,,,Symptomatic (C),C,,,,polyuria,,HP:0000103,,,https://www.ncbi.nlm.nih.gov/pubmed/16544179,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5983582/,,,,,,,
1231,,# 610768,Dipsogenic diabetes insipidus,,???,??,Q96A29,,,,,,,,,,,,,,affected functional activity,,HP:0025142*,,,,,,,,,,,
1232,148,# 274270,Dihydropyrimidine dehydrogenase (DPD) deficiency,,DPYD,dihydropyrimidine dehydrogenase,Q96A29,uridine triacetate,,DB09144,,,,,,Functional interaction(Mechanistic B),B,,,,,,done,,,https://www.sciencedirect.com/science/article/pii/S0041008X18302709?via%3Dihub,,,,,,,,
1233,,# 274270,Dihydropyrimidine dehydrogenase (DPD) deficiency,,DPYD,dihydropyrimidine dehydrogenase,Q96A29,,,,,,,,,,,,,,developmental delay,,HP:0001263,,,https://link.springer.com/chapter/10.1007%2F8904_2017_14,https://link.springer.com/chapter/10.1007%2F8904_2017_14,,,,,,,
1234,149,# 261630,Dihydropteridine reductase deficiency,,QDPR,quinoid dihydropteridine reductase,Q96A29,BH4,,DB00360,,,,,,Functional interaction (Mechanistic B),B,,,,developmental delay,,HP:0001263,,,https://www.ncbi.nlm.nih.gov/pubmed/23430801,https://www.ncbi.nlm.nih.gov/pubmed/26817292,,,,,,,
1235,,# 261630,Dihydropteridine reductase deficiency,,QDPR,quinoid dihydropteridine reductase,Q96A29,folinic acid,,DB00650,,,,,,Functional interaction (Mechanistic B),B,,,,receptive language abnormality,,HP:0010863*,,,https://www.ncbi.nlm.nih.gov/pubmed/23430801,https://www.ncbi.nlm.nih.gov/pubmed/26817292,,,,,,,
1236,,# 261630,Dihydropteridine reductase deficiency,,QDPR,quinoid dihydropteridine reductase,Q96A29,L-dopa,,DB01235,,,,,,Functional interaction (Mechanistic B),B,,,,unalertencess,,HP:0002329*,,,https://www.ncbi.nlm.nih.gov/pubmed/23430801,https://www.ncbi.nlm.nih.gov/pubmed/26817292,,,,,,,
1237,,# 261630,Dihydropteridine reductase deficiency,,QDPR,quinoid dihydropteridine reductase,Q96A29,carbidopa,,DB00190,,,,,,Functional interaction (Mechanistic B),B,,,,unresponsiveness,,HP:0004372,,,https://www.ncbi.nlm.nih.gov/pubmed/23430801,https://www.ncbi.nlm.nih.gov/pubmed/26817292,,,,,,,
1238,,# 261630,Dihydropteridine reductase deficiency,,QDPR,quinoid dihydropteridine reductase,Q96A29,5-hydroxytryptophan,,DB02959,,,,,,Functional interaction (Mechanistic B),B,,,,abnormal blood Phe levels,,HP:0010893,,,https://www.ncbi.nlm.nih.gov/pubmed/23430801,https://www.ncbi.nlm.nih.gov/pubmed/26817292,,,,,,,
1239,,# 261630,Dihydropteridine reductase deficiency,,QDPR,quinoid dihydropteridine reductase,Q96A29,entacapone,,DB00494,,,,,,Supportive (C),C,,,,high plasma phenylalanine level,,HP:0004923,,,https://www.ncbi.nlm.nih.gov/pubmed/23430801,https://www.ncbi.nlm.nih.gov/pubmed/26817292,,,,,,,
1240,,# 261630,Dihydropteridine reductase deficiency,,QDPR,quinoid dihydropteridine reductase,Q96A29,selegiline,,DB01037,,,,,,Supportive (C),C,,,,,,done,,,https://www.ncbi.nlm.nih.gov/pubmed/23430801,https://www.ncbi.nlm.nih.gov/pubmed/26817292,,,,,,,
1241,,# 261630,Dihydropteridine reductase deficiency,,QDPR,quinoid dihydropteridine reductase,Q96A29,pramipexole,,DB00413,,,,,,Supportive (C),C,,,,dopamine deficiency,,HP:0012656,,,https://www.ncbi.nlm.nih.gov/pubmed/22325981,https://www.sciencedirect.com/science/article/pii/S1096719212000170?via%3Dihub,https://www.sciencedirect.com/science/article/pii/S0022510X16303495?via%3Dihub,,,,,,
1242,,# 261630,Dihydropteridine reductase deficiency,,QDPR,quinoid dihydropteridine reductase,Q96A29,,,,,,,,,,,,,,movement disability,,HP:0100022,,,,,,,,,,,
1243,,# 261630,Dihydropteridine reductase deficiency,,QDPR,quinoid dihydropteridine reductase,Q96A29,,,,,,,,,,,,,,behavioral disability,,HP:0000708,,,,,,,,,,,
1244,,# 261630,Dihydropteridine reductase deficiency,,QDPR,quinoid dihydropteridine reductase,Q96A29,,,,,,,,,,,,,,hyperprolactinemia,,HP:0000870,,,,,,,,,,,
1245,,# 261630,Dihydropteridine reductase deficiency,,QDPR,quinoid dihydropteridine reductase,Q96A29,rotigotine,,DB05271,,,,,,Functional interaction (B),B,,,,parkinsonian symptoms,,HP:0001300,,,https://www.sciencedirect.com/science/article/pii/S0022510X16303495?via%3Dihub,,,,,,,,
1246,150,# 222748,Dihydropyrimidinase deficiency,,DPYS,dihydropyrimidinase,Q96A29,NA,,DB05271,,,,,,,,,,,,,done,,,https://www.sciencedirect.com/science/article/pii/S0022510X16303495?via%3Dihub,,,,,,,,
1247,151,# 246900,Dihydrolipoamide dehydrogenase deficiency,,DLD,dihydrolipoamide dehydrogenase,Q96A29,Riboflavin,,DB00140,,,,,,Direct interaction ( Mechanistic A),A,,,,exercise intolerance,,HP:0003546,,,https://www.ncbi.nlm.nih.gov/pubmed/25251739,https://www.sciencedirect.com/science/article/pii/S1567724914001299?via%3Dihub,,,,,,,
1248,,# 246900,Dihydrolipoamide dehydrogenase deficiency,,DLD,dihydrolipoamide dehydrogenase,Q96A29,biotin,,DB00121,,,,,,Supportive (C),C,,,,mitochondrial proliferation in the muscle.,,HP:0003200,,,https://www.ncbi.nlm.nih.gov/pubmed/25251739,https://www.sciencedirect.com/science/article/pii/S1567724914001299?via%3Dihub,,,,,,,
1249,,# 246900,Dihydrolipoamide dehydrogenase deficiency,,DLD,dihydrolipoamide dehydrogenase,Q96A29,coenzyme Q,,DB09270,,,,,,Supportive (C),C,,,,myopathy,,HP:0003198,,,https://www.ncbi.nlm.nih.gov/pubmed/25251739,https://www.sciencedirect.com/science/article/pii/S1567724914001299?via%3Dihub,,,,,,,
1250,,# 246900,Dihydrolipoamide dehydrogenase deficiency,,DLD,dihydrolipoamide dehydrogenase,Q96A29,carnitine,,DB00148,,,,,,Supportive (C),C,,,,high lactic acid level,,HP:0003648,,,https://www.ncbi.nlm.nih.gov/pubmed/25251739,https://www.sciencedirect.com/science/article/pii/S1567724914001299?via%3Dihub,,,,,,,
1251,,# 246900,Dihydrolipoamide dehydrogenase deficiency,,DLD,dihydrolipoamide dehydrogenase,Q96A29,Thiamine,,DB00152,,,,,,Supportive (C),C,,,,recurrent vomiting,,HP:0002572,,,https://www.ncbi.nlm.nih.gov/books/NBK220444/,https://www.sciencedirect.com/science/article/pii/S1567724914001299?via%3Dihub,,,,,,,
1252,,# 246900,Dihydrolipoamide dehydrogenase deficiency,,DLD,dihydrolipoamide dehydrogenase,Q96A29,sodium dichloroacetate,,DB08809,,,,,,Supportive (C),C,,,,muscle weakness,,HP:0001324,,,https://www.ncbi.nlm.nih.gov/pubmed/23478190,https://www.ncbi.nlm.nih.gov/books/NBK220444/,,,,,,,
1253,,# 246900,Dihydrolipoamide dehydrogenase deficiency,,DLD,dihydrolipoamide dehydrogenase,Q96A29,,,,,,,,,,,,,,Encephalopathy,,HP:0001298,,,,,,,,,,,
1254,,# 246900,Dihydrolipoamide dehydrogenase deficiency,,DLD,dihydrolipoamide dehydrogenase,Q96A29,Lipoic acid,,DB00166,,,,,,Symptomatic (C),C,,,,lactic acidemia,,HP:0003128*,,,,,,,,,,,
1255,,# 246900,Dihydrolipoamide dehydrogenase deficiency,,DLD,dihydrolipoamide dehydrogenase,Q96A29,,,,,,,,,,,,,,pyruvic acidemia,,HP:0001941,,,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024040/,,,,,,
1256,152,# 222730,Dicarboxylic aminoaciduria,,SLC1A1,solute carrier family 1 member 1,Q96A29,NA,,,,,,,,,,,,,,,done,,,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024040/,,,,,,
1257,154,# 125370,Dentatorubral-pallidoluysian atrophy,,ATN1,atrophin 1,Q96A29,levetiracetam,,DB01202,,,,,,Symptomatic (C),C,,,,Epileptic seizures,,HP:0001250,,,https://www.ncbi.nlm.nih.gov/pubmed/25558587,https://www.ncbi.nlm.nih.gov/pubmed/24816443,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024040/,,,,,,
1258,,# 125370,Dentatorubral-pallidoluysian atrophy,,ATN1,atrophin 1,Q96A29,olanzapine,,DB00334,,,,,,Symptomatic (C),C,,,,psychosis,,HP:0000709,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953024/,https://www.ncbi.nlm.nih.gov/pubmed/24816443,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024040/,,,,,,
1259,,# 125370,Dentatorubral-pallidoluysian atrophy,,ATN1,atrophin 1,Q96A29,haloperidol,,DB00502,,,,,,Symptomatic (C),C,,,,hallucinatory-paranoid state,,HP:0011999*,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953024/,https://www.ncbi.nlm.nih.gov/pubmed/24816443,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024040/,,,,,,
1260,,# 125370,Dentatorubral-pallidoluysian atrophy,,ATN1,atrophin 1,Q96A29,levomepromazine,,DB01403,,,,,,Symptomatic (C),C,,,,auditory hallucinations,,HP:0008765,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953024/,https://www.ncbi.nlm.nih.gov/pubmed/24816443,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3024040/,,,,,,
1261,,# 125370,Dentatorubral-pallidoluysian atrophy,,ATN1,atrophin 1,Q96A29,,,,,,,,,,,,,,elicited hyperactivity,,HP:0000752,,,,,,,,,,,
1262,,# 125370,Dentatorubral-pallidoluysian atrophy,,ATN1,atrophin 1,Q96A29,perampanel,,DB08883,,,,,,Symptomatic (C),C,,,,Diminished intellectual abilities,,HP:0001249,,,,,,,,,,,
1263,,# 125370,Dentatorubral-pallidoluysian atrophy,,ATN1,atrophin 1,Q96A29,,,,,,,,,,,,,,myoclonic seizures,,HP:0002123,,,,,,,,,,,
1264,,# 125370,Dentatorubral-pallidoluysian atrophy,,ATN1,atrophin 1,Q96A29,,,,,,,,,,,,,,inability to walk,,HP:0002540,,,,,,,,,,,
1265,155,# 602398,Desmosterolosis,,DHCR24,3-beta-hydroxysterol delta-24-reductase,Q96A29,riboflavin,,DB00140,,,,,,Functional interaction(Mechanistic B),B,,,,High desmosterol levels (Abnormality of cholesterol metabolism)*,,HP:0003107*,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995031/,,,,,,,,
1266,,# 602398,Desmosterolosis,,DHCR24,3-beta-hydroxysterol delta-24-reductase,Q96A29,nicotinamide,,DB02701,,,,,,Functional interaction(Mechanistic B),B,,,,High desmosterol/cholesterol ratio (Abnormality of cholesterol metabolism)*,,HP:0003107*,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995031/,,,,,,,,
1267,,# 602398,Desmosterolosis,,DHCR24,3-beta-hydroxysterol delta-24-reductase,Q96A29,thiamine,,DB00152,,,,,,Functional interaction(Mechanistic B),B,,,,,,done,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995031/,,,,,,,,
1268,,# 602398,Desmosterolosis,,DHCR24,3-beta-hydroxysterol delta-24-reductase,Q96A29,cholesterol,,DB04540,,,,,,Functional interaction(Mechanistic B),B,,,,High desmosterol levels (Abnormality of cholesterol metabolism)*,,HP:0003107*,,,https://jhu.pure.elsevier.com/en/publications/inborn-errors-of-cholesterol-biosynthesis-6,,,,,,,,
1269,156,# 105650,Diamond-Blackfan anemia,,"RPS19, RPL5,  RPS10, RPL11, RPL35A, RPS7,  RPS17, RPS24,  RPS26 and GATA1",40S ribosomal protein S19,P39019,L-leucine,,DB00149,ECO:0007121/ECO:0005542/ECO:0000352,,,,,Functional interaction(Mechanistic B),B,,,,low heamoglobin leval,,HP:0001903,,,https://clinicaltrials.gov/ct2/show/NCT02386267?cond=Diamond-Blackfan+anemia&draw=2&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/22734070,https://www.ncbi.nlm.nih.gov/pubmed/25098371,https://www.ncbi.nlm.nih.gov/pubmed/17562599,https://www.ncbi.nlm.nih.gov/pubmed/22791294,,,,
1270,,# 105650,Diamond-Blackfan anemia,,"RPS19, RPL5,  RPS10, RPL11, RPL35A, RPS7,  RPS17, RPS24,  RPS26 and GATA1",40S ribosomal protein S19,P39019,,,,,,,,,,,,,,Defect in protein synthesis (Abnormality of circulating protein level)*,,HP:0010876*,,,,,,,,,,,
1271,,# 105650,Diamond-Blackfan anemia,,"RPS19, RPL5,  RPS10, RPL11, RPL35A, RPS7,  RPS17, RPS24,  RPS26 and GATA1",40S ribosomal protein S19,P39019,,,,,,,,,,,,,,Decreased red blood cell production,,HP:0012133*,,,https://clinicaltrials.gov/ct2/show/NCT01362595?cond=Diamond-Blackfan+anemia&rank=4,,,,,,,,
1272,,# 105650,Diamond-Blackfan anemia,,"RPS19, RPL5,  RPS10, RPL11, RPL35A, RPS7,  RPS17, RPS24,  RPS26 and GATA1",40S ribosomal protein S19,P39019,Antithymocyte globulin+Cyclosporine,,DB00098+DB00091,ECO:0007121,,,,,Symptomatic (C),C,,,In other blood/bone marrow disorders of immune etiology these drugs have synergistic effects. We propose a Phase II study to explore the combined use of ATG and cyclosporine as a rational approach to the treatment of Diamond Blackfan anemia. No results were posted in the website to tell what was the actual responce to the treatment. https://clinicaltrials.gov/ct2/show/NCT00001749,Pure red bllod cell aplasia,,HP:0012410,,,https://clinicaltrials.gov/ct2/show/NCT00001749,,,,,,,,
1273,,# 105650,Diamond-Blackfan anemia,,"RPS19, RPL5,  RPS10, RPL11, RPL35A, RPS7,  RPS17, RPS24,  RPS26 and GATA1",40S ribosomal protein S19,P39019,Rituximab,,DB00073,ECO:0007121,,,,,Symptomatic (C),C,,,,low RBC count,,HP:0001877,,,https://clinicaltrials.gov/ct2/show/study/NCT00229619?cond=Diamond-Blackfan+anemia&rank=7&sect=X70156,,,,,,,,
1274,,# 105650,Diamond-Blackfan anemia,,"RPS19, RPL5,  RPS10, RPL11, RPL35A, RPS7,  RPS17, RPS24,  RPS26 and GATA1",40S ribosomal protein S19,P39019,Daclizumab,,DB00111,ECO:0007121,,,,,Symptomatic (C),C,,,,NA,,,,,https://clinicaltrials.gov/ct2/show/results/NCT00001962?cond=Diamond-Blackfan+anemia&rank=8&sect=X70156#outcome1,,,,,,,,
1275,,# 105650,Diamond-Blackfan anemia,,"RPS19, RPL5,  RPS10, RPL11, RPL35A, RPS7,  RPS17, RPS24,  RPS26 and GATA1",40S ribosomal protein S19,P39019,lenalidomide,,DB00480,ECO:0007121,,,,,Symptomatic (C),C,,,,,,done,,,https://clinicaltrials.gov/ct2/show/NCT01034592?cond=Diamond-Blackfan+anemia&rank=9,,,,,,,,
1276,,# 105650,Diamond-Blackfan anemia,,"RPS19, RPL5,  RPS10, RPL11, RPL35A, RPS7,  RPS17, RPS24,  RPS26 and GATA1",40S ribosomal protein S19,P39019,prednisolone,,DB00635,ECO:0000352,,,,,Functional interaction(Mechanistic B),B,,,,low hb level,,HP:0001903,https://link.springer.com/article/10.1007%2Fs12185-016-2044-9,https://www.ncbi.nlm.nih.gov/pubmed/?term=Clinical+features%2C+mutations+and+treatment+of+104+patients+of+Diamond-Blackfan+anemia+in+China%3A+a+single-center+retrospective+study,http://www.ncbi.nlm.nih.gov/pubmed/26758319?dopt=Abstract,http://www.ncbi.nlm.nih.gov/pubmed/26305041?dopt=Abstract,https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.13632,,,,,,
1277,,# 105650,Diamond-Blackfan anemia,,"RPS19, RPL5,  RPS10, RPL11, RPL35A, RPS7,  RPS17, RPS24,  RPS26 and GATA1",40S ribosomal protein S19,P39019,,,,,,,,,,,,,,low quality of ife,,HP:0025142*,,,,,,,,,,,
1278,,# 105650,Diamond-Blackfan anemia,,"RPS19, RPL5,  RPS10, RPL11, RPL35A, RPS7,  RPS17, RPS24,  RPS26 and GATA1",40S ribosomal protein S19,P39019,,,,,,,,,,,,,,Pathological apoptosis,,NA,,,,,,,,,,,
1279,,# 105650,Diamond-Blackfan anemia,,"RPS19, RPL5,  RPS10, RPL11, RPL35A, RPS7,  RPS17, RPS24,  RPS26 and GATA1",40S ribosomal protein S19,P39019,,,,,,,,,,,,,,erythroid progenitor depletion,,HP:0025034*,,,,,,,,,,,
1280,,# 105650,Diamond-Blackfan anemia,,"RPS19, RPL5,  RPS10, RPL11, RPL35A, RPS7,  RPS17, RPS24,  RPS26 and GATA1",40S ribosomal protein S19,P39019,,,,,,,,,,,,,,premature differentiation of erythroid cells,,HP:0012130*,,,,,,,,,,,
1281,,# 105650,Diamond-Blackfan anemia,,"RPS19, RPL5,  RPS10, RPL11, RPL35A, RPS7,  RPS17, RPS24,  RPS26 and GATA1",40S ribosomal protein S19,P39019,Prednisone +Cyclosporine,,DB00635+DB00091,ECO:0000352,,,,,Functional interaction(Mechanistic B),B,,,,low Hb level,,HP:0001903,https://link.springer.com/article/10.1007%2Fs12185-016-2044-9,,,,,,,,,,
1282,,# 105650,Diamond-Blackfan anemia,,"RPS19, RPL5,  RPS10, RPL11, RPL35A, RPS7,  RPS17, RPS24,  RPS26 and GATA1",40S ribosomal protein S19,P39019,Metoclopramide,,DB01233,ECO:0000352,,,,,Functional interaction(Mechanistic B),,,,,low Hb level,,HP:0001903,https://www.ncbi.nlm.nih.gov/pubmed/15795909,https://www.ncbi.nlm.nih.gov/pubmed/12351372/,https://www.ncbi.nlm.nih.gov/pubmed/17921858/,https://www.ncbi.nlm.nih.gov/pubmed/24744655,,,,,,,
1283,,# 105650,Diamond-Blackfan anemia,,"RPS19, RPL5,  RPS10, RPL11, RPL35A, RPS7,  RPS17, RPS24,  RPS26 and GATA1",40S ribosomal protein S19,P39019,,,,,,,,,,,,,,Reduced hematocrit,,HP:0031851,,,,,,,,,,,
1284,,# 105650,Diamond-Blackfan anemia,,"RPS19, RPL5,  RPS10, RPL11, RPL35A, RPS7,  RPS17, RPS24,  RPS26 and GATA1",40S ribosomal protein S19,P39019,Metoclopramide+prednisolone,,DB01233+DB00635,ECO:0000352,,,,,,,,,,low Hb level,,HP:0001903,https://www.ncbi.nlm.nih.gov/pubmed/24744655,,,,,,,,,,
1285,,# 105650,Diamond-Blackfan anemia,,"RPS19, RPL5,  RPS10, RPL11, RPL35A, RPS7,  RPS17, RPS24,  RPS26 and GATA1",40S ribosomal protein S19,P39019,Eltrombopag,,DB06210,ECO:0007121,,,,,Functional interaction(Mechanistic B),,,,,low Hb level,,HP:0001903,http://www.bloodjournal.org/content/128/22/2682,https://clinicaltrials.gov/ct2/show/NCT01328587,,,,,,,,,
1286,,# 105650,Diamond-Blackfan anemia,,"RPS19, RPL5,  RPS10, RPL11, RPL35A, RPS7,  RPS17, RPS24,  RPS26 and GATA1",40S ribosomal protein S19,P39019,,,,,,,,,,,,,,Thrombocytopenia,,HP:0001873,,,,,,,,,,,
1287,157,# 258870,Gyrate atrophy of the choroid and retina,,OAT,ornithine aminotransferase,2.6.1.13,vitamin B6,,DB00165,ECO:0000352,,,,,Functional interaction(Mechanistic B),B,,,,high ornithine level,,HP:0012026,https://www.ncbi.nlm.nih.gov/pubmed/29757052,,,https://www.ncbi.nlm.nih.gov/pubmed/24082780,https://www.ncbi.nlm.nih.gov/pubmed/29654911,,,,,,
1288,,# 258870,Gyrate atrophy of the choroid and retina,,OAT,ornithine aminotransferase,2.6.1.13,lysine supplementation,,DB00123,ECO:0000352,,,,,Symptomatic (C),C,,,,cystoid macular edema,,HP:0011505,https://link.springer.com/content/pdf/10.1023%2FA%3A1010545811361.pdf,,,https://www.ncbi.nlm.nih.gov/pubmed/28388263?dopt=Abstract,,,,,,,
1289,,# 258870,Gyrate atrophy of the choroid and retina,,OAT,ornithine aminotransferase,2.6.1.13,,,,,,,,,,,,,,low visual acuity,,HP:0007663,,,,,,,,,,,
1290,,# 258870,Gyrate atrophy of the choroid and retina,,OAT,ornithine aminotransferase,2.6.1.13,topical NSAIDs +systemic CAI,,DB00586+DB00311,ECO:0000352,,,,,Symptomatic (C),C,,,,cystoid macular edema,,HP:0011505,https://www.ncbi.nlm.nih.gov/pubmed/28708224?dopt=Abstract,,,,,,,,,,
1291,,# 258870,Gyrate atrophy of the choroid and retina,,OAT,ornithine aminotransferase,2.6.1.13,Intravitreal bevacizumab,,DB00112,ECO:0000352,,,,,Symptomatic (C),C,,,,choroidal neovascularization,,HP:0011506,https://www.ncbi.nlm.nih.gov/pubmed/28560651?dopt=Abstract,,,,,,,,,,
1292,,# 258870,Gyrate atrophy of the choroid and retina,,OAT,ornithine aminotransferase,2.6.1.13,,,,,,,,,,,,,,decreased visual acuity,,HP:0007663,,,,,,,,,,,
1293,,# 258870,Gyrate atrophy of the choroid and retina,,OAT,ornithine aminotransferase,2.6.1.13,,,,,,,,,,,,,,abnormal central vision,,HP:0000504,,,,,,,,,,,
1294,,# 258870,Gyrate atrophy of the choroid and retina,,OAT,ornithine aminotransferase,2.6.1.13,Gene therapy *,,NA,ECO:0007121,,,,,Direct interaction ( Mechanistic A),A,,,,,,done,https://clinicaltrials.gov/ct2/show/NCT00001735?cond=Ornithine+aminotransferase+deficiency&rank=1,,https://clinicaltrials.gov/ct2/show/NCT00001735?cond=Ornithine+aminotransferase+deficiency&rank=1,,,,,,,,
1295,158,# 612736,Guanidinoacetate methyltransferase deficiency,,GAMT,guanidinoacetate methyltransferase,EC 2.1.1.2,creatine-monohydrate,,DB00148,ECO:0000352,,,,,Functional interaction(Mechanistic B),B,,,,Extrapyramidal movement disorders,,HP:0002071,https://www.ncbi.nlm.nih.gov/pubmed/24268530,,https://www.sciencedirect.com/science/article/pii/S1096719213003107,https://www.sciencedirect.com/science/article/pii/S1096719213003661,https://www.ncbi.nlm.nih.gov/pubmed/29506905,https://www.sciencedirect.com/science/article/pii/S1096719212002971,,,,,
1296,,# 612736,Guanidinoacetate methyltransferase deficiency,,GAMT,guanidinoacetate methyltransferase,EC 2.1.1.2,l-ornithine,,DB00129,ECO:0000352,,,,,Functional interaction(Mechanistic B),B,,,,Epileptic seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/11749046,,,,,,,,,,
1297,,# 612736,Guanidinoacetate methyltransferase deficiency,,GAMT,guanidinoacetate methyltransferase,EC 2.1.1.2,,,,,,,,,,,,,,Slow background activity in the EEG(EEG abnormality)*,,HP:0002353*,,,,,,,,,,,
1298,,# 612736,Guanidinoacetate methyltransferase deficiency,,GAMT,guanidinoacetate methyltransferase,EC 2.1.1.2,,,,,,,,,,,,,,Bilateral abnormal signal intensities in the globus pallidus (Abnormality of the globus pallidus)*,,HP:0002453*,,,,,,,,,,,
1299,,# 612736,Guanidinoacetate methyltransferase deficiency,,GAMT,guanidinoacetate methyltransferase,EC 2.1.1.2,sodium benzoate+ornithin +carnitine,"The treatment reduces glycine levels, which reduces production of guanidinoacetate by conjugation and renal excretion however in one study it was mentioned that sodium benzoate did not improve moderate intellectual disability or normalize guanidinoacetate accumulation in the central nervous system.https://www.ncbi.nlm.nih.gov/pubmed/24766785",DB03793,ECO:0000352,,,,,Functional interaction(Mechanistic B),B,,,,High CSF guanidinoacetate levels,,NA,https://www.ncbi.nlm.nih.gov/pubmed/24071436,,,,,,,,,,
1300,,# 612736,Guanidinoacetate methyltransferase deficiency,,GAMT,guanidinoacetate methyltransferase,EC 2.1.1.2,,,,,,,,,,,,,,High plasma guanidinoacetate levels,,NA,https://www.ncbi.nlm.nih.gov/pubmed/24071436,,,,,,,,,,
1301,,# 612736,Guanidinoacetate methyltransferase deficiency,,GAMT,guanidinoacetate methyltransferase,EC 2.1.1.2,Creatine+l-ornithine,This drug combination is accompained by arginine restriction.https://www.ncbi.nlm.nih.gov/pubmed/16855203,,ECO:0000352,,,,,Functional interaction(Mechanistic B),,,,,Epilepsy,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/24268530,,,,,,,,,,
1302,,# 612736,Guanidinoacetate methyltransferase deficiency,,GAMT,guanidinoacetate methyltransferase,EC 2.1.1.2,,,,,,,,,,,,,,low urinary creatine excretion,,HP:0012113,https://www.ncbi.nlm.nih.gov/pubmed/16855203,,,,,,,,,,
1303,,# 612736,Guanidinoacetate methyltransferase deficiency,,GAMT,guanidinoacetate methyltransferase,EC 2.1.1.2,,,,,,,,,,,,,,low brain creatine phosphate,,NA,https://www.ncbi.nlm.nih.gov/pubmed/16855203,,,,,,,,,,
1304,,# 612736,Guanidinoacetate methyltransferase deficiency,,GAMT,guanidinoacetate methyltransferase,EC 2.1.1.2,,,,,,,,,,,,,,low cerebral creatine,,HP:0025051,https://www.ncbi.nlm.nih.gov/pubmed/16855203,,,,,,,,,,
1305,,# 612736,Guanidinoacetate methyltransferase deficiency,,GAMT,guanidinoacetate methyltransferase,EC 2.1.1.2,,,,,,,,,,,,,,High plasma guanidinoacetate levels,,NA,https://www.ncbi.nlm.nih.gov/pubmed/16855203,,,,,,,,,,
1306,,# 612736,Guanidinoacetate methyltransferase deficiency,,GAMT,guanidinoacetate methyltransferase,EC 2.1.1.2,,,,,,,,,,,,,,abnormal coordination of movements,,HP:0011443,https://www.ncbi.nlm.nih.gov/pubmed/24268530,https://www.ncbi.nlm.nih.gov/pubmed/16855203,https://rarediseases.info.nih.gov/diseases/2578/guanidinoacetate-methyltransferase-deficiency,,,,,,,,
1307,,# 612736,Guanidinoacetate methyltransferase deficiency,,GAMT,guanidinoacetate methyltransferase,EC 2.1.1.2,,,,,,,,,,,,,,behavioral abnormalities,,HP:0000708,https://www.ncbi.nlm.nih.gov/pubmed/24268530,https://www.ncbi.nlm.nih.gov/pubmed/16855203,,,,,,,,,
1308,159,# 233910,GTP cyclohydrolase I deficiency,,GCH1,GTP cyclohydrolase 1,3.5.4.16,Tetrahydrobiopterin,,DB00360,ECO:0007121/ECO:0000352,,,,,Functional interaction(Mechanistic B),B,,,Mechanistic (A),high serum phenylalanine,,HP:0004923,https://www.ncbi.nlm.nih.gov/pubmed/9667588,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-005394-35/ES,https://www.sciencedirect.com/science/article/pii/S1096719205003057?via%3Dihub,,,,,,,
1309,,# 233910,GTP cyclohydrolase I deficiency,,GCH1,GTP cyclohydrolase 1,3.5.4.16,L-dopa,,DB01235,ECO:0000352,,,,,Functional interaction(Mechanistic B),B,,,Symptomatic ©,dystonia,,HP:0001332,https://www.ncbi.nlm.nih.gov/pubmed/12391354,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.sciencedirect.com/science/article/pii/S1096719208000048,https://link.springer.com/referenceworkentry/10.1007%2F978-3-540-29676-8_1729,https://www.ncbi.nlm.nih.gov/pubmed/20818608?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/19234759?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/10078749,,,,
1310,,# 233910,GTP cyclohydrolase I deficiency,,GCH1,GTP cyclohydrolase 1,3.5.4.16,benserazide,,DB12783,ECO:0000352,,,,,Symptomatic (C),C,,,,oromandibular dystonia,,HP:0012048,https://www.ncbi.nlm.nih.gov/pubmed/10078749,https://www.ncbi.nlm.nih.gov/pubmed/12003346,,,,,,,,,
1311,,# 233910,GTP cyclohydrolase I deficiency,,GCH1,GTP cyclohydrolase 1,3.5.4.16,5-hydroxytryptophane,,DB04159,ECO:0000352,,,,,Functional interaction(Mechanistic B),B,,,,spasticity,,HP:0001257,,,,,,,,,,,
1312,,# 233910,GTP cyclohydrolase I deficiency,,GCH1,GTP cyclohydrolase 1,3.5.4.16,,,,,,,,,,,,,,abnormal motor development,,HP:0001270,,,,,,,,,,,
1313,,# 233910,GTP cyclohydrolase I deficiency,,GCH1,GTP cyclohydrolase 1,3.5.4.16,,,,,,,,,,,,,,Sleep disturbance,,HP:0002360,,,,,,,,,,,
1314,,# 233910,GTP cyclohydrolase I deficiency,,GCH1,GTP cyclohydrolase 1,3.5.4.16,,,,,,,,,,,,,,Defected neurotransmitter homeostasis in the CNS,,HP:0012535,https://www.ncbi.nlm.nih.gov/pubmed/22729819,,,,,,,,,,
1315,,# 233910,GTP cyclohydrolase I deficiency,,GCH1,GTP cyclohydrolase 1,3.5.4.16,folinic acid,,DB00650,ECO:0000352,,,,,Functional interaction(Mechanistic B),B,,,,depletion of cerebral folate,,HP:0012446,https://www.ncbi.nlm.nih.gov/pubmed/12003346,https://www.ncbi.nlm.nih.gov/pubmed/18276179,,,,,,,,,
1316,,# 233910,GTP cyclohydrolase I deficiency,,GCH1,GTP cyclohydrolase 1,3.5.4.16,,,,,,,,,,,,,,abnormal folate homeostasis in the CNS,,HP:0012335,,,,,,,,,,,
1317,,# 233910,GTP cyclohydrolase I deficiency,,GCH1,GTP cyclohydrolase 1,3.5.4.16,Amantadine,,DB00915,ECO:0000352,,,,,Symptomatic (C),C,,,,levodopa‐induced choreic dyskinesia(Dyskinesia)*,,HP:0100660*,https://www.ncbi.nlm.nih.gov/pubmed/15389992,,,,,,,,,,
1318,169,# 215140,Greenberg dysplasia,,LBR,lamin B receptor,Q14739,No treatment is available in DDIEM,,DB00915,,,,,,,,,,,,,HP:0100660*,https://www.ncbi.nlm.nih.gov/pubmed/15389992,,,,,,,,,,
1319,170,# 603358,GRACILE syndrome,,BCS1L,ubiquinol-cytochrome c reductase complex chaperone,Q9Y276,Sodium bicarbonate,,DB01390,ECO:0000352,,,,,Symptomatic (C),C,,,Symptomatic ©,lactic acidosis,,HP:0003128,https://www.ncbi.nlm.nih.gov/pubmed/15389992,,https://www.ncbi.nlm.nih.gov/pubmed/22970607,https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422,,,,,,,
1320,171,# 609056,GM3 synthase deficiency,,ST3GAL5,"GM3 synthase/sialyltransferase-9/Lactosylceramide alpha-2,3-sialyltransferase",2.4.99.9,Gangliosides,,DB12351,EC0:0007121,,,,,Direct action (Mechanistic A) Replacement,A,,,Mechanistic (A),Delayed Develoment,,HP:0001263,https://www.ncbi.nlm.nih.gov/pubmed/15389992,,https://clinicaltrials.gov/ct2/show/NCT02234024?cond=GM3+synthase+deficiency&rank=1,https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422,,,,,,,
1321,,# 609056,GM3 synthase deficiency,,ST3GAL5,"GM3 synthase/sialyltransferase-9/Lactosylceramide alpha-2,3-sialyltransferase",2.4.99.9,CoQ10,,DB09270,ECO:0000352,,,,,Symptomatic (C),C,,,,defect in eye contect,,HP:0000817,https://www.ncbi.nlm.nih.gov/pubmed/15389992,,https://www.ncbi.nlm.nih.gov/pubmed/22990144,https://www.tandfonline.com/doi/full/10.3109/0886022X.2014.900422,,,,,,,
1322,,# 609056,GM3 synthase deficiency,,ST3GAL5,"GM3 synthase/sialyltransferase-9/Lactosylceramide alpha-2,3-sialyltransferase",2.4.99.9,,,,,,,,,,,,,,abnormal interactivity,,HP:0012433,,,,,,,,,,,
1323,172,# 230500,GM1 gangliosidosis type 1,,GLB1,beta-galactosidase,EC 3.2.1.23,5aR)-5a-C-Pentyl-4-epi-isofagomine,,NA,ECO:0001565,,,,,Direct interaction ( Mechanistic A),A,,,Mechanistic (B),Neurologic abnormalities,,HP:0000707,,,https://www.ncbi.nlm.nih.gov/pubmed/27750150,,,,,,,,
1324,,# 230500,GM1 gangliosidosis type 1,,GLB1,beta-galactosidase,EC 3.2.1.23,purified recombinant human -GalWT,,NA,ECO:0001565+ECO:0005542,,,,,Direct interaction ( Mechanistic A),A,,,Mechanisitic (A),Decreased beta-galactosidase activity,,HP:0008166,,,https://www.ncbi.nlm.nih.gov/pubmed/26766614,,,,,,,,
1325,173,# 230600,GM1 gangliosidosis type 2,,GLB1,beta-galactosidase,EC 3.2.1.23,6S-NBI-DGJ,,PubChem:CID 76070514,ECO:0001565,,,,,Direct interaction ( Mechanistic A),A,,,Mechanisitic (B),Brain pathology,,HP:0001298,,,https://www.ncbi.nlm.nih.gov/pubmed/23337983?dopt=Abstract,,,,,,,,
1326,174,# 230650,GM1 gangliosidosis type 3,,GLB1,beta-galactosidase,EC 3.2.1.23,Allopregnanolone+2-hydroxypropyl-β-cyclodextrin,,DB11859+DB15146,ECO:0005542,,,,,Symptomativc (C),C,,,Mechanistic (,high intraneuronal GSL storage,,NA,,,https://www.ncbi.nlm.nih.gov/pubmed/19750228?dopt=Abstract,,,,,,,,
1327,,# 230650,GM1 gangliosidosis type 3,,GLB1,beta-galactosidase,EC 3.2.1.23,,,,,,,,,,,,,,elevated intraneuronal cholesterol,,NA,,,,,,,,,,,
1328,,# 230650,GM1 gangliosidosis type 3,,GLB1,beta-galactosidase,EC 3.2.1.23,AAV-treated βgal,,NA,ECO:0005542,,,,,Direct action (Mechanistic A) Replacement,A,,,Mechanisitic(A),Abnormally decreased rate of beta-galactosidase activity,,HP:0008166,,,https://www.ncbi.nlm.nih.gov/pubmed/17164772?dopt=Abstract,,,,,,,,
1329,,# 230650,GM1 gangliosidosis type 3,,GLB1,beta-galactosidase,EC 3.2.1.23,miglustat,,DB00419,ECO:0007121,,,,,Functional interaction(Mechanistic B),B,,,Mechanisitic (B),High ganglioside accumulation,,NA,,,https://clinicaltrials.gov/ct2/show/NCT02030015?cond=GM1+gangliosidosis&rank=1,,,,,,,,
1330,,# 230650,GM1 gangliosidosis type 3,,GLB1,beta-galactosidase,EC 3.2.1.23,,,,,,,,,,,,,,ataxic gait,,HP:0002066,,,,,,,,,,,
1331,175,# 607625,Niemann-Pick disease type C2,,NPC2,NPC2 protein,Q9VQ62,2-hydroxypropyl-beta-cyclodextrin,,DB15146,ECO:0000352,,,,,Functional interaction (B),B,,,Mechanistic (B),Elevated intraneuronal cholesterol (Abnormality of cholesterol metabolism)*,,HP:0003107*,,,https://www.intechopen.com/books/cyclodextrin-a-versatile-ingredient/use-of-2-hydroxypropyl-beta-cyclodextrin-for-niemann-pick-type-c-disease,,,,,,,,
1332,,# 607625,Niemann-Pick disease type C2,,NPC2,NPC2 protein,Q9VQ62,,,,,,,,,,,,,,High intraneuronal GSL storage,,NA,,,,,,,,,,,
1333,,# 607625,Niemann-Pick disease type C2,,NPC2,NPC2 protein,Q9VQ62,,,,,,,,,,,,,,Increased free sphingosine accumulation(Abnormality of lipid metabolism)*,,HP:0003119*,,,,,,,,,,,
1334,176,# 257220,Niemann-Pick disease type C1,,NPC1,NPC intracellular cholesterol transporter 1,Q9VQ62,N-butyldeoxynojirimycin +allopregnanolone,,DB00419 +DB11859,ECO:0005542,,,,,Functional interaction (B),B,,,Mechanistic (B),elevated intraneuronal cholesterol(Abnormality of cholesterol metabolism)*,,HP:0003107*,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2736622/,,,,,,,,
1335,,# 257220,Niemann-Pick disease type C1,,NPC1,NPC intracellular cholesterol transporter 1,Q9VQ62,2-hydroxypropyl-beta-cyclodextrin (Adrabetadex),One of the studies that was carried on mice provides useful information for developing the optimal dosage regimen for HPBCD therapy when administered intravenously to NPC patients.https://www.ncbi.nlm.nih.gov/pubmed/26027824,DB15146,ECO:0007121/ECO:0000352/ECO:0005542,,,,,Functional interaction (B),B,,,,High intraneuronal GSL storage,,NA,,,https://www.ncbi.nlm.nih.gov/pubmed/29429782,https://clinicaltrials.gov/ct2/show/NCT02534844,,,,,,,
1336,,# 257220,Niemann-Pick disease type C1,,NPC1,NPC intracellular cholesterol transporter 1,Q9VQ62,,,,,,,,,,,,,,Increased free sphingosine accumulation(Abnormality of lipid metabolism)*,,HP:0003119*,,,,,,,,,,,
1337,,# 257220,Niemann-Pick disease type C1,,NPC1,NPC intracellular cholesterol transporter 1,Q9VQ62,,,,,,,,,,,,,,Neurodegeneration,,HP:0002180,,,,,,,,,,,
1338,,# 257220,Niemann-Pick disease type C1,,NPC1,NPC intracellular cholesterol transporter 1,Q9VQ62,,,,,,,,,,,,,,Poor swallowing,,HP:0002015,,,https://www.ncbi.nlm.nih.gov/pubmed/29429782,,,,,,,,
1339,,# 257220,Niemann-Pick disease type C1,,NPC1,NPC intracellular cholesterol transporter 1,Q9VQ62,,,,,,,,,,,,,,Cognitive impairment,,HP:0100543,,,https://www.ncbi.nlm.nih.gov/pubmed/29429782,,,,,,,,
1340,,# 257220,Niemann-Pick disease type C1,,NPC1,NPC intracellular cholesterol transporter 1,Q9VQ62,,,,,,,,,,,,,,Fine motor impairment,,HP:0007010,,,https://www.ncbi.nlm.nih.gov/pubmed/29429782,,,,,,,,
1341,,# 257220,Niemann-Pick disease type C1,,NPC1,NPC intracellular cholesterol transporter 1,Q9VQ62,,,,,,,,,,,,,,Liver injury,,HP:0001392,,,https://www.ncbi.nlm.nih.gov/pubmed/26027824,,,,,,,,
1342,,# 257220,Niemann-Pick disease type C1,,NPC1,NPC intracellular cholesterol transporter 1,Q9VQ62,,,,,,,,,,,,,,Cholesterol sequestration (Abnormality of cholesterol metabolism)*,,HP:0003107*,,,https://www.ncbi.nlm.nih.gov/pubmed/26027824,,,,,,,,
1343,,# 257220,Niemann-Pick disease type C1,,NPC1,NPC intracellular cholesterol transporter 1,Q9VQ62,,,,,,,,,,,,,,Reduced life span (Mortality)*,,HP:0040006*,,,https://www.ncbi.nlm.nih.gov/pubmed/26027824,,,,,,,,
1344,,# 257220,Niemann-Pick disease type C1,,NPC1,NPC intracellular cholesterol transporter 1,Q9VQ62,Miglustat + Allopregnanolone+Cyclodextrin,,DB00419+DB11859+CHEBI:23456,ECO:0005542,,,,,Functional interaction(Mechanistic B),B,,,,Motor function impairment,,HP:0002275,,,https://www.ncbi.nlm.nih.gov/pubmed/23948640,,,,,,,,
1345,,# 257220,Niemann-Pick disease type C1,,NPC1,NPC intracellular cholesterol transporter 1,Q9VQ62,,,,,,,,,,,,,,Cerebeller neurodegeneration( neurodegeneration)*,,HP:0002180*,,,https://www.ncbi.nlm.nih.gov/pubmed/25400034,,,,,,,,
1346,,# 257220,Niemann-Pick disease type C1,,NPC1,NPC intracellular cholesterol transporter 1,Q9VQ62,,,,,,,,,,,,,,Abnormality of lipid metabolism,,HP:0003119,,,https://www.ncbi.nlm.nih.gov/pubmed/31248418,,,,,,,,
1347,,# 257220,Niemann-Pick disease type C1,,NPC1,NPC intracellular cholesterol transporter 1,Q9VQ62,,,,,,,,,,,,,,Splenomegaly,,HP:0001744,,,https://www.ncbi.nlm.nih.gov/pubmed/31248418,,,,,,,,
1348,,# 257220,Niemann-Pick disease type C1,,NPC1,NPC intracellular cholesterol transporter 1,Q9VQ62,,,,,,,,,,,,,,Increased number of splenic myeloid cells,,NA,,,https://www.ncbi.nlm.nih.gov/pubmed/31248418,,,,,,,,
1349,,# 257220,Niemann-Pick disease type C1,,NPC1,NPC intracellular cholesterol transporter 1,Q9VQ62,,,,,,,,,,,,,,,,,,,,,,,,,,,
1350,177,# 245010,Haim-Munk syndrome,,CTSC,cathepsin C,Q9VQ62,(Trimethoprim+Sulfamethoxazole)+Acitretin,,(DB00440+DB01015)+DB00459,ECO:0000352,,,,,Symptomatic (C),C,,,Symptomatic ©,Palmoplantar keratoderma,,HP:0000982,,,https://www.ncbi.nlm.nih.gov/pubmed/21393975?dopt=Abstract,,,,,,,,
1351,,# 245010,Haim-Munk syndrome,,CTSC,cathepsin C,Q9VQ62,,,,,,,,,,,,,,Periodontitis,,HP:0000704,,,,,,,,,,,
1352,,# 245010,Haim-Munk syndrome,,CTSC,cathepsin C,Q9VQ62,Acitretin,,DB00459,ECO:0000352,,,,,Symptomatic (C),C,,,,Periodontitis,,HP:0000704,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2897870/,,,,,,,,
1353,,# 245010,Haim-Munk syndrome,,CTSC,cathepsin C,Q9VQ62,etretinate,,DB00926,ECO:0000352,,,,,Symptomatic (C),C,,,,Keratoderma,,HP:0000982,,,https://www.ncbi.nlm.nih.gov/pubmed/10738634/,,,,,,,,
1354,,# 245010,Haim-Munk syndrome,,CTSC,cathepsin C,Q9VQ62,,,,,,,,,,,,,,Aggressive periodontitis(Sever periodontitis),,HP:0000166,,,,,,,,,,,
1355,,# 245010,Haim-Munk syndrome,,CTSC,cathepsin C,Q9VQ62,salicylic acid+urea,,DB00936+DB03904,ECO:0000352,,,,,Symptomatic (C),C,,,,Palmoplantar hyperkeratosis,,HP:0000972,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2897870/,,,,,,,,
1356,178,# 234500,Hartnup disease,,SLC6A19,system B(0) neutral amino acid transporter 1 (B0AT1),Q9VQ62,Niacin,,DB00627,ECO:0000352,,,,,Functional interaction(Mechanistic B),B,,,Mechanistic (A),Chronic diarrhea,,HP:0002028,,,https://www.ncbi.nlm.nih.gov/pubmed/25526748?dopt=Abstract,,,,,,,,
1357,,# 234500,Hartnup disease,,SLC6A19,system B(0) neutral amino acid transporter 1 (B0AT1),Q9VQ62,,,,,,,,,,,,,,Hypoalbuminemia,,HP:0003073,,,,,,,,,,,
1358,,# 234500,Hartnup disease,,SLC6A19,system B(0) neutral amino acid transporter 1 (B0AT1),Q9VQ62,,,,,,,,,,,,,,Exfoliative erythema,,HP:0001019,,,,,,,,,,,
1359,179,# 140350,Hawkinsinuria,,HPD,4-hydroxyphenylpyruvate dioxygenase,Q9VQ62,Ascorbic acid,,DB00126,ECO:0000352,,,,,Direct interaction (Mechanistic A),A,,,,Low activity of the immature 4-HPPD enzyme,,NA,,,https://www.degruyter.com/view/j/jpem.2016.29.issue-1/jpem-2015-0132/jpem-2015-0132.xml,http://www.scielo.br/pdf/jiems/v5/2326-4594-jiems-5-e170016.pdf,,,,,,,
1360,,# 140350,Hawkinsinuria,,HPD,4-hydroxyphenylpyruvate dioxygenase,Q9VQ62,N-acetyl-L-cysteine,,DB06151,ECO:0000352,,,,,Symptomatic (C),C,,,,secondary glutathione deficiency(Abnormality of metabolism/homeostasis)*,,HP:0001939*,,,https://link.springer.com/article/10.1007%2Fs10545-016-9963-8,,,,,,,,
1361,,# 140350,Hawkinsinuria,,HPD,4-hydroxyphenylpyruvate dioxygenase,Q9VQ62,,,,,,,,,,,,,,pyroglutamic aciduria(Organic aciduria)*,,HP:0001992*,,,,,,,,,,,
1362,,# 140350,Hawkinsinuria,,HPD,4-hydroxyphenylpyruvate dioxygenase,Q9VQ62,,,,,,,,,,,,,,metabolic acidosis,,HP:0001942,,,,,,,,,,,
1363,,# 140350,Hawkinsinuria,,HPD,4-hydroxyphenylpyruvate dioxygenase,Q9VQ62,,,,,,,,,,,,,,decreased appetite,,HP:0004396,,,,,,,,,,,
1364,,# 140350,Hawkinsinuria,,HPD,4-hydroxyphenylpyruvate dioxygenase,Q9VQ62,Medium-chain triglyceride oil,,DB13959,ECO:0000352,,,,,Symptomatic (C),C,,,Symptomatic ©,failure to thrive,,HP:0001508,,,https://link.springer.com/article/10.1007%2Fs10545-016-9963-8,,,,,,,,
1365,,# 140350,Hawkinsinuria,,HPD,4-hydroxyphenylpyruvate dioxygenase,Q9VQ62,,,,,,,,,,,,,,growth delay,,HP:0001510,,,,,,,,,,,
1366,,# 140350,Hawkinsinuria,,HPD,4-hydroxyphenylpyruvate dioxygenase,Q9VQ62,,,,,,,,,,,,,,hemolytic anemia,,HP:0001878,,,,,,,,,,,
1367,,# 140350,Hawkinsinuria,,HPD,4-hydroxyphenylpyruvate dioxygenase,Q9VQ62,,,,,,,,,,,,,,low β2 microglobulin/creatinine ratio,,NA,,,,,,,,,,,
1368,,# 140350,Hawkinsinuria,,HPD,4-hydroxyphenylpyruvate dioxygenase,Q9VQ62,phosphate,,DB14573,ECO:0000352,,,,,Symptomatic (C),C,,,,Hypophosphatemia,,HP:0002148,,,https://link.springer.com/article/10.1007%2Fs10545-016-9963-8,,,,,,,,
1369,,# 140350,Hawkinsinuria,,HPD,4-hydroxyphenylpyruvate dioxygenase,Q9VQ62,sodium bicarbonate,,DB01390,ECO:0000352,,,,,Symptomatic (C),C,,,,metabolic acidosis,,HP:0001942,,,,,,,,,,,
1370,,# 140350,Hawkinsinuria,,HPD,4-hydroxyphenylpyruvate dioxygenase,Q9VQ62,Nitisinone (NTBC),,DB00348,ECO:0005542,,,,,Direct interaction (A),A,,,,Extreme frailty (Fatigue)*,,HP:0012378*,,,https://pubs.acs.org/doi/abs/10.1021/bi1008112,https://www.ncbi.nlm.nih.gov/pubmed/20677779,,,,,,,
1371,,# 235200,"HEMOCHROMATOSIS, TYPE 1; HFE1",,HFE,Hereditary hemochromatosis protein,Q30201,Pantoprazole,,DB00213,ECO:0007121,,,,,Symptomatic (C),C,,,,High serum ferritin,,HP:0003281,,,https://clinicaltrials.gov/ct2/show/NCT01524757?cond=Hemochromatosis+type+3&draw=2&rank=7,https://www.ncbi.nlm.nih.gov/pubmed/28624580,,,,,,,
1372,,# 235200,"HEMOCHROMATOSIS, TYPE 1; HFE1",,HFE,Hereditary hemochromatosis protein,Q30201,,,,,,,,,,,,,,,,,,,,,,,,,,,
1373,,# 235200,"HEMOCHROMATOSIS, TYPE 1; HFE1",,HFE,Hereditary hemochromatosis protein,Q30201,,,,,,,,,,,,,,,,,,,,,,,,,,,
1374,180,# 602390,Hemochromatosis type 2,,HJV/HAMP,hemojuvelin/hepcidin,Q30201,Deferoxamine,,DB00746,ECO:0000352,,,,,Symptomatic (C),C,,,,iron overload(Abnormality of iron homeostasis)*,,HP:0011031*,https://www.ncbi.nlm.nih.gov/pubmed/14632789,,https://www.ncbi.nlm.nih.gov/pubmed/17124037,,,,,,,,
1375,,# 602390,Hemochromatosis type 2,,HJV/HAMP,hemojuvelin/hepcidin,Q30201,hepcidin,,NA,ECO:0007764,,,,,Direct interaction ( Mechanistic A),A,,,,Increased plasma iron concentration(Increased serum iron),,HP:0003452,https://www.ncbi.nlm.nih.gov/pubmed/14632789,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895089/,https://www.researchgate.net/publication/314493225_Clinical_management_of_hemochromatosis_current_perspectives,http://www.bloodjournal.org/content/107/7/2952.abstract?ijkey=8710a861648a7799043d81f5a481aa922c2bd6df&keytype2=tf_ipsecsha&sso-checked=true,,,,,,
1376,181,# 604250,Hemochromatosis type 3,,TFR2,transferrin receptor 2,Q30201,Deferoxamine,,DB00746,ECO:0007121,,,,,Symptomatic (C),C,,,Symptomatic ©,iron overload(Abnormality of iron homeostasis)*,,HP:0011031*,https://www.ncbi.nlm.nih.gov/pubmed/14632789,,https://link.springer.com/article/10.1007%2Fs12185-017-2365-3,https://clinicaltrials.gov/ct2/show/NCT00001203,https://www.ncbi.nlm.nih.gov/pubmed/14632789,,,,,,
1377,,# 604250,Hemochromatosis type 3,,TFR2,transferrin receptor 2,Q30201,hepcidin,,NA,ECO:0007764,,,,,Functional interaction(Mechanistic B),B,,,,Increased plasma iron concentration(Increased serum iron),,HP:0003452,https://www.ncbi.nlm.nih.gov/pubmed/14632789,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1895089/,https://clinicaltrials.gov/ct2/show/NCT00001203,https://www.ncbi.nlm.nih.gov/pubmed/14632789,,,,,,
1378,,# 604250,Hemochromatosis type 3,,TFR2,transferrin receptor 2,Q30201,LJPC-401(Synthetic human hepcidin),,NA,ECO:0007121,,,,,Functional interaction (B),B,,,,High serum iron,,HP:0003452,https://www.ncbi.nlm.nih.gov/pubmed/14632789,,https://clinicaltrials.gov/ct2/show/NCT03395704?cond=Hemochromatosis+type+3&draw=2&rank=13,https://clinicaltrials.gov/ct2/show/NCT00001203,https://www.ncbi.nlm.nih.gov/pubmed/14632789,,,,,,
1379,,# 604250,Hemochromatosis type 3,,TFR2,transferrin receptor 2,Q30201,Deferiprone (L1),,DB08826,ECO:0007121,,,,,Symptomatic (C),C,,,,elevated liver iron concentration,,HP:0040134,,,https://clinicaltrials.gov/ct2/show/NCT00350662?cond=Hemochromatosis+type+3&draw=4&rank=23,https://clinicaltrials.gov/ct2/show/NCT00733811?cond=Hemochromatosis+type+3&draw=5&rank=39,,,,,,,
1380,,# 604250,Hemochromatosis type 3,,TFR2,transferrin receptor 2,Q30201,Nifedipine,,DB01115,ECO:0007121,,,,,Symptomatic (C),C,,,,iron overload(Abnormality of iron homeostasis)*,,HP:0011031*,,,https://clinicaltrials.gov/ct2/show/NCT00712738?cond=Hemochromatosis+type+3&draw=4&rank=30,,,,,,,,
1381,,# 604250,Hemochromatosis type 3,,TFR2,transferrin receptor 2,Q30201,flavanols,,NA,ECO:0007121,,,,,Symptomatic (C),C,,,,iron overload(Abnormality of iron homeostasis)*,,HP:0011031*,,,https://clinicaltrials.gov/ct2/show/NCT03453918?cond=Hemochromatosis+type+3&draw=5&rank=34,,,,,,,,
1382,183,* 151670,Hepatic lipase deficiency,,LIPC,hepatic lipase,3.1.1.3,Rosuvastatin therapy (20 mg per day) could be used as a preventive therapy.https://www.ncbi.nlm.nih.gov/pubmed/22798447,Rosuvastatin therapy (20 mg per day) could be used as a preventive therapy,DB01098,ECO:0000352,,,,,Symptomatic(C),C,,,Symptomatic ©,High atherogenic lipoprotein(Abnormality of lipid metabolism)*,,HP:0003119*,https://www.ncbi.nlm.nih.gov/pubmed/22798447,,http://www.malacards.org/card/hepatic_lipase_deficiency,,,,,,,,
1383,,* 151670,Hepatic lipase deficiency,,LIPC,hepatic lipase,3.1.1.3,,,,,,,,,,,,,,High low-density lipoprotein (LDL)-C(Abnormality of lipid metabolism)*,,HP:0003119*,,,,,,,,,,,
1384,,* 151670,Hepatic lipase deficiency,,LIPC,hepatic lipase,3.1.1.3,,,,,,,,,,,,,,High Apolipoprotein B (ApoB)(Abnormality of lipid metabolism)*,,HP:0003119*,,,,,,,,,,,
1385,184,* 613521,Hepatoerythropoietic porphyria,,UROD,uroporphyrinogen decarboxylase,4.1.1.37,Hemin,,DB03404,ECO:0005542/ECO:0001565,,,,,Functional interaction (mechanistic B),B,,,,Acute episodic abdominal pain,,HP:0002574,https://www.ncbi.nlm.nih.gov/pubmed/24652768,,,,,,,,,,
1386,,* 613521,Hepatoerythropoietic porphyria,,UROD,uroporphyrinogen decarboxylase,4.1.1.37,,,,,,,,,,,,,,Low pancreatic zymogens,,NA,,,,,,,,,,,
1387,,# 176100,"PORPHYRIA CUTANEA TARDA,susceptability to",,HFE,Hereditary hemochromatosis protein,Q30201,Chloroquine,,DB00608,ECO:0000352,C282Y/H63D  heterozygosity or compound heterozygosity,,C282Y(Homozygous mutation),https://www.ncbi.nlm.nih.gov/pubmed/12622622,Functional interaction (mechanistic B),,,,,Increased liver protoporphyrin concentration (Abnormality of the heme biosynthetic pathway)*,,HP:0010472*,https://www.ncbi.nlm.nih.gov/pubmed/12622622,https://www.ncbi.nlm.nih.gov/pubmed/5080345,https://www.ncbi.nlm.nih.gov/pubmed/7324107,,,,,,,,
1388,,# 176100,"PORPHYRIA CUTANEA TARDA,susceptability to",,HFE,Hereditary hemochromatosis protein,Q30201,,,,,,,,,,,,,,Increased liver iron level,,HP:0012465,https://www.ncbi.nlm.nih.gov/pubmed/5080345,https://www.sciencedirect.com/science/article/pii/S0022202X15441491,,,,,,,,,
1389,,# 176100,"PORPHYRIA CUTANEA TARDA,susceptability to",,HFE,Hereditary hemochromatosis protein,Q30201,,,,,,,,,,,,,,Abnormal liver function,,HP:0002910,https://www.ncbi.nlm.nih.gov/pubmed/4739135,,,,,,,,,,
1390,,# 176100,"PORPHYRIA CUTANEA TARDA,susceptability to",,HFE,Hereditary hemochromatosis protein,Q30201,,,,,,,,,,,,,,Increased serum ferritin,,HP:0003281,https://www.ncbi.nlm.nih.gov/pubmed/4739135,,,,,,,,,,
1391,,# 176100,"PORPHYRIA CUTANEA TARDA,susceptability to",,HFE,Hereditary hemochromatosis protein,Q30201,,,,,,,,,,,,,,Elevated transferrin saturation,,HP:0012463,https://www.ncbi.nlm.nih.gov/pubmed/4739135,,,,,,,,,,
1392,,# 176100,"PORPHYRIA CUTANEA TARDA,susceptability to",,HFE,Hereditary hemochromatosis protein,Q30201,,,,,,,,,,,,,,Increased serum iron,,HP:0003452,,,,,,,,,,,
1393,185,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,asfotase alfa,,DB09105,ECO:0007121,,,,,Direct interaction ( Mechanistic A),A,,,,Defect of bone mineralisation,,HP:0004348,https://www.ncbi.nlm.nih.gov/pubmed/29405935?dopt=Abstract,https://www.sciencedirect.com/science/article/pii/S0929693X18300174?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/30811537,,,,,,,,
1394,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,,,,,,,,,,,,,growth delay,,HP:0001510,https://www.ncbi.nlm.nih.gov/pubmed/29405935?dopt=Abstract,https://www.sciencedirect.com/science/article/pii/S0929693X18300174?via%3Dihub,,,,,,,,,
1395,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,,,,,,,,,,,,,poor skeletal mineralization,,HP:0006462,https://www.ncbi.nlm.nih.gov/pubmed/30083035,,,,,,,,,,
1396,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,,,,,,,,,,,,,respiratory insufficiency,,HP:0002093,https://www.ncbi.nlm.nih.gov/pubmed/30083035,,,,,,,,,,
1397,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,,,,,,,,,,,,,rickets,,HP:0002748,https://cdn.intechopen.com/pdfs/56869.pdf,,,,,,,,,,
1398,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,,,,,,,,,,,,,gross motor dysfunction,,HP:0007015,https://www.ncbi.nlm.nih.gov/pubmed/26744272?dopt=Abstract,,,,,,,,,,
1399,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,,,,,,,,,,,,,fine motor dysfunction,,HP:0007010,,,,,,,,,,,
1400,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,,,,,,,,,,,,,cognitive impairment,,HP:0100543,,,,,,,,,,,
1401,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,,,,,,,,,,,,,muscle weakness,,HP:0001324,,,,,,,,,,,
1402,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,,,,,,,,,,,,,fatigue,,HP:0012378,,,,,,,,,,,
1403,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,,,,,,,,,,,,,delayed growth(stature),,HP:0000002,,,,,,,,,,,
1404,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,Vitamin D,Vitamin D should be given to target the lower limit of the normal range for 25-OH-vitamin D (about 20 ng/mL).,DB11094,,,,,,Direct interaction ( Mechanistic A),A,,,,secondary hyperparathyrodism,,HP:0000867,https://cdn.intechopen.com/pdfs/56869.pdf,,,,,,,,,,
1405,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,NSAID,,S01BC,ECO:0000352,,,,,Symptomatic (C),C,,,,Lower limb pain,,HP:0012514,https://www.ncbi.nlm.nih.gov/pubmed/16803637,https://www.ncbi.nlm.nih.gov/pubmed/10574582,https://www.ncbi.nlm.nih.gov/pubmed/10574582,,,,,,,,
1406,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,,,,,,,,,,,,,Abnormal prostaglandin level,,HP:0011023,https://www.ncbi.nlm.nih.gov/pubmed/10574582,,,,,,,,,,
1407,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,,,,,,,,,,,,,Low quality of life(Constitutional symptoms)*,,HP:0025142*,https://www.ncbi.nlm.nih.gov/pubmed/10574582,,,,,,,,,,
1408,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,,,,,,,,,,,,,Muscle weakness,,,https://www.ncbi.nlm.nih.gov/pubmed/10574582,,,,,,,,,,
1409,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,,,,,,,,,,,,,Abnormal walking distance,,,https://www.ncbi.nlm.nih.gov/pubmed/10574582,,,,,,,,,,
1410,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,,,,,,,,,,,,,,,,,,,,,,,,,,
1411,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,Teriparatide,,DB06285,,D378V /G339R/E191K/A176T/V423A,,N461L,,Functional interaction(Mechinistic B),B,,,,stress fractures(Pathologic fracture)*,,HP:0002756*,https://link.springer.com/article/10.1007%2Fs00198-015-3272-1,https://www.ncbi.nlm.nih.gov/pubmed/27042741,https://link.springer.com/article/10.1007%2Fs00223-011-9562-5,,,,,,,,
1412,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,,,,Ala176Thr/Val423Ala/Val522Ala,,,,,,,,,metatarsal stress fractures,,HP:0001832,https://www.ncbi.nlm.nih.gov/pubmed/20089612,,,,,,,,,,
1413,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,,,,compound heterozygotes for a p.G339R and p.E191K ALPL mutation,,,,,,,,,proximal femur pseudofractures,,HP:0100036,https://academic.oup.com/jcem/article/95/12/5174/2835157,https://www.ncbi.nlm.nih.gov/pubmed/20739387,,,,,,,,,
1414,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,,,,,,,,,,,,,High bone turnover markers,,HP:0003260*,,,,,,,,,,,
1415,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,,,,,,,,,,,,,defect in skeletal mineralization,,HP:0006462,,,,,,,,,,,
1416,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,,,,,,,,,,,,,Pain,,HP:0012531,,,,,,,,,,,
1417,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,,,,,,,,,,,,,mobility problems,,HP:0001376,,,,,,,,,,,
1418,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,,,,,,,,,,,,,High urine phosphoethanolamine,,HP:0003239,https://www.ncbi.nlm.nih.gov/pubmed/20089612,,,,,,,,,,
1419,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,,,,,,,,,,,,,High serum pyridoxal 5'-phosphate,,NA,https://www.ncbi.nlm.nih.gov/pubmed/20089612,,,,,,,,,,
1420,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,Vitamin B6,,DB00165,,,,,,,,,,,Seizure,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/17395561?dopt=Abstract,,,,,,,,,,
1421,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,BPS804 (setrusumab),,DB14778,ECO:0007121,,,,,Functional interaction (B),B,,,,bone weakness,,HP:0002749,https://clinicaltrials.gov/ct2/show/NCT01406977?cond=hypophosphatasia&rank=5,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451251/,,,,,,,,,
1422,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,,,,,,,,,,,,,bone fructure,,HP:0002757,,,,,,,,,,,
1423,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,,,,,,,,,,,,,low bone formation biomarkers,,HP:0031429,,,,,,,,,,,
1424,,# 241500,"Hypophosphatasia, INFANTILE",,ALPL,tissue-nonspecific alkaline phosphatase (TNSALP),3.1.3.1,,,,,,,,,,,,,,low bone mineral density,,HP:0004349,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451251/,,,,,,,,,,
1425,186,# 615558,Hypolipoproteinemia (Familial hypobetalipoproteinemia),,APOB,apolipoprotein B-48 + apolipoprotein B-100,3.1.3.1,Vitamin A,,DB00162,ECO:0000352,,,,,Symptomatic (C),C,,,,Fat soluble vitamin  Malabsorption,,HP:0002630,https://www.ncbi.nlm.nih.gov/pubmed/24751931,https://www.ncbi.nlm.nih.gov/pubmed/24288038,,,,,,,,,
1426,,# 615558,Hypolipoproteinemia (Familial hypobetalipoproteinemia),,APOB,apolipoprotein B-48 + apolipoprotein B-100,3.1.3.1,,,,,,,,,,,,,,Progressive ataxic retinopathy,,HP:0000488,https://www.ncbi.nlm.nih.gov/pubmed/26086616,,,,,,,,,,
1427,,# 615558,Hypolipoproteinemia (Familial hypobetalipoproteinemia),,APOB,apolipoprotein B-48 + apolipoprotein B-100,3.1.3.1,Vitamin E,,DB00163,ECO:0000352,,,,,Symptomatic (C),C,,,,Central nervous degeneration,,HP:0007009,https://www.ncbi.nlm.nih.gov/pubmed/24751931,https://www.ncbi.nlm.nih.gov/pubmed/24288038,,,,,,,,,
1428,,# 615558,Hypolipoproteinemia (Familial hypobetalipoproteinemia),,APOB,apolipoprotein B-48 + apolipoprotein B-100,3.1.3.1,,,,,,,,,,,,,,Retinal degeneration,,HP:0000546,,,,,,,,,,,
1429,,# 615558,Hypolipoproteinemia (Familial hypobetalipoproteinemia),,APOB,apolipoprotein B-48 + apolipoprotein B-100,3.1.3.1,,,,,,,,,,,,,,Neuromuscular degeneration,,HP:0002180,,,,,,,,,,,
1430,,# 615558,Hypolipoproteinemia (Familial hypobetalipoproteinemia),,APOB,apolipoprotein B-48 + apolipoprotein B-100,3.1.3.1,,,,,,,,,,,,,,Oxidative stress,,HP:0025464,,,,,,,,,,,
1431,,# 615558,Hypolipoproteinemia (Familial hypobetalipoproteinemia),,APOB,apolipoprotein B-48 + apolipoprotein B-100,3.1.3.1,,,,,,,,,,,,,,Progressive ataxic neuropathy,,HP:0003434,https://www.ncbi.nlm.nih.gov/pubmed/26086616,,,,,,,,,,
1432,187,# 615558,Homozygous Hypolipoproteinemia,,APOB,apolipoprotein B-48 + apolipoprotein B-100,3.1.3.1,Vitamin A,,DB00162,ECO:0000352,,,,,Symptomatic(C),C,,,,Fat soluble vitamin  Malabsorption (Fat malabsorption)*,,HP:0002630,https://www.ncbi.nlm.nih.gov/pubmed/24751931,https://www.ncbi.nlm.nih.gov/pubmed/24288038,,,,,,,,,
1433,,# 615558,Homozygous Hypolipoproteinemia,,APOB,apolipoprotein B-48 + apolipoprotein B-100,3.1.3.1,,,,,,,,,,,,,,Progressive ataxic retinopathy,,HP:0000488,https://www.ncbi.nlm.nih.gov/pubmed/26086616,,,,,,,,,,
1434,,# 615558,Homozygous Hypolipoproteinemia,,APOB,apolipoprotein B-48 + apolipoprotein B-100,3.1.3.1,Vitamin E,,DB00163,ECO:0000352,,,,,Symptomatic(C),C,,,,Central nervous degeneration,,HP:0007009,https://www.ncbi.nlm.nih.gov/pubmed/24751931,https://www.ncbi.nlm.nih.gov/pubmed/24288038,,,,,,,,,
1435,,# 615558,Homozygous Hypolipoproteinemia,,APOB,apolipoprotein B-48 + apolipoprotein B-100,3.1.3.1,,,,,,,,,,,,,,Retinal degeneration,,HP:0000546,,,,,,,,,,,
1436,,# 615558,Homozygous Hypolipoproteinemia,,APOB,apolipoprotein B-48 + apolipoprotein B-100,3.1.3.1,,,,,,,,,,,,,,Neuromuscular degeneration,,HP:0002180,,,,,,,,,,,
1437,,# 615558,Homozygous Hypolipoproteinemia,,APOB,apolipoprotein B-48 + apolipoprotein B-100,3.1.3.1,,,,,,,,,,,,,,Oxidative stress,,HP:0025464,,,,,,,,,,,
1438,,# 615558,Homozygous Hypolipoproteinemia,,APOB,apolipoprotein B-48 + apolipoprotein B-100,3.1.3.1,,,,,,,,,,,,,,Progressive ataxic neuropathy,,HP:0003434,https://www.sciencedirect.com/science/article/pii/S0891584915002671?via%3Dihub,,,,,,,,,,
1439,188,# 600627,Hypertryptophanemia,,TDO2,"tryptophan 2,3-dioxygenase",3.1.3.1,No treatment is available in DDIEM,,,,,,,,,,,,Drug name: Hypertryptophanemia should be regarded as a benign condition,,,HP:0003434,https://link.springer.com/article/10.1007%2Fs11010-011-1147-0,https://www.ncbi.nlm.nih.gov/pubmed/28285122,,,,,,,,,
1440,,# 600627,Hypertryptophanemia,,TDO2,"tryptophan 2,3-dioxygenase",3.1.3.1,,,,,,,,,,,,,,,,,https://link.springer.com/article/10.1023%2FA%3A1023811019023,,,,,,,,,,
1441,,# 600627,Hypertryptophanemia,,TDO2,"tryptophan 2,3-dioxygenase",3.1.3.1,,,,,,,,,,,,,,,,,https://www.sciencedirect.com/science/article/pii/S0736574803001461,,,,,,,,,,
1442,,# 600627,Hypertryptophanemia,,TDO2,"tryptophan 2,3-dioxygenase",3.1.3.1,,,,,,,,,,,,,,,,,,,,,,,,,,,
1443,189,# 239500,Hyperprolinemia,,PRODH,proline dehydrogenase 1,3.1.3.1,Vitamen B6,,DB00165,ECO:0000352,,,,,Symptomatic(C),C,,,,Seizures,,HP:0001250,https://link.springer.com/article/10.1007%2Fs10545-013-9660-9,,,,,,,,,,
1444,,# 239500,Hyperprolinemia,,PRODH,proline dehydrogenase 1,3.1.3.1,Pyridoxine phosphate,,DB02209,ECO:0000352,,,,,Symptomatic(C),C,,,,Seizures,,HP:0001250,https://link.springer.com/article/10.1007%2Fs10545-013-9660-9,,,,,,,,,,
1445,,# 239500,Hyperprolinemia,,PRODH,proline dehydrogenase 1,3.1.3.1,olanzapine,,DB00334,ECO:0000352,,,,,Symptomatic (C),C,,,,behavioural disturbance,,HP:0000708,https://www.sciencedirect.com/science/article/pii/S0387760417300086?via%3Dihub,,,,,,,,,,
1446,,# 239500,Hyperprolinemia,,PRODH,proline dehydrogenase 1,3.1.3.1,lithium,,DB14507,ECO:0000352,,,,,Symptomatic (C),C,,,,psychotic  disorder,,HP:0000725,,,,,,,,,,,
1447,,# 239500,Hyperprolinemia,,PRODH,proline dehydrogenase 1,3.1.3.1,green tea extract,,DB14307,ECO:0000352,,,,,Supportive (C),C,,,,Oxidative Stress,,HP:0025464,https://www.sciencedirect.com/science/article/pii/S075333221630645X?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/24980685,,,,,,,,,
1448,,# 239500,Hyperprolinemia,,PRODH,proline dehydrogenase 1,3.1.3.1,Vitamin D,,DB11094,ECO:0000352,,,,,Direct interaction ( Mechanistic A),A,,,,schizophrenia,,HP:0100753,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4044915/,,,,,,,,,,
1449,,# 239500,Hyperprolinemia,,PRODH,proline dehydrogenase 1,3.1.3.1,α-Tocopherol+ascorbic acid,Tα-Tocopherol should be given with the ascorbic acid(vit. C) as the latter helps The resultant tocopheroxil radical regeneration in getting back to reduced tocopherol .,DB14476+DB00126,ECO:0000352,,,,,Symptomatic (C),C,,,,impairment of reference,,,https://www.sciencedirect.com/science/article/pii/S0166432805003657,,,,,,,,,,
1450,,# 239500,Hyperprolinemia,,PRODH,proline dehydrogenase 1,3.1.3.1,,,,,,,,,,C,,,,working spatial memory impairment*,,HP:0002354,https://www.sciencedirect.com/science/article/pii/S0166432805003657,,,,,,,,,,
1451,,# 239500,Hyperprolinemia,,PRODH,proline dehydrogenase 1,3.1.3.1,,,,,,,,,,,,,,Oxidative stress,,HP:0025464,,,,,,,,,,,
1452,,# 239500,Hyperprolinemia,,PRODH,proline dehydrogenase 1,3.1.3.1,,,,,,,,,,,,,,cerebral cortex acetylcholinesterase inhibition,,NA,,,,,,,,,,,
1453,,# 239500,Hyperprolinemia,,PRODH,proline dehydrogenase 1,3.1.3.1,,,,,,,,,,,,,,"hippocampal Na+, K+-ATPase reduced activity",,NA,,,,,,,,,,,
1454,190,# 239510,Hyperprolinemia type 2,,ALDH4A1,Δ1-pyrroline 5-carboxylate dehydrogenase,3.1.3.1,No treatment is available in DDIEM,,,,,,,,,,,,,,,NA,,,,,,,,,,,
1455,191,# 264070,Hyperphenylalaninemia due to dehydratase deficiency,Protein and phenylalanine restriction should be maintained in order to avoid disease progression.,PCBD1,pterin-4 alpha-carbinolamine dehydratase,3.1.3.1,Tetrahydrobiopterin,,DB00360,ECO:0000352,,,,,Functional interaction(Mechanistic B),B,,,,Muscular hypotonia,,HP:0001252,https://link.springer.com/article/10.1007%2Fs10545-012-9506-x,,,,,,,,,,
1456,,# 264070,Hyperphenylalaninemia due to dehydratase deficiency,,PCBD1,pterin-4 alpha-carbinolamine dehydratase,3.1.3.1,,,,,,,,,,,,,,Dystonia,,HP:0001332,,,,,,,,,,,
1457,,# 264070,Hyperphenylalaninemia due to dehydratase deficiency,,PCBD1,pterin-4 alpha-carbinolamine dehydratase,3.1.3.1,,,,,,,,,,,,,,Hyperphenylalaninemia,,HP:0004923,https://www.ncbi.nlm.nih.gov/pubmed/9585615,https://www.ncbi.nlm.nih.gov/pubmed/24204001,,,,,,,,,
1458,,# 264070,Hyperphenylalaninemia due to dehydratase deficiency,,PCBD1,pterin-4 alpha-carbinolamine dehydratase,3.1.3.1,,,,,,,,,,,,,,Growth failure,,HP:0001510,https://www.ncbi.nlm.nih.gov/pubmed/9760199,,,,,,,,,,
1459,,# 264070,Hyperphenylalaninemia due to dehydratase deficiency,,PCBD1,pterin-4 alpha-carbinolamine dehydratase,3.1.3.1,,,,,,,,,,,,,,High urinary levels of primapterin (7-biopterin),,NA,https://www.ncbi.nlm.nih.gov/pubmed/24204001,,,,,,,,,,
1460,,# 264070,Hyperphenylalaninemia due to dehydratase deficiency,,PCBD1,pterin-4 alpha-carbinolamine dehydratase,3.1.3.1,Salfonylureas,,DB01124,ECO:0005542,,,,,Symptomatic (C),,,,,PCBD1-diabetes (Noninsulin-dependent diabetes)*,,HP:0005978*,https://www.ncbi.nlm.nih.gov/pubmed/24848070,,,,,,,,,,
1461,192,# 238700,Hyperlysinemia,Lysine-restricted diet achieved a mild improvement of some signs but did not reverse cognitive impairment. The moderate decrease of plasma lysine concentrations after dietary treatment in our patients supports the need of increase lysine restriction.https://www.ncbi.nlm.nih.gov/pubmed/23890588,AASS,"Aminoadipic semialdehyde synthase, mitochondrial  including Lysine ketoglutarate reductase +Saccharopine dehydrogenase",1.5.1.8+1.5.1.9,botulinum toxin,,DB00083,ECO:0000352,,,,,Symptomatic (C),C,,,,Delayed motor development,,HP:0001270,https://www.ncbi.nlm.nih.gov/pubmed/23570448,,,,,,,,,,
1462,,# 238700,Hyperlysinemia,,AASS,"Aminoadipic semialdehyde synthase, mitochondrial  including Lysine ketoglutarate reductase +Saccharopine dehydrogenase",1.5.1.8+1.5.1.9,valproate+carbamazepine,,DB00313+DB00564,,,,,,Symptomatic (C),C,,,,seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/23570448,,,,,,,,,,
1463,,# 238700,Hyperlysinemia,,AASS,"Aminoadipic semialdehyde synthase, mitochondrial  including Lysine ketoglutarate reductase +Saccharopine dehydrogenase",1.5.1.8+1.5.1.9,,,,,,,,,Symptomatic (C),C,,,,Generalized tonic convulsions,,HP:0010818,https://www.ncbi.nlm.nih.gov/pubmed/23570448,,,,,,,,,,
1464,,# 238700,Hyperlysinemia,,AASS,"Aminoadipic semialdehyde synthase, mitochondrial  including Lysine ketoglutarate reductase +Saccharopine dehydrogenase",1.5.1.8+1.5.1.9,Valproic acid+Lysin restricted diet,The drug was accompanied with lysin restricted diet,DB00313,ECO:0000352,,,,,Symptomatic (C)+Dietry restriction,,,,,seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/23570448,,,,,,,,,,
1465,,# 238700,Hyperlysinemia,,AASS,"Aminoadipic semialdehyde synthase, mitochondrial  including Lysine ketoglutarate reductase +Saccharopine dehydrogenase",1.5.1.8+1.5.1.9,pyridoxine,,DB00165,ECO:0000352,,,,,Symptomatic (C),C,,,,"No remarkable clinical improvement was observed and therefore, treatment was discontinued",,,https://www.ncbi.nlm.nih.gov/pubmed/23890588,,,,,,,,,,
1466,193,144650,Hyperlipoproteinemia type V,,APOA5,apolipoprotein A5,Q6Q788,rosuvastatin,,DB01098,ECO:00007121,,,,,Symptomatic (C),C,,,,hypertriglyceridemia,,HP:0002155,https://clinicaltrials.gov/ct2/show/NCT00473655?cond=Hyperlipoproteinemia+type+V&rank=2,https://www.ncbi.nlm.nih.gov/pubmed/23323877,,,,,,,,,
1467,,144650,Hyperlipoproteinemia type V,,APOA5,apolipoprotein A5,Q6Q788,,,,,,,,,,,,,,High LDL level,,HP:0003141,,,,,,,,,,,
1468,,144650,Hyperlipoproteinemia type V,,APOA5,apolipoprotein A5,Q6Q788,,,,,,,,,,,,,,High total cholesterol,,HP:0003124,,,,,,,,,,,
1469,,144650,Hyperlipoproteinemia type V,,APOA5,apolipoprotein A5,Q6Q788,,,,,,,,,,,,,,High Apoliporprotein B level(Abnormal abpolipoprotein level)*,,HP:0025201*,,,,,,,,,,,
1470,,144650,Hyperlipoproteinemia type V,,APOA5,apolipoprotein A5,Q6Q788,fenofibrates,,DB13873,ECO:00007121,,,,,Functional interaction (B),B,,,,hypertriglyceridemia,,HP:0002155,https://www.ncbi.nlm.nih.gov/pubmed/22129523,https://www.ncbi.nlm.nih.gov/pubmed/2653622,,,,,,,,,
1471,,144650,Hyperlipoproteinemia type V,,APOA5,apolipoprotein A5,Q6Q788,,,,,,,,,,,,,,High level of very low-density lipoprotein,,HP:0003362,,,,,,,,,,,
1472,,144650,Hyperlipoproteinemia type V,,APOA5,apolipoprotein A5,Q6Q788,,,,,,,,,,,,,,High total cholesterol,,HP:0003124,,,,,,,,,,,
1473,,144650,Hyperlipoproteinemia type V,,APOA5,apolipoprotein A5,Q6Q788,,,,,,,,,,,,,,Low HDL-cholesterol,,HP:0003233,,,,,,,,,,,
1474,,144650,Hyperlipoproteinemia type V,,APOA5,apolipoprotein A5,Q6Q788,nicotinic acid,"Caution against possible exacerbation of the glucose tolerance is necessary in the treatment of diabetic patients with nicotinic acid. Also, as marked weight control in obese patients may induce severe hypertriglyceridemia and acute pancreatitis associated with rebound of the body weight, this risk must be considered. https://www.ncbi.nlm.nih.gov/pubmed/22129523",DB00627,ECO:0000352,,,,,Functional interaction (B),B,,,,hypertriglyceridemia,,HP:0002155,https://www.ncbi.nlm.nih.gov/pubmed/1894760,,,,,,,,,,
1475,,144650,Hyperlipoproteinemia type V,,APOA5,apolipoprotein A5,Q6Q788,,,,,,,,,,,,,,High total plasma cholesterol,,HP:0003124,,,,,,,,,,,
1476,,144650,Hyperlipoproteinemia type V,,APOA5,apolipoprotein A5,Q6Q788,,,,,,,,,,,,,,Elevated LDL-C level,,HP:0003141,,,,,,,,,,,
1477,,144650,Hyperlipoproteinemia type V,,APOA5,apolipoprotein A5,Q6Q788,,,,,,,,,,,,,,High VLDL-triglycerides,,HP:0003362,,,,,,,,,,,
1478,,144650,Hyperlipoproteinemia type V,,APOA5,apolipoprotein A5,Q6Q788,,,,,,,,,,,,,,Low HDL-C,,HP:0003233,,,,,,,,,,,
1479,,144650,Hyperlipoproteinemia type V,,APOA5,apolipoprotein A5,Q6Q788,"strong statins (atorvastatin, pitavastatin, and rosuvastatin",,DB01076 or DB08860 or DB01098,ECO:0000352,,,,,Symptomatic (C),C,,,Functional interaction,hypertriglyceridemia,,HP:0002155,https://www.ncbi.nlm.nih.gov/pubmed/22129523,,,,,,,,,,
1480,,144650,Hyperlipoproteinemia type V,,APOA5,apolipoprotein A5,Q6Q788,Gemfibrozil,,DB01241,ECO:0000352/ ECO:0007121,,,,,Functional interaction (B),B,,,,Tuberoeruptive xanthomas,"The phenotype was controlled with diet, withdrawal from ethanol use, and the fibric acid derivative gemfibrozil.https://www.ncbi.nlm.nih.gov/pubmed/2702860",HP:0001013*,https://www.ncbi.nlm.nih.gov/pubmed/2702860,https://www.ncbi.nlm.nih.gov/pubmed/2681858,,,,,,,,,
1481,,144650,Hyperlipoproteinemia type V,,APOA5,apolipoprotein A5,Q6Q788,,,,,,,,,,,,,,Hyperchylomicronemia,,HP:0012238,https://www.ncbi.nlm.nih.gov/pubmed/2681858,,,,,,,,,,
1482,,144650,Hyperlipoproteinemia type V,,APOA5,apolipoprotein A5,Q6Q788,,,,,,,,,,,,,,High total plasma cholesterol leve,,,https://www.ncbi.nlm.nih.gov/pubmed/2681858,,,,,,,,,,
1483,,144650,Hyperlipoproteinemia type V,,APOA5,apolipoprotein A5,Q6Q788,,,,,,,,,,,,,,Elevated LDL-C level,,HP:0003141,https://www.ncbi.nlm.nih.gov/pubmed/2681858,,,,,,,,,,
1484,,144650,Hyperlipoproteinemia type V,,APOA5,apolipoprotein A5,Q6Q788,,,,,,,,,,,,,,High VLDL-triglycerides,,HP:0003362,https://www.ncbi.nlm.nih.gov/pubmed/2681858,,,,,,,,,,
1485,,144650,Hyperlipoproteinemia type V,,APOA5,apolipoprotein A5,Q6Q788,,,,,,,,,,,,,,Low HDL-C,,HP:0003233,https://www.ncbi.nlm.nih.gov/pubmed/2681858,,,,,,,,,,
1486,194,617347,Hyperlipidemia type 3,,APOE,apolipoprotein E,Q6Q788,Rosuvastatin+Pravastatin,,DB01098 +DB00175,ECO:0007121,,,,,Symptomatic (C),C,,,,hypertriglycernemia,,HP:0002155,https://clinicaltrials.gov/ct2/show/NCT00214604?cond=Hyperlipidemia+type+3&rank=2,,,,,,,,,,
1487,,617347,Hyperlipidemia type 3,,APOE,apolipoprotein E,Q6Q788,torcetrapib/atorvastatin,Study was terminated due to safety issues.,DB06281+ DB01076,ECO:0007121,,,,,Symptomatic (C),C,,,,,,,https://clinicaltrials.gov/ct2/show/NCT00145431?cond=Hyperlipidemia+type+3&rank=3,,,,,,,,,,
1488,,617347,Hyperlipidemia type 3,,APOE,apolipoprotein E,Q6Q788,simvastatin,"In this study""https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract"" authors claimed that gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is. IDL and apolipoprotein E levels were reduced similarly with both drugs.",DB00641,ECO:0000352,,,,,Symptomatic (C),C,,,,high non-HDL-C (Abnormality of lipid metabolism)*,,HP:0003119*,https://www.sciencedirect.com/science/article/pii/S0021915015001379?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/25768710,https://www.ncbi.nlm.nih.gov/pubmed/28098593,https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract,,,,,,,
1489,,617347,Hyperlipidemia type 3,,APOE,apolipoprotein E,Q6Q788,,,,,,,,,,,,,,High VLDL triglycerides,,,,,,,,,,,,,
1490,,617347,Hyperlipidemia type 3,,APOE,apolipoprotein E,Q6Q788,gemfibrozil,"In this study""https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract"" authors claimed that gemfibrozil is more effective in reducing total triglyceride and VLDL lipid levels than simvastatin, and simvastatin is better in reducing LDL cholesterol than gemfibrozil is. IDL and apolipoprotein E levels were reduced similarly with both drugs.",DB01241,ECO:0000352,,,,,Functional interaction (B),B,,,,high non-HDL-C (Abnormality of lipid metabolism)*,,HP:0003119*,https://www.sciencedirect.com/science/article/pii/S0021915015001379?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/25768710,https://www.ncbi.nlm.nih.gov/pubmed/28098593,https://www.ncbi.nlm.nih.gov/pubmed/10385780?dopt=Abstract,,,,,,,
1491,,617347,Hyperlipidemia type 3,,APOE,apolipoprotein E,Q6Q788,,,,,,,,,,,,,,High VLDL triglycerides,,NA,,,,,,,,,,,
1492,,617347,Hyperlipidemia type 3,,APOE,apolipoprotein E,Q6Q788,lovastatin,,DB00227,ECO:0000352,,,,,Symptomatic (C),C,,,,high non-HDL-C (Abnormality of lipid metabolism)*,,HP:0003119*,https://www.sciencedirect.com/science/article/pii/S0021915015001379?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/25768710,https://www.ncbi.nlm.nih.gov/pubmed/28098593,https://www.ncbi.nlm.nih.gov/pubmed/3162680?dopt=Abstract,,,,,,,
1493,,617347,Hyperlipidemia type 3,,APOE,apolipoprotein E,Q6Q788,clofibrate,,DB00636,ECO:0000352,,,,,Functional interaction (B),B,,,,high non-HDL-C (Abnormality of lipid metabolism)*,,HP:0003119*,https://www.sciencedirect.com/science/article/pii/S0021915015001379?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/25768710,https://www.ncbi.nlm.nih.gov/pubmed/28098593,,,,,,,,
1494,,617347,Hyperlipidemia type 3,,APOE,apolipoprotein E,Q6Q788,lovastatin and clofibrate,clinicians might only switch to combination therapy in FD patients who remain severely hypertriglyceridemic and/or hypercholesterolemic on monotherapy instead of prescribing combined statin-fibrate therapy to all FD patients that do not meet the non-HDL-C target.https://www.ncbi.nlm.nih.gov/pubmed/25768710,DB00227+DB00636,ECO:0000352,,,,,Functional interaction (B),B,,,,hypercholesterolemia,,HP:0003124,https://www.sciencedirect.com/science/article/pii/S0021915015001379?via%3Dihub,https://www.ncbi.nlm.nih.gov/pubmed/25768710,https://www.ncbi.nlm.nih.gov/pubmed/28098593,,,,,,,,
1495,,617347,Hyperlipidemia type 3,,APOE,apolipoprotein E,Q6Q788,Fenofibrate,,DB13873,ECO:0000352,,,,,Functional interaction (B),B,,,,Hypertriglyceridemia,,HP:0002155,https://link.springer.com/article/10.1007%2Fs11883-014-0440-2,https://www.ncbi.nlm.nih.gov/pubmed/25079293,,,,,,,,,
1496,,617347,Hyperlipidemia type 3,,APOE,apolipoprotein E,Q6Q788,Niacin,,DB00627,ECO:0000352,,,,,Functional interaction (B),B,,,,Hypertriglyceridemia,,HP:0002156,https://link.springer.com/article/10.1007%2Fs11883-014-0440-2,https://www.ncbi.nlm.nih.gov/pubmed/25079293,,,,,,,,,
1497,,617347,Hyperlipidemia type 3,,APOE,apolipoprotein E,Q6Q788,Fish oil,,DB13961,ECO:0000352,,,,,Symptomatic (C),C,,,,Hypertriglyceridemia,,HP:0002157,https://link.springer.com/article/10.1007%2Fs11883-014-0440-2,https://www.ncbi.nlm.nih.gov/pubmed/25079293,https://www.ncbi.nlm.nih.gov/pubmed/2065040?dopt=Abstract,,,,,,,,
1498,,617347,Hyperlipidemia type 3,,APOE,apolipoprotein E,Q6Q788,fenofibrate + atorvastatin,,DB13873+ DB01076,ECO:0000352,,,,,Functional interaction (B),B,,,,xanthomas,,HP:0000991,https://link.springer.com/article/10.1007%2Fs11883-014-0440-2,https://www.ncbi.nlm.nih.gov/pubmed/25079293,,,,,,,,,
1499,,617347,Hyperlipidemia type 3,,APOE,apolipoprotein E,Q6Q788,,,,,,,,,,,,,,stenotic coronary atherosclerosis,,HP:0001677,,,,,,,,,,,
1500,,617347,Hyperlipidemia type 3,,APOE,apolipoprotein E,Q6Q788,,,,,,,,,,,,,,angina pectoris,,HP:0001681,,,,,,,,,,,
1501,,617347,Hyperlipidemia type 3,,APOE,apolipoprotein E,Q6Q788,Atrovastatin,,DB01076,ECO:0000352,,,,,,,,,,High serum total cholesterol,,HP:0001681,https://www.ncbi.nlm.nih.gov/pubmed/12801620?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/12181212?dopt=Abstract,,,,,,,,,
1502,,617347,Hyperlipidemia type 3,,APOE,apolipoprotein E,Q6Q788,,,,,,,,,,,,,,High serum triglyceride,,,https://www.ncbi.nlm.nih.gov/pubmed/12801620?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/12181212?dopt=Abstract,,,,,,,,,
1503,,617347,Hyperlipidemia type 3,,APOE,apolipoprotein E,Q6Q788,,,,,,,,,,,,,,High remnant-like particle (RLP)-cholesterol,,,https://www.ncbi.nlm.nih.gov/pubmed/12801620?dopt=Abstract,,,,,,,,,,
1504,,617347,Hyperlipidemia type 3,,APOE,apolipoprotein E,Q6Q788,,,,,,,,,,,,,,High remnant-like particle (RLP)-TG,,,https://www.ncbi.nlm.nih.gov/pubmed/12801620?dopt=Abstract,,,,,,,,,,
1505,,617347,Hyperlipidemia type 3,,APOE,apolipoprotein E,Q6Q788,,,,,,,,,,,,,,Elevated very low-density lipoprotein (VLDL)-cholesterol/serum TG ratio,,,https://www.ncbi.nlm.nih.gov/pubmed/12801620?dopt=Abstract,,,,,,,,,,
1506,,617347,Hyperlipidemia type 3,,APOE,apolipoprotein E,Q6Q788,,,,,,,,,,,,,,Increaed apolipoprotein B level,,,https://www.ncbi.nlm.nih.gov/pubmed/12181212?dopt=Abstract,,,,,,,,,,
1507,,617347,Hyperlipidemia type 3,,APOE,apolipoprotein E,Q6Q788,probucol,,DB01599,ECO:0005542,,,,,,,,,,Atherosclerosis,,HP:0002621,https://www.ncbi.nlm.nih.gov/pubmed/9185508,,,,,,,,,,
1508,,617347,Hyperlipidemia type 3,,APOE,apolipoprotein E,Q6Q788,Bezafibrate/ atorvastatin,"Based on their study auhors of""  https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract""  presume that the combination of these drugs may contribute to reduce LDL-C/HDL-C ratio effectively as well as lowering concentrations of serum triglyceride.",DB01393/DB01076,ECO:0000352,,,,,Functional interaction (B),,,,,Atherogenic dyslipidemia(Dyslipidemia)*,,HP:0003119*,https://www.ncbi.nlm.nih.gov/pubmed/21354122?dopt=Abstract,,,,,,,,,,
1509,195,606762,Hyperinsulinism-hyperammonemia syndrome,"Treatments for hyperammonemia such as dietary protein limitation, arginine, benzoate, carbamoyl synthase activators (carglumic acid), and N-carbamoylglutamate have not been effective in reducing ammonia levels. https://www.ncbi.nlm.nih.gov/pubmed/15050973/",GLUD1,"Glutamate dehydrogenase, mitochondrial",1.4.1.3,diazoxide,,DB01119,ECO:0000352,,,,,Functional interaction (B),B,,,,hypoglycemia,,HP:0001943,https://www.ncbi.nlm.nih.gov/pubmed/23295286,https://www.ncbi.nlm.nih.gov/pubmed/20936362,https://www.ncbi.nlm.nih.gov/pubmed/25781533,https://www.ncbi.nlm.nih.gov/pubmed/?term=Hyperinsulinism+Hyperammonemia+Syndrome%2C+a+Rare+Clinical+Constellation,,,,,,,
1510,,606762,Hyperinsulinism-hyperammonemia syndrome,,GLUD1,"Glutamate dehydrogenase, mitochondrial",1.4.1.3,,,,,,,,,,,,,,epileptic seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5096481/,https://www.ncbi.nlm.nih.gov/pubmed/28621098,,,,,,,,,
1511,,606762,Hyperinsulinism-hyperammonemia syndrome,,GLUD1,"Glutamate dehydrogenase, mitochondrial",1.4.1.3,,,,,,,,,,,,,,Hyperinsulinism,,HP:0000842,https://www.ncbi.nlm.nih.gov/pubmed/10969108,,,,,,,,,,
1512,,606762,Hyperinsulinism-hyperammonemia syndrome,,GLUD1,"Glutamate dehydrogenase, mitochondrial",1.4.1.3,Carglumic acid + diazoxide+ Glucose,,DB06775+DB01119+DB01914,ECO:0000352,,,,,,,,,,hypoglycemia,,HP:0001943,https://www.ncbi.nlm.nih.gov/pubmed/26962538,,,,,,,,,,
1513,,606762,Hyperinsulinism-hyperammonemia syndrome,,GLUD1,"Glutamate dehydrogenase, mitochondrial",1.4.1.3,Levetiracetam,,DB01202,ECO:0000352,,,,,,,,,,Seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/26962538,,,,,,,,,,
1514,,606762,Hyperinsulinism-hyperammonemia syndrome,,GLUD1,"Glutamate dehydrogenase, mitochondrial",1.4.1.3,,,,,,,,,,,,,,Hyperammonemia,,HP:0001987,https://www.ncbi.nlm.nih.gov/pubmed/10969108,,,,,,,,,,
1515,196,602485,Hyperinsulinism due to glucokinase deficiency,,GCK,glucokinase-4,2.7.1.1,diazoxide,,DB01119,ECO:0000352,T65I,,GK-Y214C(De novo muttation),,Functional interaction (B),B,,,,hypoglycemia,,HP:0001943,https://www.ncbi.nlm.nih.gov/pubmed/15277402,https://www.ncbi.nlm.nih.gov/pubmed/19336674,,,,,,,,,
1516,,602485,Hyperinsulinism due to glucokinase deficiency,,GCK,glucokinase-4,2.7.1.1,,,,,(Val455Met) at codon 455,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/19336674,,HP:0001943,https://www.ncbi.nlm.nih.gov/pubmed/15133749,https://onlinelibrary.wiley.com/doi/epdf/10.1002/dmrr.448,,,,,,,,,
1517,,602485,Hyperinsulinism due to glucokinase deficiency,,GCK,glucokinase-4,2.7.1.1,,,,,M197I,,Y214C,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/19336674,,,,,,,,,,
1518,,602485,Hyperinsulinism due to glucokinase deficiency,,GCK,glucokinase-4,2.7.1.1,,,,,A456V,,ins454A,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/19336674,,,,,,,,,,
1519,,602485,Hyperinsulinism due to glucokinase deficiency,,GCK,glucokinase-4,2.7.1.1,,,,,W99R,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/19336674,,,,,,,,,,
1520,,602485,Hyperinsulinism due to glucokinase deficiency,,GCK,glucokinase-4,2.7.1.1,,,,,S64Y,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/19336674,,,,,,,,,,
1521,,602485,Hyperinsulinism due to glucokinase deficiency,,GCK,glucokinase-4,2.7.1.1,,,,,V452L,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/19336674,,,,,,,,,,
1522,,602485,Hyperinsulinism due to glucokinase deficiency,,GCK,glucokinase-4,2.7.1.1,,,,,M197I,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/19336674,,,,,,,,,,
1523,,602485,Hyperinsulinism due to glucokinase deficiency,,GCK,glucokinase-4,2.7.1.1,Octreotide,The results of this study suggest that octreotide may aid in the acute or long-term treatment of congenital hyperinsulinism in a limited number of selected cases.https://www.ncbi.nlm.nih.gov/pubmed/8410522/,,ECO:0007121,G68V,,,,Functional interaction (B),B,,,,Hypoglycemia,,HP:0001943,https://www.ncbi.nlm.nih.gov/pubmed/8410522/,,,,,,,,,,
1524,,602485,Hyperinsulinism due to glucokinase deficiency,,GCK,glucokinase-4,2.7.1.1,Dextrose +Diazoxide,,DB09341+DB01119,ECO:0000352,W99L,,,,Functional interaction (B),B,,,,Hypoglycemia,,HP:0001943,https://www.ncbi.nlm.nih.gov/pubmed/8410522/,,,,,,,,,,
1525,197,307030,Hyperglycerolemia (Isolated glycerol kinase deficiency),,GK,Glycerol kinase,2.7.1.30,Rosuvastatin,,DB01098,ECO:0000352,,,,,Symptomatic (C),C,,,,Hypertriglyceridemia,,HP:0002155,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612542/,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4612542/,,,,,,,,,
1526,198,307030,Hypercoagulability syndrome due to glycosylphosphatidylinositol deficiency,,PIGM,GPI mannosyltransferase 1,2.7.1.30,Antithrombotic agents,,B01,ECO:0000352,,,,,Symptomatic (C),C,,,,Thrombosis,,HP:0001977,https://www.ncbi.nlm.nih.gov/pubmed/16767100,,,,,,,,,,
1527,,307030,Hypercoagulability syndrome due to glycosylphosphatidylinositol deficiency,,PIGM,GPI mannosyltransferase 1,2.7.1.30,Sodium phenylbutyrate,,DB06819,ECO:0000352,,,,,Functional interaction (B),B,,,,Seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/17442906,,,,,,,,,,
1528,199,237400,Hyperbetaalaninemia,,?????,beta-alanine-alpha-ketoglutarate transaminase.,2.7.1.30,Taurine,,DB01956,ECO:0001565,,,,,Symptomatic (C),,,,,mitochondrial toxicity*,,HP:0012103,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5097872/,https://link.springer.com/article/10.1007%2Fs00726-017-2462-x,,,,,,,,,
1529,,237400,Hyperbetaalaninemia,,?????,beta-alanine-alpha-ketoglutarate transaminase.,2.7.1.30,Pyridoxine,,DB00165,ECO:0000352,,,,,Symptomatic (C),,,,??,seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/7936305,https://www.ncbi.nlm.nih.gov/pubmed/6198500,,,,,,,,,
1530,,237400,Hyperbetaalaninemia,,?????,beta-alanine-alpha-ketoglutarate transaminase.,2.7.1.30,,,,,,,,,,,,,,somnolence,,HP:0002360,https://www.ncbi.nlm.nih.gov/pubmed/7936305,,,,,,,,,,
1531,200,260920,Hyperimmunoglobulinemia D,,MVK,mevalonate kinase,2.7.1.36,anti-TNF-alpha (Adalimumab)+Etanercept,,DB00051+DB00005,ECO:0000352,,,,,Symptomatic (C),C,,,,periodic fever,,HP:0001954,https://www.ncbi.nlm.nih.gov/pubmed/24935455,,,,,,,,,,
1532,,260920,Hyperimmunoglobulinemia D,,MVK,mevalonate kinase,2.7.1.36,,,,,,,,,Symptomatic (C),C,,,,Abnormality of immune system physiology,,HP:0010978,https://www.ncbi.nlm.nih.gov/pubmed/24935455,,,,,,,,,,
1533,,260920,Hyperimmunoglobulinemia D,,MVK,mevalonate kinase,2.7.1.36,Anakinra,,DB00026,ECO:0000352,,,,,Symptomatic (C),C,,,,Arthralgia,,HP:0002829,https://www.ncbi.nlm.nih.gov/pubmed/20712835,https://www.ncbi.nlm.nih.gov/pubmed/25758134/,,,,,,,,,
1534,,260920,Hyperimmunoglobulinemia D,,MVK,mevalonate kinase,2.7.1.36,,,,,,,,,,,,,,joint swelling,,HP:0001386,,,,,,,,,,,
1535,,260920,Hyperimmunoglobulinemia D,,MVK,mevalonate kinase,2.7.1.36,Canakinumab,,DB06168,ECO:0000352,,,,,,,,,,Fever,,HP:0001945,https://www.ncbi.nlm.nih.gov/pubmed/25758134/,https://www.ncbi.nlm.nih.gov/pubmed/22740624/,,,,,,,,,
1536,,260920,Hyperimmunoglobulinemia D,,MVK,mevalonate kinase,2.7.1.36,,,,,,,,,,,,,,High serum amyloid A protein,,NA,https://www.ncbi.nlm.nih.gov/pubmed/22740624/,,,,,,,,,,
1537,,260920,Hyperimmunoglobulinemia D,,MVK,mevalonate kinase,2.7.1.36,,,,,,,,,,,,,,Elevated C-reactive protein,,HP:0011227,https://www.ncbi.nlm.nih.gov/pubmed/22740624/,,,,,,,,,,
1538,,260920,Hyperimmunoglobulinemia D,,MVK,mevalonate kinase,2.7.1.36,prednisolone + azathioprine + immunoglobulins,,DB00860+DB00993+DB00028,ECO:0000352,compound V377I and I126T mutations,,,,Symptomatic (C),C,,,,periodic fever,,HP:0001954,https://www.ncbi.nlm.nih.gov/pubmed/18839211?dopt=Abstract,,,,,,,,,,
1539,,260920,Hyperimmunoglobulinemia D,,MVK,mevalonate kinase,2.7.1.36,Thalidomide,,DB01041,ECO:0007121,,,,,Symptomatic (C),C,,,Drug withdrawn,Limited Efficacy of the drug.,,HP:0001954,https://www.ncbi.nlm.nih.gov/pubmed/11504824?dopt=Abstract,,,,,,,,,,
1540,,260920,Hyperimmunoglobulinemia D,,MVK,mevalonate kinase,2.7.1.36,steroids + simvastatin,,DB00641,ECO:0000352,,,,,Symptomatic (C),C,,,,Periodic fever,,HP:0001954,https://www.ncbi.nlm.nih.gov/pubmed/19011501?dopt=Abstract,,,,,,,,,,
1541,,260920,Hyperimmunoglobulinemia D,,MVK,mevalonate kinase,2.7.1.36,Infliximab,,DB00065,ECO:0000352,,,,,Symptomatic (C),C,,,,Nummular keratitis(keratitis)*,,HP:0000491,https://www.ncbi.nlm.nih.gov/pubmed/19656398?dopt=Abstract,,,,,,,,,,
1542,,260920,Hyperimmunoglobulinemia D,,MVK,mevalonate kinase,2.7.1.36,,,,,,,,,,,,,,Corneal scar,,HP:0000559,https://www.ncbi.nlm.nih.gov/pubmed/19656398?dopt=Abstract,,,,,,,,,,
1543,,260920,Hyperimmunoglobulinemia D,,MVK,mevalonate kinase,2.7.1.36,,,,,,,,,,,,,,Decreased visual acuity,,HP:0007663,,,,,,,,,,,
1544,,260920,Hyperimmunoglobulinemia D,,MVK,mevalonate kinase,2.7.1.36,tocilizumab,,DB06273,ECO:0000352,,,,,Symptomatic (C),C,,,,Fever,,HP:0001945,https://www.ncbi.nlm.nih.gov/pubmed/30225156,https://www.ncbi.nlm.nih.gov/pubmed/24561416,https://www.ncbi.nlm.nih.gov/pubmed/26516243,,,,,,,,
1545,,260920,Hyperimmunoglobulinemia D,,MVK,mevalonate kinase,2.7.1.36,,,,,,,,,,,,,,Fatigue,,,https://www.ncbi.nlm.nih.gov/pubmed/30225156,,,,,,,,,,
1546,,260920,Hyperimmunoglobulinemia D,,MVK,mevalonate kinase,2.7.1.36,,,,,,,,,,,,,,Pain,,,https://www.ncbi.nlm.nih.gov/pubmed/30225156,,,,,,,,,,
1547,,260920,Hyperimmunoglobulinemia D,,MVK,mevalonate kinase,2.7.1.36,,,,,,,,,,,,,,Oral ulceration,,,https://www.ncbi.nlm.nih.gov/pubmed/30225156,,,,,,,,,,
1548,,260920,Hyperimmunoglobulinemia D,,MVK,mevalonate kinase,2.7.1.36,Anakinra+ tocilizumab,,,ECO:0001565/ECO:0000352,,,,,,,,,,Inflammation,,,https://www.ncbi.nlm.nih.gov/pubmed/25173351,,,,,,,,,,
1549,201,236800,hydroxykynureninuria,,KYNU,kynureninase,2.7.1.36,Niacin,,DB00627,ECO:0000352,,,,,Functional interaction (B),B,,,,dermatitis,,HP:0011123,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2019216/pdf/archdisch01582-0040.pdf,,,,,,,,,,
1550,,236800,hydroxykynureninuria,,KYNU,kynureninase,2.7.1.36,,,,,,,,,,,,,,diarrhoea,,HP:0002014,https://www.ncbi.nlm.nih.gov/pubmed/14169454,,,,,,,,,,
1551,,236800,hydroxykynureninuria,,KYNU,kynureninase,2.7.1.36,,,,,,,,,,,,,,dementia,,HP:0000726,https://www.ncbi.nlm.nih.gov/pubmed/17334708,,,,,,,,,,
1552,,236800,hydroxykynureninuria,,KYNU,kynureninase,2.7.1.36,ascorbic acid,,DB00126,ECO:0000352,,,,,Symptomatic (C),C,,,,,,HP:0000726,https://www.ncbi.nlm.nih.gov/pubmed/10540864,,,,,,,,,,
1553,202,607015,Hurler-Scheie syndrome,,IDUA,alpha-L-iduronidase,2.7.1.36,Laronidase,,DB00090,ECO:0007121,,,,,Direct interaction (A),A,,,,Low Forced Vital Capacity,,HP:0002111,https://clinicaltrials.gov/ct2/show/results/NCT00912925?cond=Hurler-Scheie+Syndrome&rank=1&sect=X8ca970156#outcome2,,,,,,,,,,
1554,,607015,Hurler-Scheie syndrome,,IDUA,alpha-L-iduronidase,2.7.1.36,,,,,,,,,,,,,,High Apnea/Hypopnea Index(sleep apnea)*,,HP:0010535*,,,,,,,,,,,
1555,,607015,Hurler-Scheie syndrome,,IDUA,alpha-L-iduronidase,2.7.1.36,,,,,,,,,,,,,,Decreased pulmonary function,,HP:0005952,,,,,,,,,,,
1556,,607015,Hurler-Scheie syndrome,,IDUA,alpha-L-iduronidase,2.7.1.36,,,,,,,,,,,,,,Hepatomegaly,,HP:0002240,,,,,,,,,,,
1557,,607015,Hurler-Scheie syndrome,,IDUA,alpha-L-iduronidase,2.7.1.36,,,,,,,,,,,,,,Limitation of the Joint range of motion,,HP:0001376,,,,,,,,,,,
1558,,607015,Hurler-Scheie syndrome,,IDUA,alpha-L-iduronidase,2.7.1.36,,,,,,,,,,,,,,Six Minute Walk Test,,NA,,,,,,,,,,,
1559,,607015,Hurler-Scheie syndrome,,IDUA,alpha-L-iduronidase,2.7.1.36,Nanotechnology-based gene therapy,,NA,ECO:0001565,,,,,Direct interaction (A),A,,,,Low IDUA activity(Abnormal enzyme activity)*,,HP:0012379,https://www.ncbi.nlm.nih.gov/pubmed/29122734,,,,,,,,,,
1560,,607015,Hurler-Scheie syndrome,,IDUA,alpha-L-iduronidase,2.7.1.36,,,,,,,,,,,,,,,,,,,,,,,,,,,
1561,,607015,Hurler-Scheie syndrome,,IDUA,alpha-L-iduronidase,2.7.1.36,GNeo-IDUA,"GNeo-IDUA and IDUA injected intravenously resulted in reduced hepatic glycosaminoglycan accumulation but had no effect in the brain due to fast clearance from the circulation. In contrast, intranasally administered GNeo-IDUA entered the brain rapidly. Repetitive intranasal treatment with GNeo-IDUA reduced glycosaminoglycan storage, lysosome size and number, and neurodegenerative astrogliosis in the olfactory bulb and primary somatosensory cortex, whereas IDUA was less effective. The enhanced efficacy of GNeo-IDUA was not the result of increased nose-to-brain delivery or enzyme stability, but rather due to more efficient uptake into neurons and astrocytes. https://www.ncbi.nlm.nih.gov/pubmed/28958576",NA,ECO:0005542,,,,,Direct interaction (A),A,,,,neurodegenerative astrogliosis,,HP:0002180*,https://www.ncbi.nlm.nih.gov/pubmed/28958576,,,,,,,,,,
1562,,607015,Hurler-Scheie syndrome,,IDUA,alpha-L-iduronidase,2.7.1.36,,,,,,,,,,,,,,glycosaminoglycan accumulation,,HP:0004371,,,,,,,,,,,
1563,203,607014,Hurler syndrome,,IDUAgene,"iduronidase, alpha-L",2.7.1.36,Laronidase (IRT),,DB00090,ECO:0000352,,,,,Direct interaction (A),A,,,,Hepatosplenomegaly,,HP:0001433,https://www.ncbi.nlm.nih.gov/pubmed/11172140,https://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=132&Disease(s)/group%20of%20diseases=Mucopolysaccharidosis-type-1&title=Mucopolysaccharidosis%20type%201&search=Disease_Search_Simple&ChdId=0,https://clinicaltrials.gov/ct2/show/NCT00638547?cond=Hurler+syndrome&rank=1,,,,,,,,
1564,,607014,Hurler syndrome,,IDUAgene,"iduronidase, alpha-L",2.7.1.36,,,,,,,,,,,,,,Abnormality of joint mobility,,HP:0011729,,,,,,,,,,,
1565,,607014,Hurler syndrome,,IDUAgene,"iduronidase, alpha-L",2.7.1.36,,,,,,,,,,,,,,Sleep apnea,,HP:0010535,,,,,,,,,,,
1566,,607014,Hurler syndrome,,IDUAgene,"iduronidase, alpha-L",2.7.1.36,,,,,,,,,,,,,,Nocturnal hypopnea,,HP:0002877,,,,,,,,,,,
1567,,607014,Hurler syndrome,,IDUAgene,"iduronidase, alpha-L",2.7.1.36,,,,,,,,,,,,,,Abnormal apnea–hypopnea index,,NA,,,,,,,,,,,
1568,,607014,Hurler syndrome,,IDUAgene,"iduronidase, alpha-L",2.7.1.36,,,,,,,,,,,,,,Urinary glycosaminoglycan excretion,,HP:0003541,,,,,,,,,,,
1569,,607014,Hurler syndrome,,IDUAgene,"iduronidase, alpha-L",2.7.1.36,,,,,,,,,,,,,,photophobia,,HP:0000613,,,,,,,,,,,
1570,,607014,Hurler syndrome,,IDUAgene,"iduronidase, alpha-L",2.7.1.36,,,,,,,,,,,,,,conjunctival irritation,,HP:0030953,,,,,,,,,,,
1571,,607014,Hurler syndrome,,IDUAgene,"iduronidase, alpha-L",2.7.1.36,,,,,,,,,,,,,,impaired Visual acuity,,HP:0007663,,,,,,,,,,,
1572,,607014,Hurler syndrome,,IDUAgene,"iduronidase, alpha-L",2.7.1.36,,,,,,,,,,,,,,low exercise endurance,,NA,,,,,,,,,,,
1573,,607014,Hurler syndrome,,IDUAgene,"iduronidase, alpha-L",2.7.1.36,,,,,,,,,,,,,,tricuspid regurgitation,,HP:0005180,,,,,,,,,,,
1574,,607014,Hurler syndrome,,IDUAgene,"iduronidase, alpha-L",2.7.1.36,,,,,,,,,,,,,,pulmonary regurgitation,,HP:0010444,,,,,,,,,,,
1575,,607014,Hurler syndrome,,IDUAgene,"iduronidase, alpha-L",2.7.1.36,,,,,,,,,,,,,,dyspnea at rest,,HP:0012763,,,,,,,,,,,
1576,,607014,Hurler syndrome,,IDUAgene,"iduronidase, alpha-L",2.7.1.36,,,,,,,,,,,,,,pitting edema,,HP:0000969,,,,,,,,,,,
1577,,607014,Hurler syndrome,,IDUAgene,"iduronidase, alpha-L",2.7.1.36,,,,,,,,,,,,,,low quality of sleep,,HP:0002360,,,,,,,,,,,
1578,,607014,Hurler syndrome,,IDUAgene,"iduronidase, alpha-L",2.7.1.36,,,,,,,,,,,,,,Daytime somnolence,,HP:0002189,,,,,,,,,,,
1579,,607014,Hurler syndrome,,IDUAgene,"iduronidase, alpha-L",2.7.1.36,,,,,,,,,,,,,,white matter abnormalities,,HP:0002500,https://www.ncbi.nlm.nih.gov/pubmed/19748810,,,,,,,,,,
1580,,607014,Hurler syndrome,,IDUAgene,"iduronidase, alpha-L",2.7.1.36,,,,,,,,,,,,,,brain ventricular dilatation,,HP:0002119,,,,,,,,,,,
1581,,607014,Hurler syndrome,,IDUAgene,"iduronidase, alpha-L",2.7.1.36,,,,,,,,,,,,,,brain MRI abnormalities,,HP:0002500,,,,,,,,,,,
1582,,607014,Hurler syndrome,,IDUAgene,"iduronidase, alpha-L",2.7.1.36,Gene therapy,Retroviral vector carrying the full-length cDNA for alpha-L-iduronidase,NA,ECO:0001565,,,,,Direct interaction (A),A,,,In Vitro Experiment,Lysosomal storage abnormalities(Abnormality of lysosomal metabolism)*,,HP:0004356,https://www.ncbi.nlm.nih.gov/pubmed/8700879,https://www.ncbi.nlm.nih.gov/pubmed/30081189,,,,,,,,,
1583,,607014,Hurler syndrome,,IDUAgene,"iduronidase, alpha-L",2.7.1.36,Gene therapy,,NA,ECO:0005542,,,,,Direct interaction (A),A,,,in vivo (mice),ventricular hypertrophy,,HP:0001714,https://www.ncbi.nlm.nih.gov/pubmed/30170069,https://www.ncbi.nlm.nih.gov/pubmed/30081189,,,,,,,,,
1584,,607014,Hurler syndrome,,IDUAgene,"iduronidase, alpha-L",2.7.1.36,,,,,,,,,,,,,,cardiac dilation/ Heart enlargment/ cardimegaly,,HP:0001640,,,,,,,,,,,
1585,,607014,Hurler syndrome,,IDUAgene,"iduronidase, alpha-L",2.7.1.36,,,,,,,,,,,,,,left ventricularc contractility abnormalities,,HP:0006670*,,,,,,,,,,,
1586,,607014,Hurler syndrome,,IDUAgene,"iduronidase, alpha-L",2.7.1.36,,,,,,,,,,,,,,Left ventricle dysfunction,,HP:0030872,,,,,,,,,,,
1587,204,603174,Homocystinuria due to MTHFR deficiency,,MTHFR,methylenetetrahydrofolate reductase,1.5.1.20,Methyltetrahydrofolic acid+Hydroxocobalamin+pyridoxine+ betaine,,DB04789 + DB00200 +DB00165+ DB06756,ECO:0000352,,,,,Symptomatic (C),C,,,,Abnormal Folate level,,HP:0040087,https://www.ncbi.nlm.nih.gov/pubmed/11916316,,,,,,,,,,
1588,,603174,Homocystinuria due to MTHFR deficiency,,MTHFR,methylenetetrahydrofolate reductase,1.5.1.20,,,,,,,,,,,,,,Abnormal serum Methylfolate Level,,NA,,,,,,,,,,,
1589,,603174,Homocystinuria due to MTHFR deficiency,,MTHFR,methylenetetrahydrofolate reductase,1.5.1.20,Betaine+Folinic acid,"The responce to treatment reported to be poor in two patients, may be due to delayed start of treatment and the coexistence of 2 very harmful mutations, which, together with the p.A222V polymorphism, are known to reduce MTHFR enzyme activity. https://www.ncbi.nlm.nih.gov/pubmed/12673793?dopt=Abstract",DB06756+DB00650,ECO:0000352,,,,,Functional interaction (B),B,,,,Abnormality of homocysteine metabolism,,HP:0010919,https://www.ncbi.nlm.nih.gov/pubmed/25024447,,,,,,,,,,
1590,,603174,Homocystinuria due to MTHFR deficiency,,MTHFR,methylenetetrahydrofolate reductase,1.5.1.20,,,,,,,,,,,,,,low muscle tone,,HP:0001290,,,,,,,,,,,
1591,,603174,Homocystinuria due to MTHFR deficiency,,MTHFR,methylenetetrahydrofolate reductase,1.5.1.20,Topiramate,,DB00273,ECO:0000352,,,,,Symptomatic (C),C,,,Symptomatic © + Mechanistic (B),seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/25024447,,,,,,,,,,
1592,,603174,Homocystinuria due to MTHFR deficiency,,MTHFR,methylenetetrahydrofolate reductase,1.5.1.20,"Betaine, Folic acid, Vitamin B6 , Vitamin B12",,DB06756+DB00158+DB00165+DB00115,ECO:0000352,,,,,Symptomatic (C),C,,,,High plasma homocysteine level(Abnormal homocysteine level)*,,HP:0010919,https://www.ncbi.nlm.nih.gov/pubmed/29246599,,,,,,,,,,
1593,,603174,Homocystinuria due to MTHFR deficiency,,MTHFR,methylenetetrahydrofolate reductase,1.5.1.20,Vitamin B+Betaine,"Due to prenatal diagnosis ofthe patient, early treatment with B vitamins and betaine had a favorable outcome. https://www.ncbi.nlm.nih.gov/pubmed/20356773",DB00165+DB6756,ECO:0000352,,,,,Functional interaction (B),,,,,Developmental abnormality,,HP:0012759,https://www.ncbi.nlm.nih.gov/pubmed/20356773,,,,,,,,,,
1594,205,236200,Homocystinuria due to CBS deficiency,"Current treatment includes (i) the administration of pyridoxine to putatively stimulate the residual CBSactivity; (ii)restriction of dietary methionine intake to decrease the load in the affected pathway; (iii) supplementation of cystine to correct cysteine deficiency; and (iv)administration of betaine, folic acid and cobalamin to facilitate the remethylationof homocysteine back to methionine.",CBS,cystathionine beta-synthase,4.2.1.22,Pyridoxine,pyridoxine-responsive patients exhibit higher residual CBS activity in their cultured fibroblasts (typically 1–9%) or in plasma (typically 4–22%) (Fowler et al. 1978; Alcaide et al. 2015).,DB00165,ECO:0000352/ECO:0005542,"P49L, A114V, I278T, R266K, or R336H",,"R125Q, E176K, T191M, T262M, or G307S",,Functional interaction (B),B,,,Mehanistic(B),Misfolding of cystathionine β-synthase(Abnormal enzyme activity)*,,HP:0012379*,https://www.ncbi.nlm.nih.gov/pubmed/29119254,https://www.ncbi.nlm.nih.gov/pubmed/16619244?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/24355692?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/14739681,,,,,,,
1595,,236200,Homocystinuria due to CBS deficiency,,CBS,cystathionine beta-synthase,4.2.1.22,δ-aminolevulinate,,DB00855,ECO:0001565,R125Q,,,,Symptomatic (C),C,,,,Misfolding of cystathionine β-synthase(Abnormal enzyme activity)*,,HP:0012379*,https://www.ncbi.nlm.nih.gov/pubmed/20490928?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/16619244?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/24355692?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/14739681,,,,,,,
1596,,236200,Homocystinuria due to CBS deficiency,,CBS,cystathionine beta-synthase,4.2.1.22,,,,,R266K,,,,,,,,,Homocystinuria,,HP:0002156,,,,,,,,,,,
1597,,236200,Homocystinuria due to CBS deficiency,,CBS,cystathionine beta-synthase,4.2.1.22,,,,,,,H65R,,,,,,,,,,,,,,,,,,,,
1598,,236200,Homocystinuria due to CBS deficiency,,CBS,cystathionine beta-synthase,4.2.1.22,S-Adenosylmethionine,,DB00118,ECO:0001565,,,,,Direct interaction (A),A,,,,"The approach is likely unsuccessful due to reactive properties, intrinsic instability, and charged character of SAM.",,,https://www.ncbi.nlm.nih.gov/pubmed/20506325?dopt=Abstract,,,,,,,,,,
1599,,236200,Homocystinuria due to CBS deficiency,,CBS,cystathionine beta-synthase,4.2.1.22,bortezomib,"These data provide strong preclinical evidence that proteasome inhibitors should be considered as potentially useful in treatment of misfolding diseases caused by a missense mutation, such as HCU",DB00188,ECO:0005542,I278T,,,,Direct interaction (A),A,,,Tried on Mice not human,Misfolding of cystathionine β-synthase(Abnormal enzyme activity)*,,,https://www.ncbi.nlm.nih.gov/pubmed/23592311?dopt=Abstract,,,,,,,,,,
1600,,236200,Homocystinuria due to CBS deficiency,,CBS,cystathionine beta-synthase,4.2.1.22,ONX-0912,,DB11991,ECO:0005542,S466L /I278T,"However, response rates varied, with 100% (8/8) of the p.S466L animals showing correction, but only 38% (10/26) of the p.I278T animals.https://www.ncbi.nlm.nih.gov/pubmed/23592311?dopt=Abstract",,,Direct interaction (A),A,,,Tried on Mice not human,Abnormal Hcy level,,HP:0010919*,https://www.ncbi.nlm.nih.gov/pubmed/23592311?dopt=Abstract,,,,,,,,,,
1601,,236200,Homocystinuria due to CBS deficiency,,CBS,cystathionine beta-synthase,4.2.1.22,,,,,,,,,,,,,,Homocystinuria,,HP:0002156,,,,,,,,,,,
1602,,236200,Homocystinuria due to CBS deficiency,,CBS,cystathionine beta-synthase,4.2.1.22,pyridoxine/betaine,"Current treatment includes (i) the administration of pyridoxine to putatively stimulate the residual CBSactivity; (ii)restriction of dietary methionine intake to decrease the load in the affected pathway; (iii) supplementation of cystine to correct cysteine deficiency; and (iv)administration of betaine, folic acid and cobalamin to facilitate the remethylationof homocysteine back to methionine.",DB00165/DB06756,ECO:0000352,,,,,Functional interaction (B),B,,,,High total homocysteine levels,,HP:0002160,https://www.ncbi.nlm.nih.gov/pubmed/14739681,,,,,,,,,,
1603,,236200,Homocystinuria due to CBS deficiency,,CBS,cystathionine beta-synthase,4.2.1.22,,,,,,,,,,,,,,High total cysteine levels,,HP:0010918,,,,,,,,,,,
1604,,236200,Homocystinuria due to CBS deficiency,,CBS,cystathionine beta-synthase,4.2.1.22,,,,,,,,,,,,,,Low plasma serine levels,,HP:0012279,,,,,,,,,,,
1605,,236200,Homocystinuria due to CBS deficiency,,CBS,cystathionine beta-synthase,4.2.1.22,,,,,,,,,,,,,,high blood S -adenosylhomocysteine level,,NA,,,,,,,,,,,
1606,,236200,Homocystinuria due to CBS deficiency,,CBS,cystathionine beta-synthase,4.2.1.22,serine,"There was no studies, but since there is an observation of low plasma serine conc. in untreated CBS-deficient patients that merits further exploration since supplementation with serine might be a novel and safe component of treatment of homocystinuria.",DB00133,ECO:0007764,,,,,Symptomatic (C),C,,,No trials / speculation,,,NA,,,,,,,,,,,
1607,206,602360,L-arginine:glycine amidinotransferase (AGAT) deficiency,,GATM,arginine:glycine amidinotransferase,2.1.4.1,creatine/Creatine phosphate,,DB00148/DB13191,ECO:0000352,,,,,Functional interaction(Mechinistic B),B,,,,muscle weakness,,HP:0001324,https://www.ncbi.nlm.nih.gov/pubmed/22386973,https://www.ncbi.nlm.nih.gov/pubmed/20625172,,,,,,,,,
1608,,602360,L-arginine:glycine amidinotransferase (AGAT) deficiency,,GATM,arginine:glycine amidinotransferase,2.1.4.1,,,,,,,,,Functional interaction (B),B,,,,Low cerebral creatine content,,HP:0012113*,,,,,,,,,,,
1609,,602360,L-arginine:glycine amidinotransferase (AGAT) deficiency,,GATM,arginine:glycine amidinotransferase,2.1.4.1,,,,,,,,,,,,,,Low developmental score,,HP:0012759*,,,,,,,,,,,
1610,,602360,L-arginine:glycine amidinotransferase (AGAT) deficiency,,GATM,arginine:glycine amidinotransferase,2.1.4.1,,,,,,,,,,,,,,neurodevelopmental delay,,HP:0012758,,,,,,,,,,,
1611,,602360,L-arginine:glycine amidinotransferase (AGAT) deficiency,,GATM,arginine:glycine amidinotransferase,2.1.4.1,,,,,,,,,,,,,,cognitive dysfunction,,HP:0100543,https://www.ncbi.nlm.nih.gov/pubmed/20682460,,,,,,,,,,
1612,,602360,L-arginine:glycine amidinotransferase (AGAT) deficiency,,GATM,arginine:glycine amidinotransferase,2.1.4.1,,,,,,,,,,,,,,Low IQ score,,HP:0001249,,,,,,,,,,,
1613,,602360,L-arginine:glycine amidinotransferase (AGAT) deficiency,,GATM,arginine:glycine amidinotransferase,2.1.4.1,,,,,,,,,,,,,,language impairment,,HP:0002463,https://www.ncbi.nlm.nih.gov/pubmed/23770102,,,,,,,,,,
1614,,602360,L-arginine:glycine amidinotransferase (AGAT) deficiency,,GATM,arginine:glycine amidinotransferase,2.1.4.1,,,,,,,,,,,,,,behavior al abnormalities,,HP:0000708,,,,,,,,,,,
1615,,602360,L-arginine:glycine amidinotransferase (AGAT) deficiency,,GATM,arginine:glycine amidinotransferase,2.1.4.1,,,,,,,,,,,,,,communicative skills abnormalities,,HP:0002474*,,,,,,,,,,,
1616,,602360,L-arginine:glycine amidinotransferase (AGAT) deficiency,,GATM,arginine:glycine amidinotransferase,2.1.4.1,,,,,,,,,,,,,,psychomotor retardation,,HP:0001263,,,,,,,,,,,
1617,,602360,L-arginine:glycine amidinotransferase (AGAT) deficiency,,GATM,arginine:glycine amidinotransferase,2.1.4.1,,,,,,,,,,,,,,METABOLIC ENCEPHALOMYOPATHY,,NA,https://www.ncbi.nlm.nih.gov/pubmed/20625172,,,,,,,,,,
1618,207,# 612933,Lactate dehydrogenase A deficiency,,LDHA,"lactate dehydrogenase-A, which is one piece (subunit) of the lactate dehydrogenase enzyme",1.1.1.27,No treatment is available in DDIEM,,,,,,,,,,,,,,,NA,https://www.ncbi.nlm.nih.gov/pubmed/20625172,,,,,,,,,,
1619,208,# 614128,Lactate dehydrogenase deficiency,,LDHB/LDHA,"lactate dehydrogenase-A, which is one piece (subunit) of the lactate dehydrogenase enzyme",1.1.1.27,No treatment is available in DDIEM,,,,,,,,,,,,,,,NA,https://www.ncbi.nlm.nih.gov/pubmed/20625172,,,,,,,,,,
1620,209,607330,Lathosterolosis,,SC5D,3-beta-hydroxysteroid-delta-5-desaturase,1.1.1.27,cholesterol,,DB04540,ECO:0000352,,,,,Functional interaction (B),B,,,,Abnormal blood lathosterol level,,HP:0001939*,https://www.ncbi.nlm.nih.gov/pubmed/24142275,,,,,,,,,,
1621,,607330,Lathosterolosis,,SC5D,3-beta-hydroxysteroid-delta-5-desaturase,1.1.1.27,Simvastatin,The drug has been reported to be unbeneficial in one patient .,DB00641,ECO:0000352,p.K148E and p.D210E,,,,Functional interaction (B),B,,,,Abnormal neurodevelopmental profile,,HP:0012759,,,,,,,,,,,
1622,,607330,Lathosterolosis,,SC5D,3-beta-hydroxysteroid-delta-5-desaturase,1.1.1.27,,,,,,,,,,,,,,developmental delay,,HP:0001263,,,,,,,,,,,
1623,,607330,Lathosterolosis,,SC5D,3-beta-hydroxysteroid-delta-5-desaturase,1.1.1.27,,,,,,,c.479C>G p.(Pro160Arg) and c.630C>A p.(Asp210Glu),,,,,,Controversial,,,,https://www.ncbi.nlm.nih.gov/pubmed/30097991,,,,,,,,,,
1624,210,600890,LCHAD deficiency (long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency),,HADHA,3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase,1.1.1.211/4.2.1.17,heptanoate,,CHEBI:32362,ECO:0000352,,,,,Symptomatic (C),C,,,,elevation of creatine kinase,,HP:0003236,https://www.ncbi.nlm.nih.gov/pubmed/24997711/,,,,,,,,,,
1625,,600890,LCHAD deficiency (long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency),,HADHA,3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase,1.1.1.211/4.2.1.17,Docosahexaenoic acid (DHA),Dietry treatment supplementation,DB03756,ECO:0007121,,,,,Symptomatic (C),C,,,,metabolic acidosis,,HP:0001942,https://www.ncbi.nlm.nih.gov/pubmed/16040264/,,,,,,,,,,
1626,,600890,LCHAD deficiency (long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency),,HADHA,3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase,1.1.1.211/4.2.1.17,bezafibrate,,DB01393,ECO:0001565,c.1528G > C,,c.1528G > C,,Direct interaction ( Mechanistic A),A,,,,Abnormal Fatty acid oxidation,,HP:0004359*,https://www.ncbi.nlm.nih.gov/pubmed/?term=bezafibrate+in+treating+LCHAD+deficiency+(long-chain+3-hydroxyacyl-CoA+dehydrogenase+deficiency),,,,,,,,,,
1627,,600890,LCHAD deficiency (long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency),,HADHA,3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase,1.1.1.211/4.2.1.17,,,,,C2129-2A > C,,,,,,,,,Low LONG-CHAIN 3-HYDROXYACYL-CoA DEHYDROGENASE activity,,NA,,,,,,,,,,,
1628,,600890,LCHAD deficiency (long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency),,HADHA,3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase,1.1.1.211/4.2.1.17,,,,,c. 1393_1479del-Del exon,,,,,,,,,,,,,,,,,,,,,,
1629,,600890,LCHAD deficiency (long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency),,HADHA,3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase,1.1.1.211/4.2.1.17,,,,,c.180 + 3A > G,,,,,,,,,,,,,,,,,,,,,,
1630,,600890,LCHAD deficiency (long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency),,HADHA,3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase,1.1.1.211/4.2.1.17,,,,,c.914 T > A,,,,,,,,,,,,,,,,,,,,,,
1631,,600890,LCHAD deficiency (long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency),,HADHA,3-hydroxyacyl-CoA dehydrogenase/enoyl-CoA hydratase,1.1.1.211/4.2.1.17,,,,,c.982G > A and c.1072C > A,,,,,,,,,,,,,,,,,,,,,,
1632,211,535000,Leber hereditary optic neuropathy,,MT-ND1/MT-ND4L/MT-ND6,mitochondrially encoded NADH dehydrogenase 1/mitochondrially encoded NADH 4L dehydrogenase/ mitochondrially encoded NADH dehydrogenase 6,1.1.1.211/4.2.1.17,,No treatment is available in DDIEM,,,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/30107658,,,,,,,,,,
1633,,535000,Leber hereditary optic neuropathy,,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,1.1.1.211/4.2.1.17,AAV-SOD2 (adeno-associated viral vector containing the human mitochondrial superoxide dismutase (SOD2) gene),,NA,ECO:0007121,G11778A,,,,Functional interaction(Mechinistic B),B,,,,Optic nerve damage,,HP:0001138,https://www.ncbi.nlm.nih.gov/pubmed/17296905,,,,,,,,,,
1634,,535000,Leber hereditary optic neuropathy,,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,1.1.1.211/4.2.1.17,,,,,,,,,,,,,,Mitochondrial oxidative stress,,HP:0012103,,,,,,,,,,,
1635,,535000,Leber hereditary optic neuropathy,,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,1.1.1.211/4.2.1.17,"rAAV2-ND4 (recombinant Adeno-Associated Virus-NADH dehydrogenase, subunit 4 (complex I)（rAAV2-ND4))",,NA,ECO:0007121,G11778A,,,,Direct interaction ( Mechanistic A),A,,,,Abnormal visual acuity,,HP:0030532,https://clinicaltrials.gov/ct2/show/results/NCT01267422?cond=Leber+Hereditary+Optic+Neuropathy&rank=2&sect=X970156#outcome3,https://clinicaltrials.gov/ct2/show/NCT03153293?cond=Leber+Hereditary+Optic+Neuropathy&rank=1,,,,,,,,,
1636,,535000,Leber hereditary optic neuropathy,,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,1.1.1.211/4.2.1.17,MTS-AAV carrying the wild type ND4 gene (mitochondrial targeting signal peptide Adeno-Associated Virus),,NA,ECO:0007121,G11778A,,,,Direct interaction ( Mechanistic A),A,,,,Low ATP synthesis,,HP:0025464,https://www.ncbi.nlm.nih.gov/pubmed/30208599,,,,,,,,,,
1637,,535000,Leber hereditary optic neuropathy,,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,1.1.1.211/4.2.1.17,,,,,,,,,,,,,,Optic atrophy,,HP:0000648,,,,,,,,,,,
1638,,535000,Leber hereditary optic neuropathy,,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,1.1.1.211/4.2.1.17,,,,,,,,,,,,,,Abnormal visual acuity,,HP:0030534,,,,,,,,,,,
1639,,535000,Leber hereditary optic neuropathy,,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,1.1.1.211/4.2.1.17,,,,,,,,,,,,,,,,,,,,,,,,,,,
1640,,535000,Leber hereditary optic neuropathy,,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,1.1.1.211/4.2.1.17,Idebenone,"Author: ""The therapeutic potential of idebenone therapy is likely to have the highest impact if therapy is initiated early in the disease at a time when retinal ganglion cell loss is still minimal.https://www.ncbi.nlm.nih.gov/pubmed/21810891/",DB09081,ECO:0000352/ECO:0007121,"m.3460G>A, m.11778G>A, and m.14484T>C",,,,Symptomatic (C),C,,,,Abnormal visual acuity,,HP:0030532,https://www.ncbi.nlm.nih.gov/pubmed/11723211,https://www.ncbi.nlm.nih.gov/pubmed/11001192,https://www.ncbi.nlm.nih.gov/pubmed/17573650,https://www.ncbi.nlm.nih.gov/pubmed/21788663,https://www.ncbi.nlm.nih.gov/pubmed/21810891/,https://www.ncbi.nlm.nih.gov/pubmed/21483849/,https://www.ncbi.nlm.nih.gov/pubmed/29054473,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3202309/,,,
1641,,535000,Leber hereditary optic neuropathy,,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,1.1.1.211/4.2.1.17,,,,,,,,,Symptomatic (C),C,,,,Abnormal retinal ganglion cell function,,HP:0001112,https://clinicaltrials.gov/ct2/show/NCT00747487?cond=Leber+Hereditary+Optic+Neuropathy&rank=8,https://clinicaltrials.gov/ct2/show/NCT02771379?cond=Leber+Hereditary+Optic+Neuropathy&rank=16,https://clinicaltrials.gov/ct2/show/NCT01495715?cond=Leber+Hereditary+Optic+Neuropathy&rank=13,,,,,,,,
1642,,535000,Leber hereditary optic neuropathy,,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,1.1.1.211/4.2.1.17,Idebenone+Vitamin C+Vitamin B12,,DB09081+DB00126+DB00115,ECO:0000352,,,,,,,,,,Slow recovery,,HP:0012823*,https://www.ncbi.nlm.nih.gov/pubmed/11001192/,https://clinicaltrials.gov/ct2/show/NCT02771379?cond=Leber+Hereditary+Optic+Neuropathy&rank=16,https://clinicaltrials.gov/ct2/show/NCT01495715?cond=Leber+Hereditary+Optic+Neuropathy&rank=13,,,,,,,,
1643,,535000,Leber hereditary optic neuropathy,,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,1.1.1.211/4.2.1.17,EPI-743(Vatiquinone),,DB11917,ECO:0007121,,,,,Symptomatic (C),C,,,,Disease progression (Rapidly progressive)*,,HP:0003678*,https://clinicaltrials.gov/ct2/show/NCT02300753?cond=Leber+Hereditary+Optic+Neuropathy&draw=2&rank=4,https://www.ncbi.nlm.nih.gov/pubmed/22410442,https://clinicaltrials.gov/ct2/show/NCT01495715?cond=Leber+Hereditary+Optic+Neuropathy&rank=13,,,,,,,,
1644,,535000,Leber hereditary optic neuropathy,,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,1.1.1.211/4.2.1.17,,,,,,,,,,,,,,Abnormal visual acuity,,HP:0030534,,,,,,,,,,,
1645,,535000,Leber hereditary optic neuropathy,,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,1.1.1.211/4.2.1.17,Estrogens,,DB00783,ECO:0001565,,,,,Functional interaction(Mechinistic B),B,,,,Mitochondrial dysfunction,,HP:0003287,https://www.ncbi.nlm.nih.gov/pubmed/20943885,,,,,,,,,,
1646,,535000,Leber hereditary optic neuropathy,,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,1.1.1.211/4.2.1.17,elamipretide (MTP-131),,DB11981,ECO:0007121,,,,,Symptomatic (C),C,,,,Excessive Reactive Oxidative System,,HP:0003287,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6104515/,https://clinicaltrials.gov/ct2/show/NCT02693119?cond=Leber+Hereditary+Optic+Neuropathy&rank=3,https://clinicaltrials.gov/ct2/show/NCT02805790,,,,,,,,
1647,,535000,Leber hereditary optic neuropathy,,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,1.1.1.211/4.2.1.17,,,,,,,,,,,,,,Low ATP synthesis,,HP:0025464,,,,,,,,,,,
1648,,535000,Leber hereditary optic neuropathy,,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,1.1.1.211/4.2.1.17,Curcumin,,DB11672,ECO:0007121,,,,,Symptomatic (C),C,,,,Oxidative stress,,HP:0025464,https://clinicaltrials.gov/ct2/show/NCT00528151,,,,,,,,,,
1649,,535000,Leber hereditary optic neuropathy,,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,1.1.1.211/4.2.1.17,Cyclosporine,The cyclosporine trial (taken immediately upon visual loss in the first eye) is in progress in Leber's optic atrophy to prevent involvement of the fellow eye.,DB00091,ECO:0007121,,,,,Symptomatic (C),C,,,,Disease progression,,,https://www.ncbi.nlm.nih.gov/pubmed/24161764,https://clinicaltrials.gov/ct2/show/NCT02176733?cond=Leber+Hereditary+Optic+Neuropathy&rank=12,,,,,,,,,
1650,,535000,Leber hereditary optic neuropathy,,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,1.1.1.211/4.2.1.17,Corticosteroid+Antiaggregates,,H02+B01A,ECO:0000352,,,,,Symptomatic (C),,,,,Large central visual field defect,,HP:0001129,https://www.ncbi.nlm.nih.gov/pubmed/11723211,https://clinicaltrials.gov/ct2/show/NCT02176733?cond=Leber+Hereditary+Optic+Neuropathy&rank=12,,,,,,,,,
1651,,535000,Leber hereditary optic neuropathy,,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,1.1.1.211/4.2.1.17,,,,,,,,,,,,,,,,,,,,,,,,,,,
1652,,535000,Leber hereditary optic neuropathy,,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,1.1.1.211/4.2.1.17,,,,,,,,,,,,,,,,,,,,,,,,,,,
1653,,535000,Leber hereditary optic neuropathy,,MT-ND4,mitochondrially encoded NADH dehydrogenase 4,1.1.1.211/4.2.1.17,,,,,,,,,,,,,,,,,,,,,,,,,,,
1654,212,220111,"Leigh syndrome, French Canadian type","Antioxidants (idebenone, N-acetyl cysteine, resveratrol) exacerbate palmitate plus lactate-induced cell death Collectively, our results raise some concerns about the potential negative impact of a high-fat diet and of antioxidant treatments in LSFC patients.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383560/",LRPPRC,leucine-rich pentatricopeptide repeat-containing protein,1.1.1.211/4.2.1.17,methylene blue,,DB09241,ECO:0001565,A354V,,,,Functional interaction (B),B,,,,Low COX content and activity,,NA,https://www.ncbi.nlm.nih.gov/pubmed/22202226,,,,,,,,,,
1655,,220111,"Leigh syndrome, French Canadian type",,LRPPRC,leucine-rich pentatricopeptide repeat-containing protein,1.1.1.211/4.2.1.17,,,,,A354V and C12775STOP,,,,,,,,,acidotic crises,,HP:0001941*,,,,,,,,,,,
1656,,220111,"Leigh syndrome, French Canadian type",,LRPPRC,leucine-rich pentatricopeptide repeat-containing protein,1.1.1.211/4.2.1.17,propionate,,DB03766,ECO:0001565,,,,,Symptomatic (C),C,,,,Palmitate plus lactate-induced cell death,,NA,https://www.ncbi.nlm.nih.gov/pubmed/25835550,,,,,,,,,,
1657,,220111,"Leigh syndrome, French Canadian type",,LRPPRC,leucine-rich pentatricopeptide repeat-containing protein,1.1.1.211/4.2.1.17,L-carnitine,,DB00583,ECO:0001565,,,,,Symptomatic (C),C,,,,PL-induced cytotoxicity,,NA,https://www.ncbi.nlm.nih.gov/pubmed/25835550,,,,,,,,,,
1658,,220111,"Leigh syndrome, French Canadian type",,LRPPRC,leucine-rich pentatricopeptide repeat-containing protein,1.1.1.211/4.2.1.17,Trolox ornithylamide hydrochloride,,,ECO:0001565,,,,,Symptomatic (C),,,,,Increased ROS production,,HP:0025464,https://www.ncbi.nlm.nih.gov/pubmed/25620325/,,,,,,,,,,
1659,,220111,"Leigh syndrome, French Canadian type",,LRPPRC,leucine-rich pentatricopeptide repeat-containing protein,1.1.1.211/4.2.1.17,,,,,,,,,,,,,,Decreased activity of mitochondrial complex I,,HP:0011923,,,,,,,,,,,
1660,,220111,"Leigh syndrome, French Canadian type",,LRPPRC,leucine-rich pentatricopeptide repeat-containing protein,1.1.1.211/4.2.1.17,,,,,,,,,,,,,,Decreased activity of mitochondrial complex IV,,HP:0008347,,,,,,,,,,,
1661,,220111,"Leigh syndrome, French Canadian type",,LRPPRC,leucine-rich pentatricopeptide repeat-containing protein,1.1.1.211/4.2.1.17,,,,,,,,,,,,,,,,,,,,,,,,,,,
1662,213,300322,Lesch Nyhan syndrom,,HPRT1,hypoxanthine phosphoribosyltransferase 1,1.1.1.211/4.2.1.17,Ecopipam ((PSYRX 101),,DB12273,ECO:0007121,,,,,Symptomatic (C),C,,,,Self-injurious Behavior,,HP:0100716,https://clinicaltrials.gov/ct2/show/results/NCT01751802?cond=Lesch-Nyhan+Disease&rank=3&sect=X70156#outcome1,https://clinicaltrials.gov/ct2/show/results/NCT01065558?cond=Lesch-Nyhan+Disease&rank=2&sect=X01256#all,https://www.ncbi.nlm.nih.gov/pubmed/26922636/,https://www.ncbi.nlm.nih.gov/pubmed/27179999/,,,,,,,
1663,,300322,Lesch Nyhan syndrom,,HPRT1,hypoxanthine phosphoribosyltransferase 1,1.1.1.211/4.2.1.17,sapropterin,,DB00360,ECO:0007121,,,,,Symptomatic (C),C,,,,Behaviour abnormalities,,HP:0100851,https://clinicaltrials.gov/ct2/show/NCT00935753,,,,,,,,,,
1664,,300322,Lesch Nyhan syndrom,,HPRT1,hypoxanthine phosphoribosyltransferase 1,1.1.1.211/4.2.1.17,aminomidazole carboxamide riboside,,NA,ECO:0007121,,,,,Functional interaction (B),B,,,,No result was added,,,https://clinicaltrials.gov/ct2/show/NCT00004314?cond=Lesch-Nyhan+Disease&rank=4,,,,,,,,,,
1665,,300322,Lesch Nyhan syndrom,,HPRT1,hypoxanthine phosphoribosyltransferase 1,1.1.1.211/4.2.1.17,Hypoxanthine+ tetrahydrobiopterin,,DB04076+DB00360,ECO:0000352,,,,,Functional interaction (B),B,,,,No result was accessible,,,https://www.ncbi.nlm.nih.gov/pubmed/3728152,,,,,,,,,,
1666,,300322,Lesch Nyhan syndrom,,HPRT1,hypoxanthine phosphoribosyltransferase 1,1.1.1.211/4.2.1.17,SAM,,DB00118,ECO:0007121,,,,,,,,,,Self-injurious behaviour,,HP:0100716,https://www.ncbi.nlm.nih.gov/pubmed/16906475/,https://www.ncbi.nlm.nih.gov/pubmed/24001191/,https://www.ncbi.nlm.nih.gov/pubmed/24055166/,,,,,,,,
1667,,300322,Lesch Nyhan syndrom,,HPRT1,hypoxanthine phosphoribosyltransferase 1,1.1.1.211/4.2.1.17,,,,,,,,,,,,,,Aggressive behavior,,HP:0000718,https://www.ncbi.nlm.nih.gov/pubmed/24055166/,,,,,,,,,,
1668,,300322,Lesch Nyhan syndrom,,HPRT1,hypoxanthine phosphoribosyltransferase 1,1.1.1.211/4.2.1.17,,,,,,,,,,,,,,,,,,,,,,,,,,,
1669,,300322,Lesch Nyhan syndrom,,HPRT1,hypoxanthine phosphoribosyltransferase 1,1.1.1.211/4.2.1.17,Allopurinol,"Treatment with allopurinol was associated with xanthine lithiasis. https://www.ncbi.nlm.nih.gov/pubmed/17065067 
https://www.ncbi.nlm.nih.gov/pubmed/16773422/",DB00437,ECO:0000352,,,,,Symptomatic (C),C,,,,hyperuricemia,,HP:0002149,https://www.ncbi.nlm.nih.gov/pubmed/17065067,https://www.ncbi.nlm.nih.gov/pubmed/22198833,https://rarediseases.org/rare-diseases/lesch-nyhan-syndrome/,,,,,,,,
1670,,300322,Lesch Nyhan syndrom,,HPRT1,hypoxanthine phosphoribosyltransferase 1,1.1.1.211/4.2.1.17,,,,,,,,,,,,,,gouty arthritis,,HP:0001997,,,,,,,,,,,
1671,,300322,Lesch Nyhan syndrom,,HPRT1,hypoxanthine phosphoribosyltransferase 1,1.1.1.211/4.2.1.17,,,,,,,,,,,,,,,,,,,,,,,,,,,
1672,,300322,Lesch Nyhan syndrom,,HPRT1,hypoxanthine phosphoribosyltransferase 1,1.1.1.211/4.2.1.17,Baclofen,,DB00181,ECO:0000352,,,,,Symptomatic (C),C,,,,Spasticity,,HP:0001257,https://www.ncbi.nlm.nih.gov/pubmed/16549399,,,,,,,,,,
1673,,300322,Lesch Nyhan syndrom,,HPRT1,hypoxanthine phosphoribosyltransferase 1,1.1.1.211/4.2.1.17,diazepam or alprazolam,,DB00829 or DB00404,ECO:0000352,,,,,Symptomatic (C),C,,,,anxiety,,HP:0000739,https://www.ncbi.nlm.nih.gov/pubmed/21126241,,,,,,,,,,
1674,,300322,Lesch Nyhan syndrom,,HPRT1,hypoxanthine phosphoribosyltransferase 1,1.1.1.211/4.2.1.17,,,,,Spa,,,,,,,,,Abnormal muscle tone,,HP:0003808,https://www.ncbi.nlm.nih.gov/pubmed/21126241,,,,,,,,,,
1675,,300322,Lesch Nyhan syndrom,,HPRT1,hypoxanthine phosphoribosyltransferase 1,1.1.1.211/4.2.1.17,Risperidone,,DB00734,ECO:0000352,,,,,Symptomatic (C),,,,,Self-mutilation,,HP:0000742,https://www.ncbi.nlm.nih.gov/pubmed/8870064/,,,,,,,,,,
1676,,300322,Lesch Nyhan syndrom,,HPRT1,hypoxanthine phosphoribosyltransferase 1,1.1.1.211/4.2.1.17,Tetrabenazin,,DB04844,ECO:0000352,,,,,Symptomatic (C),,,,,Chorea,,HP:0002072,https://www.ncbi.nlm.nih.gov/pubmed/2455472/,https://www.ncbi.nlm.nih.gov/pubmed/12593632,,,,,,,,,
1677,,300322,Lesch Nyhan syndrom,,HPRT1,hypoxanthine phosphoribosyltransferase 1,1.1.1.211/4.2.1.17,,,,,,,,,,,,,,Dystonia,,HP:0001332,https://www.ncbi.nlm.nih.gov/pubmed/2455472/,,,,,,,,,,
1678,,300322,Lesch Nyhan syndrom,,HPRT1,hypoxanthine phosphoribosyltransferase 1,1.1.1.211/4.2.1.17,Carbidopa‐levodopa,,DB00190+DB01235,ECO:0000352,,,,,Symptomatic (C),,,,,Dystonia,,HP:0001332,https://www.ncbi.nlm.nih.gov/pubmed/2455472/,,,,,,,,,,
1679,,300322,Lesch Nyhan syndrom,,HPRT1,hypoxanthine phosphoribosyltransferase 1,1.1.1.211/4.2.1.17,,,,,,,,,,,,,,Chorea,,HP:0002072,https://www.ncbi.nlm.nih.gov/pubmed/2455472/,,,,,,,,,,
1680,,300322,Lesch Nyhan syndrom,,HPRT1,hypoxanthine phosphoribosyltransferase 1,1.1.1.211/4.2.1.17,,,,,,,,,,,,,,,,,,,,,,,,,,,
1681,214,240800,Leucine-sensitive hypoglycemia of infancy,,ABCC8,ATP binding cassette subfamily C member 8,1.1.1.211/4.2.1.17,diazoxide,,DB01119,ECO:0000352,E1506K,,,,Functional interaction (B),B,,,,hypoglycemia,,HP:0001943,https://www.ncbi.nlm.nih.gov/pubmed/15356046,,,,,,,,,,
1682,,240800,Leucine-sensitive hypoglycemia of infancy,,ABCC8,ATP binding cassette subfamily C member 8,1.1.1.211/4.2.1.17,,,,,R1353H,,,,,,,,,,,,,,,,,,,,,,
1683,,240800,Leucine-sensitive hypoglycemia of infancy,,ABCC8,ATP binding cassette subfamily C member 8,1.1.1.211/4.2.1.17,,,,,delSer1387,,,,,,,,,,,,,,,,,,,,,,
1684,215,613724,Leukoencephalopathy-dystonia-motor neuropathy syndrome(STEROL CARRIER PROTEIN 2 DEFICIENCY),,SCP2,sterol carrier protein 2,1.1.1.211/4.2.1.17,No treatment is available in DDIEM,,,,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/16685654,,,,,,,,,,
1685,216,611105,Leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation(LBSL),,DARS2,mitochondrial aspartyl-tRNA synthetase,1.1.1.211/4.2.1.17,acetazolamide,,DB00819,ECO:0000352,,,,,Symptomatic (C),C,,,,paroxysmal exercise-induced gait ataxia(exercise-induced episodic ataxia ),,HP:0002066*,https://www.ncbi.nlm.nih.gov/pubmed/21749991,,,,,,,,,,
1686,,611105,Leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation(LBSL),,DARS2,mitochondrial aspartyl-tRNA synthetase,1.1.1.211/4.2.1.17,,,,,,,,,,,,,,Seizures,,HP:0001250,,,,,,,,,,,
1687,,611105,Leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation(LBSL),,DARS2,mitochondrial aspartyl-tRNA synthetase,1.1.1.211/4.2.1.17,glucocorticosteroid.,,DB00288,ECO:0000352,,,,,Symptomatic (C),C,,,,spastic bladder,,HP:0005340,https://www.ncbi.nlm.nih.gov/pubmed/23644316,,,,,,,,,,
1688,217,607155,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2I; LGMD2I",,FKRP,fukutin-related protein (FKRP),1.1.1.211/4.2.1.17,Prednisolone,Corticosteriods might be beneficial in heterozygous mutations as patients have milder phenotypes.,DB00860,ECO:0000352/ECO:0007764,,,,,Symptomatic (C),C,,,Drug name: It has been mentioned that it might be beneficial in compound heterozygous mutations as patients have a milder phenotypes. https://www.ncbi.nlm.nih.gov/pubmed/28931339#,Myositis,,HP:0100614,https://www.ncbi.nlm.nih.gov/pubmed/28931339,https://www.ncbi.nlm.nih.gov/pubmed/17446099,,,,,,,,,
1689,,607155,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2I; LGMD2I",,FKRP,fukutin-related protein (FKRP),1.1.1.211/4.2.1.17,,,,,,,,,,,,,,Muscle weakness,,HP:0001324,,,,,,,,,,,
1690,,607155,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2I; LGMD2I",,FKRP,fukutin-related protein (FKRP),1.1.1.211/4.2.1.17,,,,,,,,,,,,,,Difficulty walking,,HP:0002355,,,,,,,,,,,
1691,,607155,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2I; LGMD2I",,FKRP,fukutin-related protein (FKRP),1.1.1.211/4.2.1.17,,,,,,,,,,,,,,Rapid progression,,HP:0003678,,,,,,,,,,,
1692,,607155,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2I; LGMD2I",,FKRP,fukutin-related protein (FKRP),1.1.1.211/4.2.1.17,rAAV-Fkrp,,,ECO:0005542,,,,,Direct interaction (Mechanistic A),A,,,,Abnormal serum creatine kinase,,HP:0040081,https://www.ncbi.nlm.nih.gov/pubmed/25048216,https://www.ncbi.nlm.nih.gov/pubmed/23817215,https://www.ncbi.nlm.nih.gov/pubmed/28334834,https://www.ncbi.nlm.nih.gov/pubmed/28480302,,,,,,,
1693,,607155,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2I; LGMD2I",,FKRP,fukutin-related protein (FKRP),1.1.1.211/4.2.1.17,,,,,,,,,,,,,,Muscle dystrophy,,HP:0006785,https://www.ncbi.nlm.nih.gov/pubmed/28107841,,,,,,,,,,
1694,,607155,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2I; LGMD2I",,FKRP,fukutin-related protein (FKRP),1.1.1.211/4.2.1.17,,,,,,,,,,,,,,Abnormal muscle function,,HP:0011804,,,,,,,,,,,
1695,218,609308,LGMD2K,,POMT1,protein O-mannosyltransferase 1,2.4.1.109,No treatment is available in DDIEM,,,,,,,,,,,,,,,HP:0011804,https://www.ncbi.nlm.nih.gov/pubmed/17339125,,,,,,,,,,
1696,219,611307,Limb-girdle muscular dystrophy type 2I (LGMD2I),,ANO5,anoctamin 5,Q75V66,No treatment is available in DDIEM,,,,,,,,,,,,,,,HP:0011804,https://www.ncbi.nlm.nih.gov/pubmed/17339125,,,,,,,,,,
1697,220,253601,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2B; LGMD2B",,DYSF,dysferlin,O75923,Resolaris (ATYR1940),,NA,ECO:0007121,,,,,Symptomatic (C),C,,,,Abnormal muscle function,,HP:0011804,https://clinicaltrials.gov/ct2/show/NCT02579239,https://musculardystrophynews.com/resolaris-atyr1940/,https://www.ncbi.nlm.nih.gov/pubmed/17339125,,,,,,,,
1698,221,253600,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2A",,CAPN3,calpain 3,EC 3.4.22.17,AAV2 /1-mSeAP-propmyoD76A,,NA,ECO:0005542,,,,,Functional interaction ( Mechanistic B),B,,,,Muscle atrophy,,HP:0003797,https://www.ncbi.nlm.nih.gov/pubmed/17330087,https://www.ncbi.nlm.nih.gov/pubmed/17339125,https://www.ncbi.nlm.nih.gov/pubmed/17339125,,,,,,,,
1699,,253600,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2A",,CAPN3,calpain 3,EC 3.4.22.17,,,,,,,,,,,,,,abnormal muscle strenght,,HP:0001324,,,,https://www.ncbi.nlm.nih.gov/pubmed/?term=Safety+and+efficacy+of+AAV-mediated+calpain+3+gene+transfer+in+a+mouse+model+of+limb-girdle+muscular+dystrophy+type+2A,,,,,,,
1700,,253600,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2A",,CAPN3,calpain 3,EC 3.4.22.17,(r) AAV2/1-mediated calpain 3,,NA,ECO:0005542,,,,,Functional interaction ( Mechanistic B),,,,,Low muscle mass,,HP:0001324,https://www.ncbi.nlm.nih.gov/pubmed/17330087,,,https://www.ncbi.nlm.nih.gov/pubmed/?term=Safety+and+efficacy+of+AAV-mediated+calpain+3+gene+transfer+in+a+mouse+model+of+limb-girdle+muscular+dystrophy+type+2A,,,,,,,
1701,222,608099,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2D; LGMD2D",,SGCA,sarcoglycan alpha,Q16586,AAV2/1-MCK-Sgca,,NA,ECO:0005542,,,,,Direct interaction(Mechanistic A),A,,,Drug name: Tried in mice not human,Decreased muscle mass,,,https://www.ncbi.nlm.nih.gov/pubmed/?term=AAV-mediated+delivery+of+a+mutated+myostatin+propeptide+ameliorates+calpain+3+but+not+α-sarcoglycan+deficiency,https://www.ncbi.nlm.nih.gov/pubmed/17339125,,,,,,,,,
1702,223,608896,"MUSCULAR DYSTROPHY, LIMB-GIRDLE, TYPE 2C; LGMD2C",,SGCG,sarcoglycan gamma,Q16586,,,,,,,,,,,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/15252120,https://www.ncbi.nlm.nih.gov/pubmed/16635485,,,,,,,,,
1703,224,246650,LIPOPROTEIN LIPASE DEFICIENCY WITH HEPATIC TRIGLYCERIDE LIPASE DEFICIENCY,,LMF1,lipase maturation factor 1,Q96S06,Fenofibrate+ω-3 fatty acids+EPA+DHA,Poor compliance to the treatment was noticed,DB01039+DB11133+DB00159 +DB03756,ECO:0000352,,,,,Symptomatic (C),C,,,Drug name: Poor compliance to the treatment was noticed,Hypertriglycridemia,,HP:0002155,https://www.ncbi.nlm.nih.gov/pubmed/19820022,https://www.ncbi.nlm.nih.gov/pubmed/16635485,,,,,,,,,
1704,,246650,LIPOPROTEIN LIPASE DEFICIENCY WITH HEPATIC TRIGLYCERIDE LIPASE DEFICIENCY,,LMF1,lipase maturation factor 1,Q96S06,gemfibrozil+ω-3 fatty acids,"Because of poor response to fenofibrate treatment, it was replaced with gemfibrozil",DB01241+DB11133,ECO:0000352,,,,,Symptomatic (C),C,,,"Drug name: Because of poor response to fenofibrate treatment, it was replaced with gemfibrozil (600 mg twice a day",Hypertriglycridemia,,HP:0002155,https://www.ncbi.nlm.nih.gov/pubmed/19820022,,,,,,,,,,
1705,,246650,LIPOPROTEIN LIPASE DEFICIENCY WITH HEPATIC TRIGLYCERIDE LIPASE DEFICIENCY,,LMF1,lipase maturation factor 1,Q96S06,Insulin aspart+Fibrate(gemfibrozil)+ ω-3 fatty acids,,DB01306+DB01241+DB11133,ECO:0000352,W464X,,,,Symptomatic (C),C,,,Drug name: Improvement in the triglycride level startrd Under insulin therapy with a good blood glucose control (glycosylated hemoglobin 5.6%) and an improved lipid profile with TG plasma levels as low as 195 mg/dl (2.2 mmol/liter),Hypertriglycridemia,,HP:0002155,https://www.ncbi.nlm.nih.gov/pubmed/19820022,,,,,,,,,,
1706,,246650,LIPOPROTEIN LIPASE DEFICIENCY WITH HEPATIC TRIGLYCERIDE LIPASE DEFICIENCY,,LMF1,lipase maturation factor 1,Q96S06,,,,,,,,,,,,,,Hyperglycemia,,HP:0003074,,,,,,,,,,,
1707,,246650,LIPOPROTEIN LIPASE DEFICIENCY WITH HEPATIC TRIGLYCERIDE LIPASE DEFICIENCY,,LMF1,lipase maturation factor 1,Q96S06,Metformin,A low fat regimen was added to metformin while treating the patient.,DB00331,ECO:0000352,,,,,Symptomatic (C),C,,,,Hypertriglycridemia,,HP:0002155,https://www.ncbi.nlm.nih.gov/pubmed/17994020/,,,,,,,,,,
1708,225,614462,Lipoic acid synthetase deficiency,,LIAS,lipoic acid synthetase,2.8.1.8,Topiramate+lamotrigine,,DB00273+DB00555,ECO:0000352,,,,,Symptomatic (C),C,,,,Seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/24777537,,,,,,,,,,
1709,226,247100,Lipoid proteinosis of Urbach and Wiethe,,ECM1,extracellular matrix protein 1,Q16610,Acitretin,,DB00459,ECO:0000352,,,,,Symptomatic (C),C,,,,Skin lesion,,HP:0011122,https://www.ncbi.nlm.nih.gov/pubmed/24748909,https://www.ncbi.nlm.nih.gov/pubmed/28720532,,,,,,,,,
1710,,247100,Lipoid proteinosis of Urbach and Wiethe,,ECM1,extracellular matrix protein 1,Q16610,,,,,,,,,,,,,,Skin papules,,HP:0200034,,,,,,,,,,,
1711,,247100,Lipoid proteinosis of Urbach and Wiethe,,ECM1,extracellular matrix protein 1,Q16610,,,,,,,,,,,,,,Mucosal lesions,,,,,,,,,,,,,
1712,,247100,Lipoid proteinosis of Urbach and Wiethe,,ECM1,extracellular matrix protein 1,Q16610,,,,,,,,,,,,,,Hoarseness,,HP:0001609,https://www.ncbi.nlm.nih.gov/pubmed/23259080/,https://www.ncbi.nlm.nih.gov/pubmed/18808438/,,,,,,,,,
1713,,247100,Lipoid proteinosis of Urbach and Wiethe,,ECM1,extracellular matrix protein 1,Q16610,,,,,,,,,,,,,,Elbow skin thickening,,HP:0001072,https://www.ncbi.nlm.nih.gov/pubmed/28681064,,,,,,,,,,
1714,,247100,Lipoid proteinosis of Urbach and Wiethe,,ECM1,extracellular matrix protein 1,Q16610,,,,,,,,,,,,,,hyperkeratosis,,HP:0000962,,,,,,,,,,,
1715,,247100,Lipoid proteinosis of Urbach and Wiethe,,ECM1,extracellular matrix protein 1,Q16610,,,,,,,,,,,,,,verrucous lesions,,HP:0012500,,,,,,,,,,,
1716,227,309000,Lowe oculocerebrorenal,,OCRL,inositol polyphosphate 5-phosphatase OCRL-1,(3.1.3.36 and 3.1.3.56) or 3.1.3.86,sodium bicarbonate,"If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood & urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency",DB01390,ECO:0000352,,,,,Symptomatic (C),C,,,,Proximal tubular dysfunction,,HP:0000114,https://www.ncbi.nlm.nih.gov/pubmed/12937245,https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33,,,,,,,,,
1717,,309000,Lowe oculocerebrorenal,,OCRL,inositol polyphosphate 5-phosphatase OCRL-1,(3.1.3.36 and 3.1.3.56) or 3.1.3.86,potassium bicarbonate,,DB11098,ECO:0000352,,,,,Symptomatic (C),C,,,,Hypokalemia,,HP:0002900,https://www.ncbi.nlm.nih.gov/pubmed/20301653,https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33,,,,,,,,,
1718,,309000,Lowe oculocerebrorenal,,OCRL,inositol polyphosphate 5-phosphatase OCRL-1,(3.1.3.36 and 3.1.3.56) or 3.1.3.86,Potassium citrate,"If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood & urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency",DB09125,ECO:0000352,,,,,Symptomatic (C),C,,,,Metabolic acidosis (Hyperchloremic metabolic acidosis),,HP:0004918,https://www.ncbi.nlm.nih.gov/pubmed/20301653,,,,,,,,,,
1719,,309000,Lowe oculocerebrorenal,,OCRL,inositol polyphosphate 5-phosphatase OCRL-1,(3.1.3.36 and 3.1.3.56) or 3.1.3.86,,,,,,,,,,,,,,Hypokalemia,,HP:0002900,,,,,,,,,,,
1720,,309000,Lowe oculocerebrorenal,,OCRL,inositol polyphosphate 5-phosphatase OCRL-1,(3.1.3.36 and 3.1.3.56) or 3.1.3.86,phosphate+calcitriol,"If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood & urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency",DB14573+DB00136,ECO:0000352,,,,,Symptomatic (C),C,,,,Renal rickets,,HP:0002748,https://www.ncbi.nlm.nih.gov/pubmed/20301653,,,,,,,,,,
1721,,309000,Lowe oculocerebrorenal,,OCRL,inositol polyphosphate 5-phosphatase OCRL-1,(3.1.3.36 and 3.1.3.56) or 3.1.3.86,,,,,,,,,Symptomatic (C),C,,,,Hypophosphatemia,,HP:0002148,https://www.ncbi.nlm.nih.gov/pubmed/20301653,,,,,,,,,,
1722,,309000,Lowe oculocerebrorenal,,OCRL,inositol polyphosphate 5-phosphatase OCRL-1,(3.1.3.36 and 3.1.3.56) or 3.1.3.86,1-OH vitamin D,"If on supplemental bicarbonate or citrate, phosphorus or calcitriol or other vitamin D analog, need kidney function assessment 1 w/blood & urine tests
May need serum vitamin D-25 hydroxy to assess for parent vitamin D deficiency",,ECO:0000352,,,,,Symptomatic (C),C,,,,Hyperparathyrodism,,HP:0000867,https://www.ncbi.nlm.nih.gov/pubmed/2017228,https://www.paediatricaindonesiana.org/index.php/paediatrica-indonesiana/article/view/59/33,,,,,,,,,
1723,,309000,Lowe oculocerebrorenal,,OCRL,inositol polyphosphate 5-phosphatase OCRL-1,(3.1.3.36 and 3.1.3.56) or 3.1.3.86,pamidronate +growth hormone,,DB00282+DB00052,ECO:0000352,,,,,Symptomatic (C),C,,,,Hypophosphatasia,,HP:0002148,https://www.ncbi.nlm.nih.gov/pubmed/19773212/,,,,,,,,,,
1724,,309000,Lowe oculocerebrorenal,,OCRL,inositol polyphosphate 5-phosphatase OCRL-1,(3.1.3.36 and 3.1.3.56) or 3.1.3.86,,,,,,,,,,,,,,Osteoporosis,,HP:0000939,,,,,,,,,,,
1725,,309000,Lowe oculocerebrorenal,,OCRL,inositol polyphosphate 5-phosphatase OCRL-1,(3.1.3.36 and 3.1.3.56) or 3.1.3.86,Thiazide,,DB01325,ECO:0000352,,,,,Symptomatic (C),C,,,,High calcium excretion,,HP:0002150,https://www.ncbi.nlm.nih.gov/pubmed/26251718,,,,,,,,,,
1726,,309000,Lowe oculocerebrorenal,,OCRL,inositol polyphosphate 5-phosphatase OCRL-1,(3.1.3.36 and 3.1.3.56) or 3.1.3.86,L-carnitine,,DB00583,ECO:0000352,,,,,Symptomatic (C),C,,,,secondary carnitine deficiency (Carnitine deficiency)*,,HP:0003234,https://pdfs.semanticscholar.org/3a8e/bd8dda73113f384215ca26d7df0fe61441a1.pdf,https://www.ncbi.nlm.nih.gov/books/NBK1480/,,,,,,,,,
1727,228,222700,Lysinuric protein intolerance,"General therapeutic management remains empirical with 3 major axes: prevention of hyperammonemia, nutritional supplementation and prevention of specific complications. There is a general consensus that a hypoproteinemic regimen should be initiated with an objective of 1 g/kg/d. associated with L-citrulline supplementation, L-carnitine 20-50 mg/kg/d., vitamins and other nutritional supplementation, if necessary. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217205/  https://www.ncbi.nlm.nih.gov/pubmed/21308987/.  https://www.ncbi.nlm.nih.gov/pubmed/22402328/",SLC7A7,Y+L amino acid transporter 1,Q9UM01,Citrulline,"Citrulline should be given in ""Low-dose"" as of 100 mg/kg/d.  https://www.ncbi.nlm.nih.gov/pubmed/21308987/.  
Adjusting l-citrulline dosage may be crucial, as excessive citrulline may worsen intracellular arginine accumulation  leading to harmful effects. https://www.ncbi.nlm.nih.gov/pubmed/22402328/ https://www.ncbi.nlm.nih.gov/pubmed/27567650",DB00155,ECO:0000352,,,,,Symptomatic (C),C,,,"Drug name: in ""Low-dose""",Hyperammonemia,,HP:0001987,https://www.ncbi.nlm.nih.gov/pubmed/27567650,https://www.ncbi.nlm.nih.gov/pubmed/25335805,https://www.ncbi.nlm.nih.gov/pubmed/22402328,https://www.ncbi.nlm.nih.gov/pubmed/6777479,https://www.ncbi.nlm.nih.gov/pubmed/25859380,,,,,,
1728,,222700,Lysinuric protein intolerance,,SLC7A7,Y+L amino acid transporter 1,Q9UM01,corticosteroids(Amcinonide),"The role of corticosteroids also remains controversial, due to increase risk of infection. As well as, it's  ineffective against the respiratory symptoms. https://www.ncbi.nlm.nih.gov/pubmed/25335805",DB00288,ECO:0000352,,,,,Symptomatic (C),C,,,"Drug namre: The role of corticosteroids also remains controversial, due to increase risk of infection. As well as, it's  ineffective against the respiratory symptoms. https://www.ncbi.nlm.nih.gov/pubmed/25335805",hemophagocytic-lymphohistiocytosis (Abnormality of immune system physiology)*,,HP:0010978,https://www.ncbi.nlm.nih.gov/pubmed/28057010,,,,,,,,,,
1729,,222700,Lysinuric protein intolerance,,SLC7A7,Y+L amino acid transporter 1,Q9UM01,cyclosporin,,DB00091,ECO:0000352,,,,,Symptomatic (C),C,,,,,,,,,,,,,,,,,
1730,,222700,Lysinuric protein intolerance,,SLC7A7,Y+L amino acid transporter 1,Q9UM01,Alendronate,"THe drug is well known to be a putative therapy for severe osteopenia, but more reliable protocols are needed.",,ECO:0000352,,,,,Symptomatic (C),C,,,,Osteopenia,,HP:0000938,https://www.ncbi.nlm.nih.gov/pubmed/16868861?dopt=Abstract,,,,,,,,,,
1731,,222700,Lysinuric protein intolerance,,SLC7A7,Y+L amino acid transporter 1,Q9UM01,ACEI (Benazepril),,DB00542,ECO:0000352,,,,,Symptomatic (C),C,,,,Kidney failure,,HP:0000083,,,,,,,,,,,
1732,,222700,Lysinuric protein intolerance,,SLC7A7,Y+L amino acid transporter 1,Q9UM01,,,,,,,,,,,,,,proteinuria,,HP:0000093,,,,,,,,,,,
1733,,222700,Lysinuric protein intolerance,,SLC7A7,Y+L amino acid transporter 1,Q9UM01,,,,,,,,,,,,,,hypertension,,HP:0000822,,,,,,,,,,,
1734,,222700,Lysinuric protein intolerance,,SLC7A7,Y+L amino acid transporter 1,Q9UM01,sodium phenylbutyrate,Drug has no difference in terms of prognosis.,DB06819,ECO:0000352,,,,,Symptomatic (C),C,,,Drug has no difference in terms of prognosis.,hyperammonemia,,HP:0001987,https://www.ncbi.nlm.nih.gov/pubmed/28057010,https://www.ncbi.nlm.nih.gov/pubmed/26865117,https://www.ncbi.nlm.nih.gov/pubmed/27567650,https://www.ncbi.nlm.nih.gov/pubmed/20301535,,,,,,,
1735,,222700,Lysinuric protein intolerance,,SLC7A7,Y+L amino acid transporter 1,Q9UM01,sodium benzoate,Drug has no difference in terms of prognosis.,DB03793,ECO:0000352,,,,,Symptomatic (C),C,,,Drug has no difference in terms of prognosis.,hyperammonemia,,HP:0001987,https://www.ncbi.nlm.nih.gov/pubmed/28057010,https://www.ncbi.nlm.nih.gov/pubmed/20301535,,,,,,,,,
1736,,222700,Lysinuric protein intolerance,,SLC7A7,Y+L amino acid transporter 1,Q9UM01,Lysine,,DB00123,ECO:0000352,,,,,Symptomatic (C),,,,,hypolysinemia,,,,,,,,,,,,,
1737,,222700,Lysinuric protein intolerance,,SLC7A7,Y+L amino acid transporter 1,Q9UM01,Lysine/Arginine/carnitine/Citrulline,"Although  there are resaerchs that have documented the correlation between LPI and GHD because of the known interaction between the amino acids (AA) arginine, ornithine, and lysine and GH secretion https://www.ncbi.nlm.nih.gov/pubmed/2903866/ https://www.ncbi.nlm.nih.gov/pubmed/14328387/ ,https://www.ncbi.nlm.nih.gov/pubmed/18029456/, https://www.ncbi.nlm.nih.gov/pubmed/6790230/ 
Other reasearchs find these supplements have neither obvious benefit nor difference in terms of prognosis. Arginine supplementation is unhelpful as oral arginine is not absorbed from intestinal mucosa.  https://www.ncbi.nlm.nih.gov/pubmed/27567650",DB00123/DB00125/DB00583,ECO:0000352,,,,,Symptomatic (C),C,,,"No obvious benefit from oral supplementation with citrulline, lysine or arginine.",orotic aciduria,The drug works through preventing the aciduria and the hyperammonemia rather than treating it.,HP:0003218,https://www.ncbi.nlm.nih.gov/pubmed/25614305,,,,,,,,,,
1738,,222700,Lysinuric protein intolerance,,SLC7A7,Y+L amino acid transporter 1,Q9UM01,,,,,,,,,Symptomatic (C),C,,,"No obvious benefit from oral supplementation with citrulline, lysine or arginine.",hypolysinemia,,HP:0001987,https://www.ncbi.nlm.nih.gov/pubmed/27567650,https://www.ncbi.nlm.nih.gov/pubmed/20301535,,,,,,,,,
1739,,222700,Lysinuric protein intolerance,,SLC7A7,Y+L amino acid transporter 1,Q9UM01,,,,,,,,,,,,,,intracellular defect of arginine,,HP:0005961,,,,,,,,,,,
1740,,222700,Lysinuric protein intolerance,,SLC7A7,Y+L amino acid transporter 1,Q9UM01,,,,,,,,,,,,,The dosage of L-citrulline dosage was a subject of controversy because of the possibility that it could increase inflammatory damages through its conversion to arginine and NO. L-Citrulline supplementation is thus usually limited to 100 mg/kg/d,hyperproteinemia,,HP:0002152,,,,,,,,,,,
1741,,222700,Lysinuric protein intolerance,,SLC7A7,Y+L amino acid transporter 1,Q9UM01,Growth hormone,,DB00052,ECO:0000352,,,,,Symptomatic (C),C,,,"In order to get a favorable outcome in GH-treated children, Treatment with rhGH should be started early.",growth impairment,,HP:0001510,https://www.ncbi.nlm.nih.gov/pubmed/16775724/,https://www.ncbi.nlm.nih.gov/pubmed/25614305,https://www.ncbi.nlm.nih.gov/pubmed/23430827/,,,,,,,,
1742,,222700,Lysinuric protein intolerance,,SLC7A7,Y+L amino acid transporter 1,Q9UM01,,,,,,,,,,,,,,Short stature,,HP:0004322,,,,,,,,,,,
1743,,222700,Lysinuric protein intolerance,,SLC7A7,Y+L amino acid transporter 1,Q9UM01,carnitine,,DB00583,ECO:0000352,,,,,Symptomatic (C),C,,,,Hyperammonemia,,HP:0001987,https://www.ncbi.nlm.nih.gov/pubmed/28057010,https://www.ncbi.nlm.nih.gov/pubmed/28057010,,,,,,,,,
1744,,222700,Lysinuric protein intolerance,,SLC7A7,Y+L amino acid transporter 1,Q9UM01,Sodium benzoate+ L-carnitine+ low dose citrulline,The regimen was accomapanied with a protein-restricted diet. https://www.ncbi.nlm.nih.gov/pubmed/27567650,DB03793+DB00583+DB00155,ECO:0000352,,,,,Symptomatic (C),C,,,,episodic behavioral abnormalities,,HP:0000708,https://www.ncbi.nlm.nih.gov/pubmed/27567650,,,,,,,,,,
1745,,222700,Lysinuric protein intolerance,,SLC7A7,Y+L amino acid transporter 1,Q9UM01,,,,,,,,,,,,,,social interaction defect,,HP:0000735,,,,,,,,,,,
1746,,222700,Lysinuric protein intolerance,,SLC7A7,Y+L amino acid transporter 1,Q9UM01,,,,,,,,,,,,,,lack eye-eye contact,,HP:0000817,,,,,,,,,,,
1747,,222700,Lysinuric protein intolerance,,SLC7A7,Y+L amino acid transporter 1,Q9UM01,,,,,,,,,,,,,,Hepatosplenomegaly,,HP:0001433,,,,,,,,,,,
1748,,222700,Lysinuric protein intolerance,,SLC7A7,Y+L amino acid transporter 1,Q9UM01,Azathioprine,,DB00993,ECO:0000352,,,,,,,,,,,,HP:0001433,,,,,,,,,,,
1749,,222700,Lysinuric protein intolerance,,SLC7A7,Y+L amino acid transporter 1,Q9UM01,,,,,,,,,,,,,,,,,,,,,,,,,,,
1750,,222700,Lysinuric protein intolerance,,SLC7A7,Y+L amino acid transporter 1,Q9UM01,,,,,,,,,,,,,,,,,,,,,,,,,,,
1751,,222700,Lysinuric protein intolerance,,SLC7A7,Y+L amino acid transporter 1,Q9UM01,Sargramostim,,DB00020,ECO:0000352,,,,,Symptomatic (C),C,,,,Pulmonary Alveolar Proteinosis,,HP:0006517,https://www.ncbi.nlm.nih.gov/pubmed/27783330,https://www.ncbi.nlm.nih.gov/pubmed/25335805,https://www.ncbi.nlm.nih.gov/pubmed/29058386,https://www.ncbi.nlm.nih.gov/pubmed/21110863/,,,,,,,
1752,,222700,Lysinuric protein intolerance,,SLC7A7,Y+L amino acid transporter 1,Q9UM01,,,,,,,,,,,,,,Low pulmonary function,,HP:0005952,,,,,,,,,,,
1753,,222700,Lysinuric protein intolerance,,SLC7A7,Y+L amino acid transporter 1,Q9UM01,rGM CSF,,DB05386,,,,,,Symptomatic (C),C,,,,Pulmonary Alveolar Proteinosis,,HP:0006517,https://www.ncbi.nlm.nih.gov/pubmed/25335805,https://www.ncbi.nlm.nih.gov/pubmed/29058386,https://www.ncbi.nlm.nih.gov/pubmed/21110863/,https://www.ncbi.nlm.nih.gov/pubmed/28649527,,,,,,,
1754,,222700,Lysinuric protein intolerance,,SLC7A7,Y+L amino acid transporter 1,Q9UM01,,,,,,,,,,,,,,Low pulmonary function,,HP:0005952,,,,,,,,,,,
1755,,222700,Lysinuric protein intolerance,,SLC7A7,Y+L amino acid transporter 1,Q9UM01,prednisolone+mycophenolate mofetil,,DB00860+DB00688,,,,,,Symptomatic (C),C,,,,membranoproliferative glomerulonephritis,,HP:0000793,https://www.ncbi.nlm.nih.gov/pubmed/28087478,,,,,,,,,,
1756,229,248360,Malonyl-CoA decarboxylase Deficiency,,MLYCD,malonyl-CoA decarboxylase,4.1.1.9,Carnitine,,DB00583,,,,,,Functional interaction (B),B,,,Fat-limited +High Carbohydrate diet,High urinary malonic acid,,HP:0012120,https://www.ncbi.nlm.nih.gov/pubmed/26858006,https://www.ncbi.nlm.nih.gov/pubmed/24613099,https://www.ncbi.nlm.nih.gov/pubmed/28781843,,,,,,,,
1757,,248360,Malonyl-CoA decarboxylase Deficiency,,MLYCD,malonyl-CoA decarboxylase,4.1.1.9,Medium‐chain triglycerides,,DB13959,,,,,,Functional interaction (B),B,,,should be at least 70% of the total fat content of the diet,High blood malonylcarnitine level,,HP:0031544,https://www.ncbi.nlm.nih.gov/pubmed/26858006,https://www.ncbi.nlm.nih.gov/pubmed/24613099,https://www.ncbi.nlm.nih.gov/pubmed/28781843,,,,,,,,
1758,,248360,Malonyl-CoA decarboxylase Deficiency,,MLYCD,malonyl-CoA decarboxylase,4.1.1.9,,,,,,,,,,,,,,Low endurance,,HP:0025142,,,,,,,,,,,
1759,,248360,Malonyl-CoA decarboxylase Deficiency,,MLYCD,malonyl-CoA decarboxylase,4.1.1.9,,,,,,,,,,,,,,Failurre to thrive,,HP:0001508,https://www.ncbi.nlm.nih.gov/pubmed/28781843,,,,,,,,,,
1760,,248360,Malonyl-CoA decarboxylase Deficiency,,MLYCD,malonyl-CoA decarboxylase,4.1.1.9,,,,,,,,,,,,,,Cardiomyopathy progrssion,,HP:0003679,,,,,,,,,,,
1761,230,614202,MAN1B1-CDG,,MAN1B1,mannosidase alpha class 1B member 1,4.1.1.9,,,,,,,,,Symptomatic (C),C,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/29908352,,,,,,,,,,
1762,231,611722,Krabbe disease atypical due to Saposin A deficiency,,PSAP,prosaposin,4.1.1.9,,,,,,,,,,,,,,,,,,,,,,,,,,,
1763,232,530000,Kearns-Sayre syndrome,,PSAP,prosaposin,4.1.1.9,Folinic acid,,DB00650,,,,,,Symptomatic (C),C,,,Drug has a controversial study regarding patients reponce to treatment. https://www.ncbi.nlm.nih.gov/pubmed/28318733,Abnormal 5‐MTHF(Low),,,https://www.ncbi.nlm.nih.gov/pubmed/16365882,https://www.ncbi.nlm.nih.gov/pubmed/28318733,,,,,,,,,
1764,,530000,Kearns-Sayre syndrome,,PSAP,prosaposin,4.1.1.9,,,,,,,,,,,,,,White matter alteration,,,,,,,,,,,,,
1765,,530000,Kearns-Sayre syndrome,,PSAP,prosaposin,4.1.1.9,,,,,,,,,,,,,,deambulation,,,,,,,,,,,,,
1766,,530000,Kearns-Sayre syndrome,,PSAP,prosaposin,4.1.1.9,Growth Hormone,,DB00052,,,,,,Symptomatic (C),C,,,,Short Stature,,,https://www.ncbi.nlm.nih.gov/pubmed/27718492,,,,,,,,,,
1767,,530000,Kearns-Sayre syndrome,,PSAP,prosaposin,4.1.1.9,coenzyme Q10,,DB09270,,,,,,Symptomatic (C),C,,,,Corneal Oedema,,,https://www.ncbi.nlm.nih.gov/pubmed/27442316,https://www.ncbi.nlm.nih.gov/pubmed/27709644,https://www.ncbi.nlm.nih.gov/pubmed/26884075,,,,,,,,
1768,,530000,Kearns-Sayre syndrome,,PSAP,prosaposin,4.1.1.9,,,,,,,,,,,,,,Oxidative stress,,,https://www.ncbi.nlm.nih.gov/pubmed/26118651,,,,,,,,,,
1769,,530000,Kearns-Sayre syndrome,,PSAP,prosaposin,4.1.1.9,l-carnitine,,DB00583,,,,,,Symptomatic(C),C,,,,electron transfer within the respiratory chain,,,https://www.ncbi.nlm.nih.gov/pubmed/26118651,,,,,,,,,,
1770,,530000,Kearns-Sayre syndrome,,PSAP,prosaposin,4.1.1.9,,,,,,,,,,,,,,Myopathy,,HP:0003198,https://www.ncbi.nlm.nih.gov/pubmed/26884075,,,,,,,,,,
1771,,530000,Kearns-Sayre syndrome,,PSAP,prosaposin,4.1.1.9,"dopamine, dobutamine, thiazide and milrinone",,DB00988+DB0084+DB00232+DB00235,,,,,,Symptomatic(C),C,,,,acute congestive heart failure,,HP:0001635,https://www.ncbi.nlm.nih.gov/pubmed/26884075,,,,,,,,,,
1772,,530000,Kearns-Sayre syndrome,,PSAP,prosaposin,4.1.1.9,mitochonic acid 5,,NA,ECO:0001565,,,,,Symptomatic (C),C,,,,Mitochondrial dysfunction,,HP:0003287,https://www.ncbi.nlm.nih.gov/pubmed/26118651,,,,,,,,,,
1773,,530000,Kearns-Sayre syndrome,,PSAP,prosaposin,4.1.1.9,,,,,,,,,,,,,,Decreased cellular ATP level,,HP:0011925*,,,,,,,,,,,
1774,,530000,Kearns-Sayre syndrome,,PSAP,prosaposin,4.1.1.9,,,,,,,,,,,,,,,,,,,,,,,,,,,
1775,,530000,Kearns-Sayre syndrome,,PSAP,prosaposin,4.1.1.9,Insuline,,DB00030,,,,,,Symptomatic (C),C,,,,Diabetes mellitus,,HP:0000819,https://www.ncbi.nlm.nih.gov/pubmed/25092642,,,,,,,,,,
1776,,530000,Kearns-Sayre syndrome,,PSAP,prosaposin,4.1.1.9,cysteamine bitartrate,,DB00847,,,,,,Symptomatic (C),C,,,Terminated (Sponsor decision to end development of RP103 for mitochondrial disease due to lack of efficacy demonstrated in base study RP103-MITO-001.),,,HP:0000819,https://clinicaltrials.gov/ct2/show/NCT02023866?cond=Kearns-Sayre+Syndrome&rank=4,https://clinicaltrials.gov/ct2/show/NCT02473445,,,,,,,,,
1777,,530000,Kearns-Sayre syndrome,,PSAP,prosaposin,4.1.1.9,Sodium Pyruvate,,DB00119,ECO:0007121,,,,,Symptomatic (C),,,,,Elevated serum lactate level,,HP:0002151,https://www.ncbi.nlm.nih.gov/pubmed/30738201,https://clinicaltrials.gov/ct2/show/NCT02473445,,,,,,,,,
1778,,530000,Kearns-Sayre syndrome,,PSAP,prosaposin,4.1.1.9,,,,,,,,,,,,,,High lactate /pyruvate ratio(Mitochondrial respiratory chain defects)*,,HP:0200125,,,,,,,,,,,
1779,,530000,Kearns-Sayre syndrome,,PSAP,prosaposin,4.1.1.9,,,,,,,,,,,,,,Increased lateral ventricular lactate level,,NA,,,,,,,,,,,
1780,,530000,Kearns-Sayre syndrome,,PSAP,prosaposin,4.1.1.9,,,,,,,,,,,,,,High serum GDF15 level,,NA,,,,,,,,,,,
1781,,530000,Kearns-Sayre syndrome,,PSAP,prosaposin,4.1.1.9,,,,,,,,,,,,,,,,,,,,,,,,,,,
1782,,530000,Kearns-Sayre syndrome,,PSAP,prosaposin,4.1.1.9,,,,,,,,,,,,,,,,,,,,,,,,,,,
1783,233,609242,Kanzaki disease/schindler Disease type 2,,NAGA,alpha-N-acetylgalactosaminidase,4.1.1.9,"iminosugar DGJNAc( 2-acetamido-1,2-dideoxy-d-galactonojirimycin)",,NA,,,,,,Direct interaction (A),A,,,"clinical candidate , tested invitro and in cellular experiments",NA,,,,,,,,,,,,,
1784,,609242,Kanzaki disease/schindler Disease type 2,,NAGA,alpha-N-acetylgalactosaminidase,4.1.1.9,1-deoxygalactonojirimycin (DGJ,,DB05018,,,,,,Direct interaction (A),A,,,clinical candidate for drug repuropsing,NA,,,https://www.ncbi.nlm.nih.gov/pubmed/23045655,,,,,,,,,,
1785,234,243500,Isovaleric acidemia,,IVD,isovaleryl-CoA dehydrogenase,4.1.1.9,carglumic acid,,DB06775,,,,,,Symptomatic (C),C,,,,acute hyperammonemia,,,https://www.ncbi.nlm.nih.gov/pubmed/21207059,,,,,,,,,,
1786,,243500,Isovaleric acidemia,,IVD,isovaleryl-CoA dehydrogenase,4.1.1.9,L-carnitine,,DB00583,,,,,,Symptomatic (C),C,,,,High toxic acyl-CoA level,,,https://www.ncbi.nlm.nih.gov/pubmed/21290185,https://www.ncbi.nlm.nih.gov/pubmed/12069539/,https://www.ncbi.nlm.nih.gov/pubmed/20807522,https://www.ncbi.nlm.nih.gov/pubmed/19210957,,,,,,,
1787,,243500,Isovaleric acidemia,,IVD,isovaleryl-CoA dehydrogenase,4.1.1.9,L- glycine,,DB00145,,,,,,Symptomatic (C),C,,,,"abnormal Na+,K+-ATPase activity",,,https://www.ncbi.nlm.nih.gov/pubmed/15624372,https://www.ncbi.nlm.nih.gov/pubmed/12069539/,https://www.ncbi.nlm.nih.gov/pubmed/20807522,https://www.ncbi.nlm.nih.gov/pubmed/19210957,,,,,,,
1788,,243500,Isovaleric acidemia,,IVD,isovaleryl-CoA dehydrogenase,4.1.1.9,,,,,,,,,Symptomatic (C),C,,,"Drug name: 1-Combined therapy with carnitine and glycine has been shown to maximize the total excretion of isovaleryl-CoA conjugates, but the clinical benefit of combined versus single therapy has not been established through controlled studies.                                                                                                                                                     2- The relative merits of the two therapies either singly or together in patients with more severe presentations including recurrent crises remains a matter of debate.              (https://www.ncbi.nlm.nih.gov/pubmed/16602101)                                                                                                  3- Combined glycine and L-carnitine therapy maximally increases isovaleryl conjugate excretion during metabolic stress but not under stable conditions.  https://www.ncbi.nlm.nih.gov/pubmed/8804338",Secondary carnitine deficiency,,,https://www.ncbi.nlm.nih.gov/pubmed/16602101,,,,,,,,,,
1789,,243500,Isovaleric acidemia,,IVD,isovaleryl-CoA dehydrogenase,4.1.1.9,,,,,,,,,,,,,,High 3-hydroxyisovaleric acid level (C5),,,https://www.ncbi.nlm.nih.gov/pubmed/17299485,,,,,,,,,,
1790,,243500,Isovaleric acidemia,,IVD,isovaleryl-CoA dehydrogenase,4.1.1.9,,,,,,,,,,,,,,metabolic stress,,,https://www.ncbi.nlm.nih.gov/pubmed/8804338,,,,,,,,,,
1791,235,611283,Isobutyryl-CoA dehydrogenase deficiency,,ACAD8,isobutyryl-CoA dehydrogenase,4.1.1.9,No treatment is available in DDIEM,,,,,,,,,,,,"Drug name: It is uncertain what treatment, if any, is required following diagnosis",,,,https://www.ncbi.nlm.nih.gov/pubmed/28053874,,,,,,,,,,
1792,,611283,Isobutyryl-CoA dehydrogenase deficiency,,ACAD8,isobutyryl-CoA dehydrogenase,4.1.1.9,L-carnitine,,DB00583,,,,,,Symptomatic (C),C,,,,,,,https://www.babysfirsttest.org/newborn-screening/conditions/isobutyrylglycinuria,,,,,,,,,,
1793,236,261000,Intrinsic factor deficiency,,GIF,gastric intrinsic factor,4.1.1.9,Vitamin B12,,DB00115,,,,,,"Disease name: Dietary treatment has proved to be very effective in preventing the devastating consequences of PAH deficiency when started early in life. https://www.sciencedirect.com/science/article/pii/S1096719207001667
Drug name:  Tetrahydrobiopterin stimulates phenylalanine hydroxylase activity in about 20% of patients, and in those patients serves as a useful adjunct to the phenylalanine-restricted diet because it increases phenylalanine tolerance and allows some dietary freedom.. A striking normalisation (within 8 h) in phenylalanine concentrations after drug administartion indicates BH4 deficiency whereas very little or no reduction in phenylalanine indicates BH4-non-responsive phenylketonuria. https://www.sciencedirect.com/science/article/pii/S0140673610609610?via%3Dihub
Mutation that didn't get benefits out the treatment: Homozygotes of R252W, IVS4-1G→A, and R413P presented with clinical symptoms typical of classical PKU. Therefore these mutations appear to abolish PAH function. https://www.sciencedirect.com/science/article/pii/S0022347699701381?via%3Dihub
Mutation improved by treatment: The serum Phe concentrations of patients have those mutaions never exceeded 20 mg/dL, even when they were not on a Phe-restricted diet, suggesting that mutant PAH molecules with P407S, A373T, and R241C have residual enzymatic activities. https://www.sciencedirect.com/science/article/pii/S0022347699701381?via%3Dihubhttps://www.sciencedirect.com/science/article/pii/S0022347699701381?via%3Dihub",B,,,,Low levels of serum vitamin B12,,,https://www.ncbi.nlm.nih.gov/pubmed/24424200,https://rarediseases.info.nih.gov/diseases/3024/intrinsic-factor-deficiency#,,,,,,,,,
1794,,261000,Intrinsic factor deficiency,,GIF,gastric intrinsic factor,4.1.1.9,,,,,,,,,,,,,,High RBC's mean corpuscular volume,,,,,,,,,,,,,
1795,,261000,Intrinsic factor deficiency,,GIF,gastric intrinsic factor,4.1.1.9,,,,,,,,,,,,,,Low Hemoglobin concentration,,,,,,,,,,,,,
1796,,261000,Intrinsic factor deficiency,,GIF,gastric intrinsic factor,4.1.1.9,,,,,,,,,,,,,,Abnormal reticulocyte count,,,,,,,,,,,,,
1797,,261000,Intrinsic factor deficiency,,GIF,gastric intrinsic factor,4.1.1.9,Corticosteroid,,DB00860,,,,,,Symptomatic (C),C,,,,Gastric mucosal atrophy,,,https://www.ncbi.nlm.nih.gov/pubmed/24424200,,,,,,,,,,
1798,237,608747,insulin-like growth factor I deficiency,,IGF1,insulin like growth factor 1,4.1.1.9,Recombinant human IGF1(Mecasermin),,DB01277,,,,,,Direct interaction ( Mechanistic A),A,,,,Low height velocity,,,https://www.ncbi.nlm.nih.gov/pubmed/10323388,https://www.ncbi.nlm.nih.gov/pubmed/27884013,https://www.ncbi.nlm.nih.gov/pubmed/24639006,https://www.ncbi.nlm.nih.gov/pubmed/23887143,https://www.ncbi.nlm.nih.gov/pubmed/17192294/,https://www.ncbi.nlm.nih.gov/pubmed/19627167,https://www.ncbi.nlm.nih.gov/pubmed/10549306,,,,
1799,,608747,insulin-like growth factor I deficiency,,IGF1,insulin like growth factor 1,4.1.1.9,,,,,,,,,,,,,,Low lean body mass,,,,,,,,,,,,,
1800,,608747,insulin-like growth factor I deficiency,,IGF1,insulin like growth factor 1,4.1.1.9,,,,,,,,,,,,,,Abnormal linear growth (Low),,,,,,,,,,,,,
1801,,608747,insulin-like growth factor I deficiency,,IGF1,insulin like growth factor 1,4.1.1.9,,,,,,,,,,,,,,low insulin senstivity,,,,,,,,,,,,,
1802,,608747,insulin-like growth factor I deficiency,,IGF1,insulin like growth factor 1,4.1.1.9,,,,,,,,,,,,,,Abnormal circulating GH level,,,,,,,,,,,,,
1803,,608747,insulin-like growth factor I deficiency,,IGF1,insulin like growth factor 1,4.1.1.9,,,,,,,,,,,,,,Abnormal circulating IGFBP level,,,,,,,,,,,,,
1804,,608747,insulin-like growth factor I deficiency,,IGF1,insulin like growth factor 1,4.1.1.9,,,,,,,,,,,,,,Abnormal circulating insulin level,,,,,,,,,,,,,
1805,,608747,insulin-like growth factor I deficiency,,IGF1,insulin like growth factor 1,4.1.1.9,,,,,,,,,,,,,,Low body mass index,,,https://www.ncbi.nlm.nih.gov/pubmed/10770174,,,,,,,,,,
1806,,608747,insulin-like growth factor I deficiency,,IGF1,insulin like growth factor 1,4.1.1.9,,,,,,,,,,,,,,Abnormal Body fat composition,,,,,,,,,,,,,
1807,,608747,insulin-like growth factor I deficiency,,IGF1,insulin like growth factor 1,4.1.1.9,,,,,,,,,,,,,,insulin resistance,,,,,,,,,,,,,
1808,,608747,insulin-like growth factor I deficiency,,IGF1,insulin like growth factor 1,4.1.1.9,,,,,,,,,,,,,,Abnormal Si,,,,,,,,,,,,,
1809,,608747,insulin-like growth factor I deficiency,,IGF1,insulin like growth factor 1,4.1.1.9,IGFBP-3 (insulin-like growth factor binding protein-3),,DB01277,,,,,,Supportive (C),C,,,"Drug name: Mecasermin rinfabate, however, is no longer available in the USA or Europe for treating conditions involving short stature, because of a legal requirement",hypoglycemia,,,https://www.ncbi.nlm.nih.gov/pubmed/19627167,,,,,,,,,,
1810,238,271245,Infantile-onset spinocerebellar ataxia,,TWNK,twinkle mtDNA helicase,4.1.1.9,phenytoin,,DB00252,,,,,,Symptomatic (C),C,,,"Drug nmae:However, phenytoin and phenobarbitates are ineffective in most affected individuals",Seizures,,,https://www.ncbi.nlm.nih.gov/pubmed/20301746,,,,,,,,,,
1811,,271245,Infantile-onset spinocerebellar ataxia,,TWNK,twinkle mtDNA helicase,4.1.1.9,valproate,,DB00313,,,,p.Y508C,,Symptomatic (C),C,,,Drug name: Should be avoided as it results in elevated liver enzymes only when treated with valproate,,,,https://www.ncbi.nlm.nih.gov/pubmed/27551684,https://www.ncbi.nlm.nih.gov/pubmed/19304794/,,,,,,,,,
1812,,271245,Infantile-onset spinocerebellar ataxia,,TWNK,twinkle mtDNA helicase,4.1.1.9,creatine,,DB00583,,,,,,Symptomatic (C),C,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/30373890,https://www.ncbi.nlm.nih.gov/pubmed/19304794/,,,,,,,,,
1813,,271245,Infantile-onset spinocerebellar ataxia,,TWNK,twinkle mtDNA helicase,4.1.1.9,glutathione [N‐acetyl‐cysteine],,DB00143,,,,,,Symptomatic (C),C,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/30373890,https://www.ncbi.nlm.nih.gov/pubmed/19304794/,,,,,,,,,
1814,,271245,Infantile-onset spinocerebellar ataxia,,TWNK,twinkle mtDNA helicase,4.1.1.9,NAD+ [nicotinamide riboside],,DB00143,,,,,,Symptomatic (C),C,,,,,,,https://www.ncbi.nlm.nih.gov/pubmed/30373890,https://www.ncbi.nlm.nih.gov/pubmed/19304794/,,,,,,,,,
1815,239,256600,Infantile neuroaxonal dystrophy,,PLA2G6,85/88 kDa calcium-independent phospholipase A2,3.1.1.4,"RT001 (11,11-di-deutero-linoleic acid ethyl ester)","The drug is a patented, first-in-class, orally available D-PUFA, a deuterated polyunsaturated fatty acid, that incorporates into mitochondrial and cellular membranes and stabilizes them. It was discovered that lipid peroxidation, the free-radical damage of polyunsaturated fats (PUFAs) in mitochondrial and cellular membranes, may be the primary source of cell death in several degenerative diseases. The presence of D-PUFAs (RT001) can help protect (“fireproof”) against this and potentially restore cellular health. https://inadcure.org/clinical-trials-research-studies/",NA,ECO:0007121,,,,,Functional interaction (B),B,compensatory complementation of a genetically defective protein,,"Drug name:  Not yet recruiting by Nov. 6th, 2018",,,,https://clinicaltrials.gov/ct2/show/NCT03570931?cond=infantile+neuroaxonal+dystrophy&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/19304794/,,,,,,,,,
1816,,256600,Infantile neuroaxonal dystrophy,,PLA2G6,85/88 kDa calcium-independent phospholipase A2,3.1.1.4,Desipramine,,DB01151,,,,,,Symptomatic (C),C,symptomatic treatment procedure,,"Drug name:  Not yet recruiting by Nov. 6th, 2019",,,,https://clinicaltrials.gov/ct2/show/NCT03570931?cond=infantile+neuroaxonal+dystrophy&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/19304794/,,,,,,,,,
1817,,256600,Infantile neuroaxonal dystrophy,,PLA2G6,85/88 kDa calcium-independent phospholipase A2,3.1.1.4,D-PUFAs,,DB01151,,,,,,,,,,,Chronic constipation,,,http://n.neurology.org/content/90/15_Supplement/P3.327,https://www.ncbi.nlm.nih.gov/pubmed/19304794/,,,,,,,,,
1818,,256600,Infantile neuroaxonal dystrophy,,PLA2G6,85/88 kDa calcium-independent phospholipase A2,3.1.1.4,,,,,,,,,,,,,,Bulbar dysfunction,,,,,,,,,,,,,
1819,,256600,Infantile neuroaxonal dystrophy,,PLA2G6,85/88 kDa calcium-independent phospholipase A2,3.1.1.4,,,,,,,,,,,,,,Abnormal motor function,,,,,,,,,,,,,
1820,,256600,Infantile neuroaxonal dystrophy,,PLA2G6,85/88 kDa calcium-independent phospholipase A2,3.1.1.4,,,,,,,,,,,,,,Defective eye motor function,,,,,,,,,,,,,
1821,,256600,Infantile neuroaxonal dystrophy,,PLA2G6,85/88 kDa calcium-independent phospholipase A2,3.1.1.4,,,,,,,,,,,,,,Poor head control,,,,,,,,,,,,,
1822,240,269920,Free sialic acid storage disease,,SLC17A5,solute carrier family 17 member 5,Q9NRA2,Treatment of manifestations:Management is symptomatic and supportive: rehabilitation to optimize mobility and communication; provision of adequate nutrition; standard treatment of seizures. Surveillance: Regular evaluation by a rehabilitation specialist to identify potentially helpful interventions.,,,,,,,,Symptomatic (C),C,,,Drug name: Treatment of manifestations: Management is symptomatic and supportive: rehabilitation to optimize mobility and communication; provision of adequate nutrition; standard treatment of seizures. Surveillance: Regular evaluation by a rehabilitation specialist to identify potentially helpful interventions.,,,,,https://www.ncbi.nlm.nih.gov/pubmed/20301643,,,,,,,,,
1823,241,604369,Salla Disease,,SLC17A5,solute carrier family 17 member 5,Q9NRA2,Levetiracetam,,DB01202,ECO:0000352,,,,,Symptomatic (C),C,symptomatic treatment procedure,,,generalized tonic-clonic seizure,,HP:0002069,https://www.ncbi.nlm.nih.gov/pubmed/28662915,https://www.ncbi.nlm.nih.gov/pubmed/20301643,,,,,,,,,
1824,,604369,Salla Disease,,SLC17A5,solute carrier family 17 member 5,Q9NRA2,Phenobarbital,,DB01174,ECO:0000352,,,,,,,symptomatic treatment procedure,,,Seizures,,,https://www.ncbi.nlm.nih.gov/pubmed/12794688,,,,,,,,,,
1825,,604369,Salla Disease,,SLC17A5,solute carrier family 17 member 5,Q9NRA2,,,,,,,,,,,,,,,,,,,,,,,,,,,
1826,,604369,Salla Disease,,SLC17A5,solute carrier family 17 member 5,Q9NRA2,,,,,,,,,,,,,,,,,,,,,,,,,,,
1827,242,605820,Inclusion body myopathy 2,,GNE,glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase,"EC:3.2.1.183, EC:2.7.1.60",ManNac (N-acetylmannosamine),,DB12536,ECO:0007121,,,,,Functional interaction(Mechanistic B),B,,,,Decreased sialylation of muscle glycans,,HP:0012350,https://clinicaltrials.gov/ct2/show/NCT02346461?cond=Distal+Myopathy+with+Rimmed+Vacuoles&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/28641925,https://www.ncbi.nlm.nih.gov/pubmed/26546927,,,,,,,,
1828,,605820,Inclusion body myopathy 2,,GNE,glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase,"EC:3.2.1.183, EC:2.7.1.60",,,,,,,,,,,,,,Low circulating levels of free sialic acids,,HP:0012363,,,,,,,,,,,
1829,,605820,Inclusion body myopathy 2,,GNE,glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase,"EC:3.2.1.183, EC:2.7.1.60",,,,,,,,,,,,,,Rimmed vacuoles,,HP:0003805,https://www.ncbi.nlm.nih.gov/pubmed/21517694,,,,,,,,,,
1830,,605820,Inclusion body myopathy 2,,GNE,glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase,"EC:3.2.1.183, EC:2.7.1.60",,,,,,,,,,,,,,Amyloid deposition,,HP:0003216*,https://www.ncbi.nlm.nih.gov/pubmed/21517694,,,,,,,,,,
1831,,605820,Inclusion body myopathy 2,,GNE,glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase,"EC:3.2.1.183, EC:2.7.1.60",Sialic Acid Extended Release (SA-ER)+ManNac (N-acetylmannosamine),,CHEBI:17012+DB12536,ECO:0007121,,,,,Functional interaction(Mechanistic B),B,,,,Muscle weakness,,HP:0001324,https://www.ncbi.nlm.nih.gov/pubmed/28641925,https://clinicaltrials.gov/ct2/show/NCT01517880?cond=Inclusion+body+myopathy+2&rank=1,https://www.ncbi.nlm.nih.gov/pubmed/26546927,https://www.ncbi.nlm.nih.gov/pubmed/20030229,,,,,,,
1832,,605820,Inclusion body myopathy 2,,GNE,glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase,"EC:3.2.1.183, EC:2.7.1.60",,,,,,,,,,,,,,Decreased sialylation of muscle glycans,,HP:0012350,,,,,,,,,,,
1833,,605820,Inclusion body myopathy 2,,GNE,glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase,"EC:3.2.1.183, EC:2.7.1.60",GNE gene lipoplex,,NA,ECO:0007121,,,,,Direct interaction ( Mechanistic A),A,,,,Decline of muscle strength (Muscle weakness),,HP:0001324,https://www.ncbi.nlm.nih.gov/pubmed/21517694,,,,,,,,,,
1834,,605820,Inclusion body myopathy 2,,GNE,glucosamine (UDP-N-acetyl)-2-epimerase/N-acetylmannosamine kinase,"EC:3.2.1.183, EC:2.7.1.60",Sialic acid,,CHEBI:17012,,,,,,Functional interaction(Mechanistic B),B,,,,Muscle weakness,,HP:0001324,https://www.ncbi.nlm.nih.gov/pubmed/21517694,,,,,,,,,,
1835,243,252500,I cell disease,,GNPTAB,(α) &(β)GlcNAc-1-phosphotransferas,"EC:3.2.1.183, EC:2.7.1.60",No treatment is available in DDIEM,,CHEBI:17012,,,,,,,,,,,,,HP:0001324,https://www.ncbi.nlm.nih.gov/pubmed/21517694,,,,,,,,,,
1836,244,261100,Imerslund-Grasbeck syndrome,,CUBN/AMN,cubilin/amnion associated transmembrane protein,"EC:3.2.1.183, EC:2.7.1.60",methylcobalamin,,DB03614,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,,,Drug name :This study has been conducted in puppies but the treatment's results are the same for humans based on this sudy https://www.ncbi.nlm.nih.gov/pubmed/18768530,Megalobalstic anaemia,,HP:0001889,https://www.ncbi.nlm.nih.gov/pubmed/14593474,https://www.ncbi.nlm.nih.gov/pubmed/27942180,https://www.ncbi.nlm.nih.gov/pubmed/26958680,https://www.ncbi.nlm.nih.gov/pubmed/26040326,https://www.ncbi.nlm.nih.gov/pubmed/23364648,https://www.ncbi.nlm.nih.gov/pubmed/22219566,,,,,
1837,,261100,Imerslund-Grasbeck syndrome,,CUBN/AMN,cubilin/amnion associated transmembrane protein,"EC:3.2.1.183, EC:2.7.1.60",,,,,,,,,,,,,,Low level of serum B12,,HP:0040126,,,,,,,,,,,
1838,,261100,Imerslund-Grasbeck syndrome,,CUBN/AMN,cubilin/amnion associated transmembrane protein,"EC:3.2.1.183, EC:2.7.1.60",,,,,,,,,,,,,,Neurological abnormalities,,HP:0000707,,,,,,,,,,,
1839,,261100,Imerslund-Grasbeck syndrome,,CUBN/AMN,cubilin/amnion associated transmembrane protein,"EC:3.2.1.183, EC:2.7.1.60",,,,,,,,,,,,,,Normocytic anemia,,HP:0001897,https://www.ncbi.nlm.nih.gov/pubmed/29572946,https://www.ncbi.nlm.nih.gov/pubmed/18768530,,,,,,,,,
1840,,261100,Imerslund-Grasbeck syndrome,,CUBN/AMN,cubilin/amnion associated transmembrane protein,"EC:3.2.1.183, EC:2.7.1.60",,,,,,,,,,,,,,Hyperammonemia,,HP:0001987,,,,,,,,,,,
1841,,261100,Imerslund-Grasbeck syndrome,,CUBN/AMN,cubilin/amnion associated transmembrane protein,"EC:3.2.1.183, EC:2.7.1.60",,,,,,,,,,,,,,Increased liver enzyme activities,,HP:0002910,,,,,,,,,,,
1842,,261100,Imerslund-Grasbeck syndrome,,CUBN/AMN,cubilin/amnion associated transmembrane protein,"EC:3.2.1.183, EC:2.7.1.60",,,,,,,,,,,,,,Abnormal methylmalonic acid level.,,HP:0012120,,,,,,,,,,,
1843,,261100,Imerslund-Grasbeck syndrome,,CUBN/AMN,cubilin/amnion associated transmembrane protein,"EC:3.2.1.183, EC:2.7.1.60",,,,,,,,,,,,,,Hyperpigmentation,,HP:0000953,https://www.ncbi.nlm.nih.gov/pubmed/24222293,,,,,,,,,,
1844,245,242600,Iminoglycinuria,,SLC36A2 /SLC6A20/SLC6A19,solute carrier family 36 member 2 +solute carrier family 6 member 20 or solute carrier family 6 member 19,"EC:3.2.1.183, EC:2.7.1.60",No treatment is available in DDIEM,,,,,,,,,,,,,,,HP:0000953,https://www.ncbi.nlm.nih.gov/pubmed/24222293,,,,,,,,,,
1845,246,605637,Inclusion body myopathy type 3,,MYH2,myosin heavy chain 2,"EC:3.2.1.183, EC:2.7.1.60",No treatment is available in DDIEM,,,,,,,,,,,,,,,HP:0000953,https://www.ncbi.nlm.nih.gov/pubmed/24222293,,,,,,,,,,
1846,247,246450,3-HYDROXY-3-METHYLGLUTARYL-CoA LYASE DEFICIENCY; HMGCLD,,HMGCL,HMG-CoA lyase,"EC:3.2.1.183, EC:2.7.1.60",No treatment is available in DDIEM,,,,,,,,,,,,,,,HP:0000953,https://www.ncbi.nlm.nih.gov/pubmed/24222293,,,,,,,,,,
1847,248,248510,Beta-mannosidosis,,MANBA,mannosidase beta,EC 3.2.1.25,No treatment is available in DDIEM,,,,,,,,,,,,,,,HP:0000953,https://www.ncbi.nlm.nih.gov/pubmed/24222293,,,,,,,,,,
1848,1,# 268200,"Myoglobinuria, acute recurrent, autosomal recessive",,LPIN1,Phosphatidate phosphatase,3.1.3.4,Tauroursodeoxycholic acid,,DB08834,ECO:0005542,,,,,Functional intearction (Mecahnistic B),,,,Drug name: Study was done on preclinical model of the disease.,ER (endoplasmic reticulum) stress,,NA,https://www.ncbi.nlm.nih.gov/pubmed/30420558,,,,,,,,,,
1849,,# 268200,"Myoglobinuria, acute recurrent, autosomal recessive",,LPIN1,Phosphatidate phosphatase,3.1.3.4,,,,,,,,,,,,,,High triglyceride levels,,HP:0002155,,,,,,,,,,,
1850,,# 268200,"Myoglobinuria, acute recurrent, autosomal recessive",,LPIN1,Phosphatidate phosphatase,3.1.3.4,,,,,,,,,,,,,,Muscle weakness,,HP:0001324,,,,,,,,,,,
1851,,# 268200,"Myoglobinuria, acute recurrent, autosomal recessive",,LPIN1,Phosphatidate phosphatase,3.1.3.4,bezafibrate,,DB01393,ECO:0005542,,,,,Functional intearction (Mecahnistic B),,,,Drug name: Study was done on preclinical model of the disease.,Increased muscle lipid droplets,,HP:0012240,https://www.ncbi.nlm.nih.gov/pubmed/30420558,,,,,,,,,,
1852,,# 268200,"Myoglobinuria, acute recurrent, autosomal recessive",,LPIN1,Phosphatidate phosphatase,3.1.3.4,,,,,,,,,,,,,,ER (endoplasmic reticulum) stress,,NA,,,,,,,,,,,
1853,,# 268200,"Myoglobinuria, acute recurrent, autosomal recessive",,LPIN1,Phosphatidate phosphatase,3.1.3.4,,,,,,,,,,,,,,muscle weakness,,HP:0001324,,,,,,,,,,,
1854,,# 268200,"Myoglobinuria, acute recurrent, autosomal recessive",,LPIN1,Phosphatidate phosphatase,3.1.3.4,,,,,,,,,,,,,,fiber necrosis,,HP:0003713,,,,,,,,,,,
1855,,# 268200,"Myoglobinuria, acute recurrent, autosomal recessive",,LPIN1,Phosphatidate phosphatase,3.1.3.4,,,,,,,,,,,,,,Myopathy,,HP:0003198,,,,,,,,,,,
1856,2,# 550500,Myoglobinuria recurrent,,MT-CO1/MT-CO2/MT-CO3,Cytochrome c oxidase subunit 1/Cytochrome c oxidase subunit 2/Cytochrome c oxidase subunit 3,1.9.3.1/P00403/P00414,No treatment is available in DDIEM,,,,,,,,,,,,,,,HP:0003198,,,,,,,,,,,
1857,3,# 545000,Myoclonic epilepsy with ragged red fibers,"Mitochondrion-toxic agents, including mitochondrion-toxic AEDs, such as valproate, carbamazepine, phenytoin, and barbiturates, should be avoided as well as AEDs potentially enhancing the frequency of myoclonus, such as phenytoin, carbamazepine, lamotrigine, vigabatrin, tiagabine, gabapentin, pregabalin, and oxcarbazepine.",MT-TK,Mitochondrially encoded tRNA lysine,1.9.3.1/P00403/P00414,Levetiracetam/Clonazepam/Zonisamide,"Clonazepam is a useful adjunct for myoclonus and can be used in combination with lamotrigine to avoid lamotrigine’s myoclonic effects . 
Zonisamide should remain a second-line adjunct in the treatment of JME, owing to the lack of supportive data.
https://link.springer.com/article/10.1007/s11940-011-0131-z",DB01202/DB01068/DB00909,ECO:0000352,,,,,Symptomatic (C),,,,,Myoclonic epliepsy,,HP:0002123,https://www.ncbi.nlm.nih.gov/pubmed/14981187,,https://www.sciencedirect.com/science/article/pii/S1059131117301243?via%3Dihub#bib0010,https://www.ncbi.nlm.nih.gov/books/NBK1520/,https://link.springer.com/article/10.1007/s11940-011-0131-z,,,,,,
1858,,# 545000,Myoclonic epilepsy with ragged red fibers,,MT-TK,Mitochondrially encoded tRNA lysine,1.9.3.1/P00403/P00414,Coenzyme Q10+L-carnitine+ lipoic acid,,DB09270+DB00583+ DB00166,ECO:0000352,,,,,Symptomatic (C),,,,,Ankle weakness progression(Disease progression)*,,HP:0003287,https://www.ncbi.nlm.nih.gov/pubmed/17080429,,,,,,,,,,
1859,,# 545000,Myoclonic epilepsy with ragged red fibers,,MT-TK,Mitochondrially encoded tRNA lysine,1.9.3.1/P00403/P00414,,,,,,,,,,,,,,High resting plasma lactate concentration,,HP:0003288,https://www.ncbi.nlm.nih.gov/pubmed/17275787,,,,,,,,,,
1860,,# 545000,Myoclonic epilepsy with ragged red fibers,,MT-TK,Mitochondrially encoded tRNA lysine,1.9.3.1/P00403/P00414,Levetiracetam+ l-carnitine +CoQ10,,DB01202+DB00583+DB09270,ECO:0000352,,,,,Symptomatic (C),,,,,Myoclonus,,HP:0002123,https://www.ncbi.nlm.nih.gov/pubmed/17275787,,,,,,,,,,
1861,,# 545000,Myoclonic epilepsy with ragged red fibers,,MT-TK,Mitochondrially encoded tRNA lysine,1.9.3.1/P00403/P00414,,,,,,,,,,,,,,Low quality of life (Constitutional symptoms)*,,,https://www.ncbi.nlm.nih.gov/pubmed/28686997,https://link.springer.com/article/10.1007/s11940-011-0131-z,,,,,,,,,
1862,,# 545000,Myoclonic epilepsy with ragged red fibers,,MT-TK,Mitochondrially encoded tRNA lysine,1.9.3.1/P00403/P00414,piracetam,,DB09210,ECO:0000352,m.8344A > G,"Mutation improved:  In a 71yo female with MERRF syndrome due to the mutation m.8344A > G myoclonic, seizures did only respond to piracetam. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5506757/",,,Symptomatic (C),,,,"Mutation improved:  In a 71yo female with MERRF syndrome due to the mutation m.8344A > G myoclonic, seizures did only respond to piracetam. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5506757/",Myoclonic seizures,,HP:0002123,https://www.ncbi.nlm.nih.gov/pubmed/28717435,https://link.springer.com/article/10.1007/s11940-011-0131-z,,,,,,,,,
1863,,# 545000,Myoclonic epilepsy with ragged red fibers,,MT-TK,Mitochondrially encoded tRNA lysine,1.9.3.1/P00403/P00414,Clonazepam,,DB01068,ECO:0000352,,,,,Symptomatic (C),,,,,Asterixis-like movement(Abnormality of movement),,HP:0100022,https://www.ncbi.nlm.nih.gov/pubmed/1490314,,,,,,,,,,
1864,4,# 601776,"EHLERS-DANLOS SYNDROME, MUSCULOCONTRACTURAL TYPE, 1; EDSMC1",,CHST14,Dermatan-4-sulfotransferase-1,2.8.2.35,Magnesium,,DB14513,ECO:0000352,,,,,Symptomatic (C),,,,,constipation,,HP:0002019,https://www.ncbi.nlm.nih.gov/pubmed/21744491,,,,,,,,,,
1865,5,# 300559,"GSD IXd, MUSCLE PHOSPHORYLASE KINASE DEFICIENCY",,PHKA1,alpha subunit of muscle phosphorylase kinase,2.7.11.19,cortisone,,DB14681,ECO:0000352,,,,,Symptomatic (C),,,,Disease name: Most patients do not require any specific treatment.https://rarediseases.info.nih.gov/diseases/3858/muscular-phosphorylase-kinase-deficiency#,Muscular hypotonia,,HP:0001252,https://www.ncbi.nlm.nih.gov/pubmed/15637709,,,,,,,,,,
1866,,# 300559,"GSD IXd, MUSCLE PHOSPHORYLASE KINASE DEFICIENCY",,PHKA1,alpha subunit of muscle phosphorylase kinase,2.7.11.19,Glucose,In a different study IV administration of Glucose wasn't effective.https://www.ncbi.nlm.nih.gov/pubmed/22238410,DB01914,ECO:0000352,,,,,Symptomatic (C),,,,,Exercise intolerance,,HP:0009020,https://www.ncbi.nlm.nih.gov/pubmed/18401027,,,,,,,,,,
1867,6,# 602541,Congenital megaconial myopathy,,CHKB,Choline/ethanolamine kinase,2.7.1.32/2.7.1.82,L-carnitine,,DB00583,ECO:0000352,,,,,Symptomatic (C),,,,"Disease name: Cardiac involvement occurs relatively frequently in the patients with megaconial congenital muscular dystrophy, Heart transplanation is considered a successful therapeutic option in those patients not responding to medical treatment. https://www.ncbi.nlm.nih.gov/pubmed/26855408",Neurological disorder of mitochondrail dysfunction(mitochondrail dysfunction)*,,HP:0003287*,https://www.ncbi.nlm.nih.gov/pubmed/26006750,,,,,,,,,,
1868,,# 602541,Congenital megaconial myopathy,,CHKB,Choline/ethanolamine kinase,2.7.1.32/2.7.1.82,Riboflavin,,DB00140,ECO:0000352,,,,,Symptomatic (C),,,,,Neurological disorder of mitochondrail dysfunction(mitochondrail dysfunction)*,,HP:0003287*,,,,,,,,,,,
1869,,# 602541,Congenital megaconial myopathy,,CHKB,Choline/ethanolamine kinase,2.7.1.32/2.7.1.82,Thiamine,,DB00152,ECO:0000352,,,,,Symptomatic (C),,,,,Neurological disorder of mitochondrail dysfunction(mitochondrail dysfunction)*,,HP:0003287*,,,,,,,,,,,
1870,,# 602541,Congenital megaconial myopathy,,CHKB,Choline/ethanolamine kinase,2.7.1.32/2.7.1.82,Corticosteroid,,D07A,ECO:0000352,,,,,Symptomatic (C),,,,,Nummular eczema (Eczema)*,,HP:0000964*,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4830701/,,,,,,,,,,
1871,,# 602541,Congenital megaconial myopathy,,CHKB,Choline/ethanolamine kinase,2.7.1.32/2.7.1.82,B-Blockers+Angiotensin-converting enzyme inhibitors,,C07+C09,ECO:0000352,,,,,Symptomatic (C),,,,,Cardiomyopathy,,HP:0001638,https://www.ncbi.nlm.nih.gov/pubmed/26067811,,,,,,,,,,
1872,7,# 253280,Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A3,,POMGNT1,"Protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1",Q8WZA1,botulinum toxin,,DB00083,ECO:0000352,,,,,Symptomatic (C),,,,,strabismus,,HP:0000486,https://www.ncbi.nlm.nih.gov/pubmed/29555514?dopt=Abstract,,,,,,,,,,
1873,,# 253280,Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A3,,POMGNT1,"Protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1",Q8WZA1,,,,,,,,,,,,,,esotropia,,HP:0000565,,,,,,,,,,,
1874,,# 253280,Muscular dystrophy-dystroglycanopathy congenital with brain and eye anomalies A3,,POMGNT1,"Protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1",Q8WZA1,Ad5-LARGE-eGFP,,NA,ECO:0005542,,,,,Direct interaction (Mechanistic A) +Functional interaction ( Mechanisitc B),,,,,Muscle dystrophy,,HP:0003560,https://www.ncbi.nlm.nih.gov/pubmed/15184894,,,,,,,,,,
1875,8,# 236670,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 1; MDDGA1",,POMT1,protein O-mannosyltransferase 1,2.4.1.109,Ad5-LARGE-eGFP,,NA,ECO:0005542,,,,,Direct interaction (Mechanistic A) +Functional interaction ( Mechanisitc B),,,,,Muscle dystrophy,,HP:0003560,https://www.nature.com/articles/nm1059,,,,,,,,,,
1876,9,# 613150,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 2; MDDGA2",,POMT2,Protein O-mannosyl-transferase 2,2.4.1.109,Diuretics,,C03,ECO:0000352,,,,,Symptomatic ( C),C,,,,congestive cardiac failure,,HP:0001635,https://www.ncbi.nlm.nih.gov/pubmed/28980384,,,,,,,,,,
1877,,# 613150,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 2; MDDGA2",,POMT2,Protein O-mannosyl-transferase 2,2.4.1.109,,,,,,,,,,,,,,tachypnea,,HP:0002789,,,,,,,,,,,
1878,10,# 253800,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 4; MDDGA4",,FKTN,Fukutin,O75072,Antisense oligonucleotide,,,ECO:0001565/ECO:0005542,,,,,Direct interaction (Mechanistic A),A,,,,Abnormal Fukutin function,,NA,https://www.ncbi.nlm.nih.gov/pubmed/21979053,,,,,,,,,,
1879,11,# 613153,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 5; MDDGA5",,FKRP,Fukutin-related protein,Q9H9S5,Adeno-associated Virus 9 Mediated FKRP Gene Therapy,,NA,ECO:0005542,,,,,Direct intercation (Mechanistic A),,,,,abnormal muscle function,,HP:0011804,https://www.sciencedirect.com/science/article/pii/S152500161632250X,,,,,,,,,,
1880,,# 613153,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 5; MDDGA5",,FKRP,Fukutin-related protein,Q9H9S5,Ad5-LARGE-eGFP,,NA,ECO:0005542,,,,,Direct interaction (Mechanistic A) +Functional interaction ( Mechanisitc B),,,,,Muscle dystrophy,,HP:0003560,https://www.nature.com/articles/nm1059,,,,,,,,,,
1881,12,# 613154,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 6; MDDGA6",,LARGE,LARGE xylosyl- and glucuronyltransferase 1,O95461,Ad5-LARGE-eGFP,,NA,ECO:0005542,,,,,Direct interaction (Mechanistic A) +Functional interaction ( Mechanisitc B),,,,,Muscle dystrophy,,HP:0003560,https://www.nature.com/articles/nm1059,,,,,,,,,,
1882,13,# 614643,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 7; MDDGA7",,ISPD,D-ribitol-5-phosphate cytidylyltransferase,2.7.7.40,No treatment is available in DDIEM,,NA,,,,,,,,,,,,,HP:0003560,https://www.nature.com/articles/nm1059,,,,,,,,,,
1883,14,# 614830,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 8; MDDGA8",,POMGNT2,"Protein O-linked-mannose beta-1,4-N-acetylglucosaminyltransferase 2",2.4.1.312,No treatment is available in DDIEM,,NA,,,,,,,,,,,,,HP:0003560,https://www.nature.com/articles/nm1059,,,,,,,,,,
1884,15,# 616538,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 9; MDDGA9",,DAG1,Dystroglycan,Q14118,No treatment is available in DDIEM,,NA,,,,,,,,,,,,,HP:0003560,https://www.nature.com/articles/nm1059,,,,,,,,,,
1885,16,# 615041,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 10; MDDGA10",,RXYLT1,Ribitol-5-phosphate xylosyltransferase 1,Q9Y2B1,No treatment is available in DDIEM,,NA,,,,,,,,,,,,,HP:0003560,https://www.nature.com/articles/nm1059,,,,,,,,,,
1886,17,# 615181,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 11; MDDGA11",,B3GALNT2,"UDP-GalNAc:beta-1,3-N-acetylgalactosaminyltransferase 2",2.4.1.313,Phenobarbital,,DB01174,ECO:0000352,,,,,Symptomatic (C),,,,,Seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/29273094,,,,,,,,,,
1887,18,# 615249,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 12; MDDGA12",,POMK,Protein O-mannose kinase,2.7.1.183,No treatment is available in DDIEM,,DB01174,,,,,,,,,,,,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/29273094,,,,,,,,,,
1888,19,# 615287,"MUSCULAR DYSTROPHY-DYSTROGLYCANOPATHY (CONGENITAL WITH BRAIN AND EYE ANOMALIES), TYPE A, 13; MDDGA13",,B4GAT1,"Beta-1,4-glucuronyltransferase 1",O43505,No treatment is available in DDIEM,,DB01174,,,,,,,,,,,,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/29273094,,,,,,,,,,
1889,20,151800,Multiple symmetric lipomatosis,The surgical management  is the only effective treatment for the case. Patients are usually instructed to stop alcohol consumption. https://www.ncbi.nlm.nih.gov/pubmed/1696085/ https://www.ncbi.nlm.nih.gov/pubmed/8210195/,MTTK????,"Beta-1,4-glucuronyltransferase 1",O43505,salbutamol,,DB01001,ECO:0007121,,,,,Symptomatic (C),C,,,Drug name: A correlated gene mutation has not been discovered. https://www.ncbi.nlm.nih.gov/pubmed/8190288,Rapid progression in body fat mass( Abnormality of adipose tissue* ),,HP:0009124*,https://www.ncbi.nlm.nih.gov/pubmed/2897261?dopt=Abstract,,,,,,,,,,
1890,21,# 272200,Multiple sulfatase deficiency,,SUMF1,Formylglycine-generating enzyme,1.8.3.7,No treatment is available in DDIEM,,DB01001,,,,,,,,,,,Low metabolic rate ( Abnormality of fatty acid metabolism)*,,HP:0004359*,https://www.ncbi.nlm.nih.gov/pubmed/2897261?dopt=Abstract,,,,,,,,,,
1891,22,# 162300,Multiple endocrine neoplasia type 2B,,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,2.7.10.1,Dexamethasone,,DB01234,ECO:0001565,,,,,Direct interaction( Mechanistic)>>>Activity modification,A,,,Drug name: The trial was conducted on a cell line that is held to be an in vitro model for medullary carcinoma https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6157381/,Abnormal cellular proliferation,,HP:0031377,https://www.ncbi.nlm.nih.gov/pubmed/10947080,https://www.ncbi.nlm.nih.gov/pubmed/3491070/,,,,,,,,,
1892,,# 162300,Multiple endocrine neoplasia type 2B,,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,2.7.10.1,vandetanib,"Treatment-related risks should be taken into account when considering the use of vandetanib in patients with indolent, asymptomatic, or slowly progressing disease.https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract",DB05294,ECO:0007121,M918T,,,,Direct interaction (Mechanistis A)>>>Activity modification,A,,,"Mutation improved: If data from the ARMS assay are taken into account, patients with sporadic MTC received benefit from vandetanib whether their tumors were M918T positive or negative; however, the response rate was greater in those who had an M918T mutation. https://www.ncbi.nlm.nih.gov/pubmed/22025146/",low quality of life ( Constitutional symptom)*,,HP:0025142*,https://www.ncbi.nlm.nih.gov/pubmed/23766359,https://www.ncbi.nlm.nih.gov/pubmed/3491070/,,,,,,,,,
1893,,# 162300,Multiple endocrine neoplasia type 2B,,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,2.7.10.1,,,,,,,,,,,,,,Pain,,HP:0012531,,,,,,,,,,,
1894,,# 162300,Multiple endocrine neoplasia type 2B,,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,2.7.10.1,,,,,,,,,,,,,,Objective response rate (ORR),,NA,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214082/,,,,,,,,,,
1895,,# 162300,Multiple endocrine neoplasia type 2B,,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,2.7.10.1,,,,,,,,,,,,,,disease control rate(  Rapid disease progression),,HP:0003678,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214082/,,,,,,,,,,
1896,,# 162300,Multiple endocrine neoplasia type 2B,,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,2.7.10.1,,,,,,,,,,,,,,Short Progression-free survival,,NA,https://www.ncbi.nlm.nih.gov/pubmed/22025146/,https://www.ncbi.nlm.nih.gov/pubmed/20371662/,https://www.ncbi.nlm.nih.gov/pubmed/27650489,https://www.ncbi.nlm.nih.gov/pubmed/22665903?dopt=Abstract,,,,,,,
1897,,# 162300,Multiple endocrine neoplasia type 2B,,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,2.7.10.1,,,,,,,,,,,,,,Elevated calcitonin,,HP:0003528,https://www.ncbi.nlm.nih.gov/pubmed/23766359,https://clinicaltrials.gov/ct2/show/NCT00514046,,,,,,,,,
1898,,# 162300,Multiple endocrine neoplasia type 2B,,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,2.7.10.1,,,,,,,,,,,,,,Increased plasma CEA,,HP:0031029,https://www.ncbi.nlm.nih.gov/pubmed/23766359,https://clinicaltrials.gov/ct2/show/NCT00514046,,,,,,,,,
1899,,# 162300,Multiple endocrine neoplasia type 2B,,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,2.7.10.1,,,,,,,,,,,,,,Bone pain,,HP:0002653,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4307225/,https://clinicaltrials.gov/ct2/show/NCT00514046,,,,,,,,,
1900,,# 162300,Multiple endocrine neoplasia type 2B,,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,2.7.10.1,,,,,,,,,,,,,,Low skeletal muscle mass,,HP:0003199,https://www.ncbi.nlm.nih.gov/pubmed/23543666?dopt=Abstract,,,,,,,,,,
1901,,# 162300,Multiple endocrine neoplasia type 2B,,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,2.7.10.1,,,,,,,,,,,,,,Weight loss,,HP:0001824,https://www.ncbi.nlm.nih.gov/pubmed/23543666?dopt=Abstract,,,,,,,,,,
1902,,# 162300,Multiple endocrine neoplasia type 2B,,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,2.7.10.1,,,,,,,,,,,,,,Decreased adipose tissue,,HP:0040063,https://www.ncbi.nlm.nih.gov/pubmed/23543666?dopt=Abstract,,,,,,,,,,
1903,,# 162300,Multiple endocrine neoplasia type 2B,,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,2.7.10.1,,,,,,,,,,,,,,,,,,,,,,,,,,,
1904,,# 162300,Multiple endocrine neoplasia type 2B,,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,2.7.10.1,bortezomib + vandetanib,,DB00188+DB05294,ECO:0007121,,,,,,,,,Drug name:,neoplastic growth,,HP:0002664,https://www.ncbi.nlm.nih.gov/pubmed/18381602/,https://www.ncbi.nlm.nih.gov/pubmed/26170630,https://clinicaltrials.gov/ct2/show/NCT00923247,https://www.ncbi.nlm.nih.gov/pubmed/30297385/,,,,,,,
1905,,# 162300,Multiple endocrine neoplasia type 2B,,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,2.7.10.1,cabozantinib ( XL184),,DB08875,ECO:0007121,,,,,Direct interaction (Mechanistis A),,,,,phospholylation of RET,,NA,https://www.ncbi.nlm.nih.gov/pubmed/21606412/,https://clinicaltrials.gov/ct2/show/NCT00215605,,,,,,,,,
1906,,# 162300,Multiple endocrine neoplasia type 2B,,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,2.7.10.1,,,,,,,,,,,,,,Elevated calcitonin,,HP:0003528,,,,,,,,,,,
1907,,# 162300,Multiple endocrine neoplasia type 2B,,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,2.7.10.1,,,,,,,,,,,,,,Short Progression-free survival,,NA,https://www.ncbi.nlm.nih.gov/pubmed/24002501/,https://clinicaltrials.gov/ct2/show/NCT00704730,,,,,,,,,
1908,,# 162300,Multiple endocrine neoplasia type 2B,,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,2.7.10.1,,,,,,,,,,,,,,Low tumor response rate,"The estimated tumor response rate for cabozantinib and placebo is 28% and 0%, respectively, with results varying independently on RET-status, thus making it a promising treatment option. https://www.ncbi.nlm.nih.gov/pubmed/24002501",NA,,,,,,,,,,,
1909,,# 162300,Multiple endocrine neoplasia type 2B,,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,2.7.10.1,,,,,,,,,,,,,,overall survival( premature death),"Overall survival (OS), was found to be statistically insignificant. Despite being insignificant, patients receiving cabozantinib had a median OS of 26.6 months vs. a median OS of just 21.1 months for placebo patients (HR 0.85; 95% CI 0.64 to1.12; p = 0.24), resulting in an actual difference of 5.5 months. This provides patients treated with cabozantinib a 20.68% longer survival period compared to the placebo group. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214082/",MP:    ....,,,,,,,,,,,
1910,,# 162300,Multiple endocrine neoplasia type 2B,,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,2.7.10.1,,,,,,,,,,,,,,,,,,,,,,,,,,,
1911,,# 162300,Multiple endocrine neoplasia type 2B,,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,2.7.10.1,,,,,,,,,,,,,,,,,,,,,,,,,,,
1912,,# 162300,Multiple endocrine neoplasia type 2B,,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,2.7.10.1,,,,,,,,,,,,,,,,,,,,,,,,,,,
1913,,# 162300,Multiple endocrine neoplasia type 2B,,RET,Proto-oncogene tyrosine-protein kinase receptor Ret,2.7.10.1,,,,,,,,,,,,,,,,,,,,,,,,,,,
1914,23,# 614080,Multiple congenital anomalies-hypotonia-seizures syndrome,,PIGN,GPI ethanolamine phosphate transferase 1,O95427,levetiracetam,"Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam",DB01202,ECO:0000352,,,,,Symptomatic (C),C,,,,Seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4886552/,,,,,,,,,,
1915,,# 614080,Multiple congenital anomalies-hypotonia-seizures syndrome,,PIGN,GPI ethanolamine phosphate transferase 1,O95427,topiramate,"Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam",DB00273,ECO:0000352,,,,,Symptomatic (C),C,,,,Seizures,,HP:0001250,,,,,,,,,,,
1916,,# 614080,Multiple congenital anomalies-hypotonia-seizures syndrome,,PIGN,GPI ethanolamine phosphate transferase 1,O95427,oxcarbazepine,"Patient continued to have daily seizures on oxcarbazepine, topiramate and levetiracetam",DB00776,ECO:0000352,,,,,Symptomatic (C),C,,,,Seizures,,HP:0001250,,,,,,,,,,,
1917,24,# 300868,Multiple congenital anomalies-hypotonia-seizures syndrome type 2,Ketogenic diet - A novel treatment for early epileptic encephalopathy due to PIGA deficiency. https://www.ncbi.nlm.nih.gov/pubmed/27126216,PIGA,Phosphatidylinositol N-acetylglucosaminyltransferase subunit A,2.4.1.198,No medical treatment is availble in DDDIEM,,DB00776,,,,,,,,,,,,,HP:0001250,,,,,,,,,,,
1918,25,# 300818,Paroxysmal nocturnal hemoglobinuria,PNH is caused by somatic mutations in PIGA https://www.ncbi.nlm.nih.gov/pubmed/28516949,PIGA,Phosphatidylinositol N-acetylglucosaminyltransferase subunit A,2.4.1.199,Eculizumab,,DB01257,ECO:0000352,,,,,Symptomatic (C),C,,,,Paroxysmal nocturnal hemoglobinuria,,HP:0004818,https://www.ncbi.nlm.nih.gov/pubmed/28516949,,,,,,,,,,
1919,26,# 615398,Multiple congenital anomalies-hypotonia-seizures syndrome type 3,,PIGT,GPI transamidase component PIG-T,Q969N2,Phenobarbital,Drugs has decreased rhe frequency of the tonic seizuress,DB01174,ECO:0000352,,,,,Symptomatic (C),C,,,,tonic seizures ( Focal tonic seizures),,HP:0011167*,https://www.sciencedirect.com/science/article/pii/S0387760417301742?via%3Dihub,,,,,,,,,,
1920,,# 615398,Multiple congenital anomalies-hypotonia-seizures syndrome type 3,,PIGT,GPI transamidase component PIG-T,Q969N2,Clonzepam,Drugs has decreased rhe frequency of the tonic seizuress,DB01068,ECO:0000352,,,,,Symptomatic (C),C,,,,tonic seizures ( Focal tonic seizures),,HP:0011167*,https://www.sciencedirect.com/science/article/pii/S0387760417301742?via%3Dihub,,,,,,,,,,
1921,,# 615398,Multiple congenital anomalies-hypotonia-seizures syndrome type 3,,PIGT,GPI transamidase component PIG-T,Q969N2,Potassium bromide,Drugs has decreased rhe frequency of the tonic seizuress,CHEBI:32030,ECO:0000352,,,,,Symptomatic (C),C,,,,tonic seizures ( Focal tonic seizures),,HP:0011167*,https://www.sciencedirect.com/science/article/pii/S0387760417301742?via%3Dihub,,,,,,,,,,
1922,,# 615398,Multiple congenital anomalies-hypotonia-seizures syndrome type 3,,PIGT,GPI transamidase component PIG-T,Q969N2,acetazolamide,,DB00819,ECO:0000352,,,,,Symptomatic (C),C,,,,"Epileptic apnea(Apneic episodes precipitated by illness, fatigue, stress)",,HP:0002872*,,,,,,,,,,,
1923,28,# 248510,"MANNOSIDOSIS, BETA A, LYSOSOMAL; MANSB",,MANBA,Beta-mannosidase,3.2.1.25,No medical treatment is available in DDIEM,,DB00819,,,,,,,,,,,,,HP:0002872*,,,,,,,,,,,
1924,29,# 248600,Maple syrup urine disease type Ia,"In vitro study in which a discussion about activation of MSUD E1 mutants by TMAO treatment was studied further by titrating the osmolyte concentration. The activation of E1 activity for the three type IA MSUD mutants Y368C- , F364C- , and Y393N- is insignificant below 0.4 M TMAO. Rapid rises in residual E1 activity were obtained at 0.5 M or higher TMAO concentrations. The highest degree of activation occurs at 1 M TMAO concentration for all three MSUD mutants, with Y368C- at 50%, F364C- at 39%, and Y393N- at 17% of the wild type specific activity. At higher than 1 M TMAO concentrations, elevated residual E1 activities decline precipitously.",BCKDHA,"2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial",1.2.4.4,Natural osmolyte trimethylamine N-oxide (TMAO),,CHEBI:15724,ECO:0000352,F364C- alpha,Activity of F364C- mutant E1 was increased markedly from 1% of wild type without TMAO to 30% with 0.75 M TMAO. https://www.ncbi.nlm.nih.gov/pubmed/11507102?dopt=Abstract,A209D-alpha,"The S289L- beta and A209D- alpha mutants showed 0 and 40% residual activities, respectively, in the absence of TMAO, but these activities re- mained unchanged after incubation with the osmolyte",Direct interaction( Mechanistic A),A,,,,No phenotypes were mentioned in the study. In vitro Study.,,HP:0002872*,https://www.ncbi.nlm.nih.gov/pubmed/11507102?dopt=Abstract,,,,,,,,,,
1925,,# 248600,Maple syrup urine disease type Ia,,BCKDHA,"2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial",1.2.4.4,,,,,Y368C- alpha,Y368C- E1 in that residue activity is 3% in the absence of TMAO and 27% in its presence.,,,,,,,,,,,,,,,,,,,,,
1926,,# 248600,Maple syrup urine disease type Ia,,BCKDHA,"2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial",1.2.4.4,,,,,Y393N- alpha,"TMAO also activated Y393N- E1 with activity increased from 0 to 9% of the wild type, in the absence and the presence of TMAO, respectively.",,,,,,,,,,,,,,,,,,,,,
1927,,# 248600,Maple syrup urine disease type Ia,,BCKDHA,"2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial",1.2.4.4,Norleucine,,NA,ECO:0000352,,,,,,,,,,Branched-chain amino acid accumulation,Study ws done in pups: Administering norleucine to heterozygous mothers of classic maple syrup urine disease pups reduced branched-chain amino acid accumulation in milk as well as blood and brain of these pups to enhance survival.,HP:0008344,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668944/,,,,,,,,,,
1928,,# 248600,Maple syrup urine disease type Ia,,BCKDHA,"2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial",1.2.4.4,,,,,,,,,,,,,,Encephalopathy,"The study was done on mice, The phenotype enephalopathey was not treated, however, the aim is to delay the incidence. Norleucine substantially delayed encephalopathy in intermediate maple syrup urine disease mice placed on a high protein diet that mimics the catabolic stress shown to cause encephalopathy in human maple syrup urine disease.",HP:0001298,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2668944/,,,,,,,,,,
1929,,# 248600,Maple syrup urine disease type Ia,,BCKDHA,"2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial",1.2.4.4,,,,,,,,,,,,,,High α-ketoisocaproate level,,NA,,,,,,,,,,,
1930,30,# 248600,Maple syrup urine disease type Ib,,BCKDHB,"2-oxoisovalerate dehydrogenase subunit beta, mitochondrial",1.2.4.4,Sodium phenylbutyrate,"There is no clinical role for NaPBA at present; however, ongoing studies are assessing its efficacy https://www.ncbi.nlm.nih.gov/pubmed/28919799 Phenotypes corrected were based on invivo trial on mice not humans.",DB06819,ECO:0000352,,,,,Direct interaction ( Mechanistic  A),A,,,,High plasma branched chain keto acids,,NA,https://www.sciencedirect.com/science/article/pii/S0166432812001830?via%3Dihub#bib0070,https://www.ncbi.nlm.nih.gov/pubmed/28919799,,,,,,,,,
1931,,# 248600,Maple syrup urine disease type Ib,,BCKDHB,"2-oxoisovalerate dehydrogenase subunit beta, mitochondrial",1.2.4.4,,,,,,,,,,,,,,High plasma branched chain amino acids,,HP:0008344,,,,,,,,,,,
1932,31,# 248600,Maple syrup urine disease type II,,DBT,"Lipoamide acyltransferase component of branched-chain alpha-keto acid dehydrogenase complex, mitochondrial",2.3.1.168,Thiamine,,DB00152,ECO:0000352,,,,,Functional interaction (Mechanistic B),B,,,,High plasma branched chain amino acids,,HP:0008344,https://www.ncbi.nlm.nih.gov/pubmed/?term=Thiamin-responsive+maple-syrup-urine+disease+chuang+2006,,,,,,,,,,
1933,32,# 246900,"MAPLE SYRUP URINE DISEASE, TYPE III",,DLD,"Dihydrolipoyl dehydrogenase, mitochondrial",1.8.1.4,N-acetylcysteine +deferoxamine,,DB06151+ DB00746,ECO:0000352,,,,,Symptomatic ( C),C,,,,Memory impairment,,HP:0002354,https://www.sciencedirect.com/science/article/pii/S0166432812001830?via%3Dihub#bib0070,,,,,,,,,,
1934,,# 246900,"MAPLE SYRUP URINE DISEASE, TYPE III",,DLD,"Dihydrolipoyl dehydrogenase, mitochondrial",1.8.1.4,,,,,,,,,,,,,,Oxidative stress,,HP:0025464,https://www.ncbi.nlm.nih.gov/pubmed/15938133,https://www.ncbi.nlm.nih.gov/pubmed/12927581,,,,,,,,,
1935,,# 246900,"MAPLE SYRUP URINE DISEASE, TYPE III",,DLD,"Dihydrolipoyl dehydrogenase, mitochondrial",1.8.1.4,,,,,,,,,,,,,,Behavioural abnormalites,,HP:0000708,,,,,,,,,,,
1936,,# 246900,"MAPLE SYRUP URINE DISEASE, TYPE III",,DLD,"Dihydrolipoyl dehydrogenase, mitochondrial",1.8.1.4,,,,,,,,,,,,,,cognitive imapirment,,HP:0100543,,,,,,,,,,,
1937,,# 246900,"MAPLE SYRUP URINE DISEASE, TYPE III",,DLD,"Dihydrolipoyl dehydrogenase, mitochondrial",1.8.1.4,,,,,,,,,,,,,,Learning impairment,,HP:0001328,,,,,,,,,,,
1938,,# 246900,"MAPLE SYRUP URINE DISEASE, TYPE III",,DLD,"Dihydrolipoyl dehydrogenase, mitochondrial",1.8.1.4,Riboflavin,,DB00140,ECO:0000352,,,,,Direct interaction (Mechanistic A),A,,,,Exercise intolerance,,HP:0003546,https://www.sciencedirect.com/science/article/pii/S1567724914001299?via%3Dihub,,,,,,,,,,
1939,,# 246900,"MAPLE SYRUP URINE DISEASE, TYPE III",,DLD,"Dihydrolipoyl dehydrogenase, mitochondrial",1.8.1.4,,,,,,,,,,,,,,Mitochondrial proliferation in the muscle,,HP:0003200,,,,,,,,,,,
1940,,# 246900,"MAPLE SYRUP URINE DISEASE, TYPE III",,DLD,"Dihydrolipoyl dehydrogenase, mitochondrial",1.8.1.4,,,,,,,,,,,,,,Myopathy,,HP:0003198,,,,,,,,,,,
1941,,# 246900,"MAPLE SYRUP URINE DISEASE, TYPE III",,DLD,"Dihydrolipoyl dehydrogenase, mitochondrial",1.8.1.4,,,,,,,,,,,,,,Lactic acidosis,,HP:0003128,,,,,,,,,,,
1942,33,# 261600,PHENYLKETONURIA,"Dietary treatment has proved to be very effective in preventing the devastating consequences of PAH deficiency when started early in lifeDrug name: Tetrahydrobiopterin stimulates phenylalanine hydroxylase activity in about 20% of patients, and in those patients serves as a useful adjunct to the phenylalanine-restricted diet because it increases phenylalanine tolerance and allows some dietary freedom.. A striking normalisation (within 8 h) in phenylalanine concentrations after drug administartion indicates BH4 deficiency whereas very little or no reduction in phenylalanine indicates BH4-non-responsive phenylketonuria. https://www.sciencedirect.com/science/article/pii/S0140673610609610?via%3Dihub",PAH,PHENYLALANINE HYDROXYLASE,1.14.16.1,Tetrahydrobiopterin (sapropterin),,DB00360,ECO:0000352,"P407S
A373T
R241C","The serum Phe concentrations of patients have those mutaions never exceeded 20 mg/dL, even when they were not on a Phe-restricted diet, suggesting that mutant PAH molecules with P407S, A373T, and R241C have residual enzymatic activities. https://www.sciencedirect.com/science/article/pii/S0022347699701381?via%3Dihubhttps://www.sciencedirect.com/science/article/pii/S0022347699701381?via%3Dihub","Homozygotes of R252W 
Homozygotes of IVS4-1G→A 
Homozygotes of R413P","Homozygotes of R252W, IVS4-1G→A, and R413P presented with clinical symptoms typical of classical PKU. Therefore these mutations appear to abolish PAH function. https://www.sciencedirect.com/science/article/pii/S0022347699701381?via%3Dihub",Direct interaction (Mechanistic A)>>Functional interaction( Functional complementation or a defective protein by stimulation),A,,,,Hyperphenylalaninemia,,HP:0004923,https://www.ncbi.nlm.nih.gov/pubmed/20971365,https://www.ncbi.nlm.nih.gov/pubmed/19323589,https://clinicaltrials.gov/ct2/show/results/NCT01977820?cond=sapropterin&rank=1,https://www.sciencedirect.com/science/article/pii/S0022347699701381?via%3Dihub,,,,,,,
1943,34,# 261600,"HYPERPHENYLALANINEMIA, NON-PKU MILD, INCLUDED",,PAH,PHENYLALANINE HYDROXYLASE,1.14.16.1,Tetrahydrobiopterin,,DB00360,ECO:0000352,,,,,Direct interaction (Mechanistic A),A,,,,Hyperphenylalaninemia,,HP:0004923,,,,,,,,,,,
1944,,# 261600,"HYPERPHENYLALANINEMIA, NON-PKU MILD, INCLUDED",,PAH,PHENYLALANINE HYDROXYLASE,1.14.16.1,Pegvaliase,,DB12839,ECO:0007121+ECO:0005542,,,,,Functional interaction ( Mechanistic B),B,,,,Abnormal blood Phenylalanine levels,,HP:0004923,https://www.sciencedirect.com/science/article/pii/S1096719218300210,https://www.sciencedirect.com/science/article/pii/S1525001605000845,https://www.pnas.org/content/96/5/2339.short,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short,,,,
1945,35,# 520000,Maternally inherited diabetes and deafness,,MTTL1/MTTE/MTTK,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,Coenzyme Q10,,DB09270,ECO:0000352,,,,,Symptomatic (C),,,,,Muscle weakness,,HP:0001324,https://www.ncbi.nlm.nih.gov/pubmed/19323589,https://www.ncbi.nlm.nih.gov/pubmed/24746802,https://www.pnas.org/content/96/5/2339.short,https://clinicaltrials.gov/ct2/show/NCT01212744?cond=Pegvaliase&rank=4,https://www.sciencedirect.com/science/article/pii/S1096719205001733,https://www.tandfonline.com/doi/abs/10.1081/BIO-120006117,https://www.pnas.org/content/96/5/2339.short,,,,
1946,,# 520000,Maternally inherited diabetes and deafness,,MTTL1/MTTE/MTTK,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,Vitamin B12+imipramine,"Effect of those two drugs was short-term response. Disease Name: There are many drugs with known detrimental effect on mitochondrial function. These include antibiotics like tetracycline and chloramphenicol; antiepileptics like valproate, phenytoin, antiretroviral agents and metformin. Overall their effects in patients with MIDD are not known. Statin therapy should be avoided in patients especially with myopathy. HMG Co-A reductase inhibitors can reduce both cholesterol and Co-enzyme Q via mevalonate pathway. These patients may have higher rate of lactic acidosis and intolerance to statins resulting in myalgia and may worsen the symptoms of existing myopathy. https://www.sciencedirect.com/science/article/pii/S1056872714000610?via%3Dihub#bb0115",DB00115+DB00458,ECO:0000352,,,,,Symptomatic (C),,,,,Diabetic polyneuropathy,,HP:0001271,https://www.ncbi.nlm.nih.gov/pubmed/28766015,,,,,,,,,,
1947,,# 520000,Maternally inherited diabetes and deafness,,MTTL1/MTTE/MTTK,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,Prokinetic agents,,NA,ECO:0000352,,,,,Symptomatic (C),,,,,Epigastric pain,,HP:0410019,https://www.ncbi.nlm.nih.gov/pubmed/28766015,,,,,,,,,,
1948,,# 520000,Maternally inherited diabetes and deafness,,MTTL1/MTTE/MTTK,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,,,,,,,,,,,,,,Acid regurgitation,,HP:0002020,,,,,,,,,,,
1949,,# 520000,Maternally inherited diabetes and deafness,,MTTL1/MTTE/MTTK,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,pregabalin,,DB00230,ECO:0000352,,,,,Symptomatic (C),,,,,Neuropathic pain(Abnormality of pain sensation)*,,HP:0010832*,https://www.ncbi.nlm.nih.gov/pubmed/28766015,,,,,,,,,,
1950,,# 520000,Maternally inherited diabetes and deafness,,MTTL1/MTTE/MTTK,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,insulin,,DB00030,ECO:0000352,,,,,Symptomatic (C),,,,,Diabetes,"Mitochondrial diabetes is treated as other forms of diabetes; however, the use of metformin should be avoided due to the increased risk of lactic acidosis. https://www.ncbi.nlm.nih.gov/pubmed/27966441 Cases were treated with metformin at some stage and also received statins which could be harmful in such patients. https://www.ncbi.nlm.nih.gov/pubmed/24746802",HP:0000819,https://www.ncbi.nlm.nih.gov/pubmed/28756474,,,,,,,,,,
1951,,# 520000,Maternally inherited diabetes and deafness,,MTTL1/MTTE/MTTK,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,clonazepam,,DB01068,ECO:0000352,,,,,Symptomatic (C),,,,,Involuntary movement,,HP:0004305,https://www.ncbi.nlm.nih.gov/pubmed/28756475,,,,,,,,,,
1952,,# 520000,Maternally inherited diabetes and deafness,,MTTL1/MTTE/MTTK,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,Immunosuppressent +Carbonic anhydrase inhibitors,"The cystoid changes responed to treatment with systemic immunosuppression and a topical carbonic anhydrase inhibitor (CAI), recurred when treated with topical CAI monotherapy.",L04+S01EC,ECO:0000352,,,,,Symptomatic (C),,,,,Macular cystoid changes,,HP:0008028,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568973/,,,,,,,,,,
1953,,# 520000,Maternally inherited diabetes and deafness,,MTTL1/MTTE/MTTK,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,Triamcinolone acetonide,The drug was administered through intravitreal injection.,DB00620,ECO:0000352,,,,,Symptomatic (C),,,,,Macular cystoid changes,,HP:0011505,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5568973/,,,,,,,,,,
1954,,# 520000,Maternally inherited diabetes and deafness,,MTTL1/MTTE/MTTK,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,,,,,,,,,,,,,,Abnormal visual acuity,,HP:0030532,,,,,,,,,,,
1955,,# 520000,Maternally inherited diabetes and deafness,,MTTL1/MTTE/MTTK,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,,,,,,,,,,,,,,Intraretinal cystoid spaces (Retinal disease)*,,HP:0000479*,,,,,,,,,,,
1956,,# 520000,Maternally inherited diabetes and deafness,,MTTL1/MTTE/MTTK,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,Non-steroidal anti-inflammatory agents,,M02AA,ECO:0000352,,,,,Symptomatic (C),,,,,Intraretinal cystoid spaces (Retinal disease)*,,HP:0000479*,https://www.ncbi.nlm.nih.gov/pubmed/23806424/,,,,,,,,,,
1957,,# 520000,Maternally inherited diabetes and deafness,,MTTL1/MTTE/MTTK,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,Vitamins,,A11,ECO:0000352,,,,,Symptomatic (C),,,,,Malnutrition,,HP:0004395,,,,,,,,,,,
1958,,# 520000,Maternally inherited diabetes and deafness,,MTTL1/MTTE/MTTK,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,Coenzyme Q10+Vitamin C+Vitamin B+Vitamin K +Carnitine,,DB09270+A11EB+B02BA+ DB00583,ECO:0000352,,,,,Symptomatic (C),,,,,Mitochondrial dysfunction,,HP:0003287,,,,,,,,,,,
1959,36,# 540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS","MELAS syndrome can be caused by mutation in several genes, including MTTL1/ MTTQ /MTTH/MTTK / MTTC/ MTTS1/ MTND1/ MTND5/ MTND6/ MTTS2. https://www.omim.org/entry/540000",MTTL1/ MTTQ /MTTH/MTTK / MTTC/ MTTS1/ MTND1/ MTND5/ MTND6/ MTTS2,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,Coenzyme Q10,,DB09270,ECO:0000352,,,,,Symptomatic (C),,,,,Myopathy,,HP:0003198,https://www.ncbi.nlm.nih.gov/pubmed/26823911,https://www.ncbi.nlm.nih.gov/pubmed/10601810?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/29596118,,,,,,,,
1960,,# 540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MTTL1/ MTTQ /MTTH/MTTK / MTTC/ MTTS1/ MTND1/ MTND5/ MTND6/ MTTS2,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,,,,,,,,,,,,,,Reduced electron transport chain activity(Decreased activity of mitochondrial respiratory chain)*,,HP:0008972*,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5625994/,,,,,,,,,,
1961,,# 540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MTTL1/ MTTQ /MTTH/MTTK / MTTC/ MTTS1/ MTND1/ MTND5/ MTND6/ MTTS2,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,arginine hydrochloride,,DB00125,ECO:0000352,,,,,Symptomatic (C),,,,,Stroke-like episodes,,HP:0002401,https://www.ncbi.nlm.nih.gov/pubmed/26954033,https://www.ncbi.nlm.nih.gov/pubmed/15728297,https://www.ncbi.nlm.nih.gov/pubmed/26095523,,,,,,,,
1962,,# 540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MTTL1/ MTTQ /MTTH/MTTK / MTTC/ MTTS1/ MTND1/ MTND5/ MTND6/ MTTS2,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,,,,,,,,,,,,,,Painful neuropathy(neuropathy)*,,HP:0009830*,,,,,,,,,,,
1963,,# 540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MTTL1/ MTTQ /MTTH/MTTK / MTTC/ MTTS1/ MTND1/ MTND5/ MTND6/ MTTS2,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,,,,,,,,,,,,,,Congestive heart failure,,HP:0001635,,,,,,,,,,,
1964,,# 540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MTTL1/ MTTQ /MTTH/MTTK / MTTC/ MTTS1/ MTND1/ MTND5/ MTND6/ MTTS2,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,,,,,,,,,,,,,,Pancreatic beta-cell dysfunction,,HP:0006279,,,,,,,,,,,
1965,,# 540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MTTL1/ MTTQ /MTTH/MTTK / MTTC/ MTTS1/ MTND1/ MTND5/ MTND6/ MTTS2,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,Nicotinamide Riboside,,DB03227,ECO:0007121,,,,,Symptomatic (C),,,,,Muscle abnormality related to mitochondrial dysfunction,,HP:0003800,https://clinicaltrials.gov/ct2/show/NCT03432871?cond=Chronic+progressive+external+ophthalmoplegia&rank=2,http://ichgcp.net/clinical-trials-registry/NCT03432871,,,,,,,,,
1966,,# 540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MTTL1/ MTTQ /MTTH/MTTK / MTTC/ MTTS1/ MTND1/ MTND5/ MTND6/ MTTS2,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,Sodium Pyruvate,,DB00119,ECO:0007121,,,,,,,,,,Elevated serum lactate level,,HP:0002151,https://www.ncbi.nlm.nih.gov/pubmed/30738201,,,,,,,,,,
1967,,# 540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MTTL1/ MTTQ /MTTH/MTTK / MTTC/ MTTS1/ MTND1/ MTND5/ MTND6/ MTTS2,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,,,,,,,,,,,,,,High lactate /pyruvate ratio,,NA,,,,,,,,,,,
1968,,# 540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MTTL1/ MTTQ /MTTH/MTTK / MTTC/ MTTS1/ MTND1/ MTND5/ MTND6/ MTTS2,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,,,,,,,,,,,,,,Increased lateral ventricular lactate level,,NA,,,,,,,,,,,
1969,,# 540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MTTL1/ MTTQ /MTTH/MTTK / MTTC/ MTTS1/ MTND1/ MTND5/ MTND6/ MTTS2,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,,,,,,,,,,,,,,High serum GDF15 level,,NA,,,,,,,,,,,
1970,,# 540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MTTL1/ MTTQ /MTTH/MTTK / MTTC/ MTTS1/ MTND1/ MTND5/ MTND6/ MTTS2,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,Duloxetine,,DB00476,ECO:0000352,,,,,Symptomatic (C),,,,,Depression,,HP:0000716,https://www.ncbi.nlm.nih.gov/pubmed/29596118,,,,,,,,,,
1971,,# 540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MTTL1/ MTTQ /MTTH/MTTK / MTTC/ MTTS1/ MTND1/ MTND5/ MTND6/ MTTS2,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,Taurine,,DB01956,ECO:0000352,,,,,,,,,,Oxidative stress,,HP:0025464,,,,,,,,,,,
1972,,# 540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MTTL1/ MTTQ /MTTH/MTTK / MTTC/ MTTS1/ MTND1/ MTND5/ MTND6/ MTTS2,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,,,,,,,,,,,,,,Mitochondrial dysfunction,,HP:0003287,,,,,,,,,,,
1973,,# 540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MTTL1/ MTTQ /MTTH/MTTK / MTTC/ MTTS1/ MTND1/ MTND5/ MTND6/ MTTS2,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,Idebenone,,DB09081,ECO:0007121,,,,,Symptomatic (C),,,,,Decreased activity of mitochondrial ATP synthase complex,,HP:0011925,https://clinicaltrials.gov/ct2/show/NCT00887562,https://www.ncbi.nlm.nih.gov/pubmed/8757046,,,,,,,,,
1974,,# 540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MTTL1/ MTTQ /MTTH/MTTK / MTTC/ MTTS1/ MTND1/ MTND5/ MTND6/ MTTS2,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,Idebenone+Riboflavin,,DB09081+DB00140,ECO:0000352,,,,,Symptomatic (C),,,,,Neurological abnormality,,HP:0000707,https://www.ncbi.nlm.nih.gov/pubmed/11382201,https://www.ncbi.nlm.nih.gov/pubmed/8757046,,,,,,,,,
1975,,# 540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MTTL1/ MTTQ /MTTH/MTTK / MTTC/ MTTS1/ MTND1/ MTND5/ MTND6/ MTTS2,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,,,,,,,,,,,,,,Abnormal EEG (focal epileptiform activity),,HP:0002353,,,,,,,,,,,
1976,,# 540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MTTL1/ MTTQ /MTTH/MTTK / MTTC/ MTTS1/ MTND1/ MTND5/ MTND6/ MTTS2,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,,,,,,,,,,,,,,Hyperintensity of cerebral white matter on MRI,,HP:0030890,,,,,,,,,,,
1977,,# 540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MTTL1/ MTTQ /MTTH/MTTK / MTTC/ MTTS1/ MTND1/ MTND5/ MTND6/ MTTS2,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,,,,,,,,,,,,,,Stroke-like attacks,,HP:0002401,,,,,,,,,,,
1978,,# 540000,"MITOCHONDRIAL MYOPATHY, ENCEPHALOPATHY, LACTIC ACIDOSIS, AND STROKE-LIKE EPISODES; MELAS",,MTTL1/ MTTQ /MTTH/MTTK / MTTC/ MTTS1/ MTND1/ MTND5/ MTND6/ MTTS2,tRNA-LEU MITOCHONDRIAL 1/tRNA-GLU MITOCHONDRIAL/tRNA-LYS MITOCHONDRIAL,NA,Idebenone+Coenzyme Q10,,DB09081+DB09270,ECO:0000352,,,,,Symptomatic (C),,,,,Abnormal EEG,,HP:0002353,https://www.sciencedirect.com/science/article/pii/0022510X89901123,,,,,,,,,,
1979,37,# 610090,PNPO deficiency,,PNPO,Pyridoxamine 5'-phosphate oxidase,1.4.3.5,Pyridoxine,,DB00165,ECO:0000352,R229W,,,,Direct interaction ( Mechanistic A),,,,,Seizures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/?term=Clinical+and+Laboratory+Findings+in+Twins+with+Neonatal+Epileptic+Encephalopathy+Mimicking+Aromatic+L-Amino+Acid+Decarboxylase+Deficiency,,,,,,,,,,
1980,,# 610090,PNPO deficiency,,PNPO,Pyridoxamine 5'-phosphate oxidase,1.4.3.5,,,,,,,,,,,,,,Clonic contractions,There was partial improvement then patients died,,,,,,,,,,,,
1981,,# 610090,PNPO deficiency,,PNPO,Pyridoxamine 5'-phosphate oxidase,1.4.3.5,,,,,,,,,,,,,,Lip-smacking automatisms(Epilepsy)*,,HP:0001250,,,,,,,,,,,
1982,,# 610090,PNPO deficiency,,PNPO,Pyridoxamine 5'-phosphate oxidase,1.4.3.5,,,,,,,,,,,,,,,,,,,,,,,,,,,
1983,,# 610090,PNPO deficiency,,PNPO,Pyridoxamine 5'-phosphate oxidase,1.4.3.5,,,,,,,,,,,,,,,,,,,,,,,,,,,
1984,,# 610090,PNPO deficiency,,PNPO,Pyridoxamine 5'-phosphate oxidase,1.4.3.5,,,,,,,,,,,,,,,,,,,,,,,,,,,
1985,,# 610090,PNPO deficiency,,PNPO,Pyridoxamine 5'-phosphate oxidase,1.4.3.5,,,,,,,,,,,,,,,,,,,,,,,,,,,
1986,,# 610090,PNPO deficiency,,PNPO,Pyridoxamine 5'-phosphate oxidase,1.4.3.5,,,,,,,,,,,,,,,,,,,,,,,,,,,
1987,,# 610090,PNPO deficiency,,PNPO,Pyridoxamine 5'-phosphate oxidase,1.4.3.5,Pyridoxal phosphate,,DB00114,ECO:0000352,,,,,Direct interaction ( Mechanistic A),,,,,Siezures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/12747882,,,,,,,,,,
1988,,# 610090,PNPO deficiency,,PNPO,Pyridoxamine 5'-phosphate oxidase,1.4.3.5,,,,,,,,,,,,,,Developmental delay,,HP:0001263,,,,,,,,,,,
1989,,# 610090,PNPO deficiency,,PNPO,Pyridoxamine 5'-phosphate oxidase,1.4.3.5,,,,,,,,,,,,,,,,,,,,,,,,,,,
1990,,# 610090,PNPO deficiency,,PNPO,Pyridoxamine 5'-phosphate oxidase,1.4.3.5,Phenobarbitone,,DB01174,ECO:0000352,,,,,Symptomatic (C),,,,,Siezures,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/21310277,,,,,,,,,,
1991,38,# 613839,Megaloblastic anemia due to dihydrofolate reductase deficiency,,DHFR,Dihydrofolate reductase,1.5.1.3,Folinic acid,,DB00650,ECO:0000352,,,,,Symptomatic (C),,,,,Low total RBC folate level,,HP:0040087,https://www.ncbi.nlm.nih.gov/pubmed/21310277,,,,,,,,,,
1992,,# 613839,Megaloblastic anemia due to dihydrofolate reductase deficiency,,DHFR,Dihydrofolate reductase,1.5.1.3,,,,,,,,,,,,,,Bone marrow megaloblastic changes,,HP:0001980,https://www.ncbi.nlm.nih.gov/pubmed/21310277,,,,,,,,,,
1993,,# 613839,Megaloblastic anemia due to dihydrofolate reductase deficiency,,DHFR,Dihydrofolate reductase,1.5.1.3,,,,,,,,,,,,,,Low 5-MTHF level,,HP:0012446,https://www.ncbi.nlm.nih.gov/pubmed/21310277,https://www.ncbi.nlm.nih.gov/pubmed/21310276?dopt=Abstract,,,,,,,,,
1994,,# 613839,Megaloblastic anemia due to dihydrofolate reductase deficiency,,DHFR,Dihydrofolate reductase,1.5.1.3,,,,,,,,,,,,,,Abscent 5-MTHF(Abnormal CSF metabolite level)*,,HP:0025454*,https://www.ncbi.nlm.nih.gov/pubmed/21310277,,,,,,,,,,
1995,,# 613839,Megaloblastic anemia due to dihydrofolate reductase deficiency,,DHFR,Dihydrofolate reductase,1.5.1.3,,,,,,,,,,,,,,Abnormal CSF folate level,,HP:0012446,https://www.ncbi.nlm.nih.gov/pubmed/21310277,,,,,,,,,,
1996,,# 613839,Megaloblastic anemia due to dihydrofolate reductase deficiency,,DHFR,Dihydrofolate reductase,1.5.1.3,,,,,,,,,,,,,,Megaloblastic anemia,,HP:0001889,https://www.ncbi.nlm.nih.gov/pubmed/21310276?dopt=Abstract,,,,,,,,,,
1997,,# 613839,Megaloblastic anemia due to dihydrofolate reductase deficiency,,DHFR,Dihydrofolate reductase,1.5.1.3,,,,,,,,,,,,,,,,,,,,,,,,,,,
1998,,# 613839,Megaloblastic anemia due to dihydrofolate reductase deficiency,,DHFR,Dihydrofolate reductase,1.5.1.3,,,,,,,,,,,,,,,,,,,,,,,,,,,
1999,,# 613839,Megaloblastic anemia due to dihydrofolate reductase deficiency,,DHFR,Dihydrofolate reductase,1.5.1.3,Hydroxycobalamin + Folic acid,,DB00200+DB00158,ECO:0000352,,,,,Symptomatic (C),,,,,Abnormal hemoglobin level,,HP:0025546,https://www.ncbi.nlm.nih.gov/pubmed/21310277,,,,,,,,,,
2000,,# 613839,Megaloblastic anemia due to dihydrofolate reductase deficiency,,DHFR,Dihydrofolate reductase,1.5.1.3,,,,,,,,,,,,,,Abnormal MCV level,,HP:0025065,,,,,,,,,,,
2001,,# 613839,Megaloblastic anemia due to dihydrofolate reductase deficiency,,DHFR,Dihydrofolate reductase,1.5.1.3,Phenobarbitone+levetiracetam,,DB01174+DB01202,ECO:0000352,,,,,Symptomatic (C),,,,Phenotype improved: There was a partial control to seizures with phenobarbitone and levetiracetam.,seizure,,HP:0001250,https://www.ncbi.nlm.nih.gov/pubmed/21310277,,,,,,,,,,
2002,39,# 309400,Menkes disease,,ATP7A,Copper-transporting ATPase 1,7.2.2.8,Copper Histadine,"The response to early copper treatment depends on the ATP7A genotype and that optimal outcomes occur only in patients with mutations that permit some residual copper transport . https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/ Parenteral copper supplementation has been used as a potential disease-modifying treatment of Menkes disease for decades. However, recent evidence suggests its efficacy only when treatment is started within days after birth, which also has important implications related to the techniques that enable early diagnosis. https://www.ncbi.nlm.nih.gov/pubmed/30594472 They proposed a 3-year treatment period on the basis of the expected nephrotoxicity of the study drug and the knowledge that brain myelination is typically completed by 24 months of age. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/ A great guidline on treatment is available @ https://www.sciencedirect.com/science/article/pii/S1096719218304104?via%3Dihub 
Cu therapy in milder MD needs close monitoring to avoid systemic Cu accumulation; important to closely follow connective tissue problems
- Administration may be adjusted in relation to new knowledge about nurture of the brain
- Functional classification of mutations may facilitate patient specific therapy
- Cu-HIS therapy may ameliorate, but never cure. https://www.ncbi.nlm.nih.gov/pubmed/30384011",DB01174+DB01202,ECO:0000352/ECO:0007121,G666R,,2757delAG,"We found no evidence for residual copper transport in patients with ATP7A deletions that disrupt the translational reading frame, and the nine infants with Menkes disease who had these mutations did not achieve normal neurodevelopment, despite early treatment. However, these patients had better survival and a lower incidence of clinical seizures (two of nine infants, or 22%) than would be expected among those with untreated Menkes disease,4 perhaps as a result of their access to early diagnosis and treatment. The mechanisms underlying these improvements in patients with complete loss-of-function mutations remain unclear. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/",Functional interaction( Mechanistic B),,,,"Drug name: The response to early copper treatment depends on the ATP7A genotype and that optimal outcomes occur only in patients with mutations that permit some residual copper transport . https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/

Parenteral copper supplementation has been used as a potential disease-modifying treatment of Menkes disease for decades. However, recent evidence suggests its efficacy only when treatment is started within days after birth, which also has important implications related to the techniques that enable early diagnosis. https://www.ncbi.nlm.nih.gov/pubmed/30594472
They proposed a 3-year treatment period on the basis of the expected nephrotoxicity of the study drug and the knowledge that brain myelination is typically completed by 24 months of age. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/

A great guidline on treatment is available @ https://www.sciencedirect.com/science/article/pii/S1096719218304104?via%3Dihub

Mutation that didn't get benefits out the treatment: We found no evidence for residual copper transport in patients with ATP7A deletions that disrupt the translational reading frame, and the nine infants with Menkes disease who had these mutations did not achieve normal neurodevelopment, despite early treatment. However, these patients had better survival and a lower incidence of clinical seizures (two of nine infants, or 22%) than would be expected among those with untreated Menkes disease,4 perhaps as a result of their access to early diagnosis and treatment. The mechanisms underlying these improvements in patients with complete loss-of-function mutations remain unclear. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/",Abnormal brain electrical activity,,HP:0002353,https://www.ncbi.nlm.nih.gov/pubmed/20652413/,https://www.ncbi.nlm.nih.gov/pubmed/10401004/,https://clinicaltrials.gov/ct2/show/results/NCT00001262?cond=Menkes&rank=1,,,,,,,,
2003,,# 309400,Menkes disease,,ATP7A,Copper-transporting ATPase 1,7.2.2.8,,,,,N1304S,,Del ex20–23,,,,,,,Seizures,,HP:0001250,,,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3477514/,,,,,,,,
2004,,# 309400,Menkes disease,,ATP7A,Copper-transporting ATPase 1,7.2.2.8,,,,,"IVS9,DS,+6T→G",,Q1385X,,,,,,,Neurological abnormalities.,,HP:0000707,,,https://www.ncbi.nlm.nih.gov/pubmed/30384011,https://www.ncbi.nlm.nih.gov/pubmed/9511979,,,,,,,
2005,,# 309400,Menkes disease,,ATP7A,Copper-transporting ATPase 1,7.2.2.8,,,,,,,,,,,,,,Neurologic burden,,HP:0002344,https://clinicaltrials.gov/ct2/show/results/NCT00001262,,,,,,,,,,
2006,,# 309400,Menkes disease,,ATP7A,Copper-transporting ATPase 1,7.2.2.8,,,,,,,,,,,,,,Rapid disease progression,,HP:0003678,https://www.ncbi.nlm.nih.gov/pubmed/30384011,,,,,,,,,,
2007,,# 309400,Menkes disease,,ATP7A,Copper-transporting ATPase 1,7.2.2.8,,,,,,,,,,,,,,Eplieptic discharge (Interictal EEG abnormality)*,,HP:0025373,https://www.ncbi.nlm.nih.gov/pubmed/8223785,,,,,,,,,,
2008,,# 309400,Menkes disease,,ATP7A,Copper-transporting ATPase 1,7.2.2.8,,,,,,,,,,,,,,Low muscular tone,,HP:0001290,,,,,,,,,,,
2009,,# 309400,Menkes disease,,ATP7A,Copper-transporting ATPase 1,7.2.2.8,,,,,,,,,,,,,,Appendicular hyoptonia,,HP:0012389,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341272/,,,,,,,,,,
2010,,# 309400,Menkes disease,,ATP7A,Copper-transporting ATPase 1,7.2.2.8,,,,,,,,,,,,,,Socio-cognitive abnormality(Neurodevelopmental abnormality)*,,HP:0012759*,,,,,,,,,,,
2011,,# 309400,Menkes disease,,ATP7A,Copper-transporting ATPase 1,7.2.2.8,,,,,,,,,,,,,,Poor weight gain,,HP:0001508,,,,,,,,,,,
2012,,# 309400,Menkes disease,,ATP7A,Copper-transporting ATPase 1,7.2.2.8,,,,,,,,,,,,,,Woolly hair,,HP:0002224,,,,,,,,,,,
2013,,# 309400,Menkes disease,,ATP7A,Copper-transporting ATPase 1,7.2.2.8,,,,,,,,,,,,,,Hypopigmented skin,,HP:0001010,,,,,,,,,,,
2014,,# 309400,Menkes disease,,ATP7A,Copper-transporting ATPase 1,7.2.2.8,Thiuram + Copper Dimethyldithiocarbamate (Cu-DMDTC ),"However, to the knowledge of the authors Horn et al. 2019 https://www.ncbi.nlm.nih.gov/pubmed/30384011, clinical evaluation of the copper-thiocarbamate complexes as well as of the copper-thiosemicarbazone remains to be done.",DB13245+DB09130+CHEBI:84293,ECO:0005542,,,,,Functional interaction( Mechanistic B),,,,,Low Brain Copper (Abnormal copper levels)*,,HP:0010836*,https://www.ncbi.nlm.nih.gov/pubmed/22815746,https://www.ncbi.nlm.nih.gov/pubmed/30384011,,,,,,,,,
2015,,# 309400,Menkes disease,,ATP7A,Copper-transporting ATPase 1,7.2.2.8,,,,,,,,,,,,,"Drug name: However, to the knowledge of the authors Horn et al. 2019 https://www.ncbi.nlm.nih.gov/pubmed/30384011, clinical evaluation of the copper-thiocarbamate complexes as well as of the copper-thiosemicarbazone remains to be done.",Copper accumulation in kidney(Abnormal copper levels)*,,HP:0010836*,,,,,,,,,,,
2016,,# 309400,Menkes disease,,ATP7A,Copper-transporting ATPase 1,7.2.2.8,Copper nitrilotriacetate (Cu-NTA),,DB09130+CHEBI:25548,ECO:0005542,,,,,Functional interaction( Mechanistic B),,,,,Low survival rate (Mortality)*,,HP:0040006*,https://www.ncbi.nlm.nih.gov/pubmed/?term=Copper+nitrilotriacetate%3A+A+potent+therapeutic+agent+in+the+treatment+of+a+genetic+disorder+of+copper+metabolism,,,,,,,,,,
2017,,# 309400,Menkes disease,,ATP7A,Copper-transporting ATPase 1,7.2.2.8,Alpha-lipoic acid,"Due to its strong copper chelation capability, a copper salt should be added simultaneously",DB00166,ECO:0000352,,,,,symptomatic (C),,,,Drug name: Due to its strong copper chelation capability a copper salt should be added simultaneously,Copper stroage abnormalities (Copper stroage abnormalities)*,,HP:0010836*,https://www.ncbi.nlm.nih.gov/pubmed/30384011,https://www.sciencedirect.com/science/article/abs/pii/088789949190052M,,,,,,,,,
2018,,# 309400,Menkes disease,,ATP7A,Copper-transporting ATPase 1,7.2.2.8,Glyoxal-bis(N(4)-methylthiosemicarbazonato)-copper(II) CuGTSM,Pharmaceutical studies are needed to reduce the adverse enteral effects.https://www.ncbi.nlm.nih.gov/pubmed/30127521,NA,ECO:0005542,,,,,Functional interaction( Mechanistic B),,,,,Low life span (Mortality)*,,HP:0040006*,https://www.ncbi.nlm.nih.gov/pubmed/30127521,https://www.sciencedirect.com/science/article/abs/pii/088789949190052M,,,,,,,,,
2019,,# 309400,Menkes disease,,ATP7A,Copper-transporting ATPase 1,7.2.2.8,Recombinant adeno-associated virus serotype 9 (rAAV9)-ATP7A +sc copper histidine,,NA,ECO:0005542,,,,,Direct interaction ( Mechanistic A),,,,,Low brain copper levels (Abnormal copper levels)*,,HP:0010836*,https://www.ncbi.nlm.nih.gov/pubmed/30090842,,,,,,,,,,
2020,,# 309400,Menkes disease,,ATP7A,Copper-transporting ATPase 1,7.2.2.8,,,,,,,,,,,,,,Abnormal brain neurochemical levels (Abnormality of neurotransmitter metabolism)*,,HP:0012535*,,,,,,,,,,,
2021,,# 309400,Menkes disease,,ATP7A,Copper-transporting ATPase 1,7.2.2.8,,,,,,,,,,,,,,Abnormal growth,,HP:0001507,,,,,,,,,,,
2022,,# 309400,Menkes disease,,ATP7A,Copper-transporting ATPase 1,7.2.2.8,,,,,,,,,,,,,,Brain mitochondrial abnormalities (Mitochondrial dysfunction),,HP:0003287*,,,,,,,,,,,
2023,,# 309400,Menkes disease,,ATP7A,Copper-transporting ATPase 1,7.2.2.8,,,,,,,,,,,,,,Behavioral abnormality,,HP:0000708,,,,,,,,,,,
2024,,# 309400,Menkes disease,,ATP7A,Copper-transporting ATPase 1,7.2.2.8,,,,,,,,,,,,,,Neurological abnormalties,,HP:0000707,,,,,,,,,,,
2025,40,# 249900,METACHROMATIC LEUKODYSTROPHY DUE TO SAPOSIN B DEFICIENCY,,PSAP,Prosaposin,P07602,No medical treatment is available in DDIEM,,,,,,,,,,,,,,,HP:0000707,,,,,,,,,,,
2026,41,# 250850,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",Recommendation and guidlines in treating this disease and other inherited methylation disorders can be found in this link: https://www.ncbi.nlm.nih.gov/pubmed/27671891,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,S-adenosylmethionine,,DB00118,ECO:0000352,,,,,Functional interaction( Mechanistic B),,,,,Poor appetite,Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,HP:0004396,https://www.ncbi.nlm.nih.gov/pubmed/27671891,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,,,,,,,,,
2027,,# 250850,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,,,,,,,,,,,,,,Low IQ,,HP:0001249,https://www.ncbi.nlm.nih.gov/pubmed/27671891,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,,,,,,,,
2028,,# 250850,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,,,,,,,,,,,,,,Behavioural abnormalities,,HP:0000708,https://www.ncbi.nlm.nih.gov/pubmed/27671891,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,,,,,,,,,
2029,,# 250850,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,,,,,,,,,,,,,,Abnormal Awake EEG,,HP:0002353,https://www.ncbi.nlm.nih.gov/pubmed/27671891,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,,,,,,,,
2030,,# 250850,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,,,,,,,,,,,,,,Delayed mylination,,HP:0012449,https://www.ncbi.nlm.nih.gov/pubmed/27671891,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,,,,,,,,,
2031,,# 250850,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,,,,,,,,,,,,,,Restricted diffusion in the corpus callosum in MRI (Abnormality of the nervous system)*,,HP:0000707,https://www.ncbi.nlm.nih.gov/pubmed/27671891,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,,,,,,,,,
2032,,# 250850,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,,,,,,,,,,,,,,Hyperreflexia,,HP:0001347,https://www.ncbi.nlm.nih.gov/pubmed/30389272,,,,,,,,,,
2033,,# 250850,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,,,,,,,,,,,,,,Irritability,,HP:0000737,https://www.ncbi.nlm.nih.gov/pubmed/30389272,,,,,,,,,,
2034,,# 250850,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,,,,,,,,,,,,,,Foot clouns,,HP:0011448,https://www.ncbi.nlm.nih.gov/pubmed/30389272,,,,,,,,,,
2035,,# 250850,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,,,,,,,,,,,,,,Poor traction response,,NA,https://www.ncbi.nlm.nih.gov/pubmed/30389272,,,,,,,,,,
2036,,# 250850,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,,,,,,,,,,,,,,Poor weight gain,,HP:0001508,https://www.ncbi.nlm.nih.gov/pubmed/30389272,,,,,,,,,,
2037,,# 250850,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,,,,,,,,,,,,,,Delayed motor milestone,,HP:0001270,https://www.ncbi.nlm.nih.gov/pubmed/30389272,,,,,,,,,,
2038,,# 250850,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,,,,,,,,,,,,,,Neurodevelopmental abnormalities,,HP:0012759,https://www.ncbi.nlm.nih.gov/pubmed/30389272,,,,,,,,,,
2039,,# 250850,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,,,,,,,,,,,,,,Brain demylination,,HP:0007266,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,https://www.ncbi.nlm.nih.gov/pubmed/19585268,https://www.sciencedirect.com/science/article/pii/014067369192373A,,,,,,,,
2040,,# 250850,"Methionine adenosyltransferase deficiency/ Hypermethioninemia, persistent",,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,Valproic acid,,DB00313,ECO:0000352,,,,,Symptomatic (C),,,,,Myoclonic epilepsy,,HP:0002123,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.ncbi.nlm.nih.gov/pubmed/19585268,https://www.sciencedirect.com/science/article/pii/014067369192373A,,,,,,,,
2041,42,# 250850,Persistent Hypermethioninemia,,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,S-adenosylmethionine,,DB00118,ECO:0000352,,,,,Functional interaction ( Mechanistic B),,,,,Poor appetite,Phenotype was improved in combination of  AdoMat and disetry restriction. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,HP:0004396,https://www.ncbi.nlm.nih.gov/pubmed/27671891,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,,,,,,,,,
2042,,# 250850,Persistent Hypermethioninemia,,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,,,,,,,,,,,,,,Low IQ,,HP:0001249,https://www.ncbi.nlm.nih.gov/pubmed/27671892,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,,,,,,,,
2043,,# 250850,Persistent Hypermethioninemia,,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,,,,,,,,,,,,,,Behavioural abnormalities,,HP:0000708,https://www.ncbi.nlm.nih.gov/pubmed/27671893,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,,,,,,,,,
2044,,# 250850,Persistent Hypermethioninemia,,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,,,,,,,,,,,,,,Abnormal Awake EEG,,HP:0002353,https://www.ncbi.nlm.nih.gov/pubmed/27671894,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,,,,,,,,
2045,,# 250850,Persistent Hypermethioninemia,,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,,,,,,,,,,,,,,Delayed development,,HP:0001263,https://www.ncbi.nlm.nih.gov/pubmed/27671895,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,,,,,,,,,
2046,,# 250850,Persistent Hypermethioninemia,,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,,,,,,,,,,,,,,Restricted diffusion in the corpus callosum in MRI(Abnormality of the nervous system)*,,HP:0000707,https://www.ncbi.nlm.nih.gov/pubmed/27671896,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,,,,,,,,,
2047,,# 250850,Persistent Hypermethioninemia,,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,,,,,,,,,,,,,,Hyperreflexia,,HP:0001347,https://www.ncbi.nlm.nih.gov/pubmed/30389272,,,,,,,,,,
2048,,# 250850,Persistent Hypermethioninemia,,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,,,,,,,,,,,,,,Irritability,,HP:0000737,https://www.ncbi.nlm.nih.gov/pubmed/30389272,,,,,,,,,,
2049,,# 250850,Persistent Hypermethioninemia,,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,,,,,,,,,,,,,,Foot clouns,,HP:0011448,https://www.ncbi.nlm.nih.gov/pubmed/30389272,,,,,,,,,,
2050,,# 250850,Persistent Hypermethioninemia,,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,,,,,,,,,,,,,,Poor traction response (Poor muscle tone)*,,HP:0001290,https://www.ncbi.nlm.nih.gov/pubmed/30389272,,,,,,,,,,
2051,,# 250850,Persistent Hypermethioninemia,,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,,,,,,,,,,,,,,Poor weight gain,,HP:0001508,https://www.ncbi.nlm.nih.gov/pubmed/30389272,,,,,,,,,,
2052,,# 250850,Persistent Hypermethioninemia,,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,,,,,,,,,,,,,,Delayed motor milestone,,HP:0001270,https://www.ncbi.nlm.nih.gov/pubmed/30389272,,,,,,,,,,
2053,,# 250850,Persistent Hypermethioninemia,,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,,,,,,,,,,,,,,Neurodevelopmental abnormality,,HP:0012759,https://www.ncbi.nlm.nih.gov/pubmed/30389272,,,,,,,,,,
2054,,# 250850,Persistent Hypermethioninemia,,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,,,,,,,,,,,,,,Brain demylination,,HP:0007266,https://www.sciencedirect.com/science/article/pii/S1096719211006093#bb0025,https://www.ncbi.nlm.nih.gov/pubmed/19585268,https://www.sciencedirect.com/science/article/pii/014067369192373A,,,,,,,,
2055,,# 250850,Persistent Hypermethioninemia,,MAT1A,S-adenosylmethionine synthase isoform type-1,2.5.1.6,Valproic acid,,DB00313,ECO:0000352,,,,,Symptomatic (C),,,,,Myoclonic epilepsy,,HP:0002123,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4545930/,https://www.ncbi.nlm.nih.gov/pubmed/19585268,https://www.sciencedirect.com/science/article/pii/014067369192373A,,,,,,,,
2056,43,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,Hydroxicobalamin + betaine+ Folinic acid,"Treatment with hydroxycobalamin is effective in many patients when started early, it has minimal side effects, and it is available at negligible costs (US $1/day). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368212/ 
Treatment with OHCbl and betaine should be initiated as soon as there is a suspicion for cblC disease, without waiting for confirmatory testing and after determining baseline plasma metabolites and vitamin B12 levels",DB00200+DB06756+DB00650,ECO:0000352,,,,,Functional interaction ( Mechanistic B)+Symptomatic (c)+Symptomatic (c),,,,,Haemolysis,,HP:0001878,https://www.ncbi.nlm.nih.gov/pubmed/24210589,https://reader.elsevier.com/reader/sd/pii/S0140673615000768?token=4389B95C8EA9D0F160CF217C15E330D411BC795585FAED16D84C10BB5F2FDE929AA9811F76C4A655C40F1DB4ABEA64EA,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,,,,,,,,
2057,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,,,,,,,,,,,,Elevated total plasma homocysteine,,HP:0002160,https://www.ncbi.nlm.nih.gov/pubmed/24210590,https://reader.elsevier.com/reader/sd/pii/S0140673615000768?token=4389B95C8EA9D0F160CF217C15E330D411BC795585FAED16D84C10BB5F2FDE929AA9811F76C4A655C40F1DB4ABEA64EA,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,https://link.springer.com/article/10.1023/A:1005353530303,,https://www.ncbi.nlm.nih.gov/pubmed/19821145,,,,,
2058,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,,,,,,,,,,,,High urine methylmalonic acid level,,HP:0012120,https://www.ncbi.nlm.nih.gov/pubmed/19821145,,,,,,,,,,
2059,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,,,,,,,,,,,,Impaired renal function,,HP:0012211,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368212/,,,,,,,,,,
2060,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,,,,,,,,,,,,decreased glomerular filtration rate,,HP:0012213,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5368212/,,,,,,,,,,
2061,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,,,,,,,,,,,,Fatigue,,HP:0012378,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,,,,,,,,,,
2062,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,,,,,,,,,,,,Anorexia,,HP:0002039,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,,,,,,,,,,
2063,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,,,,,,,,,,,,Delirium,,HP:0031258,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,,,,,,,,,,
2064,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,,,,,,,,,,,,Spasticity,,HP:0001257,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,,,,,,,,,,
2065,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,,,,,,,,,,,,Lower limb hyperreflexia,,HP:0002395,https://www.ncbi.nlm.nih.gov/pubmed/3950820/,,,,,,,,,,
2066,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,Hydroxicobalamin + betaine+ Folinic acid+Vitamin B complex,All patients received OHCbl (intramuscular injection; 0.5–1 mg/week) and betaine (oral administration; 1–3 g/day). Some patients also took oral administration of folic acid (10–30 mg/day) and compound vitamin B (20–60 mg/day),DB00200+DB06756+DB00650+A11EA,ECO:0000352,,,,,Functional interaction ( Mechanistic B)+Symptomatic (c)+Symptomatic (c)+Symptomatic (c),,,,,Psychiatric disturbances,,HP:0000708,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391119/,,,,,,,,,,
2067,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,,,,,,,,,,,,Lower extremity weakness,,HP:0007340,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391119/,,,,,,,,,,
2068,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,,,,,,,,,,,,Gait instability,,HP:0002317,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391119/,,,,,,,,,,
2069,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,,,,,,,,,,,,,,,,,,,,,,,,,
2070,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,Hydroxicobalamin + betaine+ carnitine,"Bartholomwe et al. have suggested in their paper in 1988 that daily injections of OH-B12 are not necessary to maintain metabolic control and that orally administered OH-B12 is unlikely to be effective. Betaine appears to act synergistically with OH-B12 and should be part of the treatment regimen. Although there are theoretical reasons for using L-carnitine and folinic acid, we could not document their effectiveness in these two patients. https://www.ncbi.nlm.nih.gov/pubmed/3257264/",DB00200+DB06756+DB00583,ECO:0000352,,,,,Functional interaction ( Mechanistic B)+Symptomatic (c)+Symptomatic (c),,,,,High urine methylmalonic acid level,,HP:0012120,https://link.springer.com/article/10.1023/A:1005353530303,https://www.ncbi.nlm.nih.gov/pubmed/25511120,,,,,,,,,
2071,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,,,,,,,,,,,,Elevated total plasma homocysteine,,HP:0002160,https://link.springer.com/article/10.1023/A:1005353530304,https://www.ncbi.nlm.nih.gov/pubmed/25511120,,,,,,,,,
2072,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,,,,,,,,,,,,High urine methylmalonic acid level,,HP:0012120,https://www.ncbi.nlm.nih.gov/pubmed/2873525/,,,,,,,,,,
2073,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,,,,,,,,,,,,Abnormal brain stem auditory evoked potentials,,HP:0006958,https://www.ncbi.nlm.nih.gov/pubmed/2873525/,,,,,,,,,,
2074,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,,,,,,,,,,,,Abnormal visual evoked potentials,,HP:0000649,https://www.ncbi.nlm.nih.gov/pubmed/2873525/,,,,,,,,,,
2075,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,,,,,,,,,,,,Mental impairment,,HP:0100543,https://www.ncbi.nlm.nih.gov/pubmed/2873525/,,,,,,,,,,
2076,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,,,,,,,,,,,,Emotional lability,,HP:0000712,https://www.ncbi.nlm.nih.gov/pubmed/2873525/,,,,,,,,,,
2077,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,,,,,,,,,,,,Psychiatric disturbances,,HP:0000708,https://www.ncbi.nlm.nih.gov/pubmed/2873525/,,,,,,,,,,
2078,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,,,,,,,,,,,,Difficulty walking,,HP:0002355,https://www.ncbi.nlm.nih.gov/pubmed/2873525/,,,,,,,,,,
2079,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,,,,,,,,,,,,Dementia,,HP:0000726,https://www.ncbi.nlm.nih.gov/pubmed/17431913,,,,,,,,,,
2080,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,,,,,,,,,,,,,,,,,,,,,,,,,
2081,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,Hydroxicobalamin,,DB00200,ECO:0000352,,,,,Functional interaction(Mechanistic B),,,,,Megaloblastic anemia,,HP:0001889,https://www.ncbi.nlm.nih.gov/pubmed/7357085/,https://www.ncbi.nlm.nih.gov/pubmed/17431913,,,,,,,,,
2082,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,,,,,,,,,,,,Methylmalonic aciduria,,HP:0012120,https://www.ncbi.nlm.nih.gov/pubmed/7357085/,https://www.ncbi.nlm.nih.gov/pubmed/17431913,,,,,,,,,
2083,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,,,,,,,,,,,,Elevated blood homocystine,,HP:0002160,https://www.ncbi.nlm.nih.gov/pubmed/19821145,,,,,,,,,,
2084,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,,,,,,,,,,,,Dementia,,HP:0000726,https://www.ncbi.nlm.nih.gov/pubmed/6749192/,https://www.ncbi.nlm.nih.gov/pubmed/25511120,,,,,,,,,
2085,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,,,,,,,,,,,,Myelopathy,,HP:0002196,https://www.ncbi.nlm.nih.gov/pubmed/6749192/,,,,,,,,,,
2086,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,,,,,,,,,,,,Gait instability,,HP:0002317,https://www.ncbi.nlm.nih.gov/pubmed/17431913,,,,,,,,,,
2087,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,Coumadin,,DB00682,ECO:0000352,,,,,Symptomatic (C),,,,,Deep venous thrombosis,,HP:0002625,https://www.ncbi.nlm.nih.gov/pubmed/11320193/,,,,,,,,,,
2088,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,Fluoxetine,,DB00472,ECO:0000352,,,,,Symptomatic (C),,,,,Emotional lability,,HP:0000712,https://www.ncbi.nlm.nih.gov/pubmed/25511120,,,,,,,,,,
2089,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,,,,,,,,,,,,Poor eye contact,,HP:0000817,https://www.ncbi.nlm.nih.gov/pubmed/25511120,,,,,,,,,,
2090,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,lorazepam,,DB00186,ECO:0000352,,,,,Symptomatic (C),,,,,Abnormal mental status,,HP:0100543,https://www.ncbi.nlm.nih.gov/pubmed/25511120,,,,,,,,,,
2091,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,Zonisamide,The drug has beeen weaned when patient developed visual hallucinatuion before his presentation with a status epilepticus attack. https://www.ncbi.nlm.nih.gov/pubmed/25511120,DB00909,ECO:0000352,,,,,Symptomatic (C),,,,,sleep cycle disturbance,,HP:0002360,https://www.ncbi.nlm.nih.gov/pubmed/25511120,,,,,,,,,,
2092,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,"Methylprednisolone sodium succinate +
Immune Globulin","Selection of this drug combinstion """"Methylprednisolone sodium succinate +
Immune Globulin """" was based on the presumption that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120",DB14644+DB00028,ECO:0000352,,,,,Symptomatic (C),,,,,Autoimmune encephalopathy(Encephalopathy)*/(Autoimmune disorder)*,"Doctors prescribed these drugs combination""""Methylprednisolone sodium succinate +
Immune Globulin """" as they presumed that the patient had autoimmune encephalopathy. https://www.ncbi.nlm.nih.gov/pubmed/25511120",HP:0001298*/HP:0002960*,https://www.ncbi.nlm.nih.gov/pubmed/25511120,,,,,,,,,,
2093,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,Risperidone,,DB00734,ECO:0000352,,,,,Symptomatic (C),,,,,Psychiatric disturbance,,HP:0000708,https://www.ncbi.nlm.nih.gov/pubmed/17431913,,,,,,,,,,
2094,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,Hydroxicobalamin + betaine+Folinic acid+ carnitine,,DB00200+DB06756+DB00650+DB00583,ECO:0000352,,,,,Functional interaction ( Mechanistic B)+Symptomatic (c)+Symptomatic (c)+Symptomatic (c),,,,,High urine methylmalonic acid level,,HP:0012120,https://www.ncbi.nlm.nih.gov/pubmed/18848477,,,,,,,,,,
2095,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,,,,,,,,,,,,Elevated total plasma homocysteine,,HP:0002160,https://www.ncbi.nlm.nih.gov/pubmed/18848477,,,,,,,,,,
2096,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,Vatiquinone (Epi-743),,DB11917,ECO:0007121,,,,,Symptomatic (C),,,,,Oxidative stress,,HP:0025464,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884027/,https://clinicaltrials.gov/ct2/show/NCT01793090?cond=methylmalonic+acidemia+and+homocystinuria%2C+cblC+type&rank=1,,,,,,,,,
2097,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,,,,,,,,,,,,,,,,,,,,,,,,,
2098,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,,,,,,,,,,,,,,,,,,,,,,,,,
2099,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,,,,,,,,,,,,,,,,,,,,,,,,,
2100,,# 277400,"METHYLMALONIC ACIDEMIA AND HOMOCYSTINURIA, cblC TYPE",,MMACHC,Methylmalonic aciduria and homocystinuria type C protein,Q9Y4U1,,,,,,,,,,,,,,,,,,,,,,,,,,,
2101,44,# 277410,"METHYLMALONIC ACIDURIA AND HOMOCYSTINURIA, cblD TYPE;",,C2orf25/MMADHC,"Methylmalonic aciduria and homocystinuria type D protein, mitochondrial",Q9H3L0,,,,,,,,,,,,,,,,,,,,,,,,,,,
2102,45,# 250940,Methylcobalamin deficiency cbl G type,,MTR,Methionine synthase,2.1.1.13,Eculizumab,,DB01257,ECO:0000352,,,,,Symptomatic (C),,,,,Microhematuria,,HP:0002907,https://www.ncbi.nlm.nih.gov/pubmed/28210839,,,,,,,,,,
2103,,# 250940,Methylcobalamin deficiency cbl G type,,MTR,Methionine synthase,2.1.1.13,,,,,,,,,,,,,,Microalbuminura,,HP:0012594,https://www.ncbi.nlm.nih.gov/pubmed/28210839,,,,,,,,,,
2104,,# 250940,Methylcobalamin deficiency cbl G type,,MTR,Methionine synthase,2.1.1.13,,,,,,,,,,,,,,Anemia,,HP:0001903,https://www.ncbi.nlm.nih.gov/pubmed/28210839,,,,,,,,,,
2105,,# 250940,Methylcobalamin deficiency cbl G type,,MTR,Methionine synthase,2.1.1.13,,,,,,,,,,,,,,Thrombocytopenia,,HP:0001873,https://www.ncbi.nlm.nih.gov/pubmed/28210839,,,,,,,,,,
2106,,# 250940,Methylcobalamin deficiency cbl G type,,MTR,Methionine synthase,2.1.1.13,,,,,,,,,,,,,,Thrombotic microangiopathy,,NA,https://www.ncbi.nlm.nih.gov/pubmed/28210839,,,,,,,,,,
2107,,# 250940,Methylcobalamin deficiency cbl G type,,MTR,Methionine synthase,2.1.1.13,Hydroxicobalamin,,DB00200,ECO:0000352,,,,,Functional interaction(Mechanistic B),,,,,Elevated plasma homocysteine concentration,,HP:0002160,https://www.ncbi.nlm.nih.gov/pubmed/28210839,,,,,,,,,,
2108,,# 250940,Methylcobalamin deficiency cbl G type,,MTR,Methionine synthase,2.1.1.13,,,,,,,,,,,,,,Megaloblastic anemia,,HP:0001889,https://www.ncbi.nlm.nih.gov/pubmed/28210839,,,,,,,,,,
2109,,# 250940,Methylcobalamin deficiency cbl G type,,MTR,Methionine synthase,2.1.1.13,,,,,,,,,,,,,,Thrombocytopenia,,HP:0001873,https://www.ncbi.nlm.nih.gov/pubmed/28210839,,,,,,,,,,
2110,,# 250940,Methylcobalamin deficiency cbl G type,,MTR,Methionine synthase,2.1.1.13,,,,,,,,,,,,,,Granulocytopenia,,HP:0001913,https://www.ncbi.nlm.nih.gov/pubmed/28210839,,,,,,,,,,
2111,,# 250940,Methylcobalamin deficiency cbl G type,,MTR,Methionine synthase,2.1.1.13,,,,,,,,,,,,,,Microhematuria,,HP:0002907,https://www.ncbi.nlm.nih.gov/pubmed/28210839,,,,,,,,,,
2112,,# 250940,Methylcobalamin deficiency cbl G type,,MTR,Methionine synthase,2.1.1.13,,,,,,,,,,,,,,Neurological abnormality,,HP:0000707,https://www.ncbi.nlm.nih.gov/pubmed/28210839,,,,,,,,,,
2113,,# 250940,Methylcobalamin deficiency cbl G type,,MTR,Methionine synthase,2.1.1.13,,,,,,,,,,,,,,Developmental delay,,HP:0001263,https://www.ncbi.nlm.nih.gov/pubmed/28210839,,,,,,,,,,
2114,,# 250940,Methylcobalamin deficiency cbl G type,,MTR,Methionine synthase,2.1.1.13,,,,,,,,,,,,,,,,,,,,,,,,,,,
2115,,# 250940,Methylcobalamin deficiency cbl G type,,MTR,Methionine synthase,2.1.1.13,,,,,,,,,,,,,,,,,,,,,,,,,,,
2116,46,# 236270,"HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblE COMPLEMENTATION TYPE; HMAE",,MTRR,Methionine synthase reductase,1.16.1.8,Hydroxycobalamin,,DB00200,ECO:0000352,,,,,,,,,,,,,,,,,,,,,,,
2117,,# 236270,"HOMOCYSTINURIA-MEGALOBLASTIC ANEMIA, cblE COMPLEMENTATION TYPE; HMAE",,MTRR,Methionine synthase reductase,1.16.1.8,,,,,,,,,,,,,,,,,,,,,,,,,,,
2118,,# 157640,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 1",,POLG,DNA polymerase subunit gamma-1,2.7.7.7,levodopa,,DB01235,ECO:0000352,,,,,Symptomatic(c),,,,,Limb dystonia,,HP:0001332,https://www.ncbi.nlm.nih.gov/pubmed/30838265,,,,,,,,,,
2119,,# 157640,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 1",,POLG,DNA polymerase subunit gamma-1,2.7.7.7,,,,,,,,,,,,,,Axial dystonia,,HP:0002530,https://www.ncbi.nlm.nih.gov/pubmed/30838265,,,,,,,,,,
2120,,# 157640,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 1",,POLG,DNA polymerase subunit gamma-1,2.7.7.7,,,,,,,,,,,,,,Gait abnormality,,HP:0001288,https://www.ncbi.nlm.nih.gov/pubmed/30838265,,,,,,,,,,
2121,,# 157640,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 1",,POLG,DNA polymerase subunit gamma-1,2.7.7.7,,,,,,,,,,,,,,Parkinsonism,,HP:0001300,https://www.ncbi.nlm.nih.gov/pubmed/24943079,,,,,,,,,,
2122,,# 157640,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 1",,POLG,DNA polymerase subunit gamma-1,2.7.7.7,,,,,,,,,,,,,,Tremor,,HP:0001337,https://www.ncbi.nlm.nih.gov/pubmed/30941926,,,,,,,,,,
2123,,# 157640,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 1",,POLG,DNA polymerase subunit gamma-1,2.7.7.7,,,,,,,,,,,,,,Rigidity,,HP:0002063,https://www.ncbi.nlm.nih.gov/pubmed/30941926,,,,,,,,,,
2124,,# 157640,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 1",,POLG,DNA polymerase subunit gamma-1,2.7.7.7,,,,,,,,,,,,,,Bradykinesia,,HP:0002067,https://www.ncbi.nlm.nih.gov/pubmed/30941926,,,,,,,,,,
2125,,# 610131,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,POLG2,"DNA polymerase subunit gamma-2, mitochondrial",2.7.7.7,Phenytoin+oxcarbazepine+levetiracetam,"The combination of three antiepileptic drugs and LGIT""modified KD"" is effective and well tolerated as treatment for severe episodes of POLG-related mitochondrial epilepsy. They suggest as well that combining LGIT to antiepileptic drug treatment should be considered in this potentially life-threatening condition.https://www.ncbi.nlm.nih.gov/pubmed/23248042?dopt=Abstract",DB00252+DB00776+ DB01202,ECO:0000352,,,,,Symptomatic(c),,,,,Mitochondrial epilepsy(Epilepsy)*,,HP:0001250*,https://www.ncbi.nlm.nih.gov/pubmed/23248042?dopt=Abstract,,,,,,,,,,
2126,,# 610131,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,POLG2,"DNA polymerase subunit gamma-2, mitochondrial",2.7.7.7,,,,,,,,,,,,,,,,,,,,,,,,,,,
2127,,# 610131,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,POLG2,"DNA polymerase subunit gamma-2, mitochondrial",2.7.7.7,coenzyme Q10,,DB09270,,,,,,Symptomatic (C),C,,,,Mitochondrial myopathy,,HP:0003737,https://www.ncbi.nlm.nih.gov/pubmed/27442316,,,,,,,,,,
2128,,# 610131,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,POLG2,"DNA polymerase subunit gamma-2, mitochondrial",2.7.7.7,,,,,,,,,,,,,,Low energy level,,HP:0003473,,,,,,,,,,,
2129,,# 610131,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,POLG2,"DNA polymerase subunit gamma-2, mitochondrial",2.7.7.7,prednisone,,DB00635,,,,,,Symptomatic (C),C,,,,Inflammatory myopathy,,HP:0009071,https://www.ncbi.nlm.nih.gov/pubmed/25674260,,,,,,,,,,
2130,,# 610131,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,POLG2,"DNA polymerase subunit gamma-2, mitochondrial",2.7.7.7,,,,,,,,,,,,,,dysphagia,,HP:0002015,,,,,,,,,,,
2131,,# 610131,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,POLG2,"DNA polymerase subunit gamma-2, mitochondrial",2.7.7.7,,,,,,,,,,,,,,,,,,,,,,,,,,,
2132,,# 610131,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,POLG2,"DNA polymerase subunit gamma-2, mitochondrial",2.7.7.7,,,,,,,,,,,,,,neck muscle weakness,,HP:0000467,,,,,,,,,,,
2133,,# 610131,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,POLG2,"DNA polymerase subunit gamma-2, mitochondrial",2.7.7.7,,,,,,,,,,,,,,,,,,,,,,,,,,,
2134,,# 610131,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,POLG2,"DNA polymerase subunit gamma-2, mitochondrial",2.7.7.7,,,,,,,,,,,,,,dysarthria,,HP:0001260,,,,,,,,,,,
2135,,# 610131,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,POLG2,"DNA polymerase subunit gamma-2, mitochondrial",2.7.7.7,,,,,,,,,,,,,,,,,,,,,,,,,,,
2136,,# 610131,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,POLG2,"DNA polymerase subunit gamma-2, mitochondrial",2.7.7.7,,,,,,,,,,,,,,,,,,,,,,,,,,,
2137,,# 610131,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 4",,POLG2,"DNA polymerase subunit gamma-2, mitochondrial",2.7.7.7,,,,,,,,,,,,,,,,,,,,,,,,,,,
2138,,# 258450,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL RECESSIVE 1",,POLG,DNA polymerase subunit gamma-2,2.7.7.7,levodopa,Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking.  https://www.ncbi.nlm.nih.gov/pubmed/12872260,DB01235,ECO:0000352,,,,,Symptomatic(c),,,,,Parkinsonism,,HP:0001300,https://www.ncbi.nlm.nih.gov/pubmed/12872260,,,,,,,,,,
2139,,# 609283,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 2",,SLC25A4,ADP/ATP translocase 1,P12235,,,,,,,,,,,,,,,,,,,,,,,,,,,
2140,,# 616479,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL RECESSIVE 2",,RNASEH1,Ribonuclease H1,3.1.26.4,No treatment is available in DDIEM,,,,,,,,,,,,,,,,,,,,,,,,,,
2141,,# 609286,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 3",,TWNK,"Twinkle protein, mitochondrial",3.6.4.12,Levodopa,Whether in this patient levodopa responsive Parkinsonism is caused bythe co-occurrence of the Twinkle R344Q and POLG G848S mutations remains elusive since brain autopsymaterial for mtDNA analysis was lacking. https://www.ncbi.nlm.nih.gov/pubmed/12872260,DB01235,ECO:0000352,,,,,Symptomatic(c),,,,,Parkinsonism,,HP:0001300,https://www.ncbi.nlm.nih.gov/pubmed/24076137,https://www.ncbi.nlm.nih.gov/pubmed/12872260,,,,,,,,,
2142,,# 617069,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL RECESSIVE 3",,TK2,"Thymidine kinase 2, mitochondrial",2.7.1.21,,,,,,,,,,,,,,,,,,,,,,,,,,,
2143,,# 617069,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL RECESSIVE 3",,TK2,"Thymidine kinase 2, mitochondrial",2.7.1.21,,,,,,,,,,,,,,,,,,,,,,,,,,,
2144,,# 617070,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL RECESSIVE 4",,DGUOK,"Deoxyguanosine kinase, mitochondrial",2.7.1.113,,,,,,,,,,,,,,,,,,,,,,,,,,,
2145,,# 613077,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 5",,RRM2B,Ribonucleoside-diphosphate reductase subunit M2 B,1.17.4.1,,,,,,,,,,,,,,,,,,,,,,,,,,,
2146,,# 618098,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL RECESSIVE 5",,TOP3A,DNA topoisomerase 3-alpha,5.6.2.2,,,,,,,,,,,,,,,,,,,,,,,,,,,
2147,,# 615156,"PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA, AUTOSOMAL DOMINANT 6",,DNA2,DNA replication ATP-dependent helicase/nuclease DNA2,3.6.4.12/3.1.-.-,Vitamin E+L-carnitine+Dichloroacetate+Creatine,,DB00163+DB00583+DB08809+DB00148,ECO:0000352,,,,,Symptomatic(c),,,,,Difficulty walking,,HP:0002355,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728770/,,,,,,,,,,
2148,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,Idebenone,"There is controversy about idebenone effect on LVM index ; although there were some studies suggested its effect on reducing LVM index and neurological problems, there are some that documented its faiure in acheiving this result. https://www.ncbi.nlm.nih.gov/pubmed/21392622
https://www.ncbi.nlm.nih.gov/pubmed/20697044",DB09081,ECO:0007121/ECO:0000352,,,,,,,,,,High left ventricular mass index ( Left ventricular hypertrophy)*,,HP:0001712*,https://www.ncbi.nlm.nih.gov/pubmed/11907009,https://www.ncbi.nlm.nih.gov/pubmed/12771264,https://www.ncbi.nlm.nih.gov/pubmed/12069112,https://www.ncbi.nlm.nih.gov/pubmed/12771265,,,,,,,
,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,,,,,,,,,,,,Interventricular septal thickning (Ventricular septum abnormality)*,,HP:0010438*,https://www.ncbi.nlm.nih.gov/pubmed/12771264,,,,,,,,,,
,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,,,,,,,,,,,,Neurological abnormality,,Another study has an opposing results https://www.ncbi.nlm.nih.gov/pubmed/20697044,https://www.ncbi.nlm.nih.gov/pubmed/17826341,https://www.ncbi.nlm.nih.gov/pubmed/12368988,,,,,,,,,
,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,,,,,,,,,,,,Cerebellar dysfunction,,HP:0001317,https://www.ncbi.nlm.nih.gov/pubmed/12368988,,,,,,,,,,
,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,,,,,,,,,,,,Saccadic ocular movement abnormality (Abnormality of saccadic eye movements),,HP:0000570,https://www.ncbi.nlm.nih.gov/pubmed/12368988,,,,,,,,,,
,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,,,,,,,,,,,,Nystagmus,,HP:0000639,https://www.ncbi.nlm.nih.gov/pubmed/12368988,,,,,,,,,,
,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,,,,,,,,,,,,Ataxia,,HP:0001251,,,,,,,,,,,
,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,,,,,,,,,,,,Disease progression (Rapid progression)*,,HP:0003678,https://www.ncbi.nlm.nih.gov/pubmed/18234531,,,,,,,,,,
,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,recombinant human erythropoietin (rhuEPO),,DB00016,ECO:0001565/ECO:0007121,,,,,Functional interaction( Mechanistic B),,,,,Low Frataxin expression level,,NA,https://www.ncbi.nlm.nih.gov/pubmed/16269021?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/17702040?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/21597884/,https://www.ncbi.nlm.nih.gov/pubmed/18759345?dopt=Abstract,,,,,,,
,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,,,,,,,,,,,,Oxidative stress,,HP:0025464,https://www.ncbi.nlm.nih.gov/pubmed/17702040?dopt=Abstract,https://www.ncbi.nlm.nih.gov/pubmed/18759345?dopt=Abstract,,,,,,,,,
,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,,,,,,,,,,,,High urinary 8-hydroxydeoxyguanosine level(Abnormality of DNA repair)*,,HP:0003254,https://www.ncbi.nlm.nih.gov/pubmed/17702040?dopt=Abstract,,,,,,,,,,
,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,,,,,,,,,,,,Neurological impairment,,HP:0000707,https://www.ncbi.nlm.nih.gov/pubmed/18759345?dopt=Abstract,,,,,,,,,,
,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,,,,,,,,,,,,Tiredness,,HP:0012378,https://www.ncbi.nlm.nih.gov/pubmed/18759345?dopt=Abstract,,,,,,,,,,
,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,,,,,,,,,,,,High ferritin level,,HP:0003281,https://www.ncbi.nlm.nih.gov/pubmed/21597884/,,,,,,,,,,
,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,,,,,,,,,,,,,,Low NADH/NAD ratio(Mitochondrial dysfunction),,HP:0003287,https://www.ncbi.nlm.nih.gov/pubmed/21597884/,,,,,,,,,,
,,# 229300,Friedreich Ataxia,,FXN,"Frataxin, mitochondrial",1.16.3.1,Rosuvastatin,,DB01098,ECO:0007121,,,,,Symptomatic (C),,,,,,,HP:0003287,https://clinicaltrials.gov/ct2/show/NCT02705547,,,,,,,,,,
